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Abstract 
Acting as protein-protein inhibitors, phosphotyrosine/serine-mimetics have demonstrated potent 
and diverse therapeutic activities, particularly against cancer. In particular, phosphotyrosine-
derived molecules, peptic or peptidomimetic, could be applied to re-establishing control of the 
hyperactivated STAT/JAK pathway in several cancers. Overexpression of tumour-promoting genes 
has been associated with abnormal accumulations of signal transducer and activator of 
transcription (STAT) proteins being phosphorylated at their SH2 domain, by specific Janus Kinases 
(JAKs), at specific phosphotyrosine residues. Abundancies of phosphorylated STAT proteins can 
dimerise, allowing translocation to the nucleus where overexpression of survival genes occurs, 
aiding tumourigenesis. 
Small, synthetic molecules that mimic the STAT3 phosphotyrosine residue and inhibit STAT3 
homodimerisation have been shown to prohibit dimerisation and gene overexpression. Despite 
their therapeutic promise, phosphotyrosine-mimetic drugs have not progressed to the clinics 
owing to their biocleavable and charged phosphate moieties. The repulsive charge of the 
phosphate group makes this class of compounds impermeable to cell membranes. This shortfall is 
paralleled in phosphoserine-mimetic drug molecules, which also contain charged phosphate 
functionalities. In this work, we explored how encaging these phosphate groups in a novel 
prodrug form would overcome their permeability issue, which could translate into improved 
pharmacological activity. 
To this end, the research hypothesis was evaluated on a known phosphotyrosine-mimetic STAT3 
inhibitor, ISS-610, as a proof-of-concept. A small library of novel ISS-610-Me phosphoramidate 
prodrugs was synthesised and evaluated for their anti-STAT3 activity and stability. The positive 
results from this small series validated the proposal and the prodrug technology was thus 
progressed to a novel STAT3 inhibitor, derived from the anti-STAT3 pharmacophore, S31-201. A 
larger library of novel phosphoramidate and known phosphate prodrugs was synthesised for this 
series, alongside a novel phosphate prodrug delivery system, which also displayed improved 
potency and good stability.  
The prodrug application was then applied to phosphopeptide-mimetic molecules, specifically to 
two anticancer molecules, which inhibit STAT5b or 14-3-3 dimerisation. Upon synthesis of these 
compounds and their prodrugs, the biological activity of the prodrugs was found to be superior to 
the parent compounds. In conclusion, this work collectively highlights the potential and 
applicability of phosphoramidate prodrug technology for improving the delivery and, thus, the 
pharmacological activity of phosphopeptide-mimetic (anticancer) therapeutics. 
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Abbreviations 
°C Degrees Celsius 
Ac Acetyl 
Ar Aryl 
Bn Benzyl 
Boc tert-Butyloxycarbonyl 
br Broad 
cat. Catalytic 
CC50 Half maximal cytotoxicity concentration 
COSY Homonuclear correlation spectroscopy 
d Doublet 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
DEAD Diethyl azodicarboxylate 
DIPEA N,N-Diisoproylethylamine 
DMAP 4-Dimethylaminopyridine 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
ES Electrospray 
Et Ethyl 
EtOAc Ethyl acetate 
EtOH Ethanol 
Et3N Triethylamine 
eq. Equivalent 
FDA Food and drug administration 
Fmoc Fluorenylmethyloxycarbonyl 
g Gram(s) 
HOMO Highest occupied molecular orbital 
HPLC High performance liquid chromatography 
hr Hour(s) 
HRMS High resolution mass spectrometry 
HSQC Heteronuclear single quantum coherence spectroscopy 
iPr Isopropyl 
IC50 Half maximal inhibitory concentration 
J Coupling constant (Hz) 
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JAK Janus kinase 
K Lysine 
Ki Inhibitor constant 
L-al L-alanine 
LCMS Liquid chromatography mass spectrometry 
Leu Leucine 
logP Partition coefficient 
LUMO Lowest unoccupied molecular orbital 
mCPBA meta-chloroperbenzoic acid 
Me Methyl 
MeOH Methanol 
CD3OD Deuterated methanol 
MHz Megahertz 
m Multiplet 
MeCN Acetonitrile 
mg Milligram(s) 
µ Micro 
µL Microlitre(s) 
µM Micromolar 
min Minute(s) 
mL Millilitre(s) 
mmol Micromolar 
mol Mole(s) 
Ms Methanesulfonyl 
MS Mass spectrometry 
NA Nucleoside analogue 
Np Napthyl 
nM Nanomolar 
NMI N-Methylimidazole 
NMR Nuclear magnetic resonance spectroscopy 
Nu Nucleoside 
P Proline 
p Pentet 
PG Protecting group 
Ph Phenyl 
pKa Acid dissociation constant at logarithmic scale 
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POC Bis-isopropyloxycarbonyloxymethyl 
POM pivaloyloxymethyl 
POMTide Aryloxy pivaloyloxymethyl nucleotide prodrugs 
ppm Parts per million 
ProTic Phosphopeptide-mimetic prodrugs 
ProTide Pronucleotide prodrugs 
pSer Phosphoserine 
pTyr Phosphotyrosine 
Py Pyridine 
pY Phosphotyrosine 
PyBOP (Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) 
q Quartet 
RDS Rate-determining step 
Rf Retardation factor 
tR Retention time 
RLS Rate-limiting step 
RT Room temperature 
s Singlet 
SATE S-acyl-2-thioethyl 
SDTE S-[(2-hydroxyethyl)sulﬁdyl]-2-thioethyl 
SH2 Src homology 2 
SN2 Bimolecular nucleophilic substitution 
STAT Signal transducer and activator of transcription 
Ser Serine 
t Triplet 
TBAF Tetrabutylammonium fluoride 
tBu tert-Butyl 
TBDMS tert-Butyldimethylsilyl 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
Ts p-Toluenesulfonyl 
Tyr Tyrosine 
UV Ultraviolet 
Y Tyrosine 
 
 7 
 
Table of Contents 
Acknowledgments  ................................................................................................................... 1 
Abstract  .................................................................................................................................. 2 
Thesis Publications ................................................................................................................... 3 
Abbreviations .......................................................................................................................... 4 
Table of Contents  .................................................................................................................... 7 
Chapter 1: Cancer and Therapy  .............................................................................................. 11 
1.1. Hallmarks of Cancer ............................................................................................................... 11 
1.2. The JAK/STAT Pathway  .......................................................................................................... 14 
1.2.1. Mechanism of Action ...................................................................................................... 14 
1.2.2. JAK/STAT Activation in Cancer ........................................................................................ 16 
1.2.3. Developing JAK Inhibitors  .............................................................................................. 17 
1.2.4. Developing STAT Inhibitors  ............................................................................................ 19 
1.2.5. STAT3 SH2 Domain Inhibitor Groundwork  .................................................................... 20 
1.2.6. Peptidomimetic STAT3 SH2 Domain Inhibitors  .............................................................. 21 
1.2.7. Nonpeptidic STAT3 SH2 Domain Inhibitors  ................................................................... 23 
1.2.8. STAT5 SH2 Domain Inhibitors  ........................................................................................ 25 
1.3. Developing 14-3-3 Inhibitors.................................................................................................. 27 
1.3.1. 14-3-3 Protein Activation in Cancer ................................................................................ 28 
1.3.2. 14-3-3 Inhibitors ............................................................................................................. 28 
Chapter 2: Organophosphorus Prodrugs ................................................................................. 31 
2.1. The Prodrug Concept  ............................................................................................................ 31 
2.2. Developing Phosphate Prodrugs ............................................................................................ 32 
2.2.1. Phosphate Ester Prodrug Groundwork ........................................................................... 32 
2.2.2. CycloSal Phosphate Prodrugs ......................................................................................... 33 
2.2.3. BisPOM Phosphate Prodrugs .......................................................................................... 34 
2.2.4. BisPOC Phosphate Prodrugs ........................................................................................... 35 
2.2.5. BisSATE Phosphate Prodrugs .......................................................................................... 36 
2.2.6. BisSDTE Phosphate Prodrugs .......................................................................................... 37 
 8 
 
2.2.7. HepDirect Phosphate Prodrugs ...................................................................................... 38 
2.3. Developing Phosphoramidate Prodrugs ................................................................................ 39 
2.3.1. Borch Phosphoramidate Prodrugs .................................................................................. 39 
2.3.2. ProTide Phosphoramidate Prodrugs ............................................................................... 40 
2.3.3. Phosphorodiamidate Prodrugs ....................................................................................... 42 
2.4. Developing Phosphonate Prodrugs ........................................................................................ 43 
Chapter 3: Research Aims and Objectives ............................................................................... 45 
3.1. Research Hypothesis  ............................................................................................................. 45 
3.2. Research Objectives  .............................................................................................................. 46 
Chapter 4: Design, Synthesis and Evaluation of ISS-610-Me Phosphoramidate Prodrugs ........... 48 
4.1. Aims and Objectives ............................................................................................................... 48 
4.2. ISS-610-Me ProTic Retrosynthetic Analysis ........................................................................... 51 
4.3. Synthesis of ISS-610-Me ProTic Prodrugs .............................................................................. 52 
4.4. Synthesis of ISS-610-Me ......................................................................................................... 57 
4.5. ISS-610-Me Series Compound Library .................................................................................... 63 
4.6. ISS-610-Me Library Immunoblotting ...................................................................................... 63 
4.7. ISS-610-Me ProTic Human Serum Stability ............................................................................ 66 
4.8. Conclusions ............................................................................................................................ 70 
Chapter 5: Design, Synthesis and Evaluation of POMTide Prodrugs .......................................... 71 
5.1. POMTide Prodrug Concept  ................................................................................................... 71 
5.2. Exploring POMTide Prodrug Metabolism .............................................................................. 72 
5.3. Aims and Objectives ............................................................................................................... 73 
5.4. Retrosynthetic Analysis of d4T POMTide ............................................................................... 74 
5.5. Synthesis of d4T POMTide  .................................................................................................... 75 
5.6. Synthesis of 5-FU POMTide Prodrugs .................................................................................... 85 
5.7. Synthesis of 5-FdU POMTide Prodrugs .................................................................................. 87 
5.8. 5-FdU Prodrug Compound Library ......................................................................................... 88 
5.9. Biological Evaluation .............................................................................................................. 89 
5.10. 5-FdU POMTide and ProTide Human Serum Stability.......................................................... 91 
 9 
 
5.11. 5-FdU POMTide pH 1 and pH 7.4 Stability ........................................................................... 92 
5.12. Conclusions .......................................................................................................................... 93 
Chapter 6: Design, Synthesis and Evaluation of S31-201 Phosphoramidate Prodrugs ................ 95 
6.1. S31-201 Derivatisation  .......................................................................................................... 95 
6.2. S31-201 para-Phosphate ........................................................................................................ 96 
6.3. S31-201 meta-Phosphate  ...................................................................................................... 97 
6.4. Aims and Objectives  .............................................................................................................. 98 
6.5. S31-201 Phosphate Library Retrosynthetic Analysis .............................................................. 99 
6.6. Synthesis of S31-201 ............................................................................................................ 100 
6.7. Synthesis of meta-S31-201 ProTic Prodrugs ........................................................................ 100 
6.8. Synthesis of para-S31-201 ProTic Prodrugs  ........................................................................ 102 
6.9. Synthesis of S31-201 Diethyl Phosphate Prodrugs .............................................................. 105 
6.10. Synthesis of S31-201 Phosphoric Acids .............................................................................. 105 
6.11. Synthesis of S31-201 POMTic Prodrugs ............................................................................. 113 
6.12. Synthesis of S31-201 BisPOM Prodrugs ............................................................................. 117 
6.13. Synthesis of S31-201 Sulphonamide Derivatives ............................................................... 120 
6.14. Compound Library .............................................................................................................. 122 
6.15. S31-201 POMTic Human Serum Stability ........................................................................... 123 
6.16. S31-201 Library Immunoblotting ....................................................................................... 124 
6.17. Conclusions ........................................................................................................................ 125 
Chapter 7: Design, Synthesis and Evaluation of Stafib-1 Phosphoramidate Prodrugs .............. 127 
7.1. Stafib-1  ................................................................................................................................ 127 
7.2. Aims and Objectives  ............................................................................................................ 128 
7.3. Stafib-1 ProTic Retrosynthetic Analysis  .............................................................................. 129 
7.4. Synthesis of Stafib-1 Phosphoramidate Prodrug ................................................................. 130 
7.5. Stafib-1 Phosphonamidate Derivatisation ........................................................................... 135 
7.6. (3,4-Diiodophenyl)methanamine Retrosynthetic Analysis  ................................................. 138 
7.7. Synthesis of (3,4-Diiodophenyl)methanamine  ................................................................... 139 
7.8. Conclusions  ......................................................................................................................... 142 
 10 
 
Chapter 8: Design, Synthesis and Evaluation of 14-3-3 Phosphoramidate Prodrugs  ............... 144 
8.1. 14-3-3 Proteins ..................................................................................................................... 144 
8.2. Aims and Objectives ............................................................................................................. 145 
8.3. 14-3-3 Inhibitor ProTic  Retrosynthetic Analysis .................................................................. 146 
8.4. Synthesis of 14-3-3 Inhibitor ProTic Prodrugs ..................................................................... 147 
8.5. 14-3-3 Inhibitor ProTic New Retrosynthetic Analysis .......................................................... 152 
8.6. New Synthesis of 14-3-3 Inhibitor ProTic Prodrugs ............................................................. 153 
8.7. Synthesis of 14-3-3 Diethyl Phosphate Prodrug .................................................................. 157 
8.8. Synthesis of 14-3-3 Inhibitor Phosphoric Acid ..................................................................... 157 
8.9. 14-3-3 Inhibitor Series Compound Library ........................................................................... 159 
8.10. 14-3-3 Inhibitor ProTic Human Serum Stability ................................................................. 160 
8.11. 14-3-3 Inhibitor Library Biological Evaluation .................................................................... 161 
8.12. Conclusions ........................................................................................................................ 163 
Chapter 9: Conclusions and Future Work .............................................................................. 165 
9.1. Research Conclusions ........................................................................................................... 165 
9.2. Future Work ......................................................................................................................... 167 
Chapter 10: Experimental Procedure .................................................................................... 169 
10.1. General Experimental ........................................................................................................ 169 
10.2. Stability Assay Procedures ................................................................................................. 170 
10.3. Immunoblotting Procedures .............................................................................................. 171 
10.4. Cytotoxicity Procedures ..................................................................................................... 172 
10.5. Docking Procedures ........................................................................................................... 173 
10.6. Chemistry Procedures ........................................................................................................ 174 
Chapter 11: Bibliography ...................................................................................................... 258 
11.1. References.......................................................................................................................... 258 
  
Cancer and Therapy                                                                                           Chapter 1 
  
11 
 
Chapter 1: Cancer and Therapy 
1.1. Hallmarks of Cancer 
Cancer is a collection of diseases defined as “uncontrolled divisions of cells that invade nearby 
tissues and distinctive organs”.1 The term originates from the Greek word ‘karkinos’ which 
translates to ‘crab’, famously detailed by the Greek physician Hippocrates in 400 BC to depict the 
likeliness of a malignant breast tumour to a crab outspread in the sand. Several hundred years 
later the Roman philosopher, Celsus, translated this to the Latin phrase for crab, ‘cancer’. To this 
day, the ever-evolving disease is now second only to cardiovascular diseases for the highest 
mortality rate. In 2018, it was estimated that 18.1 million new cancer cases were reported 
globally, causing over 9.6 million people to lose their lives.2 It is predicted that within the 21st 
century, cancer will rise to be the leading cause of global death.2  
To effectively combat cancer, it is imperative to fully understand the complexities of the causes 
and mechanisms of neoplastic progression. To this end, an extensive review by D. Hanahan and R. 
A. Weinberg highlighted six distinctive cancer hallmarks that provide rationalisations as to how 
normal cells transpire into cancer cells, exponentially replicate and invade surrounding tissues 
(Figure 1.1).3 It is hypothesised that all six complementary biological capabilities derive from 
either random, mutation-induced genomic instability or inflammatory-state cellular conditions.3,4  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The proposed six hallmarks of cancer (Reprinted from Cell, 575 /144, D. Hanahan and 
R. A. Weinber, Hallmarks of Cancer: The Next Generation 646–674, Copyright 2011, with 
permission from Elsevier).3 
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The dominant characteristic in tumourigenesis is believed to be the sustained, proliferative 
signalling which erodes a cell’s regulatory control of the signalling cascades responsible for growth 
and division.5 This abnormal proliferation in cancer is mostly attained by ‘high-jacking’ key 
signalling pathways involving growth factors binding to cell surface receptors and inciting their 
hyperactivation.3 Upregulation of these pathways and overexpression of their downstream target 
genes, induced by cancer, place the cell in a state of proliferative independence, enabling chronic 
replication and even adaptive drug resistance.3,5 Consequently, malignant cells have rapid cell 
cycle progression and enhanced cellular growth which influences further components, such as 
promotion of energy metabolism and cell survival.5  
To complement enhanced proliferation, a second hallmark of cancer involves evading growth 
suppressors, which provide barriers to abnormal proliferation. This manifests into the form of 
inactivation of retinoblastoma-associated (RB) and p53 transcription factor (Tp53) proteins, two 
critical tumour suppressors.3 Both complementary proteins facilitate checkpoint-limitations to 
cellular growth and division, thereby governing whether a cell can proliferate or initiate cellular 
senescence.6 The facilitated absence of both these proteins in malignant cells encourages the 
uncontrolled growth generated from the previously discussed, chronic proliferative capability.3  
A further characteristic is resisting cell death, which is achieved by evading apoptotic and 
autophagy mechanisms.3 The apoptotic process is comprised of downstream effectors and 
upstream regulators, relaying cellular death signals.3 These extracellular signals are received and 
processed, leading to intracellular components integrating the signals and activating proteases, 
caspase 8 and 9, which initiate proteolysis and trigger apoptosis.3,7 Malignant cells disrupt this by 
overexpressing antiapoptotic genes, such as the regulatory proteins of the Bcl-2 family, and 
downregulating proapoptotic-triggering proteins.3,8 This is mirrored in autophagy, the cellular 
process by which organelles are degraded and recycled through autophagosomes and lysosomes. 
Tumour cells promote AKT, PI3K and mTOR kinase signalling pathways that block autophagy.9  
The aggressive growth and replication exerted by neoplastic tissue significantly increases the cell’s 
demand for oxygen and nutrients. Neoplastic cells address this requirement by ensuring a 
constant state of angiogenesis, the process of forming and developing new blood vessels, which is 
typically transiently ‘switched on’ for short instances such as wound healing.10 The angiogenic 
‘switch’ is engaged when angiogenesis inhibitors or inducers, such as thrombospondin-1 (TSP-1) 
and vascular endothelial growth factor-A (VEGF-A), are expressed as signals.3 Early in cancer 
progression, growth factor VEGF-A is overexpressed to trigger a constant state of angiogenesis, 
stimulating endothelial cell growth to sufficiently generate blood vessels to sustain the unlimited 
replicative cancer capability.11 
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By avoiding two essential limitations to proliferation, senescence (irreversible cell cycle arrest) 
and crisis (a period of extensive apoptosis), malignant cells can emerge into an immortalisation 
transition.12,13 Resultantly, the cells can proceed through more cell division and growth cycles than 
are natively permitted.3 This is principally achieved by exploiting the roles of telomeres which 
protect the ends of chromosomes.3,13 Telomeres are assemblies of tandem hexanucleotide 
repeats which erode in length periodically as they protect fusion-events from damaging 
chromosomal DNA ends.13,14 This system dictates the number of cell generations which can pass, 
as when the telomere length becomes too short, the protective function is lost and senescence is 
induced.3 Cells that bypass senescence can continue to replicate until telomere length becomes 
critically short, which then initiates crisis.13 In some cells, a polymerase known as ‘telomerase’ is 
expressed to repair the lost length of telomeres and evade senescence/crisis.3 Cancer cells 
overexpress these telomerases to abolish telomere erosion and enable unlimited cellular cycles.14 
The final, of the six proposed hallmarks of cancer, is the ability to successfully activate invasion 
and metastasis.3 The process is believed to be a sequence of steps, known as the ‘invasion-
metastasis cascade’ that initiates the local invasion of cancer cells through neighbouring 
haematogenous and lymphatic systems.3 Once escaping into new tissues, cancer cells form small 
nodules which develop and grow into macroscopic tumours.15 Malignant cells achieve this by 
disrupting the regulation of key cell-to-cell and cell-to-ECM (extracellular matrix) adhesion 
molecules, such as E-cadherin.3 In normal cells, E-cadherin is downregulated to supress metastasis 
and ensure regulated assembly of epithelial sheets and cell quiescence is maintained.16 Cancer 
cells reverse this by upregulating molecules, such as E-cadherin, to promote epithelial sheet 
formation and enhance the ability of the malignant cells for dissemination (spreading).3 
Two emerging hallmarks of cancer are also now being established which comprise of 
reprogramming energy metabolism and evading immune destruction.3 Normal cells produce 
adenosine triphosphate (ATP), the source of cellular energy, under aerobic conditions via glucose 
metabolism and under anaerobic conditions by glycolysis.17 The hypoxic conditions tumour cells 
typically operate under highly favours glycolysis, as the primary form of energy production, which 
is further reprogrammed for oxygen-present microenvironments, is named aerobic glycolysis.17 To 
counteract the limitations of energy production using primarily glycolysis (18-fold less ATP 
produced), neoplasms upregulate glucose transporters, such as GLUT1, and glycolytic enzymes to 
enhance the glycolysis pathway.3 In regards to immune system evasion, cancer cells are further 
believed to secrete immunosuppressive factors, such as TGF-β, to impair the function of cytotoxic 
T lymphocytes, helper T cells and natural killer cells, which all contribute to immune surveillance 
and immunological killing.3,18 
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1.2. The JAK/STAT Signalling Cascade 
1.2.1. Mechanism of Action 
In efforts to combat cancer, directly targeting a particular hallmark has proved extremely 
challenging due to the highly complementary nature of each hallmark.3 For example, to target 
growth suppressor evasiveness, reinstatement of cell cycle checkpoint control has been reported 
by using small-molecules to activate mutant p53 to restore p53 function and re-induce 
apoptosis.6,19 To challenge this, neoplasms adapt and reduce the dependence on that particular 
hallmark and become more dependent on others to counteract the treatment.3 The ramifications 
of this mean that it is exceedingly ineffective to treat cancer via targeting only one capability. 
More promising strategies involve targeting several of the hallmarks simultaneously or outright 
destroying the cell, such as breaking cellular DNA. Fortunately, there are a number of druggable 
signalling pathways that are involved in multiple of the hallmarks of cancer, such as the JAK/STAT 
signalling pathway.20 
The ubiquitous JAK/STAT signalling pathway was first discovered in 1992 and is one of few 
cascades that profoundly regulate proliferation, differentiation, immune response, migration, cell 
cycle, cell survival and apoptosis.20,21 Mammalian signal transducers and activators of 
transcription (STATs) are a seven isoform-containing family of cytoplasmic proteins (STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6) and Janus kinases (JAKs) are four-membered 
tyrosine kinases (JAK1, JAK2, JAK3 and Tyk2) bound to the cytoplasmic regions of type I and type II 
cytokine receptors.22,23 The signalling transductions between STATs and JAKs are particularly 
essential for a plethora of homeostatic and developmental processes, such as maintaining stem 
cells and developing immune cells.24 Both components withhold a conserved SH2 domain (Src 
homology 2) which binds and docks specifically to critical phosphotyrosine residues (Figure 1.2).22  
 
 
 
 
 
 
 
 
 
Figure 1.2: Schematic representations of STATs and JAKs. 
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The phospho-regulatory signalling cascade initiates at the transmembrane receptors where 
influxes of various cytokines, such as interlukin-6 (IL-6) and interferon-gamma (IFN-γ), or other 
extracellular ligands bind to the receptors, stimulating their activation (Figure 1.3).25 The receptor 
subunits then form heteromultimers, bringing their constitutively associated cytoplasmic JAKs 
into close proximity to enable trans-phosphorylation.20 The impending phosphorylation activates 
the JAKs, which further phosphorylate specific tyrosine residues within intracellular regions of the 
receptor, generating docking sites to facilitate the recruitment of STAT proteins.22 Docking of STAT 
SH2 domains, with the receptor-complex phosphotyrosine residues, enable the activated JAKs to 
specifically phosphorylate a highly conserved tyrosine residue in the C-terminal domain of the 
STAT, promoting their respective activation (pSTAT) and undocking from recruitment sites.22,23 
The activated STAT phosphotyrosine residue then binds to the SH2 domains of other STAT 
proteins, forming hetero- and homodimers, which are rapidly translocated to the nucleus.26 STAT 
dimers recognise and bind to specific DNA promotor regions, forming STAT-DNA complexes, that 
exponentially increase or reduce the transcription rate of target genes.22,26 Objectively, the 
purpose of the signal transduction is to tightly regulate and modulate the transcription of specific 
target genes whose products directly play focal roles in proliferation, cell cycle, apoptosis, as well 
as other numerous essential cellular processes.27 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: JAK/STAT signalling cascade. C = cytokine, R = receptor and P = phosphate. 
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1.2.2. JAK/STAT Activation in Cancer 
In approximately 70% of all human breast, lung, pancreatic, colon, head, neck and leukemic 
cancers, the JAK/STAT pathway is hyperactivated and notably leads to an overexpression of 
activated STAT3 and STAT5.25,28 The principal mechanism for the activation is yet to be elucidated, 
with increased expressions of interleukins, mutations within JAKs and downregulation of negative 
pathway-modulators, all considered as being attributing factors.29,30 Nonetheless, with the 
signalling cascade directly regulating components of almost every capability of the hallmarks of 
cancer, hyperactivation of the JAK/STAT pathway immeasurably promotes tumourigenesis via 
stimulating the hypertranscription of a plethora of cancer-promoting downstream target genes.29  
It has been well established that STAT3 hyperactivation has a pronounced effect on evading 
growth suppressors through stimulating the hypertranscription and overexpression of cell cycle 
regulatory proteins, such as cyclin D1, that bypasses cell checkpoint control.3 This is exacerbated 
with STAT3 also directly downregulating p53 proteins, transcriptionally and post-transcriptionally, 
which are critical tumour suppressors.25 Constitutively activate STAT3 can bind to p53 promoters 
and directly supress their expression, which disables growth control.31 In 2005, Niu and co-
workers confirmed this mechanism by blocking STAT3, with a dominant negative STAT3 mutant in 
A2058 cancer cells, resulting in notable increases in p53 expression that led to p53-mediated, 
tumour cell-arrest.25,31  
Disruptive JAK/STAT signalling also has implications for the angiogenesis hallmark, owing to STAT3 
positively regulating VEGF expression.25 In malignancies, abnormal accumulations of activated 
STAT3 upregulate VEGF production through hypertranscribing the transcription factor, hypoxia-
inducible factor-1 (HIF-1), which STAT3 positively modulates.25,32 Upregulation of HIF-1 promotes 
upregulation of VEGF which engages angiogenesis to recruit endothelial cells and generate new 
blood vessels.33 A study by Wei and co-workers demonstrated this by expressing a dominant 
negative STAT3, in pancreatic cancer cells, that significantly supressed VEGF expression and 
reduced tumour growth.32 
A further example of the pathway’s exploitation in cancer was shown with the promotion of the 
metastasis hallmark. Metalloproteinases (MMPs) are critical for the metastatic process, as they 
digest extracellular matrixes and enable malignancies to escape into nearby blood vessels and 
disseminate.25 STAT3 positively regulates MMP-2 and overexpresses the protein accordingly in 
cancer, heavily promoting metastasis.34 The effects of this were further confirmed when Xie and 
co-workers showed that expressing a dominant negative STAT3, in K-1735 cancer cells, drastically 
supressed MMP-2 activity and its overall metastatic potential in neoplastic progression.25,34 
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1.2.3. Developing JAK inhibitors 
The deeply centralised role of the hyperactivated JAK/STAT pathway in neoplastic development, 
maintenance and progression has highlighted it as an extraordinarily attractive target to inhibit as 
a potential form of chemotherapy.35 Over the last 20 years, significant efforts to supress or inhibit 
the pathway have highlighted several targeting opportunities within the signalling pathway. 
Beginning with the upstream targets, attempts to inhibit the influx of cytokine or their respective 
receptor complexes have effectively reversed JAK/STAT activation.35 However, these components 
are not limited to the JAK/STAT cascade and these approaches have lacked pathway-selectivity, 
amounting to significant off-targeting effects of pro-inflammation and immunesupression.22 To 
allow for a more selective route, inhibition of more exclusive components, such as JAKs, has been 
investigated.28 
Indeed, successful JAK inhibition has been reported to selectively re-establish control of the 
pathway and inhibit the phosphorylation of overexpressed STATs. To date, there are two FDA-
approved JAK inhibitors, Ruxolitinib and Tofacitinib, which behave as ATP mimetics (Figure 1.4).28 
The mechanism of action involves both compounds acting as reversible, competitive inhibitors 
that bind to the ATP binding site, in the JAK kinase domain, and prohibit the JAK-activating 
phosphorylation event, blocking downstream STAT hyperactivation.36 Throughout their respective 
treatments, both Ruxolitinib (myelofibrosis) and Tofacitinib (arthritis) display dose-dependent 
decreases in activated STAT3 and STAT5, resulting in inhibition of proliferation.37,38 
 
 
 
 
 
 
 
 
 
Figure 1.4: A) Structures of FDA-approved JAK inhibitors. B) Evaluated inhibitor activities.28 
Compound JAK1 IC50 (µM) JAK2 IC50 (µM) JAK3 IC50 (µM) 
1 0.038 0.060 1.940 
2 0.030 0.130 0.074 
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Challengingly, with both compounds, selectivity for their target JAK, JAK1, is relatively poor and 
the off-target activity, induced by inhibiting other isoforms, has resulted in severe haematological 
side effects.39 Second generation JAK inhibitors thereby require increased selectivity for a singular 
JAK isoform comparatively to the current generation of inhibitors.39 To this end, a promising novel 
JAK inhibitor was reported in 2018, by Grimster and co-workers at AstraZeneca, which possessed 
a high degree of selectivity and potency for the JAK1 member in attempts to inhibit the JAK/STAT 
pathway.28 Through structure-based design and focused library screening, the team developed 
AZ-3 (Figure 1.5), an ATP-competitive JAK inhibitor with 1,000-fold selectivity for JAK1.28 
 
 
 
 
 
 
 
 
 
Figure 1.5: A) AZ-3 JAK1 inhibitor development. B) Evaluated inhibitor activities.28 
The group first screened over 50,000 compounds from an in-house library and 1,400 were 
identified with IC50 values <100 nM against JAK1.
28 Rescreening the 1400 hit-compounds with 
considerations for other parameters, such as IC50 values for JAK2 and JAK3, gave rise to the potent 
JAK1 inhibitor, compound 3, as a base structure. Substitution of the 3-chloro-2,4-diﬂuoroaniline 
motif for a more hydrophilic 3-hydroxymethylaniline significantly reduced the logD to a more 
suitable value of 1.75, enabling further modifications, such as pyrimidine C-5 methylation and 
substitution of the piperizane functionality for a bicyclic base, to yield compound 4.28 These 
modifications produced an extremely selective JAK1 inhibitor, which could potently inhibit 
downstream activated STAT3 but also, inhibit proliferation in an A549 cellular assay, where JAK1 
knockdown should have no effect.28 To remedy this, final derivatisations were made to afford lead 
compound 5 with 1,000-fold selectivity for JAK1, inactivity in the A549 cellular assay and potent 
downstream pSTAT3 inhibition.28 
Compound JAK1 IC50 (µM) JAK2 IC50 (µM) JAK3 IC50 (µM) pSTAT3 EC50 (µM) 
3 <0.003 0.036 0.464 - 
4 0.040 >30 >30 0.068 
5 (AZ-3) 0.034 >30 >30 0.030 
Cancer and Therapy                                                                                           Chapter 1 
  
19 
 
1.2.4. Developing STAT Inhibitors 
Despite compelling breakthroughs in the development of potent and selective JAK inhibitors, 
when used to treat solid tumours, the poor efficacies and persistent off-target toxicities observed, 
have limited their effectiveness.40 In alternative efforts to improve selectivity for the JAK/STAT 
cascade, the conceptual foundation of directly targeting the overexpressed phospho-regulatory 
STAT proteins was established. A particular therapeutic focus is on inhibiting STAT3, which is 
regarded as the ‘master regulator’ of the cell and remains the most well-documented and 
therapeutically relevant isoform to cancer.41 Interestingly, there are a number of approaches 
when targeting STAT3 proteins, with the most explored strategies focusing on inhibiting the 
STAT3-DNA binding domain, N-terminal domain or the conserved SH2 domain.40,41 
With the STAT3 DNA-binding domain directly binding to DNA response elements and facilitating 
the transcription of target genes, it was theorised that small-molecules could inhibit the domain, 
block STAT-DNA binding and supress STAT3 transcriptional activity.40,42 Indeed, studies show that 
classes of platinum (IV) compounds, similarly designed to cisplatin, can successfully disrupt STAT3-
DNA binding.41 This resultantly reduced expression of activated STAT3, supressed downstream 
targets genes, such as Cyclin-D1 and BcL-xL, that induced cell cycle arrest in malignant cells.43  
A second approach targets the STAT3 N-terminal domain, which mediates the protein-protein 
interactions between STAT3 dimer assemblies or STAT3 dimer-DNA binding.41 Through deriving 
small peptide sequences from the helices present within the STAT3 N-terminal domain and 
modifying them into cell-permeable analogues, agents that selectively bind to the domain and 
supress STAT3 transcriptional activity have been reported.44 Further developments have 
demonstrated peptide sequences specifically binding to the STAT3 N-terminal domain, can induce 
apoptosis and cancer cell arrest in human STAT3-activated cancer cell lines. 
Conversely, the overwhelmingly popular and most successful strategy is directly targeting the 
STAT3 SH2 domain.41 The highly conserved nature of STAT3 SH2 domains and their essential roles 
in STAT3-activation highlights them as extremely attractive targets for inhibition.40 STAT3 SH2 
domain inhibition involves blocking the STAT3 homodimerisation event, which occurs from 
reciprocal binding between the SH2 domain and the critical phosphotyrosine residue (pY705) of 
STAT3 monomers.45 By designing small-molecules, which can chemically mimic this 
phosphotyrosine residue, that specifically binds to the STAT3 SH2 domain, phosphotyrosine-
mimetic STAT inhibitors can selectivity inhibit the SH2 domain with high binding-affinity.45 
Resultantly, activated STAT3 is prevented from binding to its cognate site, disrupting dimerisation, 
ceasing target gene transcription and inducing apoptosis.45 
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1.2.5. STAT3 SH2 Domain Inhibitor Groundwork 
Despite the challenges of developing protein-protein inhibitors for the large surface areas of 
protein interfaces, many selective and potent STAT3 SH2 domain inhibitors have been reported.35 
These inhibitors target two or more of the three available sub-pockets within the STAT3 SH2 
domain (Figure 1.6), which were elucidated after the X-ray crystal structure of STAT3:STAT3–DNA 
ternary complex was solved by Becker and co-workers in 1998.46 The sub-pockets comprise one 
polar (pY) and two hydrophobic (pY+1 and pY-1) sub-pockets.45 The hydrophilic pY site primarily 
interacts via electrostatic and hydrogen bonding interactions that accommodates the highly-
charged phosphotyrosine motif.45 The remaining two binding sub-pockets are hydrophobic, where 
the pY-1 sub-pocket is unique to the STAT3 isoform and can be exploited for selectivity.45 
Therefore, to develop high binding-affinity and selective STAT3 SH2 domain inhibitors, the 
molecules must be phosphotyrosine-mimetic and engage with multiple sub-pockets. 
 
 
 
 
 
 
Figure 1.6: Recreated STAT3 structure and SH2 domain surface representation (Reprinted from 
Biochemical and Biophysical Research Communications, 374 /1,  Z. Ren et al., Crystal structure of 
unphosphorylated STAT3 core fragment, 1-5, Copyright 2008, with permission from Elsevier) 
(Republished with permission of Patrick T. Gunning, from Progress towards the Development of 
SH2 domain inhibitors, P. T. Gunning et al., 42, 8, Copyright 2013; permission conveyed through 
Copyright Clearance Center, Inc.).45,47  
The earliest account of a protein-protein inhibitor of the STAT3 SH2 domain was reported in 2001 
by Turkson and co-workers, with the discovery of a PpYLKTK peptide sequence.48 The peptide 
sequence was derived from several essential amino acid residues surrounding the STAT3 SH2 
domain phosphotyrosine, that bind and dimerise with other STAT3 SH2 domains.48 It was 
hypothesised that by mimicking the chemical environment of these residues, the peptide agent 
could selectively bind and inhibit the SH2 domains of constitutively active STAT3 proteins.40 The 
proof-of-concept protein established weak STAT3 SH2 domain binding with an IC50 value of 182 
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µM and the ability to successfully disrupt the key STAT3 dimerisation event in vitro and in vivo.48 
The reduction of STAT3 activity was concluded to be facilitated by the associations of STAT3 SH2 
domains with PpYLKTK, forming PpYLKTK:STAT3 inactive monomer complexes.48 This study was a 
significant foundation for confirming the hypothesis of inhibiting STAT3 via its SH2 domain.  
1.2.6. Peptidomimetic STAT3 SH2 Domain Inhibitors 
Peptide agents, such as PpYLKTK, often have poor pharmacokinetic properties, low cellular 
permeability and offer poor stability in vitro.40 To address this, peptidomimetic derivatives were 
considered to alleviate some of the negative properties of employing native peptides. Using a 
template tripeptide sequence, PpYL, from PpYLKTK, the first series of anti-STAT3 peptidomimetics 
were subsequently reported by Turkson and co-workers in 2004.49 Numerous substitutions were 
made to the pY-1 residue within the critical PpYL sequence, from aryls to heterocycles, to yield 
the  lead peptidomimetic ISS-610 (Figure 1.7), with a five-fold higher activity (IC50 = 42 µM), 
49 
 
 
 
 
 
 
 
Figure 1.7: A) ISS-610 (6). B) Docking (ISS-610 green, PpYLKTK orange) within STAT3 SH2 domain 
(Reprinted from Molecular Cancer Therapeutics, Copyright 2004, 3/3, 261-269, J. Turkson et al., 
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization 
and biological activity, with permission from AACR).49  
Computational models (Figure 1.7) confirmed a similar affiliation of the phosphotyrosine motif 
within the pY sub-pocket for both ISS-610 and PpYLKTK.49 ISS-610 facilitated a greater occupation 
of the desired pY-1 sub-pocket with the modified 4-cyanobenzoate functionality, increasing the 
overall binding affinity.49 From the electrophoretic mobility shift assay (EMSA) results (Figure 1.8), 
ISS-610 displays a superior dose-dependent decrease in STAT3 dimer expression, relative to 
PpYLKTK, rationalised by its enhanced STAT3 SH2 domain binding.49 It was then shown that 
treatment of ISS-610 to STAT3 overexpressed cancer cell lines, MDA-MB-231 and MDA-MB-435, 
significantly supressed proliferation and induced apoptosis at high concentrations (>1 mM).45 
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Figure 1.8: EMSA analysis of STAT3 dimerisation with ISS-610 and PpYLKTK (Reprinted from 
Molecular Cancer Therapeutics, Copyright 2004, 3/3, 261-269, J. Turkson et al., Novel 
peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and 
biological activity, with permission from AACR).49  
The phosphopeptide approach, validated by ISS-610’s improved ability to mimic an anti-STAT3 
peptide and disrupt dimerisation, encouraged a global interest in developing second generation 
ISS-610 derivatives and new anti-STAT3 peptidomimetic designs. Computational models of ISS-
610 were used to elucidate libraries of new peptidomimetics, with higher binding-affinities for the 
STAT3 SH2 domain, better selectivity for the STAT3 isoform (targeting the unique STAT3 pY-1 sub-
pocket) and potency for STAT3 dimerisation disruption, such as inhibitors 7 and 8 (Figure 1.9). 
However, selectivity and high binding-affinities are not the only factors in drug development and 
remnant issues from peptic properties elsewise remain to restrict STAT3 inhibitor progress. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Reported STAT3 SH2 domain peptidomimetic inhibitors 7-9.45,50–52  
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Alongside poor stability (due to the phosphate’s susceptibility to hydrolysis by endogenous 
cellular phosphatases), peptidomimetics are highly impermeable to cell membranes due to 
retention of anionic charges and multiple polar side chains.40 To address this, Wang and co-
workers designed a peptidomimetic, compound 9, with the side chains redesigned as a 1,2,3-
triazole ring to increase the molecule’s lipophilicty and improve cellular uptake through the 
membrane (Figure 1.9).52 The annulated STAT3 inhibitor was designed, using click chemistry, to 
cyclise two lysine residues of the parent inhibitor, Ac-pYLKTK-amide, which facilitated a 3-fold 
potency increase (IC50 = 25.9 µM to 7.3 µM).
45,52 This modification highlighted that improving 
permeability of STAT3 inhibitors was a significant consideration. 
1.2.7. Nonpeptidic STAT3 SH2 Domain Inhibitors 
The interesting strategies to remedy poor cellular uptake of STAT3 inhibiting peptidomimetics, 
such as Wang and co-workers cyclisation efforts, still fell short of the required capabilities. To this 
end, there are currently no FDA-approved STAT3 SH2 domain peptidomimetic inhibitors. The 
main implicated factors are poor stability, insufficient cellular uptake and resultantly low 
biological activities. Consequently, nonpeptidic anti-STAT3 small-molecules, with improved 
physiochemical properties, have been considered to alleviate these drawbacks.41 One of the more 
successful and heavily derivatised nonpeptidic STAT3 inhibitors, S31-201 (Figure 1.10), was 
reported in 2007 by Turkson and co-workers to disrupt the STAT3 dimerisation event.53  
 
 
 
 
 
 
Figure 1.10: A) S31-201 (10). B) S31-201 docking within the STAT3 SH2 domain (Copyright (2017) 
National Academy of Sciences).53 
Through structure-based virtual screening, S31-201 was identified as a lead, high-scoring binder 
and inhibitor of the STAT3 SH2 domain; with a weak IC50 value of 86 µM.
45 Computational 
modelling (Figure 1.10) confirmed the salicylic group was behaving as a phosphotyrosine-mimetic 
and could sit tightly in the pY SH2 domain sub-pocket.53 The tosylate tail was also revealed to 
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accommodate well into the STAT3-specific, pY-1 hydrophobic sub-pocket, resulting in an overall 
binding-affinity score of -11.7 kcal/mol.53 EMSA results (Figure 1.11) demonstrated dose-
dependent disruption of STAT3 dimerisation with S31-201 treatment, with a high degree of 
selectivity for STAT3:STAT3 dimers over STAT1:STAT1 or STAT3:STAT1 dimers.53 To investigate the 
ability of S31-201 to inhibit constitutively active STAT3, it was treated with the STAT3-activated 
mouse fibroblast and cancer cell lines, NIH 3T3/v-Src and MDA-MB-231 (Figure 1.11), in search for 
fluctuations in three STAT3 target genes: Survivin (survival), BcL-xL (anti-apoptotic) and Cyclin-D1 
(cell cycle).41,53 Western blot results definitively show suppression of these genes after treating 
both cell lines with S31-201 (100 µM, for 48 hours), in comparison to the untreated cells, 
signifying that S31-201 was disrupting dimerisation and overall STAT3 transcriptional activity.53 
 
 
 
 
 
Figure 1.11 A) EMSA analysis of S31-201 STAT dimerisation. B) Western blot analysis of 
(NIH3T3/v-Src) and MDA-MB-231 cells gene expression after S31-201 (100µM) treatment for 48 
hours (Copyright (2017) National Academy of Sciences).53  
Indeed, the positive contributions from S31-201 led to derivatisations of the core structure to 
facilitate better binding, to both the pY and pY-1 sub-pockets, but also to the additional pY+1 
hydrophobic sub-pocket, which had mostly remained unexplored.54 Interaction with this pocket 
was investigated by incorporating derivatives of S31-201 with hydrophobic benzylic groups on the 
central amide nitrogen, such as compound 11, which improved potency (Figure 1.12).55 Whereas 
the hundreds of reported nonpeptidic STAT3 inhibitors demonstrate improved permeability and 
stability, they now conversely exhibit weaker binding-affinities and insufficient activities.45 
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Figure 1.12: Reported STAT3 SH2 domain nonpeptidic inhibitor examples.54–56 
1.2.8. STAT5 SH2 Domain Inhibitors 
Exploring the STAT3 protein has yielded numerous innovative anticancer agents, but the overall 
poor activities have perpetuated their clinical trial failures.35,40 An alternative approach focuses on 
STAT5 proteins, which are also hyperactivated in cancer and contain an analogous highly 
conserved SH2 domain.45 Problematically, the STAT5 SH2 structure has been far less explored, 
presenting challenges for developing selective and potent STAT5 inhibitors. However, the 
STAT5a/b SH2 domain shares approximately 40% homology with STAT3’s, enabling screenings of 
large libraries of SH2 domain binders to establish which are selective for STAT5. A 2018 study by 
Wingelhofer and co-workers validated this hypothesis, with AC-4-130 (Figure 1.13).57 
 
 
 
 
 
 
Figure 1.13: A) AC-4-130 (14). B) AC-4-130 docking within the STAT5b SH2 domain (Public license: 
https://creativecommons.org/licenses/by/4.0).57  
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From a large chemical library screening of known SH2 domain binders, AC-4-130 (14), was 
identified as a selective inhibitor of STAT5, over both STAT1 and STAT3.57 The compound retained 
the S31-201 derivative, BP-1-102 (Figure 1.12), pharmacophore developed by Gunning and co-
workers, showcasing the similarities between STAT SH2 domains.57–59 From docking the 
compound into the STAT5 SH2 domain (Figure 1.13), calculations revealed benzoic acid 
interactions with key Arg-618 and Ser-622 residues that are involved with phosphotyrosine 
binding (pY).59 Likewise, pentaﬂuorobenzene sulfonamide and 4-chlorobenzyl substituents were 
engaging in π-π interactions within an amphiphilic pocket, resulting in favourable binding.57,59 The 
overall STAT5-isoform selectivity was rationalised by benzylic cation-π interactions with the 
STAT5b-specific, Asn-64 residue, which is not present within the other STAT isoforms.59   
To study the activity profile, constitutively active STAT5b cell lines, Ba/F3 FLT3-ITD+, were treated 
with AC-4-130 at various concentrations for 24 hours (Figure 1.14).57 Both cytoplasmic and nucleic 
pSTAT5 saw dose-dependent decreases upon AC-4-130 treatment, establishing its ability to inhibit 
dimerisation (reduced cytoplasmic pSTAT5) and nuclear translocation (less nucleic pSTAT5).  
In sequential investigations, STAT5 perturbed cells, MV4–11 and MOLM-13, underwent AC-4-130 
treatment and displayed dose-dependent cleavage of poly (ADP-ribose) polymerase (PARP) and 
caspase 3, the notable signatures for initiation of apoptosis (Figure 1.14).57,60,61 Collectively, AC-4-
130 had demonstrated to be a selective STAT5b SH2 binder, inhibitor of STAT5 dimerisation and 
inducer of apoptosis, certifying the STAT5 SH2 domain-inhibition concept.57 
 
 
 
 
 
 
Figure 1.14: A) Western blot analysis of Ba/F3 FLT3-ITD+ cells pSTAT5 levels with AC-4-130,                
B) Western blot analysis of MV4–11 and MOLM-13 cells PARP and CASPASE 3 levels with AC-4-130 
(Public license: https://creativecommons.org/licenses/by/4.0).57  
There have been copious advances in developing small-molecules for selective STAT5 SH2 
domain-inhibition (Figure 1.15). For example, Romagnoli and co-workers reported a potent STAT5 
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inhibitor, compound 15, which reduced pSTAT5 expression and induced apoptosis in K562 and 
KCL-22 human chronic myeloid leukemia cells.62 In 2008, Berg and co-workers screened 17,000 
compounds for selective STAT5b SH2 domain binding, elucidating chromone-derived acyl 
hydrazine 16 as a promising STAT5b dimerisation disruptor.63 However, likewise to STAT3 
inhibitors, these compounds have not progressed through clinical trials owing to poor activities.  
 
 
 
 
 
 
Figure 1.15: Reported STAT5 SH2 domain nonpeptidic inhibitor 15 and 16.62,64 
1.3. Targeting 14-3-3 Proteins 
1.3.1. 14-3-3 Protein Activation in Cancer 
Additionally to STAT proteins, other phospho-regulatory signalling proteins, such as 14-3-3 
proteins, are overexpressed in many cancers.65 The protein was first identified in 1967 and named 
from the elution fraction number of the protein after chromatography, alongside the migration 
position following electrophoresis.66 14-3-3 proteins possess many unparalleled similarities to 
STAT proteins and their malignant hyperactivation also promotes several hallmarks of cancer 
involving proliferation, cell cycle, apoptosis, cell survival and metastasis.65,67  
In mammalians, there are seven isoforms of 14-3-3 proteins (β, γ, ε, ζ, η, σ, and τ), which are 
highly conserved and ubiquitously expressed across tissue.68 In an analogous manner to STATs, 
14-3-3 proteins facilitate homo/heterodimerisation and bind to numerous binding partners, 
namely signalling proteins, to regulate signalling activity.65,69 The 14-3-3 binding-domain protein-
protein interactions are of particular interest, due to their resemblance to the STAT SH2 domain, 
which specifically binds to phosphotyrosine residues.65 However, 14-3-3 proteins binding domains 
specifically recognise their substrates via phosphoserine (or threonine) residues, constituting 
them as an additional class of signalling domain.70,71 Binding of 14-3-3 dimers, through 
phosphoserine interactions, to host signalling proteins can induce conformational changes, 
Cancer and Therapy                                                                                           Chapter 1 
  
28 
 
enhance or supress further target protein-protein interactions and even hinder the accessibility of 
the protein to modifying enzymes.65  
There have been various studies that showed 14-3-3 proteins (particularly the 14-3-3σ isoform) to 
be overexpressed in many cancers, thus facilitating the hyperactivation of numerous other 
affiliated pathways, such as impairing the activity of critical p53 tumour suppressor proteins.65,68,69 
The cancer-promoting implications of overexpressed 14-3-3 proteins therefore highlights them as 
potentially druggable targets to inhibit for anticancer therapy. Moreover, it is their mechanistic 
likeliness to hyperactivated STATs which draws particular excitement, as the established and well-
documented science of STAT phosphotyrosine-mimetic inhibition could, in theory, be applied and 
prove equally as successful for 14-3-3 overexpression.65 It has therefore been proposed that 
employing small-molecules, that mimic key phosphoserine residues, could selectively bind to 14-
3-3 binding domains, inhibit their interactions and prohibit their cancer-promoting activations.67 
1.3.2. 14-3-3 Inhibitors 
In the search of small molecules that target 14-3-3, not much progress has been made discovering 
14-3-3 dimerisation inhibitors. The first example of a 14-3-3 dimerisation inhibitor came in 1997, 
when Yaffe and co-workers first established that 14-3-3 proteins bind to their target proteins 
through hexaphosphopeptide (RXX[pS/pT]XP) or heptaphosphopeptide (RXXX[pS/pT]XP) binding 
sequences, where X = any amino acid.67,72 This premise enabled inhibitory peptide sequences to 
be constructed which recognise these binding sites, such as RFRpSYPP and LFGpSLLR.72 These 14-
3-3 protein binding-domain peptide sequences could further be employed as scaffolds to aid the 
design of 14-3-3 peptidomimetic inhibitors, with improved drug-like properties. Resultantly, in 
2010, the first small-molecule examples of a 14-3-3 phosphoserine-mimetic, protein-protein 
inhibitors were reported by Yao and co-workers.67 The structures were attained through a small-
molecule microarray (SMM), which assisted a high-throughput screening to convert the 
established 14-3-3-binding peptide, RFRpSYPP, into more favourable small-molecule 
peptidomimetics.67,73 The series-wide lead inhibitor, compound 17 (Figure 1.16) retained the 
critical phosphoserine residue and incorporated two flanking, high 14-3-3σ-affinity fragments.67 
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Figure 1.16: Reported 14-3-3σ inhibitor 17 and unphosphorylated analogue 18.67,73 
Phosphoserine-derived, 14-3-3 inhibitor 17 and its corresponding unphosphorylated derivative 18 
were first subjected to competitive fluorescence polarisation experiments which established that 
dose-dependent 14-3-3σ binding could be observed with phosphorylated inhibitor 17, but not 
with the alcohol analogue (18).67 Moreover, the evaluated IC50 value towards 14-3-3σ for 
compound 17 (2.6 µM) was approximately ten-fold lower than the parent peptide, a reasonable 
overall trade-off for peptidomimetic-derivatisation.67 The group then investigated both 
compounds abilities to competitively bind to 14-3-3σ and disrupt its protein-protein interactions 
with two of its substrate proteins, p53 and Raf-1 (Figure 1.17).65,67 Phosphorylated 17 and 
unphosphorylated compound 18 were thus pre-incubated with bead-immobilised GST-14-3-3σ 
and then added to A549 cell lysates.67 Immunoblotting then demonstrated compound 17 could 
successfully disrupt 14-3-3σ binding to both Raf-1 and p53 proteins, which was not observed with 
unphosphorylated compound 18.67 Furthermore, an XTT cell viability assay in A549 cells 
concluded that inhibitor 17 was also weakly inducing time-dependant suppression of proliferation 
at 100 µM (Figure 1.17), confirming inhibitor 17 was disrupting 14-3-3σ/ligand binding and thus 
inducing apoptosis.67,73 
 
 
 
 
 
 
 
Figure 1.17: A) In vitro competitive binding of 17 (100 µM) and 18 (100 µM) with cellular proteins 
in A549 cells for 24 hours. TCL = total cell lysate. GST = just beads. B) XTT assay for time-
dependent inhibition of A549 cell proliferation with 17 and 18 treatment at 100 µM (Reprinted 
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from Angewandte Chemie International Edition, 49 /37, H. Wu et al., Microarray‐Assisted High‐
Throughput Identification of a Cell‐Permeable Small‐Molecule Binder of 14‐3‐3 Proteins, 6528-
6532, Copyright 2010, with permission from John Wiley and Sons).67  
The elegant work reported by Yao confirmed that designing 14-3-3 inhibitors, which bind and 
block associated 14-3-3/ligand interactions, could successfully induce apoptosis in cancer cells and 
has encouraged other research groups to develop their own 14-3-3 inhibitors (Figure 1.18). In 
2013 Thiel and et al. developed an anti-14-3-3 phosphonate inhibitor, compound 19, through 
virtual screening.74 The group reported the compound’s ability to significantly inhibit 14-3-3-
induced metalloproteinase, MMP-1, overexpression in human lung fibroblasts, demonstrating its 
ability to combat neoplastic metastasis.74 A further example is FOBINSIN101 (20) which was 
developed by Zhao and co-workers in 2011 and displayed good selectivity for the 14-3-3ζ 
isoform.75 The phosphoserine-mimetic inhibitor exhibited the capability to prohibit the binding of 
14-3-3ζ to its Raf-1 substrate and remains to be one of many promising inhibitors for 14-3-3 
proteins.75 However, as with phosphotyrosine-mimetic inhibitors; phosphoserine-mimetics are 
also plagued by poor cellular stability and membrane penetration.65 With the current strategies to 
alleviate these shortfalls being inadequate, new strategies to increase their activities are required. 
 
 
 
 
 
Figure 1.18: Reported 14-3-3 inhibitor examples.74,75 
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Chapter 2: Organophosphorus Prodrugs 
2.1 The Prodrug Concept 
A prodrug is defined as “a biologically inactive compound that can be metabolised in the body to 
produce a therapeutically active drug”.76 The concept was first brought forward by Albert in 1958 
and was later reclassified into the two key subcategories of bioprecursors and carrier-linked 
prodrugs.77 Both subsets fundamentally aim to enhance the pharmaceutical, pharmacokinetic and 
pharmacodynamic profiles of drugs via derivatisation with ‘masking’ functionalities to remedy 
deficiencies, such as poor bioavailability, site-specificity and instability.78   
Bioprecursor prodrugs are designed to be inactive in their dosed state until metabolic activation 
through phosphorylation, oxidation, reduction or hydrolysis.79 A retrometabolic strategy is used to 
design and chemically modify a therapeutically active molecule into an inactive precursor, which 
can act as a substrate for enzymes to activate and metabolise into its active state.79 
Retrospectively, it is important to design the bioprecursor to withhold specificity for one pathway, 
to avoid competitive inactivation from other pathways and biotransformations.79   
Alternatively, carrier-linked prodrugs inactivate the parent drug through covalently-linked carriers 
or ‘promoeities’ which are enzymatically or chemically labile.79 Through this key promoeity, the 
physico-chemical properties are temporarily modified until cleavage and activation. Carrier-linked 
prodrugs can be bipartite, where the carrier ‘mask’ is directly linked to the parent drug or 
tripartite, where a spacer will link the carrier and the parent drug.80 These modifications are built 
upon functional groups involved in the drug’s activity, where cleavage can liberate the active drug 
from the linker/carrier.80 Additionally, active drugs can even be synthetically linked together to 
form mutual prodrugs, in which each drug is a carrier to the other until released.80 
Designing any prodrug requires the compound to be sufficiently lipophilic, stable in blood plasma, 
metabolise correctly in cells, produce non-toxic by-products which are easily excreted and finally, 
remain therapeutically inactive in its prodrug state.81 Their overall success has led to 
approximately 10% of all medicines now being prodrugs, such as aspirin and codeine.81 Therefore, 
it was hypothesised that this powerful prodrug approach could be used for the phosphate 
bioisostere, to neutralise their anionic charges, by synthetically attaching cleavable chemical 
promoeities to each acid. As an electronically neutral phosphate prodrug, with increased 
lipophilicity, the species could now facilitate passive diffusion into the cell where predesigned 
chemical or enzymatic cleavage can deliver the active drug inside. The reintroduced capacity for 
passive diffusion may remedy their poor bioavailability, by significantly improving the membrane 
permeability and elevate cellular uptake of the phosphate drug. 
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2.2. Developing Phosphate Prodrugs 
2.2.1. Phosphate Ester Prodrug Groundwork 
The first examples of phosphorus prodrugs were phosphate/phosphonate esters, whereby both 
phosphoric acids were substituted with ester motifs to yield phosphotriesters. However, as 
phosphotriesters are unnatural biological substrates, endogenous enzymes capable of mediating 
their intracellular cleavage remained elusive.82 Consequently, promoeities for early phosphate 
prodrugs were predominantly chemically-labile and facilitated hydrolysis via nucleophilic attack. 
To this end, prototype phosphotriesters were first reported in the 1970’s as bipartite, carrier-
linked prodrugs. Those commonly investigated were bismethyl, bisethyl and bisphenyl esters.83 
Bis-alkylation of the two phosphoric acid functionalities enabled the prodrug to contain increased 
lipophilicity (logP) and also remain electronically neutral under physiological conditions.83 This 
enables passive diffusion of prodrug 21 through the cell membrane, into the cytoplasm, where 
adventitious cellular nucleophiles begin the metabolic process (Figure 2.1). Problematically, after 
the nucleophile-driven cleavage of the first alkyl promoeity ester (22), the resultant 
phosphodiester becomes more stable, limiting the second un-masking step to requiring slow 
enzymatic assistance from phosphodiesterases.82 Bipartite bisalkyl phosphotriester prodrugs 
consequently offer slow metabolic rates and overall, poor relative success thus far.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Bisalkyl phosphotriester metabolism. X = nucleophile. Nu = nucleoside. R =alkyl.82 
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2.2.2. CycloSal Phosphate Prodrugs 
To address the slow, metabolic shortfall, Meier and co-workers reported a novel cyclic-
phosphotriester bipartite prodrug approach in 1996 (Figure 2.2).84 The prodrug maintained the 
electronic neutrality required for passive diffusion but utilised a single promoeity, cyclosaligenyl, 
which cyclised around both phosphoric acids to mask their charges (25). This did not require the 
rate-limiting enzymatic cleavage for release.84 The ‘CycloSal’ design offered a sophisticated, 
tandem liberation mechanism, where under alkaline conditions, the phenolic carrier is 
preferentially cleaved, owing to its greater leaving group capacity and hence, susceptibility to 
hydrolysis.84 Metabolite 26 could then proceed via its slower hydrolytic- cleavage of the less labile 
benzylphosphate ester, to deliver the active drug (24) inside the cell, with one equivalent of 
salicylalcohol (27) by-product.84  
 
 
 
 
 
 
 
 
 
 
  
Figure 2.2: CycloSal prodrug metabolism. X = nucleophile. Nu = nucleoside. R = Alkyl, halogen.82 
Metabolic fine-tuning was also possible with CycloSal phosphate prodrugs, where ring 
substitutions could favour primary or secondary cleavage.82 Incorporation of electron-
withdrawing moieties, such as halogens, in the para-position activate the phenolic substituent 
and enhance its tendency for nucleophilic cleavage.84 Adversely, substitution of the para-position 
with electron-donating groups, such as alkyls, stabilises the phenolic position and decreases the 
rate of hydrolysis.84 Consequently, the overall rates of hydrolysis can be predetermined in the 
CycloSal prodrug design which has enabled several antiviral CycloSal designs to be trialed.85,86 
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2.2.3. BisPOM Phosphate Prodrugs 
In 1983, Farquhar and co-workers reported the first conversion of a monophosphate nucleotide 
into an electronically-neutral, tripartite phosphotriester prodrug (Figure 2.3).87,88 By installing two 
pivaloyloxymethyl (POM) masking groups, the resulting phosphotriester or “bisPOM phosphate 
prodrug” molecule (28) withheld a significantly higher lipophilicity.87,89 The electronic neutrality 
and amplified logP of the prodrug enables passive diffusion through the cell membrane, in which 
cytoplasmic carboxylate esterases cleave a carboxylate promoeity to afford reactive methoxy 
species 29.89,90 Owing to instability, metabolite 29 spontaneously dissociates the linker and 
releases phosphate 31 alongside one equivalent of formaldehyde (30).88,89 A second cycle 
completes the metabolism and active drug 24 is liberated inside the cell.88,89 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: BisPOM phosphate prodrug metabolism. Nu = nucleoside.89 
The bisPOM phosphate prodrug approach is currently the most popular phosphate prodrug 
design and has so far produced one FDA-approved prodrug (adefovir dipivoxil) for treating 
hepatitis B, amongst numerous others in clinical trials.82,89 This is supported by the good buffer 
and plasma stability of typical bisPOM phosphate prodrugs, alongside the dramatically improved 
bioavailability (up to 13-fold higher) versus the parent phosphate.90 However, there are 
drawbacks to the bisPOM prodrug, where metabolite 31 is a poorer esterase substrate, which 
manifests into a slow second cleavage cycle, with additional production of toxic formaldehyde 
and pivalic acid by-products.90,91    
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2.2.4. BisPOC Phosphate Prodrugs 
In efforts to remedy the pivalic acid by-product toxicities with pivaloyloxymethyl phosphate 
masking groups, Naesens and co-workers reported bis-isopropyloxycarbonyloxymethyl (POC) 
tripartite, phosphotriester prodrugs in 1998.92 Similarly to bisPOM phosphate prodrugs, bisPOC 
prodrugs (33) are electronically neutral and lipophilic carrier-linked prodrugs. Mechanistically, 
bisPOC prodrugs metabolise through esterase-mediated cleavage of the isopropyl promoeity, to 
generate carboxylate 34 and expel CO2 (Figure 2.4).
92 This resultantly drives a spontaneous 
degradation of the linker motif, analogously to POM metabolism, to complete the liberation of 
the first POC mask for metabolite 36, alongside one equivalent of formaldehyde.89,92 A second 
cleavage cycle fully unmasks the prodrug and releases the active drug (24) to the cell.92  
 
 
 
 
 
 
 
 
 
 
Figure 2.4: BisPOC phosphate prodrug metabolism. Nu = nucleoside.92  
With the bisPOC phosphate prodrug approach, the toxic pivalic acid by-products are removed 
whilst maintaining electronic neutrality and a high lipophilicity. Furthermore, the POC masking 
groups have also demonstrated good buffer and plasma stability, analogously to the POM 
derivatives.91 These advantages have helped facilitate the FDA-approval of a bisPOC phosphate 
triester prodrug, tenofovir disoproxil, which is used to treat HIV.89,93 Although bioavailability is 
increased from the parent drug, there are, however, still concerns of formaldehyde toxicity and 
poor chemical stability of bisPOCs, presenting challenges for its application to many drug 
molecules.82 
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2.2.5. BisSATE Phosphate Prodrugs 
To develop a carrier-linked phosphotriester prodrug without production of toxic formaldehyde by-
products, Imbach and co-workers designed S-acyl-2-thioethyl (SATE) phosphate-masking groups 
as alternatives in 1995.94 BisSATE phosphate prodrugs (38) follow a similar metabolism to POM 
and POC protecting groups, in which they are activated by cytoplasmic carboxyesterases (Figure 
2.5).95 As previously seen, the esterases catalyse the hydrolysis of the carboxylate promoeity, 
liberating pivalic acid and thiol species 39.94 A spontaneous, intramolecular nucleophilic attack of 
the thiol-linker, to the phosphate ester α-carbon, initiates thiirane 40 elimination to yield 
phosphodiester metabolite 41.94 A second, identical repeating metabolic cycle generates the 
active drug (24) inside the cell with another equivalent of pivalic acid and thiirane 40.94 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: BisSATE phosphate prodrug metabolism. Nu = nucleoside.96 
BisSATE prodrugs can successfully mask both phosphoric acids and deliver the therapeutically 
active species inside cells, via passive diffusion, without formation of toxic formaldehyde.94 
Furthermore, this approach benefits from the synthetic accessibility to formulate the bisSATE 
prodrug, due to the bioactivatable group’s chemical stability, enabling powerful phosphorus (III) 
chemistry for its construction.82 Thereby, bisSATE prodrugs have been trialed and yielded some 
success as antiviral nucleotide prodrugs but recent reports of new bis SATE prodrugs have been 
limited. Unfortunately, the unwanted pivalic acid and episulfide 40 by-product toxicities and 
premature hydrolysis may rationalise the lack of progression of the prodrug technology.91,97  
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2.2.6. BisSDTE Phosphate Prodrugs 
In 1993, an alternative thiol-based carrier-linked phosphotriester prodrug strategy was reported 
by Gosselin and co-workers that utilised enzymatic cleavage of a disulphide promoeity with 
reductases.96 By using replacement S-[(2-hydroxyethyl)sulﬁdyl]-2-thioethyl (SDTE) esters, bisSDTE 
prodrugs (43) were able to enhance phosphate lipophilicity and enable passive diffusion through 
the membrane (Scheme 2.6).96 Metabolically, DTE disulphide bonds are hydrolysed by reductases 
to yield thiol metabolites 45, akin to metabolite 39, where an episulfide 40 elimination also 
finalises the liberation of the mask.96 As seen with all the previous cases, an identical series of 
metabolic steps cleaves the second masking group and releases the active compound (24).96 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: BisSDTE phosphate prodrug metabolism. Nu = nucleoside.96 
The bisSDTE prodrug strategy draws many similarities to bisSATE phosphate prodrugs. The 
enzymatic-cleavage of the promoeity differs via utilisation of reductase enzymes to decompose 
the promoeity disulphide bond, unlike previously seen approaches, where esterases facilitate the 
activation. Although the prodrug system is capable of masking both phosphoric acid substituents, 
its application was somewhat insignificant, with only a handful of nucleotide systems being 
reported as bisSDTE phosphate prodrugs.90 Concerns of insufficient lipophilicty, and to a greater 
extent, production of potentially toxic thioethanol 44 and episulfide 40 side products, have 
ultimately hindered the progress of both bisSDTE and bisSATE phosphate prodrugs in recent 
years.90 
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2.2.7. HepDirect Phosphate Prodrugs 
Alternative prodrug designs also establish forms of delivery site-selectivity, such as with HepDirect 
prodrugs. In 2002, Erion and co-workers first reported a cyclised phosphate prodrug with cyclic 
1,3-propyl esters known as HepDirect prodrugs.98 The innovative prodrug design not only 
sufficiently masks the parent phosphoric acid charges, to enable passive diffusion through the 
membrane, but also employs efficacious liver-targeting selectivity.95 After passive HepDirect 
prodrug (47) internalisation, oxidation, by specific cytochrome P450 enzymes generates the key 
alcohol metabolite 48 (Figure 2.7).98 Sequentially, a spontaneous ring-opening and β-hydride 
elimination liberate the active drug (24) and one equivalent of a corresponding aryl vinyl ketone 
51, which metabolises further and is excreted out as non-toxic metabolites.89,95 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: HepDirect phosphate prodrug metabolism. Nu = nucleoside. B = base.98 
The liver-selectivity of the prodrug release is rationalised by the liver being the predominant site 
that expresses the specific P450 enzymes required to activate the prodrug metabolism.98 In blood 
and other non-liver tissues, the prodrugs are sufficiently stable.98 Consequently, the HepDirect 
prodrug approach has been successfully used to facilitate numerous liver-targeting nucleotide 
prodrugs into clinical trials, such as pradefovir and MB07133, for treating hepatitis.89 No reports 
of the progress of these prodrugs have been documented since the beginning of the clinical trials 
but the improved bioavailability and liver-selectivity of HepDirect prodrugs are indeed promising. 
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2.3. Developing Phosphoramidate Prodrugs 
2.3.1. Borch Phosphoramidate Prodrugs 
In addition to phosphate ester masking groups, considerations for phosphoramidate masking 
groups date back as far as the 1970s owing to the known presence of endogenous 
phosphoramidase enzymes, capable of hydrolysing P-N bonds and delivering phosphoric acids.99 
In 2000, Borch and co-workers began developing an interesting methyl aryl haloalkyl 
phosphoramidate prodrug design, entailing use of one phosphoramidate mask and one 
phosphate ester leaving group, whilst retaining electronic neutrality.100 The approach was 
modified over the years, and in 2006, it was suitably optimised to include a nitrofuryl leaving-
moiety and a chloropropyl phosphoramidate mask.101 
After passive diffusion through the lipid bilayer, the lead prodrug (66) is susceptible to enzymatic 
reduction, which facilitates the cleavage of the nitrofuryl leaving group (Figure 2.8).101 A resultant, 
spontaneous intramolecular cyclisation expels a chloride ion and yields metabolite 55.101 
Enzymatic-cleavage of the remaining aziridinium ion 55, by endogenous phosphoramidases, 
liberates the active drug (24) inside the cell.101 This elegant prodrug delivery mechanism and 
increased lipophilicity has demonstrated the ability to enhance the bioavailability of many 
phosphate drugs. However, despite its wide-range of recorded applications, the prodrug has yet 
to produce any clinical candidates. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Borch phosphoramidate prodrug metabolism. Nu = nucleoside.101 
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2.3.2. ProTide Phosphoramidate Prodrugs 
The most powerful phosphate prodrug technology to date is an aryloxy phosphoramidate triester 
approach, known as pronucleotides (ProTides). Developed by Chris McGuigan, the design evolved 
from his earlier work in 1989, which entailed modifying his dialkyl/haloalkyl phosphotriesters into 
primitive phosphoramidates in 1990.102 By substituting one alkyl promoeity with various amino 
acid esters and retaining one alkyl ester leaving group, it became apparent that L-alanine esters 
(Me, iPr, benzyl, etc.), phosphoramidate masks and labile alkyl leaving groups (iPr, tBu, etc.) were 
potent combinations.103 By changing the amino acid/ester and alkyl leaving group, the potency of 
the prodrug could be modified, which promoted further investigation. Resultantly, an optimised 
redesign in 1993, with various L-alanine esters and aryloxy groups gave rise to ProTides.104  
Once ProTide 56 diffuses into the cell, endogenous carboxypeptidases, such as carboxypeptidase 
Y, hydrolyse the L-alanine ester to yield acid 57 (Figure 2.9).105 Under physiological conditions, 
metabolite 57 is anionically charged and the carboxylate ion can facilitate an intramolecular 
cyclisation, to expel the aryl leaving group and form five-membered heterocycle 59.106 
Adventitious water can open the strained intermediate, via attack to the carbonyl or phosphoryl 
positions, to yield metabolite 60.106 Enzymatic cleavage, by phosphoramidase-type enzymes, such 
as HINT1, hydrolyses the masking P-N bond and releases the active drug (24).106 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: ProTide (L-alanine) phosphoramidate prodrug metabolism. Nu = nucleoside. R = 
Alkyl.106 
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Retention of aryloxy leaving groups and alkyl L-alanine ester groups significantly increases the 
phosphate-containing drug’s lipophilicty and ensures electronic neutrality for passive diffusion.107 
Resultantly, the elegant delivery mechanism and enhanced logP values of ProTide prodrugs 
facilitates dramatically improved bioavailabilities and cellular uptake. This is reinforced further 
with the aryloxy and alanine esters being heavily modifiable, enabling the synthesis of various 
ProTide-derivative libraries to establish optimal combinations for lipophilicty and rate of 
metabolism.107 Typically, the favoured L-alanine esters are methyl, isopropyl and benzyl esters 
which have demonstrated faster hydrolysis by carboxypeptidases.108 The aryloxy leaving group is 
somewhat more case-specific, where phenol, napthol and halogenated phenols have all produced 
promising results in various designs.108 Nonetheless, the ProTide approach is readily fine-tuned 
and capable of transporting a higher quantity of phosphate into a cell than all other prodrugs.109 
To date, there are two FDA-approved ProTides (antiviral) on the market (Figure 2.10), Sofosbuvir 
(61) and Tenofovir alefenamide (62), with over 10 more currently in clinical trials.89 Their high 
stability, under physiological and low pH conditions, as well as blood plasma, has promoted the 
ProTide design as a viable prodrug approach for both oral and intravenous treatment.89 The 
aryloxy phosphoramidate triester strategy is becoming the most popular design for delivering 
phosphate therapeutics and will overtake the bisPOM approach due to its superior capabilities. 
  
 
 
 
 
 
Figure 2.10: FDA-approved ProTide phosphoramidate prodrugs.109 
However, one of the major challenges of the ProTide and Borch phosphoramidate prodrug 
methodologies is the introduction of chirality to the phosphate prodrug molecule. The tetrahedral 
geometry of phosphates/phosphoramidates can generate a stereogenic phosphorus centre (PS 
and PR) when possessing four different substituents.
110 Consequently, racemic mixtures of both 
enantiomers (Borch) or diastereoisomers (ProTides) are generated during current synthetic 
strategies, which can display differing rates of metabolism (PS > PR) and potentially even different 
pharmacology, pharmacokinetics or toxicology; this therefore, requires chiral resolution.110   
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2.3.3. Phosphorodiamidate Prodrugs 
In efforts to address the lack of stereogenic-control in phosphoramidate prodrug synthesis, 
McGuigan and co-workers simultaneously investigated using symmetrical phosphorodiamidates in 
1991.111 By symmetrically masking both phosphoric acid substituents with various methyl ester 
amino acids (glycine, L-alanine, etc.), changes in overall activity were made evident. In 2011, 
McGuigan and co-workers developed this further, in an elaborate search for achiral phosphate 
prodrug clinical candidates.112 The new diamidate prodrug general design (63) was sufficiently 
lipophilic to passively diffuse into the cell, where carboxypeptidases, such as Cathepsin A, could 
hydrolyse the various amino acid esters to generate dianion 64 (Figure 2.11).112 An intramolecular 
cyclisation, akin to ProTide’s, would then liberate the respective amino acid and yield the strained 
heterocycle 59.112 Ring-opening hydrolysis facilitates unmasking and enables phosphoramidase-
type enzymes, such as HINT1, to finalise the metabolism and deliver the active drug (24).112 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Phosphorodiamidate (L-alanine) prodrug metabolism. Nu = nucleoside. R = Alkyl.112  
In the largest study of its kind, a number of achiral phosphorodiamidate prodrugs displayed good 
antiviral activities but were all less superior to the ProTide derivatives.112 Consequently, the 
ProTide prodrug design was still favoured over phosphorodiamidate approaches and the general 
focus has now shifted to alternatively developing diastereoselective ProTide synthetic strategies, 
such as chiral auxiliary groups, diastereoselective chiral catalysts and improved chiral-HPLC 
methodologies.113  
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2.4. Developing Phosphonate Prodrugs 
The increased bioavailabilities, provided from using phosphate prodrugs, still fail to remedy the 
additional poor stability issues of phosphate groups, owing to their hydrolytic susceptibility. 
Indeed, endogenous phosphatase enzymes actively dephosphorylate phosphate-retaining 
molecules and phosphate prodrugs alike, in which the drug molecule loses significant biological 
activity.114 To combat this shortfall, numerous groups have tried to identify phosphate 
bioisosteres that can mimic the phosphate properties but also improve resistance to 
phosphatase-mediated hydrolysis. 
The high susceptibility of phosphates to suffer phosphatase-mediated hydrolysis derives from the 
lability of the P-O bridging bond.114 In efforts to address the poor stability of this critical bond, 
under biological environments, alternative linkers have been considered, such as a 
phosphoramidate P-N bond, phosphonate P-C bond and thiophosphate P-S bond.115 Interestingly, 
the bond dissociation energies (kJ/mol) for the linkers are as follows: P-N (617), P-O (597), P-C 
(518) and P-S (346).116 This data is indicative that the stronger phosphoramidate P-N linkers would 
be energetically superior to phosphates. However, the copious amounts of endogenous enzymes 
that catalyse the hydrolysis of these bonds (phosphoramidases) also facilitate high instabilities 
under physiological conditions.115  
Despite phosphonates demonstrating weaker dissociation bond energies than native phosphates, 
their significantly enhanced resistance to enzymatic cleavage overcomes this slight deficiency and 
places phosphonates as theoretically superior, phosphatase-resistant phosphate surrogates. 
Indeed, considerable research has been invested with phosphonate-derived phosphate mimetics, 
which can also incorporate all the numerous phosphate prodrug systems to increase their 
bioavailabilities. However, one significant shortfall arises with phosphonate derivatisation, which 
is possession of notably higher pka values that introduce several concerning implications.115,117 
Higher pka values of phosphonic acid hydroxy groups (first = 2.4, second = 7.5) to the hydroxy 
groups of phosphoric acid (first = 1.5, second = 6.3) results in phosphonates only achieving mono-
deprotonation under physiological conditions and remaining as a monoanion.115 This has 
significant consequences for drug solubility, target binding-affinities/recognition and lessens 
interaction with enzymatic active sites.117 To rectify this, in 1986 the Blackburn team reported 
halogenating the methylene phosphonate linker to reduce its electron density and hence, lower 
the pka to a value similar to the native phosphate.118 Gratifyingly, introduction of two fluorines 
(pka = 5.4) or one fluorine (pka = 6.5) to the bridge restores the ability to bis-deprotonate and 
become dianionic.118 The (α,α-difluoroalkyl)phosphonate approach is now being applied for 
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derivatising numerous phosphate prodrugs, to complement their improved bioavailability, with 
this enhanced intracellular stability. 
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Chapter 3: Research Aims and Objectives 
3.1. Research Hypothesis 
As discussed in Chapter 1, the field of employing phosphopeptide-mimetics (tyrosine and serine) 
to inhibit overexpressed phospho-regulatory proteins in cancerous pathways has matured into a 
state, where numerous potent and selective inhibitors have been developed. The more promising 
protein-protein inhibitors very frequently have a phosphate group, key to their capacity to mimic 
essential phosphotyrosine or phosphoserine recognition sites on their respective therapeutic 
targets. Retention of these phosphate groups, highlighted in Chapter 2, incites a number of 
limitations towards successful treatment with such agents.119 The established poor cellular uptake 
and susceptibility to phosphatase-mediated hydrolysis have hindered the development of these 
promising inhibitors and remains to be the next challenge in the hunt for their clinical 
candidates.120 
There have been attempts to introduce a phosphate prodrug or an (α,α-
difluoroalkyl)phosphonate approach in the literature but these, however, have not produced 
sufficient improvements.121 The prodrug choice for phosphotyrosine-mimetic STAT SH2 domain 
inhibitors is exclusively seen as bisPOM prodrugs, and for phosphoserine-mimetic 14-3-3 
inhibitors, the Borch methyl aryl haloalkyl phosphoramidate design.122,123 Whilst both prodrug 
designs facilitate improved bioavailability, the incorporation and liberation capabilities are too 
weak to mediate the overall prodrug into a clinical candidate. What both fields desperately 
require is a far more powerful prodrug technology. 
Fortunately, such a powerful phosphate prodrug design exists in the world of antiviral and 
anticancer nucleotide therapeutics, the aryloxy phosphoramidate, ProTide strategy. In head-to-
head studies, the ProTide design was the superior strategy and facilitates more of the active 
phosphate drug into the cell than any other phosphate prodrug approach.90 Therefore, the novel 
application of the ProTide technology to phosphotyrosine-mimetic STAT and for phosphoserine-
mimetic 14-3-3 inhibitors may reproduce the effects observed with nucleotides and also produce 
considerably more potent phosphate prodrugs.  
It is hypothesised that the ProTide prodrug derivatisation of both anticancer inhibitor classes will 
significantly elevate their lipophilicities and logP values, compared to the already trialed prodrug 
approaches. The enhanced lipophilicty could facilitate more of the prodrug into the cell, by 
withholding more favourable properties for passive diffusion. Consequently, this increased 
cellular uptake and bioavailability of the STAT SH2 domain or 14-3-3 inhibitor, ProTide prodrugs 
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may translate into increased biological activities. This viewpoint unequivocally warrants 
investigation into the novel application of the technology to these anticancer agents. 
3.2. Research Objectives 
With the proposed research hypothesis being how the novel application of the ProTide prodrug 
technology to phosphopeptide-mimetic inhibitors could significantly increase their biological 
activity, a proof-of-concept study was required to first validate the theory. An ideal point to 
initiate the investigation was by using an already established phosphopeptide-mimetic inhibitor 
and functionalising it as a novel ProTide prodrug for direct comparison. Owing to the STAT3 
isoform SH2 domain being the best recognised and retaining the largest library of documented 
phosphotyrosine-mimetic inhibitors, it presented itself as a good candidate to explore first in 
order to confirm the research hypothesis as depicted in Figure 3.1.35 Akin to the ‘ProTide’ 
abbreviation for pronucleotide aryloxy phosphoramidate triester prodrugs, this class of novel 
phosphopeptide-mimetic prodrugs will be abbreviated to ‘ProTics’. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Research hypothesis for anti-STAT3 ProTic internalisation, metabolism and activity.  
Once a suitable STAT3 inhibitor (peptidomimetic or nonpeptidic) had been ascertained, its 
respective aryloxy phosphoramidate ProTic derivative library could be synthesised. Slight variation 
in the L-alanine ester group has previously been reported to facilitate significant changes to 
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overall potency, which would therefore suggest creating a small library of these prodrugs, with 
different esters, would be advantageous. With a small library of the STAT3 inhibitor prodrug 
analogues in hand, the original unmasked STAT3 phosphate inhibitor must also be synthesised as 
a positive control. The collection of inhibitors could then be evaluated for their activities, in 
constitutively active STAT3 cancer cell lines, to determine if the prodrug approach is more potent 
and which alanine ester is superior. This would be achieved by directly comparing each 
compound’s ability to supress hyperactivated STAT3 transcription genes, such as Survivin and 
Cyclin-D1, by Western Blot analysis. If the ProTic hypothesis was deemed correct, the lead 
phosphoramidate prodrug’s stability, in human serum, would also need to be investigated to 
distinguish whether further modifications to the prodrug design were needed to ensure it was 
soluble and stable under physiological conditions.    
The second phase of the research would entail optimising the prodrug system further, based on 
any complications arising from the proof-of-concept phase. If poor solubility is observed, the 
lipophilicty could be too high and substitution of the aryloxy group to a more polar derivative 
might be necessary going forward. Poor overall activities may suggest the metabolism of the 
ProTic prodrug to the active drug is too slow or facing difficulties, owing to factors such as steric 
bulkiness or electronics. Ultimately, the ProTide design has only been robustly evaluated on 
nucleotide systems and it is challenging to predict how its first application to phosphopeptide-
mimetic systems might fare. It is conceivable that a radical redesign of the delivery system might 
be required to cater to the differing chemical environments of peptidomimetics.  
The validation of the hypothesis and optimisations to the prodrug delivery system would then 
enable some freedom to begin developing a novel STAT3 inhibitor and functionalise it as a ProTic 
prodrug series. There are many promising anti-STAT3 pharmacophores recorded in the literature 
and the introduction of a phosphate bioisostere into many of these could certainly improve the 
accommodation of the drug molecule into the phosphotyrosine-selective pY sub-pocket of the 
SH2 domain. ProTic derivatisation would then nullify the consequential poor cellular uptake of 
this modification and formulate the groundwork for a novel anti-STAT3 ProTic clinical candidate. 
The final stages of this research will be developing more proof-of-concept phosphopeptide-
mimetic inhibitor ProTic prodrugs for other overexpressed STAT isoforms, such as STAT5, or new 
phospho-regulatory protein targets, such as hyperactivated 14-3-3 proteins. Small libraries of 
these will be synthesised, alongside the original parent phosphate drug, and directly compared in 
Western Blot analysis. Lead candidates will also have their physiological stabilities evaluated to 
investigate how other ProTic systems tolerate environments, such as human serum, over time.  
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Chapter 4: Design, Synthesis and Evaluation of ISS-610-Me 
Phosphoramidate Prodrugs 
4.1. Aims and Objectives 
In this Chapter, the use of the aryloxy triester phosphoramidate prodrug approach in improving 
the drug-like properties of phosphoserine-containing molecules was validated. Focusing on the 
STAT3 isoform was believed to be the strategic option, as this contains the most numerous and 
detailed accounts of successful STAT SH2 domain inhibition.53 To this end, one of the pioneering 
STAT3 SH2 domain-inhibiting peptidomimetics, ISS-610 (6), was believed to be an excellent test 
system, through its accessible phosphate motif, ease of synthesis and well established anti-STAT3 
mode of action (Figure 4.1).45  
 
 
 
 
 
 
Figure 4.1: ISS-610 (6) and the first generation ISS-610 ProTics. R = Me (66), iPr (67) or Bn (68).  
As discussed in Chapter 1, ISS-610 is a STAT3 isoform-selective, SH2 domain dimerisation inhibitor 
with an IC50 of 42 µM.
45 The retention of a phosphotyrosine residue enables its modification to a 
ProTic prodrug, which can be further derivatised as a series (66-68). The classical design used on 
both FDA-approved ProTide aryloxy phosphoramidate prodrugs, of one L-alanine 
phosphoramidate mask and one phenyl aryloxy leaving group, was first considered.89,105 Three 
different ester derivatives would further be required to construct a small library of three ProTic 
analogues to evaluate the most potent design. The initial L-alanine esters were chosen to be the 
typically most potent, a methyl (66), an isopropyl (67) and a benzyl ester (68).108  
Unfortunately, this prodrug set-up (66-68) works perfectly for nucleotides but theoretically, 
presents challenges when applied to phosphotyrosine-mimetic drug molecules. There are two 
significant problems associated with the current design that could negatively affect the ability of 
the ProTic prodrug to correctly metabolise and liberate the desired compound inside the cell. 
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The hypothetical cellular entry of the current ISS-610 ProTic prodrug should be sufficiently 
capable to endure carboxypeptidase-mediated hydrolysis of the various L-alanine esters to yield 
anion 69 (Figure 4.2). Unlike nucleotide ProTide prodrugs at this metabolic stage, the ISS-610 
phosphotyrosine-mimetic contains two aryloxy leaving groups on the phosphate which includes 
the intended phenolic leaving group but also, the tyrosine-retaining core structure of the drug. It 
is reasonable to assume that both phenolic substituents are susceptible to expulsion, to drive the 
cyclisation metabolic step and yield the formation of two possible metabolic products.  
Problematically, these resultant competing intramolecular cyclisations (A and B) can either 
generate the correct metabolite, heterocycle 70, by correctly issuing liberation of phenol, or a 
side product dephosphorylated phenol 72, through expulsion of the tyrosine phenol. Without a 
phosphate motif, phenol 72 would lose significant hydrogen bonding affinity for the STAT3 SH2 
domain pY pocket and substantial biological activity would be lost. Ultimately, lack of favoured 
leaving group capacity for the phenol is likely to induce this cellular degradation of ISS-610 and 
must be resolved by redesigning the prodrug delivery components. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: A) Desired intramolecular cyclisation metabolite (70) formation. B) Theoretical 
intramolecular cyclisation side-product metabolite (72) formation.  
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A second potential problem arises from ISS-610 carrying a free leucine carboxylic acid which could 
act competitively with the L-alanine acid in the initial cyclisation metabolic step (Figure 4.3). If the 
leucine carboxylic acid possessed an equal or greater nucleophilic capacity to L-alanine’s it could 
preferentially cyclise over L-alanine and formulate cyclic product 73. Formation of this side 
product may result in the prohibition of further metabolism or possibly facilitate a ring-opening 
hydrolysis to expel the tyrosine aryl. This would enable a phosphate-migration to the leucine 
carboxylic acid, where the resultant unstable species would be hydrolysed to metabolite 72. 
 
 
 
 
 
 
Figure 4.3: C) Theoretical intramolecular cyclisation metabolite (73) formation.  
To redesign the prodrug structure to avoid these outcomes, two key modifications were, 
therefore, proposed. The leucine carboxylic acid would be methylated to cease its theoretical 
competitive participation in the key metabolic cyclisation step. It is reasoned that this acid does 
not engage with either the key pY or pY-1 sub pockets and should not drastically affect activity via 
its methylation.49 Furthermore, substitution of the phenol leaving group, for a napthol, would 
significantly increase the prodrug aryl leaving group capacity and introduce preference for its 
elimination over the tyrosine. Resultantly, three new ProTic prodrugs were envisioned (74-76) for 
the concept study (Figure 4.4). 
 
 
 
 
 
 
 
Figure 4.4: Lead ISS-610-Me ProTic design. R = Me (74), iPr (75) or Bn (76).  
Design, Synthesis and Evaluation of ISS-610-Me Phosphoramidate Prodrugs                       Chapter 4 
  
51 
 
4.2. ISS-610-Me ProTic Retrosynthetic Analysis 
To synthesise the three desired ISS-610-Me ProTic analogues, a convergent synthesis of three key 
fragments was required (Scheme 4.1). The synthesis was started with commercially available Boc-
L-tyrosine 77, where introduction of the methylated L-leucine ester motif, via amidation with the 
carboxylic acid substituent, would yield amide 78. Deprotection of the Boc functionality would 
then be achieved, using standard acidic conditions, to form the free amine 79 required for 
incorporating the second fragment. This second, 4-cyanobenzoic acid fragment can be purchased 
commercially, directly chlorinated and then chemoselectivly introduced in an acid chloride-
mediated amidation to generate the key dipeptide 80. 
To incorporate the final fragment, each ProTic will require one of three unique phosphoramidate 
motifs: methyl, isopropyl or benzyl L-alanine esters. These will be synthesised according to the 
conventional McGuigan ProTide synthesis, to yield three different phosphorochloridates with no 
diastereoselectivity.89 Phosphorylation of each of these to the phenol group of compound 80, 
under basic conditions, will furnish each of the three desired ProTic prodrugs in a mixture of 
diastereoisomers (74-76). The lack of diastereoisomeric control is consistently seen in literature 
and would not be problematic at this stage, as this was only a test system.105 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.1: ISS-610-Me ProTic 74-76 retrosynthetic analysis. R = Me (74), iPr (75) or Bn (76).  
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4.3. Synthesis of ISS-610-Me ProTic Prodrugs 
The synthesis towards the first fragment was initialised with Boc-tyrosine 77 (Scheme 4.2). Using 
literature conditions, Boc-L-tyrosine 77 can reportedly attain successful activated-amidification 
with L-leucine methyl ester hydrochloride (81) via treatment with N,N'-dicyclohexylcarbodiimide 
(DCC) and N-hydroxybenzotriazole (HOBt).124,125 In our hands, the reaction proceeded to produce 
peptide 78 with an unprecedentedly low yield of 25%. Considering the vast amounts of material 
required to complete the numerous steps for this library, efforts were redirected to find a more 
scalable approach to synthesise the peptide. 
 
 
 
 
 
Scheme 4.2: Synthesis of peptide 78 and attempted synthesis of succinimide 82. a) (78, R = L-
leucine) L-leucine hydrochloride (81), HOBt, DCC, Et3N, DCM, 0 °C, 12 hours, 25%. b) (82, R = 
succinimide) N-hydroxysuccinimide, DCC, 1,4-dioxane, 4 hours, 0%. 
A rationale for the poor yield of the coupling reaction was centred on the potentially poorly-
activated tyrosine carboxylic acid, where promoting it as a more reactive succinimide, derivative 
82, was then trialed to address this lack of activator lability (Scheme 4.2).126 Another DCC-
catalysed reaction, of Boc-L-tyrosine 77 with N-hydroxysuccinimide, was attempted to synthesise 
succinimide 82 but was unfortunately unsuccessful and no product could be identified by NMR.126 
Being unable to produce the more reactive carboxylic acid derivative, a more powerful coupling 
activating reagent, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP), that is used in the literature to yield peptide 78 in superior yield was considered.127 
Mechanistically, after deprotonation with a base such as triethylamine, carboxylic acid 84 is 
sufficiently nucleophilic to attack the PyBOP pyrrolidinophosphonium centre, establishing the 
formation of the reactive intermediate 86 and eliminating anionic HOBt (Scheme 4.3).128 With the 
incorporation of the good phosphonium leaving group, intramolecular attack by free HOBt anions, 
at the reactive carbonyl carbon, induces nucleophilic exchange to generate the final key 
intermediate, ester 88.128 A subsequent, nucleophilic attack at the carbonyl centre, with the 
reactive L-leucine primary amine lone pair, finalises the coupling to form peptide 78.128 
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Scheme 4.3: PyBOP-mediated peptide 78 coupling mechanism.128 
There are, however, drawbacks to using phosphonium (or uronium) coupling agents such as 
PyBOP that derive from the potential racemisation of intermediates 86 or 88 and loss of 
stereochemical conformation.129 Unfortunately, this risk could prove problematic as the L-tyrosine 
stereogenic centre is required for activity and the synthesis must progress with its absolute 
retention.129  
Nonetheless, when applied to our system, the PyBOP-mediated amidation generated peptide 78 
in an excellent yield of 94% (Scheme 4.4). Alongside PyBOP’s ability to promote the peptide 
reaction, evidence from the 1H NMR spectrum determined that racemisation did not occur. This 
was made evident by the splitting pattern of the tyrosine benzylic methylene protons remaining 
as a doublet (equivalent) and not being rendered as non-equivalent doublet of doublets, 
displayed by known DL-tyrosine racemates.130 Furthermore, all analytical data aligned perfectly 
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with the previous synthesis and literature values.131 This resistance to racemisation, reported by 
Goodman and co-workers, is thought to be due to the possession of the electron-withdrawing Boc 
substituent which disfavours the formation of the oxazolone intermediate responsible for the 
racemisation side-reaction.129 
 
 
 
 
 
 
 
 
Scheme 4.4: PyBOP-mediated synthesis of peptide 78 and TFA-acidified synthesis of amine 79. 
Successful introduction of the L-leucine motif then enabled the Boc-protecting group to be 
acidified to reveal the free amine for the next installation. Using excess TFA, in DCM, the Boc-
protecting group was removed and the desired amine 79, as a TFA salt, was produced in 
quantitative yield (Scheme 4.4). The resultant amine-TFA salt was then basified, to pH 8, with 10% 
sodium hydroxide solution to the free amine and stored awaiting the synthesis of the second, 4-
cyanobenzoic acid fragment, before their resultant amidation to complete the core structure (80). 
Introduction of the next fragment began with the refluxed chlorination of 4-cyanobenzoic acid 
(90) with excess thionyl chloride and catalytic DMF (Scheme 4.5). The chlorination reaction 
proceeded to produce the reactive intermediate, acyl chloride 91, in quantitative yield. With this 
chloridate in hand, it could be directly coupled with the previously synthesised free amine 79. The 
reaction proceeded at 0 °C and through dropwise addition of triethylamine, to give the dipeptide 
(80) in a yield of 42%. The coupling proceeded with disappointing chemoselectivity for amidation, 
over the additionally possible esterification reaction double-addition product (92). Although 
reasonable quantities of this side product (92) were identified, its purification was challenging and 
full characterisation was not possible. However, the 1H NMR spectrum clearly demonstrated 
doubled integrations for 4-cyanobenzoic-resemblant protons, suggesting that this was produced 
alongside the desired product (80) rationalising the observed poor yield. 
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Scheme 4.5: Synthesis of acid chloride 91 and amide-coupling to yield dipeptide 80 and suspected 
side product 92. 
The successful synthetic route to formulate core structure 80 enabled subsequent scale-up 
reactions to facilitate an appropriate amount of material to begin phosphorylating into the three 
final ProTic prodrugs. To this end, three analogous phosphorochloridates, with the three different 
L-alanine esters, were required for the final phosphorylation reaction. The phosphorochloridates 
were synthesised from phosphoryl chloride 93 using standard procedures (Scheme 4.6).108 
From a solution of phosphoryl chloride and napthol in anhydrous diethyl ether, cooling the 
solution to -78 °C and introducing triethylamine dropwise facilitated phosphorodichloridate 94 in 
a very high 98% yield.108 This temperature was employed to minimise the exothermic response 
which could incite double-addition.112 The extremely reactive product (94) was then taken 
forward as a crude mixture owing to its excessive reactivity and high susceptibility to hydrolytic-
degradation during purification.  
Crude phosphorodichloridate 94 was then investigated for its suitability to yield one ProTic 
prodrug (methyl ester) on a trial run. Dropwise treatment of triethylamine to a solution of 
dichloridate 94 and L-alanine methyl ester hydrochloride, at -78 °C, produced the desired mono-
phosphorochloridate 95 in a good yield of 70%. From the 31P NMR spectrum it was evident that an 
approximately equal 1:1 mixture of two diastereoisomers (RP and SP) was formed, each denoted 
by a singlet peak at 8.29 and 7.93 ppm. This lack of diastereoisomeric control was expected, 
owing to both alanine nucleophilic attack trajectories being equally as plausible in the SN2 
substitution. 
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Scheme 4.6: Synthesis of dichloride 94 crude and L-alanine ester phosphorochloridates (95 R = Me 
(70%), 96 R = iPr (72%) and 97 R = Bn (97%)). Synthesis of target ISS-610-Me ProTic prodrugs (74 R 
= Me (70%), 75 R = iPr (91%) and 76 R = Bn (93%)). 
To synthesise ProTic 74, dipeptide 80 and triethylamine were added to a solution of 
phosphorochloridate 95 in anhydrous DCM. The reaction generated the desired ISS-610-Me 
ProTic methyl ester diastereoisomers (74) in an excellent yield of 70% (Scheme 4.6). Notably, this 
high yield is atypical of these phosphorylation reactions as they rarely exceed 30%.105 It is 
reasoned that the napthylic leaving group on the phosphorochloridate could perhaps enhance its 
electrophilic capacity and susceptibility to attack. 
The high-yielding synthesis of the first methyl ester ProTic did not require optimisation and was 
directly applied for the remaining two prodrugs (Scheme 4.6). Resultantly, dichloridate 94 was 
then scaled-up and used to analogously generate the two alternative phosphorochloridate L-
alanine ester derivatives, isopropyl ester (96) and benzyl ester (97), in parallel synthesis. Both 
phosphorochloridates (96 and 99) followed the same conditions with their respective L-alanine 
ester precursors and were produced in similar yields of 72% and 97%, respectively.  
In an identical manner to the methyl Prodrug phosphorylation reaction, each 
phosphorochloridate was treated with dipeptide 80 and triethylamine, in anhydrous DCM, for 24 
hours. Both ISS-610-Me ProTic diastereoisomeric prodrugs, isopropyl ester 75 and benzyl ester 76, 
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were synthesised in similarly high yields of 91% and 93%, respectively. For these sterically larger L-
alanine ester analogues, the diastereoisomeric ratio was no longer exactly 1:1, which is indicative 
that the phosphorylation reaction can proceed with some degree of diastereoisomeric control 
that is evidently derived from this added L-alanine ester steric hindrance.  
The novel ISS-610-Me ProTics, 74-76, were thus each synthesised in seven steps, as a 
diastereoisomer mixture. Moreover, the overall yields for the total ProTic prodrug synthesis were 
values of 19% (74), 25% (75) and 34% (76). 
4.4. Synthesis of ISS-610-Me  
Successful attainment of the prodrug library now meant the two positive controls, unmasked ISS-
610 and unmasked ISS-610-Me, were required before biological evaluation could commence. The 
approach to synthesise the novel unmasked ISS-610-Me (98) control was theorised to be 
achievable by directly phosphorylating dipeptide 80 with phosphoryl chloride, followed by an in 
situ hydrolysis with water (Scheme 4.7). This is the typical literature procedure for the 
introduction of phosphoric acid substituents to alcohols and often proceeds with high yields.132  
 
 
 
 
 
 
 
 
 
Scheme 4.7: Attempted synthesis of ISS-610-Me (98) by hydrolysis (Route 1) and hydrogenation 
(Route 2). Base = DBU, tBuMgCl or NaH. 
In our hands, no clear sign of reaction completion was observed and the highly polar product was 
suspected to be trapped within a seemingly inseparable crude mixture after hydrolysis. The 
isolation was made harder without any form of reverse-phase chromatography being available. 
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Attempts to crystallise the product out of the reaction mixture and also, extracting it from an 
acidified aqueous layer were both unsuccessful, meaning a new synthetic approach was required. 
To avoid the reverse-phase purification of the phosphoric acid crude mixture, a second 
hypothesised route using dibenzyl phosphate masking groups, to enable normal-phase 
chromatography, followed by a global un-masking hydrogenation, was trialed (Scheme 4.7). 
Synthesis began with the routine chlorination of dibenzyl phosphate 99, with oxalyl chloride and 
catalytic DMF, to produce crude chloridate intermediate 100 that was confirmed by TLC.133 
Unfortunately, the couplings of chloridate 100 with dipeptide 80, using DBU, NaH or tBuMgCl as 
bases, were all unsuccessful. 
This reactivity issue appears to be a field-wide problem, as many phenolic tyrosine derivatives 
suffer from poor reactivity at the hydroxyl position, particularity towards pentavalent phosphorus 
species. To address the reactivity issue of phosphates, they are commonly substituted for 
phosphites (trivalent), which have demonstrating successful phosphorylations of seemingly inert 
alcohols in the literature.134 Phosphochloridites are generally regarded to possess far greater 
reactivity than phosphochloridates owing to less steric hindrance and better accommodation of 
nucleophiles.135 
This hypothesis was directly evaluated by using phenol as a test system (Scheme 4.8). As 
illustrated, di-addition of benzyl alcohol to PCl3 under basic conditions would generate the 
extremely reactive di-substituted phosphorochloridite 101.136 Coupling of the chloridite with the 
desired phenol has been recorded to yield successful phosphorylation.136 As this product contains 
phosphorus in a P(III) state, treatment with an oxidising agent such as mCPBA, could later furnish 
the desired phosphate. Hydrogenation of the phosphate with a Pd/C catalyst and molecular 
hydrogen would remove the benzyl protecting groups and present the phosphoric acid as desired. 
Using triethylamine for the initial reaction proved unsuccessful, where only benzyl alcohol was 
observed by TLC analysis.137 Substitution for NMI demonstrated a new lipophilic spot and 
complete conversion of benzyl alcohol on the TLC plate, indicative of chloridate formation. Crude 
101 was thus reacted with phenol and NMI, but the desired product 102 was not observed.138 It 
was believed steric hindrance from the large benzyl rings may have prohibited the 
phosphorylation.  
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Scheme 4.8: Attempted synthesis of dibenzyl phosphite 103. a) PCl3, Et3N, DCM, 12 hours, 0%. b) 
PCl3, NMI, DCM, 12 hours, >99% 
As the principal objective here was to generate a protected phosphate and hydrogenate it to 
release the phosphoric acid, an abundance of other protecting groups could also be used in place 
of the problematic benzyls. In parallel to benzyls, the sterically smaller allyl protecting group can 
be added and removed in an identical fashion, promoting their candidacy for this reaction. Allyl 
alcohol 104 was thus substituted for the benzyl alcohol and the reaction was replicated, but 
unfortunately, the same outcome was observed with no evidence of allyl alcohol consumption or 
product 105 formation being accounted for by NMR experiments (Scheme 4.9).139  
As these reactions were all literature procedures, it was likely that this failure was induced by the 
reagent’s hydrolytic or oxidative degradation. To evaluate this, a test synthesis of the well-known 
tris-allyl phosphite product 106 was trialed.140 In our hands, this reaction would still not produce 
the desired product, despite being routinely reported in literature.140 Evidently, the excessive 
reactivity of phosphorochloridite reagents was problematic and a new synthetic strategy was 
required to overcome this problem. 
 
 
 
 
 
Scheme 4.9: Attempted synthesis of diallyl phosphite 105 and triallyl phosphite 106. a) (105, R = 
Cl) PCl3, Et3N, DCM, 12 hours. b) (106, R =allyl ether) PCl3, Et3N, DCM, 12 hours. 
Following the failure of the previous attempts to synthesise phosphoric acid 98 from the 
furnished peptide core, it was postulated that starting the synthesis with the phosphate already 
attached would eliminate the troublesome phosphorylation reaction. Therefore, Fmoc-tyrosine 
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phosphate 107 (Scheme 4.10) was elected as a starting material that would allow a series of 
amide coupling and Fmoc-deprotection reactions to furnish the phosphoric acid.  
Commercially available, Fmoc-tyrosine phosphate 107 was treated with L-leucine methyl ester 
and PyBOP in anhydrous DMF to ensure complete solubilisation of exceedingly polar reagents. A 
non-nucleophilic base, triethylamine, was selected to deprotonate the carboxylic acid moiety and 
promote nucleophilic attack to attain peptide 108. In practice, TLC analysis indicated the 
consumption of starting material 107 after four hours at room temperature but several new spots 
appeared on the TLC plate. After work-up and purification, with flash column chromatography, 
the product was not isolated.  
 
 
 
 
 
 
Scheme 4.10: Attempted synthesis of phosphopeptide 108. a) L-leucine hydrochloride, PyBOP, 
Et3N, DMF. b) L-leucine hydrochloride, HATU, Et3N, DMF. 
It was later revealed that PyBOP undesirably activates the phosphoric acid groups, such as 109, to 
participate in  esterification reactions, working in competition with the desired amidification 
reaction of the carboxylic acid motif (Scheme 4.11).141,142 Consequently, there is a literature 
consensus that phosphate mono/di-esters 110 are far more favoured in formation (near 
quantitative yield) over the desired amidation 111, rationalising the unsuccessful coupling 
attempt thus far with PyBOP.127  
A known solution to address this lack of apparent chemoselectivity is to substitute the PyBOP 
coupling-activating agent for 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxid hexafluorophosphate (HATU), which has previously been documented to complete the 
coupling.141 Activation of the carboxylic acid is reported to be more favoured, over the phosphoric 
acid, when using the uronium reagent HATU which might resolve the selectivity issue.127 
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Scheme 4.11: PyBOP-mediated esterification versus amidation mechanism. R = alkyl chain.127 
Following literature precedent, PyBOP was exchanged for HATU and the reaction was repeated 
(Scheme 4.11).127 N,N-Diisopropylethylamine (DIPEA) was used as the base, to allow for complete 
replication of literature accounts. Unfortunately, the desired product could not be identified and 
only starting material was observed by TLC. It was suggested that using solid-phase peptide 
synthesis was required for this class of coupling reaction to proceed, but without access to a 
specialised peptide-synthesiser, this was not a plausible option at the time. 
Evidently, phosphorus (III) and phosphate-containing starting material strategies were not 
providing the required product. Fortunately, an additional strategy was uncovered in the 
literature, whereby employment of  N,N,N',N'-tetramethylphosphorodiamidic chloride (112), with 
a base, can supposedly phosphorylate tyrosine phenols in high yield (Scheme 4.12).143 Moreover, 
the protective tetramethyldiamidate groups can be easily removed, under weak acidic conditions, 
to afford the unmasked phosphoric acid in reported quantitative yields.143 This strategy was then 
trialed on the phenol functionality of dipeptide 80, in hopes to replicate this. 
 
 
 
 
 
Scheme 4.12: Synthesis of phosphorodiamidate 113. a) 112, Et3N, THF, 0%. b) 112, DMAP, DBU, 
THF, 50%. 
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The reaction displayed no evidence of starting material consumption by TLC and in NMR studies, 
with no new phosphorus environment in the crude product identified. A further literature search 
identified that the Gunning group developed a next generation derivative of ISS-610, which 
included this phosphorylation strategy.144 Interestingly, the group stated the requirement of 
catalytic DMAP and use of a stronger base, such as DBU.144 These results then encouraged the 
same conditions to be trialed on dipeptide 80 (Scheme 4.12). 
The phosphorylation reaction, undertaken with the new conditions, afforded the sought product 
in moderate yield, which was evidently due to the catalytic role of DMAP.145 By substituting with 
the phosphoryl chloride, DMAP generates a reactive intermediate (115) with the phosphate that 
now behaves as an enhanced electrophile, owing to its increased leaving group capacity (Scheme 
4.13). Increased electrophilic properties of phosphoramidate 115 therefore, promote the 
phosphorylation reaction with the poorly nucleophilic phenol. 
 
 
 
 
 
Scheme 4.13: DMAP-catalysed synthesise of phosphorodiamidate 113 mechanism. R = 80.145 
With the phosphorylation complete and diamidate 113 in hand, the final step to yield ISS-610-Me 
would be deprotection of the masking groups, to provide the unmasked final compound 98 
(Scheme 4.14). Using a TFA/water system, complete consumption of the starting material was 
observed and ISS-610-Me 98 was synthesised in 76% yield, with an overall yield of 15% over six 
steps.144 
 
 
 
 
 
 
Scheme 4.13: Synthesis of ISS-610-Me phosphoric acid 98. 
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4.5. ISS-610-Me Series Compound Library  
Having successfully synthesised the small ProTic library (74-76) and the unmasked ISS-610-Me 
derivative 98, the native ISS-610 parent positive control was commercially available and, thus, 
was purchased to complete the set of five compounds required for biological evaluation and 
confirmation of the research hypothesis (Figure 4.2). 
 
 
 
 
 
 
Figure 4.2: Compound library prior to evaluation using Molinspiration and HPLC for purity. 
From the tabulated data, derivatisation of phosphoric acids, ISS-610 and ISS-610-Me, to aryloxy 
phosphoramidate triester (ProTic) prodrugs substantially increases the clogP value of the parent 
compounds. The increased lipophilicity of these compounds will enhance their passive diffusion 
across membranes, which would translate into improved pharmacological activity. However, the 
clogP values for the isopropyl (75) and benzyl (76) derivatives were exceedingly high and this may 
result in reduced water-solubility in the ever-present drug trade-off between lipophilicty and 
aqueous solubility. 
The final evaluation, before biological testing, is focused on the compound’s purity. For 
generation of results with high confidence, the compound’s purity must succeed 95%. To evaluate 
our library, reverse-phase analytical HPLC (UV) was used for each final compound and the total 
area % of each species’ peak was measured for an overall % purity. All ProTic prodrugs were 
greater than 95% pure, apart from the ISS-610-Me compound, which despite numerous 
attempted purification strategies, was only 87% pure. 
Compound R1 R2 R3 Overall Yield cLogP M.W. Purity 
ISS-610 (6) H OH OH (Purchased) -0.01 503.45 >95% 
ISS-610-Me 98 Me OH OH 15% (6 steps) 2.06 517.47 87% 
ProTic 74 Me L-Al-Me Napthol 19% (7 steps) 5.46 728.74 99% 
ProTic 75 Me L-Al-iPr Napthol 25% (7 steps) 6.20 756.79 99% 
ProTic 76 Me L-Al-Bn Napthol 34% (7 steps) 7.05 804.84 97% 
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A deeper inspection of the analytical HPLC UV ISS-610-Me data demonstrated that there was an 
additional species at 12% total area. Attempts to identify the impurity were challenging as NMR 
spectra data, such as the 31P spectrum (Figure 4.3), show one major phosphate environment and 
only solvent-derived impurities within the 1H NMR spectrum. Consequently, the impurity must 
retain a strong resemblance to the ISS-610-Me (98) and for its identification, and subsequent 
strategy for removal, other analytical experiments must be used instead. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: 31P NMR (202 MHz, CD3OD) of ISS-610-Me (98). 
The inability of NMR experiments to elucidate the impurity then promoted the use of mass 
spectrometry. Indeed, within the LCMS data resided a large fragment, alongside the parent ISS-
610-Me [M-H]- anion, with a m/z of 502 which was indicative of the ISS-610 (6) [M-H]- anion 
species. Retrospectively, its formation during the final acidification stage was probable, owing to 
the leucine methyl ester being highly labile in prolonged acidic conditions. The acid-catalysed 
hydrolysis of this ester, to generate the unmethylated ISS-610 derivative with TFA could explain 
the near-identical proton and 31P NMR spectrum peaks, as this methyl ester is isolated and should 
not affect other chemical shifts. On this basis, the impurity of ISS-610-Me was highly likely to be 
the methyl-hydrolysed, ISS-610 (6). With both ISS-610 and ISS-610-Me only acting as positive 
controls, for comparison against the ProTic prodrugs, the 12% of ISS-610 contaminating ISS-610-
Me would not be problematic as their activities were anticipated to be almost identical and thus 
ISS-610-Me was progressed at 87% purity. 
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4.6. ISS-610-Me Library Immunoblotting  
To evaluate and confirm the first research hypothesis, each of the five compounds were to be 
assayed using a constitutively active STAT3 cell line, in a dose-dependent manner, for a set 
duration. Western blots of the resultant cell lysates would then demonstrate whether the ProTic 
prodrug derivatisation would facilitate greater anti-STAT3 activity than ISS-610 and ISS-610-Me. 
This would be elucidated by investigating changes in total STAT3 expression, and two downstream 
STAT3 target genes, BcL-xL and Survivin.25 In these Western blotting studies, total Beta Actin 
protein levels, a known housekeeping protein, were used as loading controls.54 If the hypothesis is 
correct, all ProTic prodrugs will retain equal total STAT3 expression but greater dose-dependently 
reduced Survivin and BcL-xL. 
The whole library, of five compounds, was given to a colleague at Cardiff University, Binar Dhiani, 
who investigated their anti-STAT3 activity with MDA-MD-468 cells, which are a well-known 
STAT3-hyperactivated breast cancer cell line (Figure 4.5).146 The compounds were incubated with 
the cells for 24 hours to ensure there was enough time for the prodrugs to metabolise and deliver 
the active drug to the cells. Concentrations of 0.1, 1, 10, 30 and 100 µM were to be used for each 
compound to investigate whether does-dependant STAT3 inhibition could be observed. 
The results show both ISS-610 and ISS-610-Me shared near-identical activities, with both 
compounds showing a small amount of Survivin suppression at 100 µM, which establishes any 
changes in activity will definitively not derive from this methyl esterification of leucine. The benzyl 
ProTic 76 displayed a similar activity, with only a small change of Survivin noted at 100 µM, which 
is perhaps due to the compound being excessively lipophilic and ‘crashing’ out of solution. On the 
other hand, the methyl (74) and isopropyl (75) ProTics demonstrated substantially increased 
dose-dependent suppression of Survivin , which was observed with concentrations as little as 30 
µM. For the ProTic 75, dose-dependent suppression of BcL-xL was evident at 30 µM, which is far 
superior to the native parent compounds, ISS-610 and ISS-610-Me.  
The isopropyl prodrug, compound 75, thus appeared to be the most active out of the whole 
library and was taken forward as the lead prodrug design for the stability study. Collectively, this 
data shows successful incorporation, metabolism, increased suppression of target genes and 
greater anti-STAT3 activity with ProTics. 
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Figure 4.5: Expression of total STAT3, pSTAT3, BcL-xL and Survivin in MDA-MD-468 cell following a 
24 hour treatment with ISS-610 (100 µM), ISS-610-Me, 74, 75 and 76. Proteins were separated by 
SDS-PAGE and transferred to a nitrocellulose membrane before being incubated with antibodies 
against total STAT3, P-STAT3 and Survivin. Beta Actin was used as a loading control. 
4.7. ISS-610-Me ProTic Human Serum Stability 
The previous study clearly demonstrated the significantly improved ability of a ProTic prodrug (iPr) 
to supress STAT3 activity by downregulating the transcription of its two downstream genes, 
Survivin and BcL-xL, in a breast cancer cell line. This success confirmed the hypothesis and the first 
research objective by demonstrating the increased biological activity for ProTic prodrugs. The next 
aim was to take the lead compound, isopropyl ProTic 75, and evaluate its stability under 
physiological conditions. The literature approach to achieve this involves 5 mg of the prodrug 
being dissolved in deuterated DMSO and D2O (1:1, 0.15 mL/0.15 mL) and incubated with human 
serum.147 The sample is then warmed to 37 °C and prodrug stability is monitored through NMR 
experiments.147 By using the 31P NMR spectrum, the intensity of the doublet of singlet peaks (RP 
and SP) is followed at set timed intervals to indicate whether there are changes in the two 
phosphorus chemical environments. Formation of new phosphorus signals or decreases in the 
76 75 74
98
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original prodrug signal intensity would suggest that the ProTic is starting to degrade under these 
conditions.147 
This typical literature procedure was optimised on the nucleotide ProTide derivatives and had not 
been trialed on systems such as phosphotyrosine-mimetics. Resultantly, it was unclear whether its 
direct application to our ProTic prodrug would replicate its success for nucleotide therapeutics. 
Initially, attempts to dissolve the ProTic prodrug in the reported solvent combinations were 
unsuccessful, due to the significantly higher logP of the compound. To remedy this, more DMSO 
was added (2:1, 0.30 mL/0.15 mL) to aid solubility.  
With the compound now acceptably dissolved in deuterated solvent, a blank 31P NMR experiment 
of that solution was run as a control. Defrosted human serum (0.3 mL) was then injected into the 
tube and a phosphorus NMR experiment was taken every half an hour, for 12 hours, at 37 °C. 
Unfortunately, the high lipophilicty drove the prodrug to slowly crash out of solution over time 
and the resultant NMR spectra had progressively weaker signals because of this, albeit with no 
new signals. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: 31P NMR spectrum (202 MHz, DMSO/D2O) of ProTic 75 (control) sample before human 
serum treatment at 25 °C.  
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Figure 4.7: 31P NMR spectrum (202 MHz, DMSO/D2O) of ProTic 75 sample after 12 hour treatment 
with human serum at 37 °C. 
Comparison of the control 31P NMR spectrum (Figure 4.6) and the 12 hour incubation with human 
serum NMR spectrum (Figure 4.7) demonstrates that the signal for the parent diastereoisomers (-
1.25 and -0.70 ppm) is still present but substantially decreased. If there was a new set of 
phosphorus environments appearing it would suggest the compound had degraded. However, 
this is not observed in this spectrum, which might simply suggest that the prodrug was stable but 
insufficiently soluble over the 12 hour period. Consequently, this loss of phosphorus signal 
intensity was providing inconclusive results, as it could be reasoned that the ProTic prodrug was 
stable but insoluble over time or it could be degrading into numerous small peaks that were too 
low in intensity to distinguish from the background noise. To validate which theory was correct, a 
mass spectrometry analysis was conducted, as the signal to noise ratio of the NMR spectras could 
not be improved. 
To use mass spectrometry to evaluate the potential ProTic metabolism in the serum, two control 
experiments were required (Figure 4.8). A blank LCMS of the prodrug 75 sample (A) and a blank 
LCMS of the human serum (B) were facilitated to identify the expected parent ion or fragments 
(m/z = 779.28) of the prodrug and any species within the serum (m/z = 506.55 and 529.11). From 
both control spectrums, artefacts from the column (m/z = 298.5, 413.3 and 528.5) could also be 
established. With all the expected peaks elucidated, a sample from the prodrug incubated in 
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human serum after 12 hours was taken and an LCMS was ran (C). The spectrum clearly 
demonstrates only the presence of the serum/artefact peaks (m/z = 413.28, 506.55 and 529.11) 
and the intact ProTic 75 peak (m/z = 779.32). With no other fragmentation observed, this data 
coincides with the 31P NMR spectrum in suggesting that the ProTic is stable in human serum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: A) LCMS (ES+) spectrum of ProTic 75 blank. B) LCMS (ES+) spectrum of human serum 
blank. C) LCMS (ES+) spectrum of sample tube incubated with human serum for 12 hours at 37 °C. 
As the serum solution contained large quantities of DMSO, the stability data is only preliminary as 
it is unknown whether the DMSO was affecting the enzymes present within the serum. Therefore, 
future studies would be required to show that using 33% DMSO was not denaturing the enzymes 
present within the serum and prohibiting their interactions with the prodrug in solution. Until this 
is answered, this study cannot confirm whether the ProTic would be stable. 
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4.8. Chapter 4 Conclusions 
In this chapter, the research objective was to synthesise the first documented phosphotyrosine-
mimetic STAT3 SH2 domain inhibitors as ProTic prodrugs. To this end, a small library of three 
novel ProTic prodrugs of a suitably derivatised known STAT3 inhibitor, ISS-610-Me, was 
synthesised as diastereoisomers, in seven steps with overall yields of 19-34%. To complement 
this, the unmasked ISS-610-Me derivative was also synthesised in six steps, with an overall yield of 
15%. Together with commercially available ISS-610, a library of five compounds was finalised for 
evaluation. 
The compound library was given to colleague, Binar Dhiani, who treated the drug molecules to 
the STAT3 hyperactivated breast cell line, MDA-MD-468. In the study, the lead ProTic prodrug 
(isopropyl ester 75) display increased capacity to inhibit STAT3 and supress its downstream target 
genes, Survivin and BcL-xL, over a 24 hour treatment. This confirmed two key research questions, 
in which, the ProTic prodrugs were evidently able to metabolise correctly to produce the active 
species and were more potent than unmasked derivatives. The increased potency is through the 
prodrugs increased logP values, improved cellular uptake and larger drug accumulations within 
the cancer cells. Consequently, this study confirmed the hypothesis of whether derivatising 
phosphotyrosine-mimetic STAT3 inhibitors as ProTics will improve their cross-membrane 
penetration and translate into increased biological (anti-STAT3) activity over their parent drugs. 
Interestingly, the typically most active ester for nucleotide ProTides, benzyl derivative 76, was 
poorly active, which is possibly due to its exceptionally high clogP value of 7.05. The exceedingly 
lipophilic nature of the molecule could make the prodrug poorly soluble inside the cell and limit 
its ability to remain in its aqueous environment. 
The final aim of Chapter 4 was to confirm these prodrugs are suitably stable under physiological 
conditions. To achieve this, lead ProTic 75 was dissolved in deuterated DMSO/D2O and incubated 
with human serum for 12 hours. Collectively, between the 31P NMR spectrum and LCMS data after 
the 12 hour incubation, it was suggestive that the lead ProTic prodrug had successfully remained 
stable under physiological conditions, as no metabolites were detected. Conversely, this may be 
due to the high quantities of DMSO present within the sample, which might denature the 
enzymes within the serum and provide inconclusive results. Consequently, further investigations 
will be required to disprove this and show that the sample solution containing 33% DMSO was not 
nullifying the contents of the serum. 
The contents of this chapter were published in MedChemComm.146 
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Chapter 5: Design, Synthesis and Evaluation of POMTide Prodrugs 
5.1. POMTide Prodrug Concept 
The work accomplished in Chapter 4 demonstrated the promising possibilities of the ProTic 
prodrug design for improving the cellular uptake and biological activities for phosphotyrosine-
mimetic STAT3 inhibitors. Unfortunately, there were some issues that needed to be resolved 
before progressing this novel technology. One concern derived from the poor aqueous solubility 
of the prodrugs when evaluating their stability in human serum. Using a napthylic leaving group 
significantly improved the leaving group capacity, but also substantially increased the 
lipophilicity.146 This may also rationalise why the benzyl derivative (76) was poorly active, due to 
its high logP value that may have resulted in its poor solvation within the cells. Therefore, the 
napthyl motif should be substituted for another “good” leaving group with reduced lipophilicity. 
Additionally, the issues stemming from the essential cyclisation metabolic step, of eliminating the 
tyrosine phenol motif, were still concerning despite the improved modification to enhance the 
leaving group. Consequently, this may result in a decreased dose of the compound. In efforts to 
reduce this, it was envisioned that employing a complementary prodrug design in future libraries, 
that did not require this phosphate cyclisation, would be advantageous. With the more potent of 
the ten or so current phosphate prodrug strategies mostly involving some form of phosphate 
cyclisation, a new phosphate prodrug technology would be required. To this end, a recent report 
by Wiemer and co-workers reported the development of a potent and interesting aryloxy 
pivaloyloxymethyl phosphonate prodrug, which was discontinued owing to a slightly better 
activity being observed with aryloxy phosphoramidate triesters.148,149 The prodrug design (Figure 
5.1) entailed one POM masking group and one aryloxy leaving group that resulted in similarly high 
logP values as ProTide/ProTic derivatives and thus contained favourable lipophilicities for good 
passive diffusion. As with using the abbreviation ‘ProTide’, this class of aryloxy pivaloyloxymethyl 
nucleotide prodrugs would be named ‘POMTides’. 
 
 
 
 
 
 
Figure 5.1: Discontinued aryloxy pivaloyloxymethyl phosphonate approach.148 
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5.2. Exploring POMTide Prodrug Metabolism 
Despite the prodrug design being discontinued before its metabolism was elucidated, it is highly 
probable that this occurred without a phosphonate cyclisation intermediate (Figure 5.2). The 
typical metabolic pathway for POM masking groups proceeds through esterase-mediated 
hydrolysis of the carboxylate promoeity and a resultant spontaneous formaldehyde linker 
liberation.94 Therefore, the first metabolic steps here were likely to involve passive diffusion of 
prodrug 116 into the cell, whereby endogenous esterases metabolise the carboxylate group which 
facilitates the formation of intermediate 118.89 It is plausible that the nucleophilic linker anion 
could cyclise, through an intramolecular attack to the phosphate and expulsion of the aryl group, 
but this is unlikely owing to the highly strained and sterically hindered nature of the four-
membered ring formed. Realistically, the more credible metabolic transformation is the expulsion 
of formaldehyde, as consistently seen in the literature, to afford acid 119.89 The aryloxy motif is 
likely to be then catalytically liberated to afford the active species through cellular 
phosphodiesterases or possibly by endogenous nucleophiles.  
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Proposed metabolism for aryloxy pivaloyloxymethyl prodrugs.  
Consequently, this prodrug approach was compelling and may represent an additional class of 
highly lipophilic phosphate prodrug if applied to nucleotide or phosphopeptide-mimetic drug 
molecules. Moreover, this approach may proceed without a phosphate cyclisation intermediate 
which was particularly advantageous for developing phosphotyrosine-mimetic prodrugs. 
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5.3. Aims and Objectives 
The application of the POMTide prodrug to phosphate-containing molecules may produce an 
alternative prodrug approach, with near identical logP values to phosphoramidates, but with the 
advantage of not having the problematic phosphate cyclisation step. Furthermore, this prodrug 
approach appears to require only one enzymatic-mediated step, the esterase hydrolysis, where 
phosphoramidate approaches, such as ProTides and ProTics, require both a carboxypeptidase and 
a phosphoramidase-type enzyme to release the active species. The use of only one enzyme could 
manifest into more versatile, efficient and faster deliveries of the active drug to the cell. It is 
conjectured that collectively, these capacities could produce a more potent phosphate prodrug 
approach, particularly for phosphopeptide-mimetic prodrugs where evasion of cyclisation in the 
metabolic delivery may be favourable. 
Therefore, the objectives for this chapter were to apply the POMTide phosphonate prodrug 
approach to phosphates and investigate whether its success could be replicated. The substitution 
of the phosphonate methylene bridge to a native phosphate P-O bridge might also have 
implications for the prodrug metabolism and activity that could result in enhanced performance 
for its use with phosphates. Initially, the aim was to employ this approach to known nucleoside 
derivatives, to synthesise their monophosphate prodrugs as trial systems and directly compare 
them to other prodrugs, such as ProTides.  
As a proof-of-concept, the initial investigation focused on the known antiviral nucleoside, 
Stavudine (d4T), that is used to treat HIV-1.150 The presence of only one ribose alcohol (5’) placed 
this structure as an excellent scaffold to develop and optimise the chemistry required to 
synthesise POMTides (Figure 5.3). The commercially available d4T can be readily phosphorylated 
using phosphorochloridates, which promoted the initial attempts to synthesise the d4T POMTide 
to employ similar chemistry.149,150 
 
 
 
 
 
 
Figure 5.3: Novel d4T POMTide prodrug synthetic target 121. 
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5.4. Retrosynthetic Analysis of d4T POMTide  
The synthesis towards the target prodrug molecule focused around the development of a suitable 
phosphorochloridate to couple to d4T, akin to typical ProTide and ProTic synthesis. As 
phosphorochloridate-mediated phosphorylation with d4T had been largely successful in the 
literature, this approach would be the favoured method to investigate first, in efforts to develop 
the chemistry to synthesise novel POMTide phosphate prodrugs (Scheme 5.1).163 
A first synthetic approach would start with a bis-protected phosphoric acid, such as dibenzyl 
phosphate 99, to facilitate a mono-esterification of chloromethyl pivalate with the phosphoric 
acid to yield phosphate triester 122. The successful incorporation of the pivaloyloxymethyl 
promoeity would enable both protective groups to be unmasked simultaneously, to unveil the 
native phosphoric acid 123 that could be theoretically scaled up in large quantities. 
Bischlorination of the two phosphoric acid substituents, under classical conditions, would furnish 
the desired phosphorodichloridate 124. Phenol could be carefully added at -78 °C, in a difficult 
mono-substitution, to form the key phosphorochloridate 125 as a racemate. The treatment of this 
phosphorochloridate to d4T, under basic conditions, should yield the sought POMTide 121 as an 
approximately equal pair of diastereoisomers (RP and SP). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5.1: d4T POMTide 121 retrosynthetic analysis. 
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5.5. Synthesis of d4T POMTide  
An initial route began from commercially available, dibenzyl phosphate 122, where treatment of 
chloromethyl pivalate and Hünig's base, were theorised to introduce the POM moiety for product 
122 (Scheme 5.2).151 Unfortunately, no esterification reaction progress could be confirmed by TLC 
or crude 31P NMR. Attempts to promote the incorporation were trialed through heating the 
reaction to 65 °C but this was unsuccessful. 
 
 
 
 
Scheme 5.2: Attempted synthesis of triester 122. 
Evidently, the nucleophilic capacity of the phosphoric acid, with DIPEA, was insufficient to succeed 
in the substitution. Interestingly, literature precedent for this classification of coupling reaction 
employ a methoxy phosphate ester and an in situ generation of a phosphoric anion, through a 
one-pot, iodide-mediated transesterification with chloromethyl pivalate (Scheme 5.3).152,153 This 
reaction is theorised, by Keillor and co-workers, to proceed through iodide anion attack of the 
methoxy ester and the displacement of the phosphoric anion 128 as a reactive intermediate.154 
Nucleophilic attack of this anionic intermediate 128 towards the chloromethyl pivalate 
electrophile completes the transesterification and yields product 128 which can react with 
additional equivalents of reagents to undergo multiple transesterification processes.154 
 
 
 
 
 
 
 
Scheme 5.3: Proposed iodide-mediated POM transesterification mechanism.154 
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In light of this better strategy, a new approach was devised, which could employ this chemistry to 
facilitate a mono iodide-mediated transesterification. Furthermore, by also substituting the 
dibenzyl groups for diphenyl masks, the synthesis could be completed in fewer steps. This was 
encouraged by the numerous reported strategies for selectively mono-hydrolysing bisphenyl 
phosphates that could be utilised in place of the previously proposed global deprotection through 
hydrogenation.155 Consequently, proceeding through the challenging dichloridate 124 would not 
be necessary throughout this route, which was theorised to employ more stable intermediates. 
The new synthetic route towards the d4T POMTide was initiated from commercially available, 
diphenyl phosphorochloridate 133 (Scheme 5.4). 
The synthesis began by dissolving diphenyl phosphorochloridate 133 in a methanol solvent with 
stoichiometric sodium methoxide treatment at room temperature (Scheme 5.4).156 The reaction 
generated a complex mixture by TLC analysis that was likely due to the presence of di/tri addition 
products where phenol had been displaced. On this basis, the reaction was repeated at 0 °C to 
favour mono-substitution and product 134 was obtained in a 99% yield. 
Incorporation of the desired methoxy ester substituent then enabled the first attempt of applying 
the reported iodide-mediated transesterification for mono-POM introduction. Methyl phosphate 
134 was refluxed in anhydrous acetonitrile with stoichiometric sodium iodide and chloromethyl 
pivalate for 24 hours (Scheme 5.4). Gratifyingly, successful mono-POM introduction was observed 
and the desired triester 135 was exclusively synthesised, in excellent yield. 
 
 
 
 
 
 
 
Scheme 5.4: Synthesis of methoxybisphenyl phosphate 134 and POM bisphenyl phosphate 135. 
With bisphenyl POM phosphate triester 135 in hand, efforts to achieve mono-hydrolysis of one 
phenol were carried out. The first strategy was by employing a 10% palladium on carbon catalyst 
to mono-selectively hydrogenate one phenol at atmospheric pressure with hydrogen gas (Scheme 
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5.5). This procedure had been reported in the literature, by Witkoshki and co-workers, and the 
same conditions were replicated for compound 135.157 Unfortunately, in our hands, there was no 
sign of any forward reaction (mono or bisphenyl removal) after 12 hours through crude 31P NMR 
experiments or LCMS experiments.  
 
 
 
 
Scheme 5.5: Attempted mono-selective hydrogenation of bisphenyl 135. 
A final attempt of using bisphenyl 135 as the precursor, to generate the target POMTide, was by 
directly treating it with the d4T nucleoside under basic conditions. Objectively, the phenolic 
substituent could behave as a leaving group and promote the phosphorylation directly. Choice of 
base would thus be essential, as examples like tBuMgCl, could alkylate and decompose the POM 
substituent. Resultantly, sterically-hindered DBU was first chosen as an ideal base and was 
employed to facilitate the phosphorylation (Scheme 5.6). Unfortunately, no reaction occurred 
after 24 hours, which was likely due to the lack of leaving capacity of the phenol under these 
conditions. Substitution of DBU to tBuMgCl was later trialed to investigate whether any reaction 
was occurring but no starting material or product was identified after the 24 hour reaction and a 
subsequent work-up. Although degradation products were not identified, the Grignard reagent 
was evidently participating as more than just a base and facilitating unwanted side products, 
which were prohibiting the formation of the desired product. 
 
 
 
 
 
Scheme 5.6: Attempted phosphorylation of d4T. Base = DBU or tBuMgCl. 
The lack of capacity to selectively eliminate one phenol substituent from phosphate 135 
promoted the concept of using an alternative strategy through employing a mono-phenol 
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phosphate starting material and proceeding through a mono-methylation instead. In efforts to 
achieve this, dropwise treatment of stoichiometric methanol and pyridine to phenyl 
dichlorophosphate 137, in anhydrous diethyl ether, was carried out at 0 °C (Scheme 5.7).158 
Pleasingly, the reaction conditions were sufficient to yield the selective mono-methylated ester, 
product 138, in great yield as a racemate.  
 
 
 
 
Scheme 5.7: Synthesis of methyl phosphorochloridate 138. 
With the desired phosphorochloridate 138 in hand, the compound could either be directly 
subjected to the iodide-mediate transesterification reaction or used to phosphorylate d4T first 
and enable a finalising transesterification to complete the synthesis. To establish the optimal 
strategy, both routes were to be trialed, starting with the direct transesterification. Chloridate 
138 was dissolved in acetonitrile and refluxed with sodium iodide and chloromethyl pivalate for a 
total of 12 hours. Crude 31P NMR experiments were taken throughout the reaction and numerous 
phosphorus environments were generated, alongside the complete consumption of the reagent 
peak, indicating a complex mixture. Retrospectively, this is perhaps through iodide nucleophilic 
attack and substitution of the phosphorochloridate taking preference over attack towards the 
desired methyl group, which may have produced additional phosphate species. 
With the lack of iodide nucleophilic chemoselectivity towards phosphorochloridate 138 being 
evident, achieving the d4T phosphorylation prior to this reaction, to eliminate the presence and 
participation of the phosphorochloridate functionality was alternatively investigated. Therefore, 
phosphorochloridate 138 was reacted with d4T with triethylamine in anhydrous acetonitrile 
(Scheme 5.8). The reaction successfully yielded the desired nucleotide product (139), in moderate 
yield, as an approximately equal pair of diastereoisomers. 
Successful phosphorylation with phosphorochloridate 138, to yield nucleotide 139, permitted the 
iodide-mediated transesterification reaction to complete the synthesis and yield POMTide 121. 
Refluxing the nucleotide with sodium iodide and chloromethyl pivalate, in anhydrous acetonitrile, 
afforded the POMTide final compound (121) in low yield, as a pair of approximately equal 
diastereoisomers (Scheme 5.8).  
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Scheme 5.8: Synthesis of d4T nucleotide 139 and POMTide 121. 
Although the POMTide had been successfully synthesised, the synthetic strategy to achieve this 
heavily relied on the iodide-mediated transesterification reaction fortunately not participating in 
side reactions. For future POMTide target molecules, refluxing with sodium iodide may degrade 
the reactant compound and this strategy would then be unable to facilitate the desired molecule. 
To this end, another strategy to synthesise POMTides, that could directly employ a 
phosphorochloridate with both POM and phenyl components already installed and avoid the 
iodide-mediated transesterification reaction, was desirable. With the previous attempts to 
synthesise this chloridate focusing on a bisphenyl phosphate achieving mono-dephenylation being 
unsuccessful, a new route would revolve around a bisPOM phenyl phosphate. Using the 
established chemistry, a dimethyl phosphate (140) was synthesised in high yield, as a bisPOM 
phosphate prodrug precursor (Scheme 5.9).158 
With dimethyl phenyl phosphate 140 in hand, an iodide-mediated transesterification was applied 
to achieve the bisPOM phenyl phosphate. However, with the mechanism for the reaction being 
somewhat untested, two different reaction conditions were trialed, in parallel, for closer 
evaluation (Scheme 5.9). The first reaction employed phosphate 140 and the classic conditions for 
the reaction. The second approach proceeded with phosphate 140 and commercially available 
iodomethyl pivalate (POMI) to investigate whether this was a required intermediate for the 
reaction. 
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Scheme 5.9: Synthesis of bismethyl phosphate 140 and bisPOM phosphate 121 through 
POMCl/NaI or POMI. a) POMCl, NaI, MeCN, reflux, 24 hours, 65%. b) POMI, MeCN, reflux, 24 
hours, 0%. 
Using sodium iodide and chloromethyl pivalate, the reaction proceeded to yield bisPOM 
phosphate 141 in 65% yield. Interestingly, when using just POMI, no desired product was 
identified by TLC. Evidently, the proposed mechanism of iodide attack towards the methyl 
substituent was an essential first step for transesterification and not an alternative in situ 
Finkelstein-driven iodination of chloromethyl pivalate to yield a reactive iodomethyl pivalate 
species.154 This was made clear through the reaction only proceeding through a phosphoric anion 
(via NaI) and not a methoxy lone pair attack (POMI).154 
In light of the support for the proposed mechanism, the synthesised bisPOM phenyl phosphate 
141 was progressed and investigated for a method of selective mono-hydrolysis of one POM 
group, to yield a phosphoric acid which could be chlorinated.152 Using literature precedent for 
mono-POM hydrolysis, using excess piperidine and subsequent ion exchange chromatography, 
phosphate 141 was likewise stirred in excess piperidine for 12 hours (Scheme 5.10).152 The 
reaction mixture solvent was removed under reduced pressure and the resultant crude was 
subjected to a Dowex 50WX2-100 ion-exchange column charged with HCl.152 Unfortunately, the 
eluted product was heavily contaminated with several phosphorus environments in 31P NMR 
analysis and the overall reaction provided acid 136 in very low yield (7%).  
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Scheme 5.10: Synthesis of phosphoric acid 136 using ion exchange. 
A final strategy to facilitate phosphoric acid 136, the precursor to the desired 
phosphorochloridate, involved using one benzyl masking group, which could be hydrogenated at 
the end of the synthesis and yield phosphoric acid 136. To this end, previously synthesised 
chloridate 138 was remade and reacted with stoichiometric benzyl alcohol and triethylamine in 
efforts to introduce the benzyl-masking group (Scheme 5.11). Under these conditions, isolation of 
the resultant phosphate triester was challenging, owing to copious volumes of unreacted benzyl 
alcohol co-eluting during column chromatography, which contaminated the fractions. This 
suggested only a small proportion of the alcohol had phosphorylated and the reaction, therefore, 
required a catalyst to promote the phosphorylation and reduce the problematically large volume 
of unreacted benzyl alcohol present. 
Using a modified literature precedent, species 138 was treated with  benzyl alcohol and Proton 
Sponge, in DCM.159 Pyridine-N-oxide was employed to generate a reactive intermediate with the 
phosphate, akin to DMAP, to increase its electrophilicity and susceptibility for alcohol attack.159 
These conditions now yielded product 142 in a moderate yield of 52%. 
With the complete introduction of the required methyl, phenyl and benzyl groups (142), efforts to 
substitute the methyl substituent to the desired POM group were attempted. Stoichiometric 
sodium iodide and chloromethyl pivalate were refluxed with phosphate 142 for 24 hours, in what 
was believed to be a predictable introduction of the POM substituent (Scheme 5.11). Only traces 
of desired product could be identified, leaving only starting material and one strange major 
product. After isolation and purification, by flash column chromatography, the major (identifiable) 
product appeared to be a methyl, phenyl and POM phosphate triester racemate (144). 
Consequently, this previously unreported evidence demonstrated a high reaction preference for 
iodide-mediated transesterification of benzyl substituents over the classically used methyl groups. 
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Scheme 5.11: Pyridine-N-oxide activated synthesis of phosphate triester 142 and iodide-mediated 
transesterification products 143 and 144. 
Retrospectively, iodide anion attack was evidently preferred at the benzylic position which is 
perhaps rationalised by its increased electrophilic profile, from aromatic electron withdrawal, in 
comparison to the methyl position. This promotes the benzylic carbon as the better iodide-
acceptor and overall leaving group, as benzyl iodide is more stable than methyl iodide (through 
aromaticity), to yield the desired phosphoric anion to facilitate the POM introduction.  
To investigate this further, the reaction was repeated with two equivalents of sodium iodide and 
chloromethyl pivalate to evaluate whether the methyl could now participate within the reaction 
(Scheme 5.12). Unsurprisingly, the bisPOM product (141) was obtained in 85% yield, alongside a 
small proportion of unspent starting material. This confirmed the methoxy substituent could still 
achieve transesterification but was significantly less susceptible than the competing benzyl group. 
 
 
 
 
 
Scheme 5.12: Iodide-mediated transesterification for bisPOM phosphate 141. 
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Before progressing to the next step in the synthesis, one further question remained with this 
reaction, which was whether benzyl phosphate 142 could yield the mono-POM product 144 in a 
better iodide-mediated transesterification yield than a dimethyl phenyl derivative 140. To 
elucidate this, the reaction was trialed using the same conditions on the dimethyl starting 
material 140 (Scheme 5.13). Although the reaction proceeded to yield the desired product, the 
yield was notably lower (38% versus 55%). Furthermore, the purification was significantly more 
challenging owing to the presence of similarly co-eluting minor products, such as the bisPOM 
phosphate, through this strategy. Comparing both strategies, proceeding through the benzyl 
triester was more favourable as this produced mono-methyl phosphate 144 in a higher yield and 
with easier purification methods. 
 
 
 
 
 
Scheme 5.13: Iodide-mediated transesterification from phosphate 140. 
Having established the preferred strategy to synthesis phosphate 144, efforts now focused on 
removing the methyl substituent to generate the precursor phosphoric acid. Using sodium iodide 
in acetone reflux, the methyl substituent was envisioned to be subjected to iodide attack and 
eliminated through generation of the phosphoric anion.160 Using acetone as a solvent should 
facilitate the precipitation of the anion to crystallise out of solution as the sodium salt for 
filtration.160 This reaction was carried out under reflux and successfully yielded the phosphoric 
acid salt 145, which was collected by filtration in near-quantitative yield (Scheme 5.14).160 
To complete the synthesis, sodium salt 145 was directly chlorinated with oxalyl chloride and 
catalytic DMF for three hours which generated racemic phosphorochloridate 125 in 99% yield 
(Scheme 5.14). 
Now with a synthetic approach for obtaining phosphorochloridate 125, which could couple to a 
nucleoside to generate POMTides, the feasibility of the phosphorylation reaction was trialed on 
the known d4T system for comparison. Treatment of a solution of d4T, in acetonitrile, with 
chloridate 125 and triethylamine successfully facilitated the desired d4T POMTide 121, with 
identical analytical data to the previously synthesised d4T POMTide (Scheme 5.14). 
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Scheme 5.14: Iodide-mediated synthesis of salt 145, chlorination for chloride 125 and 
phosphorylation of d4T with for phosphate 121. 
The success to generate phosphorochloridate 125 and its ability to directly phosphorylate 
nucleosides into POMTides now enabled two separate strategies to synthesise POMTides 
(Scheme 5.15). In comparison, route one involved phosphorylation of the nucleoside with a 
methyl, phenyl phosphorochloridate (139) and then applying the iodide-mediated 
transesterification which totalled to three steps, with an overall yield of 13%. The alternative 
route two revolved around synthesising phosphorochloridate 125 and directly coupling it to the 
nucleoside, to yield the POMTide in six steps with an overall yield of 11%. Additionally to having a 
higher overall yield, route 1 possessed a significantly shorter synthetic route and was thus the 
preferred path for future POMTide development, unless the use of NaI became problematic. 
 
 
 
 
 
 
 
Scheme 5.15: Routes 1 and 2 developed for POMTide synthesis, initialising from reagent 137. 
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5.6. Synthesis of 5-FU POMTide Prodrugs 
The next objective was designing a library of POMTide and ProTide derivatives of a therapeutic 
agent to directly evaluate and compare their activity profiles. To achieve this, the anticancer 
nucleoside 5-fluorouridine (5-FU), was identified as a suitable nucleoside to functionalise as 
ProTide and POMTide prodrugs for comparative evaluation. The study would focus on two 5-FU 
POMTide prodrugs, with a phenol or napthol substituent, and four ProTide analogues, which were 
to be synthesised by another researcher, Ashwag Alanazi (Figure 5.4). 
 
 
 
 
 
Figure 5.4: Target POMTide molecules: R1 = phenol (146), napthol (147). ProTides to be 
synthesised by Ashwag: R1 = phenol and R2 = Bn (148), R1 = phenol and R2 = tBu (149), R1 = napthol 
and R2 = Bn (150), R1 = napthol and R2 = tBu (151).  
To synthesise both POMTide target molecules, the established route 1 (Scheme 5.15) of 
employing a methoxy phosphorochloridate, for direct 5-FU phosphorylation, and a finalising 
iodide-mediated transesterification was first performed. This required the resynthesising of 
phosphorochloridate 148, with both a methyl and phenyl installed. Furthermore, the napthol 
derivative (152) was likewise a requisite and was to be made from resynthesising the napthol 
phosphorodichloridate 94 in Chapter 4. Using the same procedures as with the phenol derivative, 
treatment of this dichloridate with methanol and pyridine facilitated the desired mono-product 
(152) in 73% yield (Scheme 5.16).158 
 
 
 
 
 
Scheme 5.16: Mono-addition of napthol to synthesise chloridate 152. 
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With both key phosphorochloridates in hand (one methoxy and one phenol/napthol group), their 
subsequent phosphorylations of 5-FU were attempted in parallel, using the exact conditions for 
the d4T system of a triethylamine base (Scheme 5.17). Unfortunately, neither phosphorylation 
reaction was successful and only starting material remained in both instances. Evidently, the 
presence of the 2’ and 3’ alcohols was problematic for the reaction and new reaction conditions 
were required to generate the target molecules. 
 
 
 
 
 
 
 
 
 
Scheme 5.17: Attempted synthesis of POMTide precursors, phosphates 153 and 154. a) 5-FU, 
Et3N, THF, 12 hours. b) 5-FU, Et3N, DMF, 12 hours. c) 5-FU, pyridine, 12 hours. d) 5-FU, 
tBuMgCl, 
DMF, -78 °C, 12 hours. e) 5-FU, Me2AlCl, pyridine, 0 °C, 12 hours. 
The key considerations for the reaction failures were the insolubility of the highly polar nucleoside 
and the lack of nucleophilicity of the 5’ alcohol towards the phosphorochloridates. To this end, 
the reaction to synthesise phosphate 153 was trialed again in anhydrous DMF (Scheme 5.17). 
Despite DMF dissolving the nucleoside efficaciously, as did THF, the reaction was unsuccessful, 
with TLC analysis only showing starting material. The same result was observed when repeating 
the reaction by using pyridine as a dual solvent-base system. As a clear homogeneous solution 
was produced in all the trialed solvent systems, insolubility of the nucleoside was unlikely. 
With insolubility inciting the problems looking dubious, efforts were refocussed on improving the 
nucleophilicity of the 5’ primary alcohol towards phosphorylation. Thus, the reaction was 
repeated in DMF with a superior tBuMgCl Grignard base to formally deprotonate the alcohol.147 
This was also unsuccessful and displayed no formation of any products (Scheme 5.17). 
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Having established that both solubility and deprotonation were not the principal factors, it was 
conceivable that the poor electrophilic character of the phosphorochloridates might be 
insufficient for the forward phosphorylation reaction. A method to enhance this capacity for 
nucleophilic attack is by employing Lewis acids to co-ordinate to the phosphoryl P=O and modify 
the compound’s electronics, to promote its overall electrophilicity.161 
In 2017, Silverman and co-workers demonstrated that employment of the Lewis acid, Me2AlCl, 
could successfully co-ordinate to a phosphoryl oxygen.161 This interaction dissipates electron 
density from the phosphoryl centre towards the Lewis acid, increasing electropositivity, lowering 
the phosphorus LUMO energy level and reducing the energetic barrier required for nucleophile 
attack.161 Employing this Lewis acid-mediated phosphorylation, with 0.5 equivalents of Me2AlC 
and a pyridine base/solvent was unsuccessful (Scheme 5.17).161  
5.7. Synthesis of 5-FdU POMTide Prodrugs 
As this study did not require a specific active nucleotide, 5-FU could be exchanged for a more 
simple structure with fewer ribose hydroxy groups. To this end, the 5-fluoro-2′-deoxyuridine (5-
FdU) analogue was replaced as the new structure, to derive as POMTide and ProTide prodrugs 
(Figure 5.6). It was hypothesised that removing the 2’ hydroxy may help facilitate the 
phosphorylation, as this substrate contained fewer reactive functional groups. 
 
 
 
 
 
 
Figure 5.6: New target POMTide molecules: R1 = phenol (155), napthol (156). ProTides to be 
synthesised by Ashwag: R1 = phenol and R2 = tBu (157), R1 = phenol and R2 = Bn (158), R1 = napthol 
and R2 = tBu (159), R1 = napthol and R2 = Bn (160).  
Both phosphorochloridates, 138 and 152, were thus resynthesised and treated to 5-FdU, with 
NMI at -78 °C.106 Both desired nucleotides (161 and 162) were successfully formulated in 
moderate yields, as pairs of diastereoisomers (Scheme 5.18). 
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Scheme 5.18: Phosphorylation synthesis of nucleotides 161 and 162. Transesterification synthesis 
of POMTides 155 and 156.  
The POMTide target molecules were obtained on treatment with sodium iodide and chloromethyl 
pivalate for 24 hours (Scheme 5.18), as racemates, in moderate yields of 40-41%. Interestingly, 
the free 3’ alcohol displayed no participation in the reaction, as no side products were identified 
in either reaction, which again supports the proposed mechanism proceeding through a 
phosphoric anion instead of methoxy/hydroxy lone pairs of electrons.  
5.8. 5-FdU Prodrug Compound Library 
Both 5-FdU POMTide prodrugs were combined with the four 5-FdU ProTides, synthesised by 
Ashwag Alanazi, to complete the desired library of the six prodrugs for biological comparison 
(Figure 5.7). The four ProTides were synthesised using the established chemistry used in Chapter 
4 that yielded the prodrugs as approximately equal pairs of diastereoisomers.  
The typically most potent L-alanine benzyl ester group was employed for two of the ProTides 
(phenol and napthol) to investigate how the POMTides would compare against what are regarded 
the most active ProTide designs. Two tert-butyl ProTides (phenol and napthol) were also used to 
evaluate the closest L-alanine ester structural functionality to the POM group. It was anticipated 
these would be transiently active. However, this weak activity is reasoned to be due to the slow 
metabolism of the tert-butyl ester by carboxypeptidase enzymes, such as Cathepsin A, which have 
been consistently reported in literature on numerous occasions.106,112 
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Comparison of the clogP values (Figure 5.7) demonstrated that POMTides were considerably 
more lipophilic (phenyl POMTide 155 with phenyl/ tBu-L-alanine ProTide 157 and napthyl 
POMTide 156 with napthyl/ tBu-L-alanine ProTide 159). This suggests the POMTides might retain 
improved capacity for passive diffusion into the cell and with the POMTides being suspected of 
requiring one less enzyme, may also metabolise to the active drug faster. Ultimately, this may 
facilitate improved biological activity for the POMTides through this potentially faster delivery 
system.  
The library of compounds was progressed for biological testing by colleague, Binar Dhiani, at 
Cardiff University. To act as another control in this study, additionally to DMSO, the 5-FdU 
nucleoside analogue was also added to the library to explore whether the nucleotide prodrugs 
were more active than the native nucleoside. 
 
 
 
 
 
Figure 5.7: Compound library prior to evaluation using ChemDraw and HPLC for purity. 
5.9. Biological Evaluation 
The prodrugs were to be evaluated on their anti-proliferative ability, on MCF-7 cancer cells, via a 
MTT assay.162 The library of compounds was treated to the cells for 24 hours at different 
concentrations, ranging from 0 to 100 µM, and cell proliferation was measured (Figure 5.8). The 
napthyl POMTide was consistently the most superior compound for supressing cell proliferation. 
This initial study demonstrates that POMTides can successfully transport the phosphate 
Compound R1 R2 Overall Yield cLogP M.W. Purity 
POMTide 155 Phenol POM 12% (3 steps) 2.83 516.42 97% 
POMTide 156 Napthol POM 17% (4 steps) 3.83 566.48 96% 
ProTide 157 Phenol L-Al-Bn - 2.59 579.52 >95% 
ProTide 158 Phenol L-Al-tBu - 1.58 529.46 >95% 
ProTide 159 Napthol L-Al-Bn - 3.53 613.54 >95% 
ProTide 160 Napthol L-Al-tBu - 2.53 563.48 >95% 
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compound to the cell and metabolise correctly to deliver the active species within the cytoplasm 
and generate a therapeutic effect. 
The ProTides were all less effective than 5FdU. This is perhaps rationalised by a slow metabolic 
delivery and a longer study of 48 hours might be required. Conversely, this suggests that the 
POMTides deliver the active species much faster than ProTides, perhaps owing to their improved 
passive membrane diffusion capabilities derived from the higher logP values. However, another 
explanation might be surrounding the enzymes required for metabolising the POMTide being 
more abundant than the enzymes used with the ProTide. Nonetheless, this initial study 
demonstrates that the POMTide prodrug design is a viable prodrug strategy. Further studies are 
now being conducted to evaluate how the POMTide prodrug metabolises and whether POMTide 
prodrugs are more potent than ProTide prodrugs with other phosphate therapeutics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: MTT cell proliferation assay using Promega Technical Bulletin of CellTiter96 Non-
Radioactive Cell Proliferation Assay. MCF-7 cells were treated with the various compound 
concentrations (µM) for 24 hours with a DMSO control. 
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5.10. 5-FdU POMTide and ProTide Human Serum Stability 
With the POMTides displaying successful metabolism and excellent biological activities, their 
stability under various conditions warranted investigation for future in vivo application. POMTide 
155 and ProTide 157 were allocated for the experiment, owing to their structural similarities and 
different 31P NMR shifts. To study the prodrugs stability under physiological conditions, 3 mg of 
POMTide 155 (-7.98 ppm) and 3 mg of ProTide 157 (3.91 and 3.71 ppm) were incubated together 
in human serum, at 37 °C, and evaluated by 31P NMR experiments hourly, for 12 hours (Figure 
5.9).146 This was to directly compare their stabilities, which were resultantly stable up to 12 hours, 
where new phosphorus environments were beginning to form, indicative of slight metabolism 
after this time. It is unclear from this which of the two prodrugs were metabolising and it is even 
conceivable both were deteriorating after 12 hours. Nonetheless, this study demonstrated that 
POMTides are sufficiently stable under human serum conditions and are thus viable prodrug 
systems to deliver active phosphate drug molecules. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Stacked 31P NMR spectras (202 MHz, DMSO/D2O) of POMTide 155 (-7.98 ppm) and 
ProTide 157 (3.91 and 3.71 ppm), in human serum at 37 °C, for hourly intervals. 
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5.11. 5-FdU POMTide pH 1 and pH 7.4 Stability 
Following the successful human serum stability of the POMTide prodrug, its susceptibility to 
degradation under acid conditions was then evaluated. As ProTides can be orally administered, 
due to good acidic stability (pH 1), POMTides would also require this capacity if future lead 
compounds were to be orally dosed. To this end, 5 mg of POMTide 155 was incubated with a pH 1 
solution (KCl + HCl) for 24 hours, at 25 °C (Figure 5.10).147 A phosphorus NMR experiment was 
taken hourly and the results were stacked, as seen previously. Pleasingly, the POMTide 
diastereoisomer peaks (-8.10 and -8.16 ppm) were completely intact throughout 24 hours in 
acidic solution, with no metabolite phosphorus peaks being observed in any spectra. POMTides 
would be stable in stomach acid (pH 2) and could theoretically be used as orally treated drugs. 
Alongside the human stability data, it was becoming conclusive that POMTides were 
physiologically stable prodrugs and could mirror the excellent tolerance that ProTides possess. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Stacked 31P NMR spectras (202 MHz, DMSO/D2O) of POMTide 155 (-8.10 and -8.16 
ppm) in pH 1 solution (KCl + HCl) at 25 °C, for hourly intervals. 
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Stability at physiological pH (7.4) was  also evaluated for POMTide 155 (-7.97 and -7.99 ppm) in 
pH 7.4 Trizma buffer solution for 24 hours, at 25 °C.147 31P NMR experiments indicated complete 
stability at physiological pH, over the 24 hour period 
Collectively between the three sets of stability data, the POMTide prodrug design could 
sufficiently tolerate key biological conditions that may enable the prodrug to be a viable approach 
as a prospective method to enhance anticancer/antiviral treatments. This now presents POMTide 
prodrugs as promising novel delivery systems that could now be applied to develop powerful new 
therapeutics and may hopefully end up facilitating promising clinical candidates, akin to ProTides.  
5.12. Chapter 5 Conclusions 
In this chapter, the research objective was to identify and develop a phosphate prodrug design 
that could transport similar proportions of phosphate compounds into cells as ProTides/ProTics, 
but metabolise without a cyclic phosphate intermediate. Through a literature search, a 
discontinued phosphonate prodrug was highlighted which appeared to contain a suspected 
metabolism that proceeded without a cyclisation step. This formed the basis of designing 
conceptual ‘POMTides’ that retain one aryloxy substituent and one methoxy pivalate promoeity 
to mask nucleotide therapeutics.  
As the previous work on this design focused on phosphonates, the chemistry for its application to 
phosphates was undeveloped. To this end, the nucleoside, d4T, was nominated to be a core 
scaffold to develop POMTide prodrug derivatives. Overall, two separate synthetic approaches 
were capable of yielding the desired d4T POMTide prodrug as racemic mixtures. The first route 
involved synthesising a methyl and phenyl phosphorochloridate that can be directly coupled to a 
nucleoside. The respective nucleotide product can be tranesterified to introduce the POM 
substituent and complete the synthesis in three steps. The second route focused on synthesising a 
POMTide phosphorochloridate which could be coupled to a nucleoside directly to yield the 
POMTide, in six steps. Both methods had various advantages and a preference is circumstantial. 
The chemistry of route one was applied to a known nucleoside, 5-FU, to generate a library of two 
POMTides to compare directly against four ProTide derivatives, synthesised by another group 
member. With the coupling reaction being troublesome, the 5-FdU analogue was used instead to 
generate the library. The POMTides were yielded in three steps (phenyl) and four steps (napthyl) 
in 12% and 17% overall yields, respectively. The four ProTides were synthesised by another 
student. 
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The compounds were given to another member of the research team who evaluated their 
activities on MCF-7 cell lines, using an MTT proliferation assay. Both POMTides displayed very 
good activity which demonstrates the successful metabolism of the POMTide prodrug design. 
Furthermore, the napthyl POMTide was evidently the most active species out of all prodrugs 
tested and was far more potent than any ProTide design. This is perhaps due to faster metabolic 
delivery of the active species and also the slightly higher clogP value which could facilitate 
improved passive diffusion across cell membranes. All ProTide prodrugs were less active than the 
native nucleoside, which is indicative of slow metabolism and a longer incubation would likely be 
required for future studies. 
POMTide prodrug 155 was finally evaluated on its stability within human serum at 37 °C, which 
was shown to be stable for up to 12 hours where small metabolites were being formed. In acid 
and physiological pH (7.4) buffers, the POMTide prodrug was completely stable for over 24 hours 
at 25 °C. Collectively this shows a strong tolerance for POMTide prodrugs and makes them viable 
candidates to derivatise phosphate prodrugs to enhance their bioavailability and overall activities. 
In conclusion, this work has highlighted POMTides as an exciting novel prodrug delivery system 
for phosphoric acids. The prodrug is synthetically accessible, through two separate approaches, 
and includes a tunable aryloxy leaving group. From the data so far, the napthyl leaving group 
provides the highest potency and fastest metabolic delivery, which exceeds that observed with 
ProTides. With the POMTides proving to be highly stable under physiological conditions, the 
design is being optimised further by other researchers and is an emerging novel phosphate 
prodrug strategy.  
This research, alongside additional findings, will be published in the near future. 
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Chapter 6: Design, Synthesis and Evaluation of S31-201 
Phosphoramidate Prodrugs 
6.1. S31-201 Derivatisation 
By previously determining the hypothesised improved cellular uptake and increased anti-STAT3 
activities of ProTic prodrugs, the next phase was to apply the technology to a novel STAT3 
inhibitor and begin finding promising hit candidates. Moreover, discovery of the alternative 
POMTide technology could be equally applied, alongside other phosphate prodrug designs, to 
directly evaluate the most potent phosphate prodrug delivery system to date. The abbreviation 
for these novel aryloxy pivaloyloxymethyl phosphopeptide-mimetics will be “POMTics”. To this 
end, a novel STAT3 inhibitor was required to functionalise as ProTic, POMTic and various other 
designs, such as the classically used bisPOM phosphate prodrug, for head-to-head comparisons. 
In efforts to identify a novel inhibitor, the known STAT3 inhibitor, S31-201 (10), was explored 
(discussed in Chapter 1) as a base pharmacophore scaffold (Figure 6.1).45 Structurally different to 
the classical peptidomimetics, the compound was identified by structure-based screening by the 
National Cancer Institute and displayed selective and potent STAT3 inhibition via phosphotyrosine 
SH2 binding.45 With the ability to induce tumour regression in mouse xenografts, S31-201 
provided a good scaffold for development and enhancement of activity.163  
The salicylic functionality is a known phosphate bioisostere and exhibits a good hydrogen bonding 
capability within the STAT3 SH2 domain.115 This motif is suitable for substitution for a phosphate 
group, which may increase the compound’s overall hydrogen bonding capacity for the key pY sub-
pocket. Moreover, the incorporation of the phosphate group would then enable the various 
prodrug designs to be later facilitated. The phosphate bioisostere was to be accommodated into 
the S31-201 aminophenol via substitution of the salicylic motif (Figure 6.1). One further design 
question remained, which was to decipher the favoured ring position for the phosphate group, as 
it could be installed on either the meta- or para-positions. 
 
 
 
 
 
 
Figure 6.1: S31-201 pharmacophore and proposed phosphate derivatives.45 
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6.2. S31-201 para-Phosphate 
To explore the preferred positions, docking of the phosphates was undertaken by Dr. Hechami 
Kadri (Cardiff University). By using FRED software and the STAT3β homodimer bound to DNA (PDB 
= 1BG1), docking for the para-phosphate S31-201 regioisomer (176) and S31-201 was determined 
(Figure 6.2).53 The tosyl group maintained a similar accommodation into the hydrophobic pY-1 
sub-pocket as expected.53 Critically, the phosphate group interacted with the same key Arg-609 
and Ser-611 residues as the salicylic group on S31-201, resulting in a score of -5.85 kcal/mol. As 
the energy score for the S31-201 derivative using this software was -4.66 kcal/mol, this data was 
suggestive that the para-phosphoric acid may possess improved STAT3 binding affinity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: A) p-phosphate S31-201 163. B) Predicted docking of phosphate 163 and S31-201 into 
the STAT3 SH2 domain (Stat3β homodimer bound to DNA) using FRED software.  
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6.3. S31-201 meta-Phosphate 
Using the same methodology for the meta-isomer (177), a similar profile was established (Figure 
6.3). The tosyl substituent appeared to still be accommodated in the hydrophobic pY-1 sub-pocket 
akin to S31-201 and the para-phosphate 176.53 However, the meta-positioning of the phosphate 
motif improved the pY sub-pocket interaction with the key Arg-609 and Ser-611 residues, which 
resulted in a superior energy score of -8.55 kcal/mol.53 This data is therefore suggestive that 
substitution of the salicylic group for a meta- or para-phosphate improves the binding to the 
STAT3 SH2 domain. Furthermore, this study proposes that the meta-isomer may contain superior 
binding to the STAT3 SH2 domain, but as this is preliminary data, this is only an indication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: A) m-phosphate S31-201 164. B) Predicted docking of phosphate 164 into the STAT3 
SH2 domain (Stat3β homodimer bound to DNA) using FRED software.  
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6.4. Aims and Objectives 
Without being able to confidently ascertain the favoured position to insert the phosphate motif, 
synthesising prodrug series of both regioisomers, in parallel, would be the only way to establish 
the most active isomer. To this end, the planned series of ProTic, POMTic and various other 
designs would be required for each of the regioisomer phosphate compounds. With the target 
library doubling in size through this decision, only three other prodrug approaches, the POMTic, 
bisPOM and bisethyl, were to be synthesised as comparatives for each isomer (Figure 6.4). 
The phosphoramidate derivatives were to also be redesigned, owing to the poor aqueous 
solubility observed with the ISS-610-Me proof-of-concept prodrugs in Chapter 4. Introduction of 
the napthyl group was envisioned to increase the leaving group preference of the prodrug aryloxy 
over the key tyrosine core structure. Whilst this modification was undoubtedly positive for the 
correct metabolic delivery of the active species, the napthol group increased the lipophilicity too 
drastically which deteriorated aqueous solubility. As a result, the prodrug was poorly soluble in 
aqueous solution, which is significantly problematic for a drug molecule. To overcome this, the 
napthyl group must be substituted for another “good” aryloxy leaving group, relative to phenol, 
but also retain good aqueous solubility. Out of the numerous candidates, 4-nitrophenol, was 
opted as the leaving group for this library of phosphoramidate prodrugs owing to its significantly 
increased polarity (Figure 6.4). 
To once again evaluate the most potent L-alanine ester functionality, a library of four different 
esters would be synthesised for each regioisomer of a methyl, isopropyl, tert-butyl and benzyl 
ester. The resultant eight phosphoramidate prodrug targets and known phosphate prodrug 
designs will be accompanied by one POMTic derivative (phenol) for each regioisomer, bringing the 
total library to 14 prodrugs (seven for each regioisomer). For the positive controls, the phosphoric 
acids, unphosphorylated phenolic structures and the original S31-201 control would also be 
required. This now brings the library for this chapter to 19 target molecules (Figure 6.4). 
 
 
 
 
 
Figure 6.4: Target library of S31-201 regioisomer phosphoramidate prodrugs (R1 = Me, iPr, tBu or 
Bn) and phosphate prodrugs (R2 = POM or ethyl. R3 = Phenol, POM or ethyl). 
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6.5. S31-201 Phosphate Library Retrosynthetic Analysis 
Being the larger components of the target library, the phosphoramidate ProTic prodrugs were to 
be synthesised first, in a multistep convergent synthesis for each regioisomer (Scheme 6.1). 
Starting from the commercially available glycolic acid 165, a Fischer esterification reaction with 
ethanol and acidic conditions, would protect the carboxylic acid motif, in the form of ester 166. 
This would then enable a sulphonation, with tosyl chloride, to install the tosyl moiety and yield 
tosylate 167. With the tosyl substituent now attached, the ester-protected carboxylic functional 
group could be readily de-protected with sodium hydroxide to obtain compound 168. Amide 
coupling of 4-/3-aminophenol, using standard coupling conditions with the carboxylic acid motifs, 
would then yield the key phenolic regioisomers 169-170 as positive controls and as the 
phosphorylation precursors. 
To complete the synthesis, four phosphorochloridates would be formulated, using the previously 
established chemistry for their napthyl analogues and directly coupled to both phenols. 
Phosphorylation of each phosphorochloridate to both phenols should facilitate all eight desired 
ProTic prodrugs as diastereoisomer pairs. Furthermore, the same methodology could then be 
applied to yield the two remaining phosphoric acids, POMTic prodrugs, bisPOM prodrugs and 
diethyl prodrugs from the key phenolic core structures 169 and 170. This would complete the 
required library of compounds, which could then be progressed for biological evaluation. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6.1: Retrosynthetic analysis of S31-201 ProTic regioisomers (R = Me, iPr, tBu or Bn). 
Design, Synthesis and Evaluation of S31-201 Phosphoramidate Prodrugs                             Chapter 6 
  
100 
 
6.6. Synthesis of S31-201 
The proposed retrosynthetic route was first investigated on the S31-201 pharmacophore. From 
glycolic acid 165, a Fischer esterification with concentrated sulphuric acid and ethanol facilitated 
ester 166 in modest yield (Scheme 6.2).164 Unfortunately, the high volatility of the product caused 
evaporation of large quantities of the compound during rotary evaporation-mediated solvent 
removal, which subsequently eroded the overall yield to 44%. Nonetheless, with the acid 
functionality protected as an ethyl ester, the tosyl substituent could be safely installed, via a SN2 
nucleophilic substitution with 4-toluenesulfonyl chloride, under basic conditions, at 0°C (Scheme 
6.2) to produce tosylate 167 in a yield of 81%. 
 
 
 
 
 
 
 
 
 
 
Scheme 6.2: Synthesis of S31-201 (10). 
Treatment of ester 167 with 5% sodium hydroxide solution and stirring for two hours (Scheme 
6.2) gave the acid 168 in an 86% yield.165 To promote the amidation, acid 168 was converted to an 
acyl chloride through a reflux with excess thionyl chloride which yielded chloride 171 in 
quantitative yield (Scheme 6.2).166 4-Aminosalicylic acid was then coupled to product 171 with 
triethylamine to furnish the desired S31-201 (10) in 69% yield and with an overall yield of 21% 
(five steps). 
6.7. Synthesis of meta-S31-201 ProTic Prodrugs 
With the S31-201 positive control now synthesised, efforts were redirected to generating the 
eight phosphoramidate prodrugs. Acyl chloride 171 provided a good intermediate to install either 
the 3/4-amino phenol substituents, to afford both phenolic regioisomers. To this end, acid 
chloride 171 was scaled-up and separately treated with 3-aminophenol or 4-aminophenol in THF 
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(Scheme 6.3), using triethylamine and stirring for 12 hours. The desired meta-phenol (159) and 
para-phenol (160) products were obtained in good yields. 
 
 
 
 
 
Scheme 6.3: Synthesis of meta-phenol product (169) and para-phenol product (170). 
Now, with both phenolic core structures in hand, the four phosphorochloridate components were 
required to directly phosphorylate and complete the synthesis of the S31-201 ProTic derivatives. 
As a test system, just the L-alanine methyl ester derivative was to be synthesised and reacted with 
the meta-phenol (169) to investigate the scope and feasibility of the phosphorylation reaction. 
By employing the same chemistry that was optimised in Chapter 4, phosphoryl chloride 93 was 
dissolved in anhydrous diethyl ether and cooled to -78 °C, to promote a mono-addition of 4-
nitrophenol via dropwise treatment of triethylamine, to give the dichloridate 172 in 98% yield 
(Scheme 6.4).146 A second mono-addition reaction to install the finalising L-alanine methyl ester 
group, using the same conditions, yielded the desired phosphorochloridate (173) as equal pairs of 
diastereoisomers in good yield. The same chemistry was then employed to formulate the 
remaining three phosphoramidates. The isopropyl (174, 64%), tert-butyl (175, 52%) and benzyl 
(176, 69%) chloridates were all synthesised as diastereoisomeric mixtures (Scheme 6.4). 
 
 
 
 
 
 
 
Scheme 6.4: Synthesis of phosphorodichloridate 172 crude and L-alanine ester 
phosphorochloridates (173 R = Me (58%), 174 R = iPr (64%), 175 R = tBu (52%) and 176 R = Bn 
(69%)). 
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The mono-addition yields for synthesising 4-nitrophenol-derived phosphorochloridates were 
consistently lower than their napthyl counterparts reported in Chapter 4. This is perhaps 
rationalised by the 4-nitrophenol substituent containing a weaker capacity to dissipate electron 
density from the phosphorus centre than a napthol substituent, which may supress the overall 
electrophilic capacity and reactivity of the phosphorochloridate towards nucleophiles. 
The meta-phenol core (169) was treated with two equivalents of chloridate 173 with 
triethylamine and stirred for 12 hours to produce the first S31-201 ProTic prodrug, compound 
177, in low yield as an equal pair of diastereoisomers (Scheme 6.5). Large proportions of the 
phenolic starting material remained unspent throughout the reaction, despite a further addition 
of two equivalents of phosphorochloridate 173 and triethylamine. Nonetheless, the correct 
product was synthesised in eight steps, with an overall yield of 2% and with the remaining 
unreacted starting material being recyclable for future use. 
 
 
 
 
 
Scheme 6.5: Synthesis of meta-S31-201 ProTic prodrugs (177 R = Me, 19%. 178 R = iPr, 11%. 179 R 
= tBu, 12%. 180 R = Bn, 25%). 
The three remaining chloridates were then individually reacted with meta-phenol compound 169, 
using the established conditions previously employed, which successfully produced the remaining 
meta-S31-201 ProTic prodrugs (Scheme 6.5). The prodrugs (178-180) were all synthesised as 
diastereoisomeric pairs and were low yielding (11-25%). The comparatively low overall yields for 
this prodrug library, in regards to that observed in Chapter 4, that employed similar chemistry, 
was suggestive that the substitution of the napthyl leaving group for the 4-nitrophenol derivative 
also affected yield as well as logP values.  
6.8. Synthesis of para-S31-201 ProTic Prodrugs 
The now established chemistry used to synthesise the meta-derivatives was employed to the 
para-derivative, phenol 170, in efforts to complete the library component of eight ProTic prodrugs 
(Scheme 6.6). However, this direct synthetic application towards the para-analogues failed to 
replicate the success formerly discussed. For both isopropyl (182) and tert-butyl (183) L-alanine 
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ester derivatives, the phosphorylation reactions were able to produce both desired para-S31-201 
ProTic prodrugs in similarly low yields of 16% and 12%, respectively.  
For the benzyl ester, compound 184, isolation of the desired product was extremely challenging. 
This was due to several co-eluting species contaminating the product fractions during flash 
column chromatography. Despite investigating different eluent systems, reaction conditions and 
starting material batches, the purification of the compound was not sufficient. Consequently, only 
a 2% yield of the ProTic prodrug could be isolated, which was still heavily contaminated. As HPLC 
purification was not available at the time, the compound was put aside until such a facility was 
accessible to enable purification of the compound to above 95% purity, as required for evaluation. 
 
 
 
 
 
 
 
Scheme 6.6: Synthesis of remaining para-S31-201 ProTic prodrugs (181 R = Me, 0%. 182 R = iPr, 
16%. 183 R = tBu, 12%. 184 R = Bn, 2%).  
With the synthesis of seven, albeit one impure, out of the eight S31-201 phosphoramidate 
prodrugs complete, the remaining derivative was the para-S31-201 methyl ester ProTic prodrug 
(181). Using the exact same conditions that furnished the previous seven other analogues, this 
surprisingly failed to produce this compound (Scheme 6.6). Instead, what was evident, after work-
up and column chromatography was large quantities of unreacted starting material 170 and one 
new species that bore resemblance to the desired molecule 181.  
The side product contained the para-substituted phosphoramidate fragment that was attached to 
a phenol-glycol core. However, this molecule did not possess a tosyl substituent and through NMR 
and LCMS analysis, the species in question was indeed the phosphorylation product but with the 
tosyl group apparently hydrolysed, which exclusively generated alcohol 185, in 20% yield (Scheme 
6.7). 
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Scheme 6.7: Synthesis of para-S31-201 methyl ester ProTic prodrug side product 185 and 
attempted tosylation to synthesise prodrug 181. 
As the tosyl group was paramount for the reported anti-STAT3 activity, a simple tosylation 
reaction with 4-toluenesulfonyl chloride and triethylamine was envisioned to regenerate the 
target molecule (Scheme 6.7). Unfortunately, the reaction was completely unsuccessful after 24 
hours and only starting material was present by TLC analysis. The reaction was repeated with a 
stronger base, DBU, which also proved unsuccessful, with only starting material being apparent by 
TLC and NMR analysis once again. 
With a direct tosylation reaction, using the conditions that were previously successful, being 
unable to formulate the final prodrug from alcohol 185, the original phosphorylation was re-
repeated using a new batch of starting material, in case the problem was reagent related. 
Unfortunately, the same alcohol product (185) was produced and no compound 181 could be 
identified prior to or post work-up and purification. Without a rationalisation to ascertain this 
strange phenomenon of tosyl hydrolysis and with the same result being observed with new 
reagents, the prodrug was revoked from the library in efforts to prioritise the synthesis of the 
numerous other prodrugs required for the series. Consequently, the seven S31-201 ProTic 
prodrugs were progressed for biological evaluation. 
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6.9. Synthesis of S31-201 Diethyl Phosphate Prodrugs 
To complement the seven phosphoramidate prodrugs, both regioisomer diethyl phosphate 
prodrugs were required for further comparison. Using the two phenolic cores (169 and 170), it 
was envisioned that a direct phosphorylation with triethylamine and diethyl chlorophosphate, 
would furnish both prodrugs. In a parallel, this was carried out using the same conditions as those 
used for the phosphoramidates (Scheme 6.8). Gratifyingly, both reactions successfully produced 
the S31-201 diethyl phosphate meta-prodrug 186 and the para-prodrug 187, in 19% and 18% 
yields, respectively. These yields were identical to those displayed for the phosphoramidate 
phosphorylation which indicates that the rationale for the low yields is derived from poor 
nucleophilicity of the phenols, as varying the chloridate seems to be make no difference. 
 
 
 
 
 
Scheme 6.8: Synthesis of meta-S31-201 diethyl phosphate 186 and para-phosphate 187. 
6.10. Synthesis of S31-201 Phosphoric Acids 
To synthesise both phosphoric acid positive controls, the chemistry employed in Chapter 4 to 
produce the ISS-610-Me phosphoric acid, was applied to both regioisomer phenols in an attempt 
to replicate its success.54 THF solutions of compounds 169 and 170 were each reacted with 
N,N,N',N'-tetramethylphosphorodiamidic chloride, catalytic DMAP and DBU for 12 hours (Scheme 
6.9). In either case, this was unsuccessful and only starting material was evident by TLC analysis.  
 
 
 
 
 
 
Scheme 6.9: Attempted synthesis of diamidates 188 and 189. 
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The evidently poor nucleophilicity of both regioisomer phenolic hydroxy substituents was likely 
exacerbated by the poor electrophilic capacity of N,N,N',N'-tetramethylphosphorodiamidic 
chloride, owing to I+ stabilisation. To overcome this, a more electrophilic bis-protected 
phosphorochloridate was required to promote the reaction and with sterics not being considered 
an issue on either regioisomer system, electrophilic dibenzyl phosphorochloridate 110 was 
identified as a potentially more reactive substitute. Consequently, meta-S31-201 phenol 169 was 
reacted with dibenzyl phosphorochloridate 110 and triethylamine (Scheme 6.10). Sadly, the 
reaction was also deemed unsuccessful via TLC analysis. 
In efforts to force the forward phosphorylation, the reaction was repeated with a stronger base, 
DBU, to investigate whether insufficient phenol deprotonation was instigating the outcome 
(Scheme 6.10). A parallel reaction with triethylamine, also failed to afford the desired product 
after 12 hours, with only starting material being observed. A final attempt focused on repeating 
the reaction with catalytic DMAP, which was demonstrated in Chapter 4 to be essential for 
promoting the reaction. Unfortunately, this approach was also unsuccessful and no new species 
was generated. 
 
 
 
 
 
Scheme 6.10: Attempted synthesis of dibenzyl phosphate 190. a) 110, Et3N, THF, 12 hours. b) 110, 
DBU, THF, 12 hours. c) 110, DBU, DMAP, THF, -78 °C, 12 hours. 
With the catalysed and un-catalysed coupling of phosphorochloridate reagents proving 
challenging, the more reactive phosphoryl chloride species was hypothesised to react more 
favourably with the substrate phenol. Furthermore, a subsequent hydrolysis with stoichiometric 
water would also furnish the desired phosphoric acid directly in one pot. This strategy was thus 
attempted on compound 169 with a triethylamine base at -78 °C, but after the 12 hour reaction, 
several new species were apparent by TLC analysis (Scheme 6.11). Despite numerous attempts to 
isolate and purify these species, their high polarity proved too difficult to achieve this without 
reverse-phase chromatography or preparative HPLC. Consequently, no product compound could 
be identified or isolated and another strategy to synthesise the phosphoric acid positive controls 
was required. 
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Scheme 6.11: Attempted synthesis of phosphoric acid 164. 
With both N,N,N',N'-tetramethylphosphorodiamidic chloride and dibenzyl phosphorochloridate 
lacking the electrophilic profile to facilitate the desired phosphate product, another masked 
phosphorochloridate was investigated, the diphenyl phosphorochloridate. The coupling was 
attempted with DIPEA (Scheme 6.12) but was evidently unsuccessful as no phosphate 191 was 
identifiable.  
 
 
 
 
 
Scheme 6.12: Attempted synthesis of diphenyl phosphate 191. 
A literature search for alternative approaches highlighted a powerful phosphorylation reaction 
known as the Atherton-Todd phosphorylation (Scheme 6.13). This reaction employs a generic 
dialkylphosphite that when treated with a hindered base, such as triethylamine, generates a 
deprotonated reactive intermediate 193.167 The unstable nature of this species promotes a 
nucleophilic attack to carbon tetrachloride, producing reactive chloridate 194 in situ.167 The 
reaction is completed by a subsequent attack by the desired nucleophile to furnish the phosphate 
product.167   
 
 
 
 
Scheme 6.13: Atherton-Todd phosphorylation mechanism.167 R= alkyl. Nu = nucleophile. 
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The numerous reports of literature success with the Atherton-Todd reaction warranted its 
investigation on our system. Unfortunately, as the carbon tetrachloride reagent required was 
prohibited under University regulations, N-chloro succinimide was substituted in as the source of 
electrophilic chloride.167 Using dibenzyl phosphite, N-chloro succinimide and DIPEA, the reaction 
was carried out (Scheme 6.14). Despite these conditions being reported in literature for similar 
phenolic structures, no products were detectable by TLC or LCMS analysis.  
A second approach was by employing carbon tetrabromide as an alternative to carbon 
tetrachloride, which produced some interesting results.168 Although no product 190 was 
identifiable, 31P NMR analysis of the crude was now displaying the presence of new phosphorus 
environments, indicative of successful phosphorylation. Moreover, TLC analysis demonstrated the 
consumption of starting material 169 and a series of more polar species. Attempts to isolate these 
species was unsuccessful but LCMS analysis of the mixture showed large proportions of the 
phosphorylated product without a tosyl group being present at an m/z of 428.44 [M-Ts+H]+. This 
was suggestive that the reaction was successful but somehow a secondary detosylation occurred, 
perhaps by bromide-mediated attack. 
  
 
 
 
 
 
Scheme 6.14: Attempted synthesis of dibenzyl phosphate 190. a) Dibenzyl phosphite, DIPEA, N-
chloro succinimide, MeCN. b) Dibenzyl phosphite, DIPEA, carbon tetrabromide, MeCN. 
To explore whether the issue of detosylation was culpable for the failure of producing phosphate 
190, a new strategy would investigate whether conveying the Atherton-Todd phosphorylation 
before installing the tosyl group would sidestep the problem (Scheme 6.15). To this end, the 
glycolic acid alcohol required a suitable protecting group, to enable the amidation of acid motif 
with the aminophenol and then proceed with the Atherton-Todd phosphorylation. With this stage 
complete, removal of the protecting group, followed by a tosylation reaction, should facilitate the 
core structure 200. A finalising palladium-catalysed hydrogen would then remove both benzyl 
masking groups and yield the desired phosphoric acid in a characteristically reported quantitative 
yield. If successful for the meta-phosphoric acid 164, this approach could then be applied to the 
remaining regioisomer to complete the synthesis of both phosphoric acid positive controls. 
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Scheme 6.15: Retrosynthetic analysis of meta-S31-201 phosphate 164. PG = protecting group. 
To protect the alcohol position, a solution of ethyl ester 168 in DCM was treated with TBDMSCl 
and imidazole at 0 °C, which facilitated mono-silylation product 201 in a moderate 48% yield 
(Scheme 6.16).169 
De-protection of the ethyl ester was attempted by employing one equivalent of potassium 
hydroxide, at 0 °C, to hydrolyse the ester (Scheme 6.16). Disappointingly, the de-protected 
product could not be identified and large amounts of tert-butyldimethylsilanol were present after 
the work-up. This is likely due to the acidic (pH 3) work-up required to protonate the acid for 
extraction hydrolysing the silyl ether. The work-up was performed without the acidic conditions 
but isolation of the pure product was unsuccessful. 
 
 
 
 
Scheme 6.16: Synthesis of ester 201 and attempted synthesis of acid 202. 
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An interesting literature strategy to complete this series of reactions was reported by Wissner and 
Grudzinskas in 1978.170,171 The published work demonstrates how bis-silylated hydroxy acids can 
be directly transformed into acyl chlorides with the silyl ether group intact via treatment of oxalyl 
chloride and catalytic DMF.171 Mechanistically, oxalyl chloride and DMF generate the typical 
Vilsmeler-Haack reagent 206 that is susceptible to addition from the silyl ester carbonyl 
functionality, in the form of intermediate 208 (Scheme 6.17).171 Fragmentation of this 
intermediate then generates the desired acyl chloride (209).171 
 
 
 
 
 
 
Scheme 6.17: Mechanism for chemospecific chlorination of bis-silylated hydroxy acids. R = 
alkyl.171 
In light of this new avenue to synthesise an acyl chloride silyl ether, glycolic acid 165 was once 
again reacted with TBDMSCl and imidazole, but this time with 2.2 equivalents to ensure the global 
bis-silylation (Scheme 6.18).172 Compound 211 was then treated with oxalyl chloride using the 
literature conditions to give highly reactive species 212, which was reacted with either 3-
aminophenol or 4-aminophenol, under basic conditions, to yield both regioisomer silyl-protected 
phenolic amides (213 and 214) in good yield.171 
Generation of both phenolic amide regioisomers, with the glycols protected, enabled the 
Atherton-Todd phosphorylation. Each regioisomer was reacted with dibenzyl phosphite, carbon 
tetrabromide and triethylamine, which successfully yielded both phosphate isomers (Scheme 
6.18).168  
Both regioisomers were treated with one equivalent of TBAF to remove the TBDMS groups 
(Scheme 6.18). For the para-regioisomer (218) the reaction proceeded to produce the de-silylated 
product in a low 51%, which was surprising as this type of reaction is well-established to produce 
near-quantitative yields.  
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Scheme 6.18: Synthesis of alcohols 217 and 218. a) TBAF, THF, 0 °C, 2 hours (217, m, = 0%), (218, 
p, 51%). b) TFA, H2O, THF, 0 °C, 3 hours (217, m, = 56%), (218, p, 67%). 
With the meta-isomer, the desired product was not formed and, instead, a series of side products 
was produced. Inspection of the major side product revealed it contained the core structure of 
compound 216, but with the silyl functionality removed. However, this species now had an 
additional phosphate environment with double the proton integrations expected for retaining 
two benzyl masking groups. Evidently, after the de-silylation reaction had occurred, the molecule 
had then incorporated an additional dibenzyl phosphate group (219). This theory was confirmed 
when LCMS analysis of this compound identified the hypothesised parent adducts at m/z of 710.2 
[M+Na]+ and 688.2 [M+H]+. 
To try and rationalise this reaction outcome, two key considerations were needed. The first 
question was how this phosphorylation event occurred and then, why this was more pronounced 
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for the meta-isomer and not in the para-isomer? Mechanistically, the glycolic alcohol could only 
participate after the de-silylation reaction had occurred, as this position was previously protected. 
After the removal of the silyl motif, the alcohol formed would be formally deprotonated and 
could act as potent nucleophile (Scheme 6.19). It is likely this alkoxy anion participated in an 
intramolecular phosphorylation reaction through attacking the phosphoryl position of another 
molecule of phosphate 216 (or 218) and expelling the reasonably good leaving group, that is the 
phenolic core. Resultantly, this would theoretically generate one molecule of side product 219 
and one molecule of the dephosphorylated and de-silylated product, diol 220. This is made 
evident by the yield of this product (46%), as the molecule itself is a reagent in this secondary 
reaction. 
 
 
 
 
 
 
 
 
 
Scheme 6.19: Proposed mechanism for formation of side product 219. 
It is conceivable that this additional participation occurred for both regioisomers, which would 
help rationalise the poor yield for the para-isomer de-silylation reaction. However, the additional 
stability of the P-O bond in the para-isoform (from para-directing I+ stabilisation from the amine) 
would decrease the electrophilic profile of the phosphate and enhance its resistance to this side 
reaction, which may ascertain why this reaction was overall successful. For the meta-isoform, 
there is no para-directing I+ stabilisation and the phosphate is thus more susceptible to cleavage. 
Going forward, to eliminate the theoretical formation of anionic species 218 that was reasoned to 
initiate the secondary phosphorylation reaction, the fluoride-mediated de-silylation reaction was 
substituted for one using acidic conditions.173 Accordingly, both regioisomers (215 and 216) were 
reacted with TFA/water, at 0 °C, for three hours which successfully yielded both alcohol products 
(217 and 218) in good yield, with no bisphosphate by-products identified (Scheme 6.18).173 
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Each isomer was treated with 4-toluenesulfonyl chloride, under basic conditions at 0 °C, to 
introduce the tosyl substituents (Scheme 6.20). Tosylate 221 (meta) and tosylate 222 (para) were 
synthesised in 87% and 90% yields, respectively. Using a 1:1 polar protic solvent mixture of 
ethanol and ethyl acetate with catalytic 10% palladium on carbon and hydrogen gas, both 
phosphoric acids regioisomers (176 and 177) were produced in 99% yields (Scheme 6.28).157 The 
synthesis of both phosphoric acid positive controls was now complete, which required a total of 
seven synthetic steps each, with the overall yields for the meta-acid (164) being 15% and 20% for 
the para-acid (163) 
 
 
 
 
 
 
 
 
 
 
Scheme 6.20: Synthesis of phosphoric acid 163 and 164. 
6.11. Synthesis of S31-201 POMTic Prodrugs 
The next targets were both regioisomer POMTic prodrugs 223 and 224 which could employ the 
chemistry from either of the two strategies developed in Chapter 5 (Scheme 6.21). The first 
approach investigated using the shorter set of synthetic sequences that involved resynthesising 
methyl phenyl phosphorochloridate 138 and coupling it directly to regioisomers 169 and 170. A 
finalising iodide-mediated transesterification should complete the synthesis of both POMTic 
prodrugs. However, with both fluoride (Scheme 6.18) and bromide (Scheme 6.14) ions previously 
displaying the ability to incite detosylation, this employment of iodide ions was risky. The larger 
steric size and substantially weaker charge density of iodide ions, in comparison to fluorides and 
bromides, could conversely help supress this from occurring which warranted investigation. 
Design, Synthesis and Evaluation of S31-201 Phosphoramidate Prodrugs                             Chapter 6 
  
114 
 
 
 
 
 
 
 
 
 
 
Scheme 6.21: Retrosynthetic analysis of S31-201 POMTic prodrugs 223 and 224. 
This risky strategy was attempted on the meta-isomer 169, where phosphorochloridate 138 was 
treated with triethylamine (Scheme 6.22), to give phosphate 225 with a similarly low yield as the 
previous phosphorylations. 
The iodide-mediate transesterification was attempted using the previously established reflux 
conditions with POMCl and NaI (Scheme 6.22). Unfortunately, no POMTic product could be 
identified or isolated after 24 hours despite full consumption of the starting material by TLC 
analysis. Although this was unconfirmed, it is likely that the iodide anions facilitated detosylation 
that decomposed the starting material. 
 
 
 
 
 
 
 
 
 
Scheme 6.22: Attempted synthesis of meta-POMTide 223. 
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Owing to the sensitivity of the tosylate starting material to halides, the second synthetic 
approach, which employed the POM phenyl phosphorochloridate 125 and directly coupling it with 
each phenolic regioisomer, was investigated. THF solutions of each isomer (169 and 170) were 
treated with chloridate 125 and triethylamine (Scheme 6.23). For the meta-isomer, the reaction 
successfully yielded the racemic meta-POMTic 223 in a low 11% yield.  
In regards to the para-isomer, the reaction appeared to have been successful, where a heavily 
contaminated mixture of the product was isolated after column chromatography. The purification 
of this mixture was very challenging and without HPLC facilities to assist in its isolation, the 
product was deemed inseparable after numerous separation methods were unsuccessful. 
 
 
 
 
 
Scheme 6.23: Synthesis of meta-POMTic 223 and attempted synthesis of para-POMTic 224. 
A new attempt focused on employing a DCC-catalysed esterification of phenol 170 and the 
previously synthesised POM phenyl phosphoric acid salt 145. This approach was then attempted 
using literature procedures for similar systems of using 1.1 equivalents of DCC and a pyridine 
base/solvent system (Scheme 6.24).174 However, this ultimately ended in failure, as after 24 
hours, TLC analysis deemed that no reaction had taken place and only starting material remained.  
 
 
 
 
Scheme 6.24: Attempted synthesis of para-POMTic 224. 
To overcome this problem, the synthetic route that successfully yielded both S31-201 phosphoric 
acids was investigated for this para-POMTic. As this approach applies the tosylation reaction after 
the problematic phosphorylation step, the iodide-mediated transesterification should not 
degrade the starting material and could be used once again to substitute a methyl phosphate into 
a POM phosphate. In light of this, a new synthetic route was devised that initiated from the 
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previously synthesised silyl ether 214 (Scheme 6.25). Phosphorochloridate 138 could then be 
coupled to yield methyl phosphate 227. To eliminate potential degradation, the silyl group would 
be removed first with acid, as established previously, and then subjected to the iodide-mediated 
transesterification to formulate POM phosphate 229. A final tosylation reaction of the free 
alcohol should complete the synthesis of POMTic 224. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6.25: New retrosynthetic analysis of S31-201 POMTic prodrug 224. 
Silyl ether 214 was treated with phosphorochloridate 138 and triethylamine, which produced 
phosphate 227 in a low yield of 10% (Scheme 6.26). Addition of catalytic DMAP to promote the 
reaction increased the yield of racemic phosphate 227 to a more manageable 42%. Deprotection 
of 227, with TFA and water in THF for two hours, gave alcohol 228 in excellent yield. 
The iodide-mediated transesterification reflux reaction with chloromethyl pivalate and sodium 
iodide successfully generated the POMTic precursor 229 in moderate yield, which was 
subsequently tosylated to furnish POMTic 224 in 88% yield (Scheme 6.26). This now finalised the 
synthesis of both POMTic prodrugs where meta-POMTic 223 was synthesised in an overall yield of 
1% (11 steps) and the para-POMTide 224 was synthesised in an overall yield of 8% (8 steps). 
Comparing both strategies, the alternative method used to prepare the para-isomer was three 
steps shorter and also 7% more efficient and is now the preferential approach. 
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Scheme 6.26: Synthesis of para-POMTic 224. a) 138, Et3N, MeCN, 24 hours, 10%. b) 138, DMAP, 
Et3N, MeCN, 24 hours, 42%.  
6.12. Synthesis of S31-201 BisPOM Prodrugs 
The final phosphate prodrugs to synthesise were the bisPOM regioisomers which employ the 
design most commonly used for phosphotyrosine-mimetic prodrugs. The typical literature 
approach for facilitating these prodrugs is via generation of a bisPOM phosphorochloridate and 
coupling it directly to the target molecule, analogous to the chemistry used for the 
phosphoramidates.90 To generate this key phosphorochloridate, there were a number of different 
reported methods. 
Due to still containing reasonably large quantities of bisPOM phenyl phosphate 141 (Chapter 5), 
the compound was considered to be an interesting starting material. Cleavage of the phenyl 
group would formulate a bisPOM phosphoric acid which could be directly chlorinated using 
literature procedures.90 To this end, a reported strategy of employing a powerful hydrogenation 
reaction, catalysed by platinum oxide (Adam’s catalyst) was investigated.175 The reaction was 
carried out in the same 1:1 solvent mixture of ethanol and ethyl acetate as used previously, with 
catalytic platinum oxide and a hydrogen atmosphere (Scheme 6.27). After 48 hours the reaction 
only produced small quantities of product 230 in 8% yield which was not sufficient for what was 
required.  
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Scheme 6.27: Synthesis of bisPOM phosphoric acid 230. a) PtO2, H2, EtOH, EtOAc, 48 hours, 8%. b) 
NaOH, MeOH, 0 °C, 0%. 
Hydrolysis at 0 °C, using NaOH in methanol, was attempted but no phenol was present in the 
mixture and the starting material had fully degraded. With LCMS analysis further confirming this, 
it is presumed that the hydroxide ions hydrolysed the POM groups instead. 
Another route investigated was based on generating the phosphoric acid sodium salt akin to the 
chemistry used for the POMTide precursor fragment 145. As refluxing this with sodium iodide in 
acetone exclusively hydrolysed the methoxy group and kept the POM substituent intact, the 
question was raised whether this approach could be employed for a bisPOM methyl phosphate. 
Trimethyl phosphate 231 was refluxed with two equivalents of chloromethyl pivalate and sodium 
iodide (Scheme 6.28).152 The bis-substituted product 232 was isolated from a mixture of the tris- 
and mono- side products. Phosphate 232 was then refluxed with excess sodium iodide in efforts 
to form the phosphoric acid salt, however, after 48 hours of reflux only reactant 232 was present. 
 
 
 
 
 
Scheme 6.28: Synthesis of phosphate 232 and attempted synthesis of phosphoric acid 233. 
The piperidine/HCl-Dowex method described in Chapter 5 was explored by first subjecting 
trimethyl phosphate 233 to a tris-transesterification reaction with three equivalents of 
chloromethyl pivalate and sodium iodide in acetonitrile, to give trisPOM 234 in 66% yield (Scheme 
6.29). This was the maximum yield obtained despite prolonging the reaction time or using 
additional equivalents of both reagents. 
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To selectively remove one POM group, trisPOM 234 was reacted with excess piperidine for 24 
hours, which yielded the piperidine salt of compound 234.152 In order to chlorinate the phosphoric 
acid, the salt needed to be removed, which is typically achieved by ion-exchange 
chromatography. At the time, this methodology was not available and an alternative method of 
an acid extraction, using 0.5N HCl, was carried out to give the phosphoric acid 243 in 60% yield. 
Chlorination of the acid using excess oxalyl chloride and catalytic DMF gave the desired bisPOM 
chloridate 248 in 75% yield, which was taken forward as crude, due to its high reactivity. 152 
 
 
 
 
 
 
 
Scheme 6.29: Synthesis of phosphorochloridate 235. 
The crude chloridate was directly treated to THF solutions of each phenolic regioisomer (169 and 
170) with triethylamine as a base (Scheme 6.30), which was unsuccessful. Later attempts to 
catalyse these phosphorylations, with reagents such as DMAP or Me2AlCl, appeared to promote 
detosylation via LCMS analysis, so this approach was abandoned (Scheme 6.29).  
 
 
 
 
 
Scheme 6.30: Attempted synthesis of bisPOM phosphate prodrugs 236 and 237. a) 235, Et3N, THF. 
b) 235, DBU, DMAP, THF. c) 235, DBU, Me2AlCl, THF. 
Re-examining the chemistry used throughout this chapter, one unexplored strategy presented 
itself as a possible solution that revolved around the novel discovery of preferred iodide-mediated 
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transesterification of benzyl groups over methyl groups. The idea was postulated that using 
previously synthesised dibenzyl phosphate compounds 217 and 218, which were used to 
synthesise the phosphoric acids, as starting materials might permit a novel bis-transesterification 
to formulate the bisPOM phosphates. If successful, a tosylation would complete the synthesis. 
Accordingly, solutions of both regioisomers were each refluxed with two equivalents of 
chloromethyl pivalate and sodium iodide to give the two bisPOM products (238 and 239) in good 
yield (Scheme 6.31). This route now provides an unreported method for bisPOM phosphate 
instalment for inert phenolic substrates.  
To complete the synthesis, each isomer was subjected to a tosylation reaction using the standard 
conditions (Scheme 6.31). In each case, both reactions led to the successful yield of the target 
bisPOM prodrugs 236 and 237 in 92% and 90% yields, respectively. This now finalised the two 
remaining prodrugs in a total of seven steps and with overall yields of 9% (236) and 12% (237). 
 
 
 
 
 
 
 
 
 
Scheme 6.31: Synthesis of bisPOM phosphate prodrugs 236 and 237. 
6.13. Synthesis of S31-201 Sulphonamide Derivatives 
With all the controls and various prodrugs now being synthesised and ready for biological 
investigation, one more addition was conjectured for the series. There had been literature reports 
that S31-201 can be alkylated to the STAT3 protein through expulsion of the tosyl motif, which 
could be problematic.176 In 2007, Gunning and co-workers demonstrated that the S31-201 tosyl 
substituent was susceptible to SN2 nucleophilic attack by several cysteine residues within the 
STAT3 protein that induces its alkylation to the protein and loss of activity.176 To overcome this, 
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Fletcher and co-workers reported modifying the tosyl C-OTs bond for a non-labile C-NHTs bond in 
the form of sulphonamides that was proven to increase resistance to alkylation, albeit at the cost 
of some activity.177 
To explore whether this trade-off of alkylation resistance and activity was required for our future 
compounds, three sulphonamide derivatives of the regioisomer phenols and S31-201 control 
were to be synthesised and compared in the study to evaluate the ramifications of this 
modification. The synthesis of these compounds began from treating glycine with sodium 
hydroxide and 4-toluenesulfonyl chloride to produce the sulphonamide 241 in a 60% yield 
(Scheme 6.32). The acid was then chlorinated using oxalyl chloride and catalytic DMF to afford 
acyl chloride 242 in 99% yield. The reaction was then subsequently scaled-up for the final steps.178 
 
 
 
 
Scheme 6.32: Synthesis of sulphonamide 241 and acyl chloride 242. 
The large batch of acid chloride 242 was separated into three flasks and treated to THF solutions 
of 3-aminophenol, 4-aminophenol or 4-aminosalicylic acid. Triethylamine was added to each flask 
and then all stirred for 12 hours, to successfully yield the three desired sulphonamides in low yield 
(Scheme 6.33). The low yield was accounted for by large quantities of the aminophenol analogues 
proving to be unreactive towards chloride 242. Nonetheless, the sulphonamides were obtained 
with overall yields of 19% (243), 21% (244 and 15% (245). 
 
 
 
 
 
 
 
 
Scheme 6.33: Synthesis of sulphonamides 243, 244 and 245. 
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6.14. Compound Library 
 
 
 
 
 
Phenol X R1 R2 Overall Yield cLogP M.W. Purity 
10 O OH COOH 21% (5 steps) 2.37 365.36 99% 
169 O OH H 19% (5 steps) 1.95 321.35 97% 
170 O H OH 26% (5 steps) 1.98 321.35 99% 
243 NH OH H 19% (3 steps) 2.12 320.06 99% 
244 NH H OH 21% (3 steps) 2.15 320.06 99% 
245 NH OH COOH 15% (3 steps) 2.53 354.37 99% 
 
Phosphate m/p R3 R4 Overall Yield cLogP M.W. Purity 
164 m OH OH 15% (7 steps) 2.66 516.42 97% 
177 m 4-Nitrophenol L-Al-Me 2% (8 steps) 3.41 607.53 97% 
178 m 4-Nitrophenol L-Al-iPr 1% (8 steps) 4.15 635.58 97% 
179 m 4-Nitrophenol L-Al-tBu 1% (8 steps) 4.59 649.61 96% 
180 m 4-Nitrophenol L-Al-Bn 3% (8 steps) 5.00 683.62 99% 
186 m Ethanol Ethanol 4% (6 steps) 2.51 457.43 97% 
223 m Phenol POM 1% (11 steps) 5.01 591.57 95% 
236 m POM POM 9% (7 steps) 4.86 629.61 95% 
163 p OH OH 20% (7 steps) 1.23 516.42 96% 
182 p 4-Nitrophenol L-Al-iPr 3% (8 steps) 4.17 635.58 95% 
183 p 4-Nitrophenol L-Al-tBu 2% (8 steps) 4.62 649.61 99% 
184 p 4-Nitrophenol L-Al-Bn 1% (8 steps) 5.03 683.62 80% 
187 p Ethanol Ethanol 5% (6 steps) 2.53 457.43 95% 
224 p Phenol POM 8% (8 steps) 5.03 591.57 92% 
237 p POM POM 12% (7 steps) 4.89 629.61 92% 
 
Figure 6.5: Compound library prior to evaluation using Molinspiration and HPLC for purity. 
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With the chemical library of 21 compounds successfully synthesised, each was then evaluated by 
analytical HPLC on its purity, to confirm they were above the 95% required (Figure 6.5). For the 
overwhelming majority, the compounds were above the 95% threshold and were all proceeded 
for biological evaluation despite three being slightly under. 
Comparing the clogP values for the various phosphate prodrugs, it became evident that the 
substitution for the 4-nitrophenol aryloxy leaving group was not as drastically increasing the 
ProTic clogP value from the native phosphate as the previously used napthyl group. This was 
encouraging, as it meant aqueous solubility in this ProTic series was likely to be improved whilst 
still benefiting from a potent leaving group that should disfavour cleavage of the phenolic core.   
Interestingly, both bisPOM prodrugs and POMTic prodrugs contained larger clogP values than the 
ProTic prodrugs, suggesting they may display enhanced passive diffusion over the 
phosphoramidates. However, the rate of prodrug metabolism is equally as essential and the 
ProTic prodrugs may deliver the active drug faster. As the first study of its kind, the results from 
this head-to-head anti-STAT3 prodrug evaluation were very unpredictable. 
6.15. S31-201 POMTic Human Serum Stability 
To investigate the stability profile of the S31-201 phosphate prodrug derivatives, one prodrug was 
evaluated for its stability in human serum, as previously described. POMTic 224 was evaluated by 
31P NMR experiments hourly, for 12 hours (Figure 6.6).147 Over the course of the first 10 hours, no 
new phosphorus environments were detected and it is reasoned the POMTic was stable for this 
period under these conditions.  
At the 12 hour mark, small new environments were beginning at similar chemical shifts as the 
original parent peaks, which is indicative of slight metabolism. Furthermore, the larger 
diastereoisomer peak at -15.56 ppm appeared to lose intensity. As this only occurs at 12 hours, 
the POMTic prodrug is still sufficiently stable in human serum up to this point and was considered 
acceptable. Overall, this study further showcases that the stability of POMTics (as well as 
POMTides) are sufficiently stable under physiological conditions and are indeed viable drug 
delivery strategies. However, as discussed in Chapter 4, the large quantities of DMSO used for this 
study may be interfering with the enzymes present within the serum and may produce 
inconclusive results. Further investigations into this hypothesis are required before any 
conclusions are drawn. 
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Figure 6.6: Stacked 31P NMR spectras (202 MHz, DMSO/D2O) of POMTic 224 (-15.25 and -15.56 
ppm) in human serum at 37 °C, for hourly intervals. 
6.16. S31-201 Library Immunoblotting 
As a preliminary investigation, seven compounds were given to a collaborator, Binar Dhiani 
(Cardiff University), who evaluated them in a STAT3-hyperactivated cancer cell line (MCF-7) to 
establish their activity. The pioneering study included S31-201 (10) as a control at a single dose of 
100 µM, with both phenols, phosphoric acids and diethyl phosphate prodrugs at varying dosages 
(0.3-30 µM). Activity profiles were drawn from the ability to supress the Survivin, BcL-xL and 
Cyclin D1 STAT3 target genes.  
Survivin signals in the untreated control lanes were not visible, which made conclusions based on 
Survivin inconclusive, although all six compounds displayed dose-dependent suppression of 
Survivin. For both phenol isomers, dose-dependent inhibition of Cyclin D1 was evident at 10 µM 
(169) and 30 µM (170), but with no effect on Bcl-xL. The two phosphoric acids surprisingly still 
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retained notable activity despite being highly impermeable, with dose-dependent suppression of 
Cyclin D1 still being apparent at 10 µM concentrations. The diethyl phosphate prodrugs displayed 
a better potency than the phosphoric acids, as expected, whereby Cyclin D1 was nearly fully 
supressed at 3 µM for each isomer and suppression of Bcl-xL (186) was even occurring at 30 µM. 
From this preliminary data, both regioisomers of the novel phosphoric acid derivative of S31-201 
displayed the ability to supress STAT3-hyperactivated genes, where the meta-isomer appeared to 
be the more potent isomer. The diethyl phosphate prodrug variants of these phosphoric acids 
further improved the anti-STAT3 activity, which coincides with the research hypothesis of 
improved cellular uptake of the compounds through increased lipophilicity. For nucleotide 
therapeutics, ProTide prodrugs were significantly more potent than diethyl phosphate prodrugs 
and this is anticipated to be the same with the untested ProTics that were synthesised for this 
series.108,109 Currently, the remaining compounds are soon to be evaluated in a full study, after the 
controls have been optimised to correctly show Survivin signals. 
6.17. Chapter 6 Conclusions 
In this chapter, the aim was to identify and develop a novel phosphate-containing STAT3 inhibitor 
and derivatise the molecule as a series of differing phosphate prodrugs (ProTic, POMTic, bisPOM 
and diethyl) for direct comparison. The known anti-STAT3 pharmacophore, S31-201, was 
nominated to be the core and salicylic functionality was substituted for the phosphate bioisostere 
in hopes to facilitate improved interactions with the STAT SH2 pY sub-pocket, which may increase 
activity. Problematically, computational studies could not elucidate the favoured ring position, so 
both regioisomer series were to be synthesised in parallel to ascertain the best position. 
The positive controls of the S31-201 parent and both regioisomer phenol derivatives were first 
synthesised in five steps each. Each phenolic core structure was then used to attempt to generate 
eight phosphoramidate (ProTic) prodrugs with 4-nitrophenol and L-alanine alkyl esters (Me, iPr, 
Bn or tBu). Unfortunately, the para-isomer methyl ester derivative could not be synthesised, so 
only seven phosphoramidate prodrugs were completed (eight steps each) and progressed. Two 
diethyl phosphate prodrugs were also synthesised in a total of six steps, from the phenol isomers.  
When synthesising the POMTic prodrugs, two different synthetic methods were used owing to 
purification issues for the para-isomer, but were nonetheless both successful with the meta-
isomer being synthesised in 11 steps and the para-isomer in eight steps. For the bisPOM 
prodrugs, a novel iodide-mediated transesterification of a dibenzyl phosphate substrate was first 
reported and used to synthesise both desired bisPOM prodrugs in seven steps. To complete the 
series, three sulphonamide derivatives of the tosylate positive controls (S31-201 and both 
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phenols) were synthesised to investigate the possibility of in vitro cysteine alkylation of the drug 
molecules. These compounds were facilitated in three steps and are anticipated to resist 
alkylation. 
One POMTic prodrug, compound 224, was evaluated for its stability in human serum for 12 hours, 
at 37 °C, by 31P NMR analysis. It was evident that the compound was stable, with only small 
metabolites forming at 12 hours, which was deemed as an acceptable stability profile for a 
prodrug. However, the use of large quantities of DMSO does need further investigation on 
whether this affects the contents of the serum. 
So far, seven compounds have been biologically evaluated on their anti-STAT3 capacity that 
includes S31-201, para- and meta-phenols, para- and meta-phosphoric acids and para- and meta-
diethyl phosphate prodrugs. The preliminary results demonstrate that the phosphoric acid 
regioisomers can supress STAT3-hyperactivated genes and may be acting as STAT3 inhibitors. 
Furthermore, the most active isomer appears to be the meta-substituted compounds. As the 
control lanes did not show correct levels of target gene expression, particularly Survivin, this study 
needs to be repeated and this data is only provisional. The whole library is soon to be tested with 
these controls corrected, to establish the lead compound of the series. 
When the results are back, optimisation of the lead design can begin, which will first consider the 
most active regioisomer and then whether inclusion of the tosyl or sulphonamide linker is more 
favourable. With both of these answers ascertained, the compound can progress as, either a 
POMTic or a ProTic prodrug, which will depend on the most active prodrug design from this study. 
A further investigation to prove this prodrug is correctly metabolising to the phosphoric acid 
compound is also required. 
With these parameters decided, construction from the amide motif, as a tri-pedal design, can 
begin to introduce functionalities to interact with the additional STAT3 SH2 domain sub-pocket 
that is currently not interacting with our active species. This has been reported in the literature to 
significantly increase the STAT3 SH2 domain binding affinity and by extension, increase the overall 
activity of the STAT3 inhibitor species.144 
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Chapter 7: Design, Synthesis and Evaluation of Stafib-1 
Phosphoramidate Prodrugs 
7.1. Stafib-1 
The success of developing novel phosphoramidate prodrugs of STAT3 inhibiting phosphotyrosine-
mimetic inhibitors suggested that the technology could also be applied to other, overexpressed 
proteins, such as STAT5. Comprising of two key isoforms, STAT5a and STAT5b, STAT5 proteins play 
essential roles in T-lymphocyte production and immune responses.64,179 This role is emphasised in 
several cancers, where overexpression of STAT5b has been shown to lead to the release of 
cancer-related transcription factors.56,64 To combat this, the STAT5b phosphotyrosine SH2 binding 
domain has been targeted and phosphotyrosine-mimetics have been developed to bind and 
inhibit the overexpressed proteins in chemotherapeutic attempts.123 In addition to their similar 
binding preferences and chemical nature, a series of small molecule, SH2 binding 
phosphotyrosine-mimics have been able to selectively bind to the SH2 docking domain of the 
STAT5b isoform over STAT5a. 
Most interesting of these inhibitors is Stafib-1, a diphosphate-phosphotyrosine mimetic, with an 
extremely impressive Ki value for the STAT5b SH2 of 0.044 µM (Figure 7.1).
56 Whilst displaying a Ki 
of 2.42 µM, for STAT5a, the drug species demonstrates exceptional 50-fold selectivity for 
STAT5b.56 Based on a first generation compound, Fosfosal (259), Elumalai and co-workers 
exchanged the carboxylic acid moiety for a second, meta-phosphate, which moderately increased 
the binding affinity for the STAT5b SH2 domain.56,64 Further modifications of Fosfosal with 
hydrophobic groups, to interact with the STAT5b SH2 hydrophobic pocket, led to the 
incorporation of a napthylic side chain. Optimisation of this chain, with the incorporation of N-
phenyl carboxamide moiety, generated the research group’s second generation, Stafib-1.56 
Unfortunately, the dual-phosphate motif is anionic under physiological conditions, which 
manifests into abysmal cell membrane permeability. 
 
 
 
 
 
Figure 7.1:  Fosfosal (246) and Stafib-1 (247).56 
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7.2. Aims and Objectives 
It was postulated that ProTic derivatisation of these two phosphates would drastically increase 
the lipophilicity of the compound to a sufficient level to promote full incorporation into the 
cellular domain, as demonstrated previously with the STAT3 inhibitors. Stafib-1 was to be 
derivatised into a novel phosphoramidate prodrug (261) in efforts to investigate this (Figure 7.2).  
As the target molecule was now very lipophilic (clogP = 6.51), the classically used phenol leaving 
groups were to be employed, as groups like napthol were feared to be too hydrophobic (clogP = 
8.60). This consequently meant that the leaving group capacity of the prodrug aryloxy group was 
no longer favoured and the molecule inherited a potential risk of incorrect metabolism. With this 
possibility in mind, only one ProTic analogue of Stafib-1 was to be initially synthesised which was 
nominated to be the methyl ester derivative (261). If the synthesis was successful and the 
subsequent biological results supportive, a further library of Stafib-1 ProTic and POMTic prodrugs 
was planned to be later synthesised to widen the investigation. 
 
 
 
 
 
 
 
 
Figure 7.2: Proposed Stafib-1 ProTic Prodrug 248. 
The synthesis of prodrug 248 was envisioned to be challenging, owing to the requirement of bis-
phosphorylating a notoriously inert catechol system.180 Furthermore, the large steric congestion 
generated from the introduction of these large phosphate motifs could be problematic and 
attaining the second phosphorylation may be exceedingly more challenging than the first. When a 
suitable strategy had been developed, the prodrug would be generated as a set of four 
diastereoisomers which may metabolise at significantly different rates and could require chiral 
resolution. 
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7.3. Stafib-1 ProTic Retrosynthetic Analysis 
Napthylic acid 249 was selected as the starting scaffold, with protection of the acid moiety with 
benzyl bromide enabling chemospecific substitution at the hydroxy position to produce ether 251 
(Scheme 7.1). With the glycolic ether component fully installed, the benzyl protecting group could 
be readily de-protected in a palladium-catalysed hydrogenation reaction to yield carboxylic acid 
252. This free carboxylic substituent is then suitable for a peptide coupling reaction with aniline to 
obtain amide 253. Hydrolysis of the ethyl ester moiety would reveal another acid motif, in the 
form of compound 254, with a peptide coupling reaction to finish the construction of the Stafib-1 
core. From this catechol derivative 255, a dual-phosphorylation with the designated 
phosphoramidate should furnish diastereoisomeric STAT5b ProTic inhibitor 248. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7.1:  Stafib-1 ProTic 248 retrosynthetic analysis. 
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7.4. Synthesis of Stafib-1 Phosphoramidate Prodrug 
Napthylic acid 249 was deprotonated with treating caesium carbonate and the caesium acid salt 
was reacted with benzyl bromide (Scheme 7.2). The reaction proceeded to chemoselectively 
produce ester 250 in a low yield (31%), which could not be increased despite repetition with 
excess reagents.  
As this was the first reaction in the synthesis, a higher yielding route was required to generate the 
necessary quantities of compound 250. A second approach involved refluxing reagent 249 with 
KHCO3 and benzyl bromide for eight hours, which yielded the desired product in an improved 86% 
yield, with complete chemospecificity over ether formation (Scheme 7.2).56 However, this 
significant increase is likely due to the harsh DMF refluxing conditions.  
KHCO3 was then exchanged for the stronger base, K2CO3, to account for the increased inertness of 
napthol hydroxyls over carboxylic acids, followed by reaction of the potassium alkoxide salt with 
ethyl bromoacetate to give compound 251 in good yield (84%).56  
Debenzylation of compound 251 was achieved with a palladium-catalysed hydrogenation reaction 
(Scheme 7.2). After a four hour reaction time, using the previously established conditions for 
hydrogenation (Chapter 6), carboxylic acid 252 was produced in quantitative yield. However, the 
product was difficult to isolate from the toluene by-products generated in the reaction and 
numerous attempts of azeotropic evaporation with methanol was required for liberation. 
Following its previous demonstration of efficacious amidification, the coupling reagent PyBOP in 
DMF with triethylamine was again selected to activate and facilitate the coupling reaction of acid 
252 and aniline, to furnish peptide 253 in high yield (Scheme 7.2).  
The glycolic carboxylic acid was de-protected with sodium hydroxide in THF and the carboxylic 
acid product 254 was isolated and collected by acid extraction, in near-quantitative yields 
(Scheme 7.2). 
The Stafib-1 core drug structure was completed with an amide coupling of 3,4-
dihydroxybenzylamine and PyBOP (Scheme 7.2). These conditions successfully yielded catechol 
255, albeit in an unexpectedly low yield of 56% which was due to experimental error when 
crystallising the diol out with DCM. Compound 255 was then resynthesised on a suitable scale 
prior to the phosphorylation reaction. 
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Scheme 7.2: Synthesis of catechol 255. a) Cs2CO3, MeOH, BnBr, DMF, 12 hours, 31%. b) KHCO3, 
BnBr, DMF, reflux, 8 hours, 86%. 
With the core now completed, phosphorylation could commence to complete the ProTic prodrug. 
Sterics were a very important consideration for developing these dual-phosphorylated prodrugs, 
as the diol substituents are in close proximity and could suffer from steric congestion by the bulky 
phosphoramidate motif. To minimise this, the initial target was to be the methyl ester and phenol 
derivative. The methyl substituent would provide the smallest issue of steric hindrance, making it 
ideal to start with. This issue could be exacerbated by the inertness of the catechol diols that have 
proven difficult to overcome in previous reactions and were anticipated to be troublesome.180 
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Nevertheless, synthesis of the phosphoramidate was achieved in parallel with previous ProTics. 
Commercially available, dichlorophenyl phosphate 137 was treated with L-alanine methyl ester, 
under basic conditions at -78 °C to attain phosphorochloridate 256 in 84% yield (Scheme 7.3).146  
 
 
 
 
 
 
 
 
 
 
 
Scheme 7.3: Synthesis of chloridate 256 and attempted synthesis of ProTic 248. a) 255, Et3N, 
MeCN, 0%. b) 255, tBuMgCl, MeCN, 0%. c) 255, pyridine, 0%. d) 255, tBuMgCl, MeCN, reflux, 0%. 
e) 255, tBuMgCl, DMF, reflux, 0%. f) 255, Et3N, DMAP, MeCN, 1%. g) 255, Et3N, tetrazole, MeCN, 
0%. h) 255, Et3N, DMAP, MeCN, reflux, <1%. i) 255, 
tBuMgCl, DMAP, MeCN, reflux, <1%. 
Owing to previous success with this method on other systems, it was theorised that coupling diol 
255 with phosphorochloridate 256 with triethylamine would furnish ProTic 248. Therefore, two 
equivalents of phosphoramidate 256 were added in acetonitrile, to ensure complete homogeneity 
of the solution, to the diol in a first approach (Scheme 7.3). However, TLC analysis concluded that 
the coupling had not commenced, with only starting material spots being visible.  
The reaction was trialed again with the far stronger base, tBuMgCl, in order to establish if it was a 
deprotonation issue. As with using triethylamine, TLC analysis confirmed that the reaction had not 
proceeded with only the starting materials being present after 72 hours. With neither mono- nor 
di-phosphorylation being observed, the conventional ProTic synthesis was not sufficient. As with 
the S31-201 phenols, a similar level of inertness was evidently apparent with the catechol.  
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To investigate the possibility of solubility being an issue, a third attempt explored using excess 
pyridine as a solvent/base system. After 72 hours the reaction was likewise deemed unsuccessful 
by TLC analysis, with only catechol 255 and chloridate 256 being visible despite formation of a 
fully homogeneous solution. This was indicative deprotonation and solubility were not the 
principal factors for the failure of the bis-phosphorylations attempts thus far. 
A fourth approach investigated the potential role temperature might play in the reaction. An 
acetonitrile solution of catechol 255, chloridate 256 and tBuMgCl was refluxed for 72 hours. 
Unfortunately, after this time period no new species were identifiable by TLC analysis.  
As the boiling point of acetonitrile is only 82 °C, refluxing in DMF (153 °C) was envisioned to more 
favourably promote the reaction, which justified investigation. After refluxing the reaction in DMF 
for 72 hours, no new lipophilic products were accountable through TLC analysis. The 31P NMR 
spectrum did display several new up-field singlet phosphorus environments that were indicative 
of thermal decomposition of the phosphorochloridate under the aggressively high temperatures. 
At this point, the two remaining possibilities that were controlling the reaction outcome were 
poor nucleophilicity of the catechol hydroxy’s and/or steric congestion. To probe the effects of 
nucleophilicity, a method of generating a more reactive electrophilic phosphorus species was 
attempted by treatment of catalytic DMAP. Amazingly, when employing DMAP and triethylamine 
base, the ProTic product 248 was indeed isolated in a 1% yield. The four singlet phosphorus peaks 
(two for each diastereoisomer set) being observed at -1.5, -1.6, -1.8 and -1.9 ppm in the 31P NMR 
spectrum. The parent [M+Na]+ mass being identified, of m/z at 947.2440, validated this.  
Problematically, the yields for the reaction were extremely poor and insufficient quantities of the 
compound were isolated for full analytical profiling, despite several repeats at larger scales. To 
this end, other catalytic compounds were trialed to explore the scope of this catalysed reaction 
and using the same conditions previously, tetrazole was employed as an alternative to DMAP.181 
Sadly, this failed to produce the product as observed with the DMAP-catalysed phosphorylation. 
With catalytic DMAP being the only method of attaining the target molecule, optimisation of the 
reaction was conveyed to ascertain a better approach for increasing the overall yield. It was 
hypothesised that refluxing the reaction mixture may help promote the phosphorylation reaction 
with triethylamine or tBuMgCl. Unfortunately, this seemed to make no difference to the overall 
yield and trace quantities of the product were isolated from both mixtures. Furthermore, no 
mono-phosphorylated product had been identified in either case which was suggestive that steric 
hindrance was not prohibiting the reaction, as if this was the case, large quantities of the mono-
phosphate would be formed and isolatable, rather than just the bis-product, as observed.    
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Table 7.1: Attempted conditions to synthesis target ProTic 248. 
As large quantities of the catechol precursor had now been consumed in the attempts to facilitate 
the phosphorylation reaction, catechol 257 was used as test system to conserve material (Scheme 
7.4). Different equivalents of the reagents were trialed on the system but the original conditions 
of 4 equivalents of DMAP 256 proved to be the highest yielding, at 16%. Higher proportions of 
either reagent did not succeed this 16% threshold for the test system or 1% for prodrug 255. 
 
 
 
 
 
Scheme 7.4: Synthesis of bis-phosphoramidate 258. 
Despite successfully yielding some product, the chemistry used so far was unable to produce 
enough compound for full characterisation or biological testing. In light of this, phosphorus III 
chemistry was revisited, owing to its increased reactivity with phenolic hydroxy groups.182 It was 
hypothesised that synthesising novel phosphorochloridite 259, and coupling it with the catechol 
under basic conditions, could generate di-phosphoramidite 260 where a subsequent oxidation 
with mCPBA would furnish target 248 (Scheme 7.5). As steric hindrance of two neighbouring 
phosphoramidates was believed to be possibly detrimental to phosphorylation; this strategy was 
deemed a viable solution as the substituents were now considerably smaller and more reactive.182 
Entry Base Solvent Catalyst Temperature (°C) Time (hrs) Yield 
a Et3N MeCN - 20 24 0% 
b tBuMgCl MeCN - 20 72 0% 
c Pyridine Pyridine - 20 72 0% 
d tBuMgCl MeCN - 82 72 0% 
e tBuMgCl DMF - 153 72 0% 
f Et3N MeCN DMAP 20 72 1% 
g Et3N MeCN Tetrazole 20 72 0% 
h Et3N MeCN DMAP 82 72 <1% 
i tBuMgCl MeCN DMAP 82 72 <1% 
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Therefore, starting from one equivalent phenol and refluxing with excess PCl3, chloridite 259 was 
isolated as a crude mixture (Scheme 7.5).183 Reaction confirmation was observed by the full 
conversion of the phenolic spot to a greater lipophilic spot in TLC analysis, indicative of success. 
Crude dichloridite 259 was directly added to a stirring solution of L-alanine methyl ester 
hydrochloride and refluxed for 12 hours. Regrettably, the presence of multiple new phosphorus 
environments in the 31P NMR spectrum meant the compound would require a form of 
chromatography to purify which would be exceedingly challenging, owing to the compound’s high 
susceptibility to hydrolysis. Therefore, vacuum distillation was used to isolate the product but was 
deemed unsuccessful after several attempts. 
 
 
 
 
 
Scheme 7.5: Attempted synthesis of phosphorochloridite 259. 
7.5. Stafib-1 Phosphonamidate Derivatisation 
This failure initiated the planning of a radically different synthetic approach. With the formation 
of the phosphate P-O bond being challenging to achieve in the laboratory, it was postulated 
whether forming an alternative P-C bond phosphonate derivative might suffice through using 
different chemistry. However, as stated previously, phosphates and phosphonates behave 
differently at physiological conditions. The second deprotonation pKa of phosphates (6.3) is vastly 
more acidic than that of a phosphonate (7-8), resulting in only partial in vivo deprotonation with 
phosphonate-containing drug molecules.115 
The di-anionic phosphate and mono-anionic phosphonate thereby have different degrees of 
solubility and affinity for the target’s active site.115 To overcome this, and to ensure the 
phosphonate can mimic the chemical nature of a phosphate, the bridging CH2 can be 
difluoronated. This modification would also increase the resistance to phosphatase-mediated 
dephosphorylation and ensure the correct delivery during the metabolic cyclisation step.115 
Derivatising the phosphate target as this bis-difluorophosphonate analogue was investigated as a 
plausible substitute (Figure 7.3). 
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Figure 7.3: Proposed Stafib-1 phosphonate and difluorophosphonate ProTics. 
A wide range of synthetic strategies currently exist for direct generation of difluorophosphonate 
P-C bonds. However, for facilitating this formation with aromatic rings, as required for the 
catechol moiety, documented accounts are rare.184 A reaction system of particular interest, 
developed in 1996 by Weiming Qiu and Donald J. Burton, involves the copper-promoted cross-
coupling of aryl iodides with diethoxyphosphinyldifluoromethylcadmium reagent 263 in the 
presence of CuCl to yield the desired difluorophosphonate in excellent yield (Scheme 7.6).184,185 
Owing to its potent reactivity, the diethoxyphosphinyldifluoromethylcadmium pronucleophile 263 
is prepared in situ via coordination of acid-washed cadmium powder to difluorobromide reagent 
264 in DMF (Scheme 7.6).184,185 Incorporation of the anticipated aryl iodide 265 and strictly 
stoichiometric equivalents of CuCl, to avoid decomposition of reagent 263, readily mediates cross-
coupling to furnish the α,α-difluoro benzylic phosphonate 266 in reportedly excellent yields and 
with good toleration for both electron withdrawing and donating aryl ring substituents.185 
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Scheme 7.6: Copper-mediated cross coupling mechanism for α,α-difluoro benzylic phosphonate 
synthesis. R = Electron withdrawing/donating moiety.185 
The reaction was consequently trialed on iodobenzene (265) as a test system, using literature 
precedent (Scheme 7.7).185 Addition of cadmium to bromide 264 in DMF, exhibited by TLC 
analysis to have generated intermediate 263, allowing for a cannula transfer of the reaction 
solution to a separate flask of iodobenzene and CuCl in DMF. Subsequent work-up and 
purification by column chromatography isolated the product 267 in a moderate 39% yield. 
Interestingly, the 31P NMR spectrum displayed a triplet peak at 6.39 ppm. Triplet splitting is 
generated though equivalent 2JP-F coupling of the spin-active equivalent 
19F atoms with the 
phosphorus.186 The performed 19F NMR spectrum also showed a doublet (2JF-P) at -108.48 ppm.
186 
 
 
 
 
 
Scheme 7.7: Synthesis of difluorophosphonate 267. 
With the copper-mediated cross coupling successfully producing α,α-difluoro benzylic 
phosphonates from aryl iodides, the chemistry was envisioned to be applicable to synthesise the 
new target molecule 262. By using a diiodide analogue of catechol 255, this reaction could 
possibly facilitate a bis-cross coupling to install the two diethyl phosphonate motifs to the Stafib-1 
core. The diethyl protecting groups can be readily de-protected with bromotrimethylsilane and 
oxalyl chloride to yield dichlorophosphonates which could then be selectively treated with phenol 
and L-alanine methyl ester, in efforts to complete the synthesis of the target ProTic. If the mono-
additions were problematic, proceeding via a diamidate prodrug was considered a backup. 
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7.6. (3,4-Diiodophenyl)methanamine Retrosynthetic Analysis 
To obtain the required diiodo derivative of catechol 255, (3,4-diiodophenyl)methanamine (268) 
was required to be coupled with carboxylic acid 254 (Scheme 7.8). This was envisioned to be 
achieved using the same conditions, of PyBOP and triethylamine. Unfortunately, diiodo 
compound 268 was not commercially available and a short number of reactions were required to 
synthesise it from known starting materials, in a total of six synthetic steps.  
From 4-aminobenzoic acid 269, treatment with stoichiometric iodine and silver sulphate induces 
mono-iodination regioselectively to yield amine 270. A subsequent Sandmeyer iodination 
reaction, with KI, H2SO4, and KNO2, would furnish the diiodo functionality with compound 271. 
With the iodinations complete, the carboxylic acid moiety could be reduced with borane to 
generate alcohol 272. Being a classical method of forming an amine from a primary alcohol, 
compound 272 could be substituted with mesyl chloride to yield sulphonate 273. Reacting this 
compound with sodium azide may substitute with the mesyl group, to give azide 274. To 
complete the synthesis, a Staudinger reduction of the azide motif, with PPh3 and water, should 
yield the diiodo fragment 268. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7.8: (3,4-diiodophenyl)methanamine 268 retrosynthetic analysis. 
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7.7. Synthesis of (3,4-Diiodophenyl)methanamine  
Despite being heavily deactivated, through benzoic acid-derived electron withdrawal, treatment 
of aromatic amine 269 with mild iodination reagents, iodine and silver sulphate, has been 
reported to deliver ortho-selective electrophilic iodination.187 The iodination reaction is facilitated 
through the oxidation of elemental iodine 275 into silver iodide 276 and a source of activated 
iodine electrophile 277 (Scheme 7.9).188 By forming a σ-complex intermediate 278 with the 
aromatic ring, the electrophilic iodine species is incorporated into the ring, where a subsequent 
deprotonation restores ring aromaticity and furnishes iodoarene 270.188 Regioselectively for the 
ortho-position is governed by the strongly electron-donating amine moiety promoting the ortho- 
positions and meta-directing electron-withdrawal from the acid disfavouring meta-sites.187,188   
 
 
 
 
 
 
Scheme 7.9: Mechanism for regioselective electrophilic iodination. B = base.187,188   
Displaying promising results in the literature, the reaction was believed to be a good starting 
position to construct the diiodoarene required and was attempted (Scheme 7.10).187 In practice, 
the electrophilic iodination of aromatic amine 270 proceeded to completion in a good yield of 
65%. The reaction was deemed successful, with the removal of a singular aromatic proton in the 
1H NMR spectrum, presenting a spectra of only three aromatic protons at 8.09 (s, 1H), 7.63 (dd, 
1H) and 6.72 (d, 1H) ppm, as expected. It is noteworthy that these chemical shifts agree with 
documented literature accounts of a singular ortho-iodination for this molecule.189 
 
 
 
 
 
Scheme 7.10: Synthesis of iodoarene 270. 
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By having the aromatic amine functionality, the known Sandmeyer reaction could convert the 
amine to the second iodine substituent.190 The reaction has an intriguing mechanism, whereby 
potassium nitrite 279 is bis-protonated by sulphuric acid, to form intermediate 281, allowing for a 
following water elimination to generate the reactive nitrosonium ion 282 in situ (Scheme 7.11).191 
The potent electrophile is attacked by amine 270 and rapidly deprotonated by adventitious water 
to form nitrosamine 284, followed by subsequent reprotonation to yield cation 285.191 
Tautomerisation of the species, to intermediate 286, stabilises the cationic charge and enables a 
second deprotonation with water to generate species 287.191 An identical dehydration series 
furnishes the benzenediazonium salt 289.191 With the diazotisation step complete, KI is added to 
the reaction to iodinate species 289 to yield diiodoarene 271.191 Typically, reacting salt 289 with a 
Cu+ catalyst initiates a radical electron transfer via liberation of elemental nitrogen to produce 
radical 290.192 As iodine oxidises readily and reversibly, the Cu+ can be superseded with KI, where 
a radical transfer from the iodine nucleophile then completes the iodination.192 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Scheme 7.11: Mechanism for Sandmeyer iodination.191,192 
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The two-step diazotisation-iodination reaction, to achieve diazotisation, was performed with 
KNO2 and concentrated acid at 0 °C, followed by subsequent addition of KI to complete the 
reaction (Scheme 7.12).189 In practice, this Sandmeyer diazotisation-iodination reaction 
successfully produced diiodoarene 271 in a very high yield of 86% in approximately 17 hours. 
With both iodides installed, the carboxylic acid moiety could be reduced to begin the installation 
of the methyl amine. Using the Lewis acid, borane, complete reduction of the benzoic acid to 
benzyl alcohol could be reportedly accomplished.193 Acid 270 was reacted with 2.4 equivalents of 
borane, in THF, for 16 hours to reduce the carboxylic acid to the alcohol 272, in good yield 
(Scheme 7.12).193 The alcohol 272 was then converted to mesylate 273 in a yield of 84%.189 
 
 
 
 
 
 
Scheme 7.12: Synthesis of alcohol 272 and mesylate 273. 
The sulphonate 273 was reacted with sodium azide and triethylamine to provide azide 274 in very 
high yield (Scheme 7.13).189 To complete the synthesis of fragment 268, a Staudinger reduction of 
the azide motif would allow amination to occur with PPh3 and water (Scheme 7.13). To this end, 
the reaction was carried out with excess triphenyl phosphine in THF.189 After reaction completion, 
addition of water to the solution successfully generated the desired amine product 268 in a good 
yield of 68%. This now completed the synthesis of diiodo fragment in six steps and with an overall 
yield of 23%. 
  
 
 
 
 
Scheme 7.13: Synthesis of azide 274 and amine 268. 
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With the final motif synthesised, the copper-mediated cross-coupling of amine 268 was 
attempted using the previously effective conditions, however, a number of phosphorus-
containing side products were formed (Scheme 7.14).185 The reaction was repeated with differing 
conditions, but again only a complex mixture was obtained. 
 
 
 
 
 
 
Scheme 7.14: Attempted synthesis of bis-phosphonate 291. 
Although possible participation of the free amine in the cross-coupling may be producing the side-
products, further investigation of the reaction stopped at this point as the difficult decision to 
abandon this target series was made. This decision was based on the fact that despite the 
enormous amount of time invested on this project, the chemistry was proving too difficult to 
produce meaningful amounts of the phosphate or phosphonate derivatives of stafib-1 ProTics and 
significantly more time was required. Therefore, efforts were redirected towards exploring the 
implementation of this phosphoramidate technology to phosphoserine-mimetic inhibitors 
instead. 
7.8. Chapter 7 Conclusions 
In this chapter, the objective was to investigate the application of the ProTic technology to STAT5 
inhibitors, owing to its huge success for the STAT3 isoform. To this end, the high-affinity and 
selective STAT5b inhibitor, Stafib-1, was nominated as a model system to explore this. As the 
molecule contained two neighbouring phosphate groups, it was envisioned that both would 
require prodrug derivatisation. Owing to having a high clogP value, only one target molecule was 
to be synthesised in the investigation, which was to be the methyl L-alanine ester.  
The synthesis began with generation of the key catechol (255) precursor to the target molecule in 
six steps, where phosphorylation with two equivalents of the relevant phosphorochloridate was 
envisioned to complete the synthesis. Unfortunately, the numerous conditions explored only 
managed to generate the product in 1% yield, by using catalytic DMAP. Scale-up reactions failed 
to reproduce this and insufficient quantities of the compound were produced. Attempts to 
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optimise conditions failed to improve this, so phosphorus III methodology was attempted instead. 
This also proved to be unsuccessful as the generation of the required phosphorochloridite was 
too challenging within the current facilities available in the laboratory. 
With the generation of the phosphate P-O bond being troublesome, the generation of P-C 
phosphonate bonds was investigated. This modification meant the phosphate groups would be 
substituted for phosphonates which differ significantly in pka. To overcome the repercussions of 
this, difluorophosphonates were to be used to mimic the phosphoric acid pka’s. This chemistry 
could be interestingly achieved by copper-promoted cross-coupling of diethoxyphosphinyl 
difluoromethylcadmium pronucleophile 263 and an iodoarene compound with CuCl. This was 
successfully attempted on a test system and then applied to diiodoarene 268, which was 
synthesised in six steps. Unfortunately, the subsequent coupling reaction failed and further 
investigation was discontinued. 
Overall, the chemistry was deemed too challenging and time consuming at this point and the 
chapter was closed. This was unfortunate, as the role of the amine in the cross-coupling could 
have been detrimental and nullifying its role warranted further investigation. Furthermore, other 
phosphorochloridates could have been explored, such as POMTic or diamidates, to ascertain if 
any other known derivatives will phosphorylate the catechol system. In conclusion, as the target 
molecule could not be synthesised, this series was abandoned. 
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Chapter 8: Design, Synthesis and Evaluation of 14-3-3 
Phosphoramidate Prodrugs 
8.1. 14-3-3 Inhibitors 
The novel approach of increasing the cell permeability of phosphotyrosine-mimetic protein-
protein inhibitors, by derivatising them as ProTic prodrugs had thus far provided successful 
results. It was then considered if this strategy could be applied to phosphoserine-mimetic 
inhibitors, which also possess poor membrane permeation.67,73 To investigate this hypothesis, a 
known phosphoserine-mimicking small molecule, phosphate 17, designed to inhibit 14-3-3σ 
proteins was to be selected and modified to contain the ProTic functionality (Figure 8.1).67,73 As 
previously mentioned, 14-3-3σ protein overexpression has been directly linked to cancer 
progression, such as its focal interaction with the tumour suppression protein, p53.194,195 
Disruption of this interaction is thus an attractive therapeutic target and had motivated Ha Wu 
and co-workers to develop a small molecule inhibitor.67,73 The inhibitor was derived from a 
complex peptide that efficaciously binds to the 14-3-3σ protein and through microarray-assisted 
high-throughput identification, the pharmacophore structure was rationalised, synthesised and 
evaluated for its ability to inhibit 14-3-3σ.122,196   
From competitive fluorescence polarisation (FP) experiments, the IC50 for inhibitor 17 was 
evaluated to be 2.6 µM.67,73 This value is somewhat promising, considering the phosphate motif is 
unprotected and suffers from the poor lipid bilayer permeability, commonly associated with 
phosphoamino-mimetic compounds. Nonetheless, the compound potently induced cell death in 
A549 lung cancer cells that actively overexpress the 14-3-3σ isoform.67,73 It was confirmed that 
this cytotoxicity was induced by successful disruption of the 14-3-3σ/ligand complex, resulting in 
caspase-derived apoptosis.67,73 These encouraging results highlighted this inhibitor species as an 
excellent trial compound for novel application of the ProTic technology, in an effort to increase 
cellular uptake.  
 
 
 
 
 
Figure 8.1: Phosphoserine-mimetic 14-3-3 inhibitor 17.67,73 
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8.2. Aims and Objectives 
As with ISS-610-Me for phosphotyrosine-mimetic inhibitors in Chapter 4, this compound would 
serve as an excellent proof-of-concept system, to explore whether the application of ProTic 
technology to phosphoserine-mimetic inhibitors would increase their permeability and overall 
activity.146 Therefore, a library of four ProTic prodrugs of the inhibitor was envisioned which 
would include the methyl (292), isopropyl (293), benzyl (294) and tert-butyl (295) L-alanine esters 
(Figure 8.2). As the serine alcohol was not phenol-derived, as with tyrosines, the issue of 
competing metabolic pathways of the prodrug aryloxy and phenolic core being eliminated during 
the cyclisation delivery step was not problematic, so a phenol leaving group was to be employed. 
To widen the scope of the study, diethyl prodrug 296, was also to be synthesised for comparison. 
It was anticipated this prodrug will be much slower in delivering the active compound than the 
phosphoramidates and will be weakly active. Additionally, the phosphoric acid 17 and 
unphosphorylated alcohol 18 (Figure 1.16) were also required as positive and negative controls, 
respectively. 
The compounds would then be evaluated for their ability to successfully metabolise and deliver 
the active species to 14-3-3 hyperactivated cancer cells. As 14-3-3 proteins directly transcribe 
target genes, the markers for activity were to be cleavage of PARP, which is indicative of induced 
apoptosis by 14-3-3 inhibitors.101 If successful, the ProTic prodrugs would facilitate enhanced 
PARP cleavage in comparison to the phosphoric acid and alcohol controls. 
 
 
 
 
 
 
 
 
 
 
Figure 8.2: 14-3-3 Inhibitor target molecules. R = Me (292), iPr (293), Bn (294) or tBu (295). 
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8.3. 14-3-3 Inhibitor ProTic Retrosynthetic Analysis 
Starting from Boc-L-serine 297, direct amidation of the tyramine onto the serine was envisioned 
to start the synthetic route and proceed with great chemoselectivity (Scheme 8.1). With tyramine 
inserted, the reactive serine alcohol was to be protected as a benzyl ether. Acidification to 
remove the Boc-protecting motif, yielding free amine 300, would enable an azide-containing 
secondary fragment to be installed. Hydrogenation of this species 301 could brandish de-
benzylated alcohol 18, where a phosphorylation step would finalise the desired ProTic prodrugs. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8.1: 14-3-3 Inhibitor ProTic prodrug retrosynthetic analysis. 
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8.4. Synthesis of 14-3-3 Inhibitor ProTic Prodrugs 
The synthesis began with the amidation of commercially available, Boc-L-serine 297, with 
tyramine and triethylamine. To promote the forward reaction, the coupling reagent PyBOP was 
employed to activate the serine carboxylic acid and after 12 hours the amide 298 was successfully 
obtained in 91% yield (Scheme 8.2). The reaction progressed with very high selectivity for the 
amidation, over the competing esterification, with only traces of the side product being identified 
during LCMS analysis prior to the work-up. 
 
 
 
 
 
Scheme 8.2: Synthesis of amide 298. 
The serine alcohol 298 required protection and was treated with the classical benzylation 
conditions of sodium hydride and benzyl bromide (Scheme 8.3). Unfortunately, use of the strong 
base, sodium hydride, to formally deprotonate the alcohol resulted in a complex mixture. Despite 
the well-established superior nucleophilicity of primary alcohols over phenols, it was presumed 
that the phenol was participating in side reactions. The reaction was then repeated with a weaker 
base, triethylamine, which would not formally deprotonate the phenol. Unfortunately, no 
reaction proceeded at all with triethylamine. To overcome this, a new strategy was proposed 
which involved benzylating Boc-serine 297 first and then conveying the amidation with tyramine 
after this reaction was complete. 
 
 
 
 
 
 
 
Scheme 8.3: Attempted synthesis of benzyl ether 299. a) NaH, BnBr, THF. b) Et3N, BnBr, THF. 
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Under anhydrous conditions, benzylation of Boc-L-serine 297 was readily achieved with the same 
methodology of benzyl bromide and sodium hydride, at 0 °C in anhydrous DMF (Scheme 8.2). 
Owing to the increased nucleophilicity of the alcohol over the carboxylic acid functionality, the 
reaction fashioned the ether product 302 chemoselectivly and in a moderate yield of 70%.  
With the primary alcohol now protected, repetition of the PyBOP-activated amidation of the 
carboxylic acid, with tyramine, then completed the synthesis of peptide 299. The exceedingly 
more reactive amine substituent participated with complete chemoselectivity over the lesser 
nucleophilic phenol, and hence, rationalises why the amidation proceeded with such an excellent 
yield. Furthermore, no evidence of the competing esterification reaction was observed. 
Confirmed amide coupling of tyramine to the L-serine motif then allowed for the Boc-protecting 
group to be removed, exposing the free amine for subsequent coupling to the azide fragment. In 
practice, the Boc group was readily deprotected via acidification with trifluoroacetic acid and 
DCM (Scheme 8.4). The reaction proceeded in near-quantitative yield to give amine 300. With the 
Boc moiety removed, the amine substituent could be directly coupled with the next fragment, to 
complete the core. 
 
 
 
 
 
 
 
 
Scheme 8.4: Synthesis of benzyl ether 302, amide 299 and amine 300. 
Synthesis of the second azide fragment, to couple to compound 300, followed literature 
methodology, from 4-aziodobenzoic acid starting material 303 (Scheme 8.3).101 Initially, the acid 
was amidified with glycine ethyl ester via PyBOP-activation, under basic conditions, to afford 
ethyl-protecting ester 304 in very high yield. 
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The ethyl functional group was readily hydrolysed, using excess 5% NaOH solution in THF (Scheme 
8.5).101 In one hour, an almost quantitative amount of acid 305 was generated after a subsequent 
acidic work-up was conveyed to aid extraction. 
Despite being originally proposed to amidate acid 305 directly to amine 300, with PyBOP, to 
furnish the dipeptide core in molecule 301, it had been reported by Richard F. Borch and co-
workers that this reaction was “very problematic” and alternatively suggested that coupling acid 
305 as a succinimide-activated acid yields superior results.101 This advice was adhered to and acid 
305 was amidified with N-hydroxysuccinimide and EDC. In practice, the reaction efficaciously 
yielded compound 306 in good yield. Being such a reactive species, reaction success was first 
validated by complete conversion of acid 305 to a new species by TLC analysis and then a crude 1H 
NMR analysis. Within the crude NMR spectrum, was the addition of a hydroxysuccinimide-
indicative singlet at 2.78 ppm, with an integration of four protons, providing evidence of 
successful synthesis. With the crude succinimide derivative formed, the same procedure used by 
Borch and co-workers was followed.101 
 
 
 
 
 
 
 
 
Scheme 8.5: Synthesis of ester 304, acid 305 and hydroxysuccinimide 306. 
Applying the literature procedure, the coupling reaction was trialed with a triethylamine base but 
formation of the desired peptide 301 was not evident (Scheme 8.6).101 From here, TLC analysis 
only indicated the presence of the starting reagents and no formation of a new lipophilic species. 
This was somewhat surprising as achieving peptide couplings, with succinimide-activated 
carboxylic acids and primary amines, is a routine practice for amidation, signifying that the failure 
derived from experimental error or the possible degradation of reactive species 306.  
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Nevertheless, efforts to install the azide fragment were redirected to the original strategy 
involving the PyBOP-activated amidation of acid 305 and amine 300 (Scheme 8.6). Pleasingly, 
using these coupling reaction conditions, the tripeptide 301 was successfully synthesised in high 
yield (Scheme 8.6). Interestingly, the glycine CH2 functionality was now a doublet of doublets 
splitting pattern at 4.05 ppm, whilst containing an integration of two protons. This splitting was 
quite perplexing, as throughout the synthesis, the glycine CH2 substituent had been consistently a 
doublet that was split by the neighbouring amide NH hydrogen. Fortunately, this anomaly was 
also reported within Borch and co-workers’ analytical data which was then rationalised to be due 
to an AB spin system.101 The AB system is commonly observed with benzylic and benzyloxy methyl 
substituents and is generated through isolated CH2 protons becoming diastereotopic and hence, 
self-coupling.197 The coupled aromatic azide was evidently behaving as such and was introducing 
chirality at this position.197 
 
 
 
 
 
 
 
 
 
 
Scheme 8.6: Synthesis of peptide 301 from compound 306 and compound 305. 
Now, with the final peptide coupling completed, deprotection of the benzyl ether was required. 
Using the classical strategy for de-benzylation, of a hydrogen atmosphere and a 10% Pd/C catalyst 
in a proton-transferring solvent, hydrogenation produced the desired serine product 18 in a 
disappointingly low yield of 11% yield (Scheme 8.7).198 TLC indicated more polar products 
suggesting these reaction conditions may not only hydrogenate the benzyl functionality but also 
the azide motif. 
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Scheme 8.7: Synthesis of alcohol 18. 
Through LCMS analysis of the mixture of side products, the [M+H]+ m/z of the reduced aromatic 
azide product, aromatic amine 307, was observed at 421.15 (Figure 8.3). Although the NMR data 
of the heavily contained fraction was too complex to confirm this, known literature accounts of 
azide reductions using these conditions, alongside the LCMS data, suggested this reduction 
contained a lack of chemoselectivity that was detrimental to the alcohol yield.199 Despite the lack 
of proof, it is highly likely side products 307 and 308 were formed during the reaction. However, 
as large quantities of alcohol 18 were required to complete the synthesis of the library, a higher 
yielding route was needed which did not generate unwanted side products on this scale. 
 
 
 
 
 
 
 
 
 
 
Figure 8.3: Proposed side products from hydrogenation of compound 301. 
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8.5. 14-3-3 Inhibitor ProTic New Retrosynthetic Analysis 
To address the hydrogenation chemoselectivity issue that was generating disappointingly low 
yields, a new synthetic sequence was formulated (Scheme 8.8). Amine 300 would be synthesised 
as previously achieved, but it would now be directly hydrogenated before the azide moiety was 
incorporated, to yield alcohol 309. This would enable the same hydrogenation procedure to be 
used without simultaneously reducing the azide group. With the hydrogenation complete, the 
azide fragment could now be safely introduced, by a PyBOP-activated amide coupling, to yield 
alcohol 18. Phosphorylation of this free alcohol would then complete the synthesis of the desired 
prodrugs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8.8: New 14-3-3 inhibitor ProTic prodrug retrosynthetic analysis. 
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8.6. New Synthesis of 14-3-3 Inhibitor ProTic Prodrugs 
Using an identical hydrogenation procedure, with atmospheric hydrogen and a Pd/C catalyst, de-
benzylation of compound 300 was then readily achieved to give alcohol 309 in quantitative yield 
(Scheme 8.9).198 PyBOP-mediated amidation of amine 309 and acid 305 gave the ProTic precursor 
18 (Scheme 8.9). Despite three competing nucleophilic substituents within compound 309 
(alcohol, amine and phenol), only the amine showed any signs of reaction participation. This 
chemoselectivity enabled the amidation reaction to proceed to generate large quantities of 
alcohol 18 in good yield. 
 
 
 
 
 
 
 
Scheme 8.9: Synthesis of alcohol 309 and peptide 18. 
The first ProTic to be synthesised, as a test system, was the L-alanine tert-butyl ester derivative 
295. Using phenyl dichloridate 137, L-alanine tert-butyl ester hydrochloride was treated alongside 
dropwise addition of Et3N (Scheme 8.10).
146 This was carried out at -78 °C, to minimise the 
exothermic response of neutralisation and reduce the likelihood of double-addition.106 The 
conveyed conditions yielded diastereoisomeric phosphorochloridate 310 in a high yield of 92%. 
 
 
 
 
 
 
Scheme 8.10: Synthesis of phosphorochloridate 310. 
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Synthesis of both alcohol 18 and chloridate 310 allowed the phosphorylation to proceed, where 
one equivalent of each reagent was reacted with triethylamine in acetonitrile. Through TLC 
analysis, there was no evidence of the desired ProTic product (Scheme 8.11). Therefore, the 
reaction was repeated with tBuMgCl replacing triethylamine and with the addition of a small 
volume of pyridine, to aid solubility.147 Fortunately, the new reaction conditions successfully 
yielded ProTic 295 as a pair of diastereoisomers, however, the majority of alcohol 18 remained 
unreacted.  
To address this poor reaction conversion, excess tBuMgCl was treated to the mixture but this was 
deemed ineffective, with no further product formation observed. In an alternative approach, 
excess phosphorochloridate 310 was incorporated, but this formed several new side products 
which were suggestive that the inert phenol was now also participating as a nucleophile in the 
reaction. 
 
 
 
 
 
 
Scheme 8.11: Synthesis of chloridate 310. a) 18, Et3N, MeCN, 24 hours, 0%. b) 18, 
tBuMgCl, MeCN, 
pyridine, 24 hours, 26%. 
To confirm the phosphorylation occurred at the more reactive serine hydroxy, rather than the 
tyramine phenol, the HSQC spectra was reviewed (Figure 8.4). The equivalent serine methylene 
protons (Ha) in alcohol 18 become significantly split and diastereotopic (Ha+b) after the 
phosphorylation. This large change in chemical environment, only apparent for these protons, is 
highly indicative of serine phosphorylation as this isolated splitting could not occur if only the 
phenol hydroxy group phosphorylated.  
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Figure 8.4: HSQC NMR spectra of compound 18 and HSQC NMR spectra of compound 295. X axis = 
1H NMR (500 MHz). Y axis = 13C NMR (126MHz). 
Design, Synthesis and Evaluation of 14-3-3 Phosphoramidate Prodrugs     Chapter 8 
  
156 
 
With an established method to generate the novel 14-3-3 inhibitor ProTics, the methodology was 
applied to the remaining three derivatives in the library. The two new phosphorochloridates (311 
and 312) were synthesised using this method and the previously synthesised L-alanine methyl 
ester phosphorochloridate (256) was resynthesised. Both new phosphorochloridates were 
synthesised in high yield, as equal pairs of diastereoisomers (Scheme 8.12). 
 
 
 
 
 
Scheme 8.12: Synthesis of remaining phosphorochloridates (311 R = iPr, 83%. 312 R = Bn, 85%). 
Now with the three key chloridate derivatives in hand, the phosphorylation conditions that 
successfully synthesised the tert-butyl ProTic 295 were applied for each species (Scheme 8.13). 
Resultantly, compound 18 was reacted with each chloridate in parallel, with tBuMgCl as a base. In 
each case, the desired prodrug (292-294) was synthesised as pairs of diastereoisomers, with yields 
of 27-29%. Within the HSQC NMR spectrum of each final compound, the same significant splitting 
of the serine methylene CH2, as prodrug 295, is apparent, which supports the formation of the 
three phosphoserine products over the theoretical phosphotyramine side products. 
This completed the synthesis of the four 14-3-3 inhibitor ProTics that totalled to nine steps each 
and with overall yields of 11% (292), 10% (293), 11% (294) and 11% (295). The four products were 
synthesised as mixtures of diastereoisomeric pairs, which were not chirally resolved. 
 
 
 
 
 
Scheme 8.13: Synthesis of remaining 14-3-3 ProTic prodrugs (292 R = Me, 29%. 293 R = iPr, 27%. 
294 R = Bn, 29%. 
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8.7. Synthesis of 14-3-3 Inhibitor Diethyl Phosphate Prodrug 
With the four phosphoramidate compounds afforded, the diethyl phosphate prodrug was 
envisioned to be synthesised from the direct phosphorylation of compound 18, with commercially 
available diethyl chlorophosphate 313, using the previously discussed conditions. As this prodrug 
design is known to be slowly metabolised, it would serve as an interesting comparative prodrug 
derivative. 
The diethyl prodrug 296 was successfully synthesised in a similar phosphorylation yield of 30% 
(Scheme 8.14). To confirm the chemoselectivity of the phosphorylation, analysis of the HSQC 
NMR spectrum displayed the key splitting of the serine methylene CH2 protons, akin to the 
previous spectras. This prodrug was synthesised in eight steps, with an overall yield of 14% which 
finalised the prodrug library prior to biological evaluation. 
 
 
 
 
 
 
Scheme 8.14: Synthesis of diethyl phosphate prodrug 296. 
8.8. Synthesis of 14-3-3 Inhibitor Phosphoric Acid 
To synthesise the remaining 14-3-3 inhibitor phosphoric acid positive control, the same approach 
used throughout the previous chapters was first attempted, which involved the DMAP-catalysed 
coupling alcohol 18 with N,N,N′,N′-tetramethylphosphorodiamidic chloride and DBU base.144 
Generation of this key phosphorodiamidate species would enable a final acidification with TFA to 
furnish the desired phosphoric acid compound in a typical quantitative yield and high purity 
isolation. 
The reaction conditions were thus investigated on compound 18 in efforts to generate the 
phosphorodiamidate (Scheme 8.15). Unfortunately, this approach failed to yield any new product 
species and after 24 hours, only starting materials remained.  
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Scheme 8.15: Attempted synthesis of diamidate 314. 
The next attempt focused on using the previously successful chemistry for serine phosphorylation 
of tBuMgCl base and an acetonitrile/pyridine solvent. Alcohol 18 was reacted with chloridate 112 
and tBuMgCl for 24 hours (Scheme 8.16).147 After this time period, the reaction was deemed 
successful and amidate 314 was isolated in 40% yield. The phosphorylation produced a 
surprisingly higher yield than with the other phosphorochloridates used in this series which is, 
perhaps, rationalised by the use of brand new reagents for this particular reaction. 
To complete the synthesis of the phosphoric acid control 17, diamidate 314 was treated with 
hydrochloric acid in 1,4-dioxane, for nine hours to give the phosphoric acid positive control 
species 17 in an excellent 91% yield (Scheme 8.16).146 The desired product was synthesised in nine 
steps, with an overall yield of 17%. This now meant the novel 14-3-3 inhibitor ProTic prodrug 
compound library was complete and ready for biological evaluation. 
 
 
 
 
 
 
 
 
 
Scheme 8.16: Synthesis of diamidate 314 and phosphoric acid 17. 
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8.9. 14-3-3 Inhibitor Series Compound Library 
The library of seven compounds contains four ProTic prodrugs, one diethyl prodrug, the 
phosphoric acid and alcohol (Figure 8.5). The clogP values for the ProTic prodrugs were 
significantly higher than the parent acid but did not display the excessively high values seen in 
previous chapters. However, it was conjectured that the use of a phenyl aryloxy leaving group and 
retention of the free tyramine alcohol would help keep the ProTic prodrugs within a good balance 
of high logP, for passive diffusion, but not so high that aqueous solubility is compromised. Before 
the compounds were sent to the collaborators for testing, analytical HPLC (UV) was used to 
evaluate the purity first. For all prodrug derivatives and alcohol 18, the purity was above the 
desired 95%. Regrettably, the phosphoric acid 17 was only 88% pure. Despite several attempts to 
purify the compound via recrystallisation and trituration, this could not be improved. As this 
compound was still of high purity and serving as only a control, it was progressed at 88% purity. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.5: Compound library prior to evaluation using Molinspiration and HPLC for purity. 
Compound R1 R2 Overall Yield cLogP M.W. Purity 
 Acid 17 OH OH 17% (9 steps) 0.91 503.45 88% 
Alcohol 18 - - 46% (7 steps) 1.57 426.43 96% 
ProTic 292 L-Al-Me Phenol 11% (9 steps) 3.15 667.66 96% 
ProTic 293 L-Al-iPr Phenol 10% (9 steps) 3.89 695.67 96% 
ProTic 294 L-Al-Bn Phenol  11% (9 steps) 4.75 743.72 95% 
ProTic 295 L-Al-tBu Phenol 11% (9 steps) 4.33 709.70 98% 
Prodrug 296 Ethyl Ethyl 14% (8 steps) 2.29 562.62 96% 
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8.10. 14-3-3 Inhibitor ProTic Human Serum Stability 
As previously described, one phosphoramidate prodrug (292) was to be evaluated for human 
serum stability profiling. The solubility of the compound was evidently poor and the peak signal 
strength throughout the experiment was very weak. Although the doublet of singlets peak can 
somewhat be seen throughout the 12 hours, this study is inconclusive based on the possibility of 
any metabolites forming being ‘hidden’ within the background noise. LCMS analysis of the 
incubated sample was then required to establish whether the prodrug was stable over time. 
These results will be preliminary as large quantities of DMSO were used again for this study, 
which as discussed previously, may denature the enzymes within the serum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6: A) LCMS (ES+) spectrum of ProTic 292 blank. B) LCMS (ES+) spectrum of human serum 
blank. C) LCMS (ES+) spectrum of sample tube incubated with human serum for 12 hours at 37 °C. 
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Two control LCMS experiments were first obtained to establish the blank spectrums for prodrug 
292 sample and the human serum sample which displayed the parent m/z of the prodrug at 
690.21 [M+Na]+ and 677.19 [M+H}+ and the serum major peak at a m/z of 506.55 (Figure 8.6).146 
Artefacts from the column were also present at an m/z of 413.27. The LCMS spectrum from the 
incubated sample displayed the prodrug [M+Na]+ as the major peak (m/z of 690.18), which 
indicates the vast majority of the prodrug was stable under these conditions for 12 hours. 
Interestingly, one new minor metabolite peak was observed at an m/z of 676.21, indicative of 
hydrolysis of the methyl ester [M-Me+Na]+. This species is theoretically the first generated during 
metabolism and identification of this m/z supports the theory that a small fraction of the prodrug 
began to metabolise under physiological conditions.  
8.11. 14-3-3 Inhibitor Library Biological Evaluation 
With the class of phosphoserine-mimetic ProTic prodrugs being evaluated to be sufficiently 
stable, under physiological conditions, the compound library as a whole was assessed for its anti-
14-3-3 activity and ability to induce apoptosis, via prohibition of 14-3-3 dimerisation. To achieve 
this, the compounds were given to a collaborator, Binar Dhiani (Cardiff University), who treated 
the compounds to lung cancer cell line, A549. This cell line was chosen owing to the original 
derivatives of this inhibitor, synthesised by Borch and co-workers, being evaluated in this cell line 
as well.122 This cell line was also believed to house the required carboxypeptidase Y and Hint-1 
enzymes to metabolise the ProTic prodrugs.106 Binar treated the cells with the library of 
compounds at 12.5, 25, 50 and 100 M concentrations, for 48 and 72 hours, where an MTT assay 
was used to evaluate cell viability after incubation (Figure 8.7). 
Phosphoric acid 17, alcohol 18 and diethyl phosphate 296 displayed no change in cell viability 
after incubation for both 48 and 72 hours. This is consistent with literature precedent that the 
phosphate motif is essential for the anti-14-3-3 activity.122 The phosphoric acid and diethyl 
prodrugs showing little activity was also expected, as the phosphoric acid was evidently poorly 
membrane-permeable and the diethyl prodrug was likely not fully metabolised. 
Gratifyingly, three of the ProTic derivatives, isopropyl 293, benzyl 294 and tert-butyl 295 all 
displayed improved dose-dependent decreases in cell viability for both time incubations. This 
does not demonstrate whether the prodrugs were metabolising to release the active drug or if 
the prodrug itself was a more potent inhibitor. Future work will need to distinguish whether this 
improved ability of the prodrugs to supress cell viability is through enhanced cellular import and 
metabolism or via improved activity without metabolism. 
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Figure 8.7: MTT assay of cell viability of A549 cells treated with compounds 17, 18, 292, 293, 294, 
295 and 296, at varying concentrations, for 48 or 72 hours. 
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Interestingly, the larger and more lipophilic L-alanine esters proved to be the most potent in this 
series. This is perhaps rationalised by the increased clogP value this generated, and hence, 
enhanced capacity for passive diffusion into the cell and a resultantly larger localisation of the 
active drug inside the cytoplasm. Additionally, the most active prodrug appeared to be compound 
293, the tert-butyl ester. This derivative is typically the slowest to metabolise for nucleotide 
therapeutics which is suggestive that phosphoserine-mimetic ProTic prodrugs may follow a 
slightly different metabolic breakdown or being more active without metabolising. 
8.12. Chapter 8 Conclusions 
In this chapter, the objective was to investigate whether the application of ProTic 
phosphoramidate technology to phosphoserine-mimetic 14-3-3 inhibitors would increase their 
lipophilicity and translate into increased activity, akin to the success with phosphotyrosine. A 
known anti-14-3-3 phosphoserine-mimetic inhibitor, compound 17, was thus derivatised as a 
series of four ProTic prodrugs which include methyl, isopropyl, tert-butyl and benzyl ester 
analogues. As serine does not contain a phenol motif, the issue of competing metabolic 
cyclisation was not apparent and a classical phenol group was used as the prodrug leaving group. 
A diethyl phosphate prodrug, unphosphorylated alcohol and phosphoric acid set of control 
compounds were also required. 
The unphosphorylated alcohol was first synthesised in seven steps, which then allowed a typical 
phosphorylation reaction, with tBuMgCl, to furnish the four desired ProTic prodrugs in a total of 
nine steps each. This same alcohol was then phosphorylated with diethyl chlorophosphate to 
generate the diethyl phosphate prodrug in a total of eight steps. The remaining phosphoric acid 
was synthesised using the diamidate acidification approach, using alcohol 18 as a precursor, 
which was successful and facilitated the product in a total of nine synthetic steps. 
With the desired library of compound synthesised, one ProTic prodrug was used to evaluate the 
typical stability profile of the compounds. ProTic 292 was incubated with human serum, at 37 °C, 
for 12 hours and followed by 31P NMR experiments. The solubility of the compound was evidently 
poor and a weak peak signal meant the NMR evaluation was inconclusive. LCMS analysis of the 
incubated sample revealed the large majority of the prodrug had remained intact, with a small 
peak forming that was suggestive a proportion of the compound had started to metabolise. This 
was reasoned to be the loss of the methyl ester substituent, owing to the m/z of this ion being 
found. As mentioned previously, the DMSO concentration may also be affecting this result. 
The 14-3-3 inhibitors were then given to collaborator, Binar Dhiani, who used a MTT assay to 
evaluate cell viability of A549 cancer cells treated with different doses of the compounds for 48 
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and 72 hours. Three of the ProTic prodrugs possessed significantly improved dose-dependent 
capabilities to supress cell viability than all control compounds. A general trend appeared to be 
that larger L-alanine esters were more potent, perhaps rationalised by higher lipophilicities and 
being favourable to permeate via passive diffusion into the cell. In conclusion, the application of 
ProTic technology to phosphoserine-mimetic drug molecules is now a powerful strategy for 
increasing their bioavailabilities and overall activities. 
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Chapter 9: Conclusions and Future Work 
9.1. Research Conclusions 
Over the last 20 years, the observed hyperactivation of the STAT/JAK pathway in 70% of all 
cancers has highlighted it as a viable target to attempt to inihibit and combat neoplastic 
progression.25 The more potent and selective approaches involve developing small molecule 
inhibitors that can bind to the highly conserved STAT SH2 domain and prohibit the STAT 
dimerisation event. This globally explored inhibition strategy has identified numerous anti-STAT 
drug molecules that are designed as phosphotyrosine-mimetics. Problematically, the common 
retention of phosphoric acid bioisosteres results in highly ionised drug molecules at physiological 
pH that poorly penetrate the cell membrane and manifest into abysmal bioavailabilities. This 
deficiency is mirrored in phosphoserine-mimetic drug molecules, which are an additional form of 
overexpressed, phospho-regulatory protein inhibitor that can also be used as anticancer agents. 
Efforts to overcome these shortfalls include derivatising the phosphoric acid functionalities as 
masked phosphate prodrugs that remain electronically neutral under physiological conditions. By 
being uncharged and lipophilic by design, the phosphate prodrug can passively diffuse into a cell 
where cellular components orchestrate the metabolism of the prodrug to deliver the active 
species.108 This prodrug approach is believed to account roughly 10% of all medicines being 
classed as prodrugs. However, to date, the primitive phosphate prodrugs employed for 
phosphotyrosine-mimetic or phosphoserine-mimetic drug molecules have been insufficient and 
fail to improve the bioavailabilities to suitable levels to facilitate the compounds through clinical 
trials. 
This research investigated whether the first use of novel aryloxy phosphoramidate triester 
prodrug designs, of one L-alanine ester motif and an aryloxy leaving group, could significantly 
improve passive cellular diffusion and enzymatically release the active species to the cell. This was 
believed to introduce a superior cellular uptake in comparison to the historically reported prodrug 
designs of phosphopeptide-mimetic drug molecules. Thereby, this theorised increase of 
lipophilicity was reasoned to significantly improve the overall activity of these compounds. 
In Chapter 4, this research hypothesis was investigated on a known STAT3 inhibitor, ISS-610. A 
small library of novel ISS-610-Me phosphopeptide-mimetic prodrugs (ProTics) was synthesised, 
alongside the ISS-610-Me phosphoric acid control. The compound library was then given to a 
collaborator, Binar Dhiani, who evaluated the compounds anti-STAT3 activity in a STAT3 
hyperactivated cancer cell line, MDA-MD-468. This study demonstrated improved anti-STAT3 
activity of the majority of the ProTic prodrugs.146 Collectively, this confirms the research 
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hypothesis that these phosphoramidate prodrugs are vastly superior at inhibiting overexpressed 
STAT3 proteins in cancer cells than the native phosphoric acid. Furthermore, the lead prodrug was 
subjected to a human serum stability assessment at 37 °C. Although the prodrug displayed poor 
aqueous solubility, it remained fully stable after 12 hours. 
To complement this promising ProTic approach, a new complementary phosphate prodrug design 
was envisioned to be explored, known as aryloxy pivaloyloxymethyl nucleotide prodrugs 
(POMTides). This prodrug was theorised to metabolise through a non-cyclic phosphate 
intermediate which was advantageous for phosphotyrosine-mimetics. Two general procedures 
towards the synthesis of POMTide prodrugs were investigated in Chapter 5 and a small library of 
5-FdU nucleotide ProTides and POMTides were synthesised, with the assistance of Ashwag 
Alanazi, for direct comparison of the most potent design. The library was given to Binar Dhiani 
and the results concluded that POMTides interestingly possessed a greater potency than the 
ProTide derivatives. Moreover, the POMTide prodrugs displayed excellent stabilities in a range of 
physiological conditions. This discovery warranted further investigation of the POMTide design. 
In Chapter 6, a novel STAT3 inhibitor from the S31-201 pharmacophore was designed by 
substituting the salicylic acid bioisostere for a phosphate motif. With computational models failing 
to ascertain the favoured ring position for this phosphate group, both meta- and para-isomers 
were to be synthesised in parallel. A series of ProTic, POMTic, bisPOM, diethyl and unprotected 
phosphates were synthesised for both regioisomers for comparison of the most potent 
regioisomer and prodrug design. Sulphonamide derivatives of the control compounds were also 
synthesised to investigate possible in vitro alkylation of the drug molecules onto STAT3 by 
cysteine residues within the protein. The library was given to collaborator, Binar Dhiani, and the 
initial findings indicate the meta- isomer is more potent. All phosphate-derived compounds tested 
so far appeared to be more potent at inhibiting STAT3 than the parent, S31-201 pharmacophore. 
However, this data is inconclusive and this is only preliminary findings. The remainder of the 
library is to be tested in the future, by other collaborators, to establish the most potent design for 
inhibiting overexpressed STAT3 in STAT3-hyperactivated cancer cell lines. An initial stability profile 
of one of the prodrugs, the POMTic, indicates the molecules are sufficiently stable under 
prolonged exposure to physiological conditions. 
The success of the generic ProTic prodrug derivatisation of STAT3 inhibitors prompted its use for 
other isoforms that are overexpressed in cancer. In Chapter 7, the technology was applied to a 
STAT5b inhibitor, Stafib-1. Despite enormous amounts of time invested and numerous synthetic 
routes attempted, only a small amount of the desired target molecule was synthesised. After a 
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final attempt of synthesising the difluorophosphonate derivative failed, the difficult decision to 
discontinue the Stafib-1 prodrug series was made and efforts were shifted elsewhere. 
In Chapter 8, the ProTic technology was applied to phosphoserine-mimetic inhibitors, to explore 
the scope of its applications. A series of phosphoserine-mimetic, 14-3-3 inhibitor ProTic prodrugs 
and a diethyl phosphate prodrug were synthesised alongside the parent phosphoric acid. The 
series was given to a collaborator who investigated the anticancer activities of the library. The 
results demonstrated the enhanced anti-14-3-3 activity and ability to supress cell viability in 
cancer cells with ProTic prodrugs, relative to the unmasked parent phosphoric acid. The more 
sterically bulky and hydrophobic ester derivatives proved to more significantly reduce cell 
viability. Furthermore, the ProTic prodrugs displayed acceptable stability under physiological 
conditions, with only small metabolites being observed after 12 hours. 
This successfully confirms the research hypothesis and validates the exploration of ProTics as 
viable prodrug designs to improve the bioavailabilities and activities of phosphopeptide-mimetic 
anticancer agents. In conclusion, this research has developed two novel prodrug strategies for 
anticancer phosphopeptide-mimetic inhibitors that both illustrated improved activities over their 
parent compounds and excellent stability profiles under physiological conditions. 
9.2. Future Work 
With Chapters 4, 5 and 8 being successful proof-of-concept studies and Chapter 7 being 
discontinued, the work applied in Chapter 6 provides the best foundation for optimisation. When 
the full library has been evaluated, it will be clear which regioisomer, prodrug design and sulphur 
bond (O-S or N-S) is more potent. Establishment of these parameters permits further construction 
of the lead drug molecule. By building-out from the secondary amide nitrogen, lipophilic 
functionalities can be installed into the molecule to begin interacting with the third STAT3 SH2 
domain sub-pocket (Figure 9.1). Interaction with this additional pocket will provide improved 
binding-affinities for STAT3 protein and will increase the overall anti-STAT3 activity of the drug 
molecule. As this particular sub-pocket is predominantly lipophilic, functionalities such as 4-
cyclohexenebenzyl could be explored, which have been shown in the literature to interact with 
this additional STAT3 sub-pocket.54,55 Furthermore, the substitution of difluorophosphonates for 
the phosphate motif would enable esterase-resistant STAT3 inhibitors to be formed. Collectively, 
these modifications could develop an extremely potent, bioavailable and physiologically stable 
STAT3 inhibitor. 
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Figure 9.1: Future S31-201 STAT3 inhibitor prodrug. R = any discussed promoeity. X = NH or O. 
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Chapter 10: Experimental Procedures 
10.1. General Experimental 
Solvent, Reagents and Reaction Conditions 
All solvents used were received from commercial suppliers. All of the other reagents used in the 
synthesis were purchased from Sigma-Aldrich, Fisher Scientific, Fluorochem, Alfa-Aesar or 
Carbosynth. All reactions were carried out under an argon or nitrogen atmosphere unless stated 
otherwise.  All glassware was oven-dried overnight and allowed to cool under dry argon/nitrogen.  
Thin Layer Chromatography (TLC) 
Reactions were monitored with analytical TLC on Merck silica gel 60-F254 precoated aluminium 
plates of 0.2 mm thickness. Plate visualisation was carried out with UV (254 nm), potassium 
permanganate stain (with heating) or phosphomolybdic acid stain (with heating). 
Flash Column Chromatography 
Column chromatography was performed on silica gel (35−70 μM) as a stationary phase and with 
the described solvent system. Glass columns were slurry-packed under gravity and fractions 
containing product were identified by TLC analysis or 31P NMR analysis. 
Nuclear Magnetic Resonance Spectroscopy 
NMR spectra data were recorded on a Bruker AVIII300 (1H, 300 MHz; T = 295 K. 19F, 300 MHz; T = 
295 K. 31P, 121 MHz; T = 295 K), AVIII400 (13C, 101 MHz; T = 295 K) or a Bruker Avance 500 (1H, 500 
MHz; T = 295 K. 13C, 125 MHz; T = 295 K. 19F, 407 MHz; T = 295 K. 31P, 202 MHz; T = 295 K) 
spectrometer in the deuterated solvents indicated where the spectra were calibrated on residual 
solvent peaks. Chemical shifts (δ) are quoted in ppm (parts per million), and J values are quoted in 
Hz. In reporting spectral data, the following abbreviations were used: s (singlet), d (doublet), dd 
(doublet of doublet), t (triplet), q (quartet) and m (multiplet). 1D 13C NMR spectra was recorded 
using PENDANT pulse sequences. 
Mass Spectrometry 
EI mass spectra was recorded on a VG ZabSpec magnetic sector mass spectrometer by the 
analytical staff and facilities at the School of Chemistry, University of Birmingham. ES mass spectra 
was manually recorded on a Bruker microtof mass spectrometer, operating in positive or negative 
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ion modes. High resolution mass spectrometry was performed as a service by Bath University, 
using a 6545 LC/Q-TOF mass spectrometer. 
High Performance Liquid Chromatography 
HPLC was carried out on a DIONEX summit P580 quaternary low-pressure gradient pump with a 
built-in vacuum degasser using a Summit UVD 170s UV/vis multichannel detector. Solvents were 
used as HPLC grade and not purified further. Chromeleon software was used to visualise and 
process the obtained chromatograms. Analytical separations used a flow rate of 1 mL/min. All 
tested compounds had a purity (total % area of product peak at 254 nm) of ≥95% as shown by 
HPLC. 
10.2. Stability Assay Procedures 
ISS-610-Me ProTic 75 Human Stability Assay Procedure147 
In a NMR tube, prodrug 75 (5 mg) was dissolved in DMSO-d6 (0.25 mL) and D2O (0.15 mL), forming 
a grey solution. A 31P NMR (202 MHz) experiment was conducted at 37 °C, as a control study. 
Defrosted human serum (0.30 mL) was then added to the NMR tube, forming a white suspension, 
and a 31P NMR experiment (202 MHz) was conducted every 30 minutes, for a total of 13 hours at 
37 °C. After 13 hours, the contents of the NMR tube was dissolved in water (10 mL) and extracted 
into ethyl acetate (3 x 10 mL), with the organic phase dried over MgSO4, filtered and concentrated 
under reduced pressure to afford a white solid. The white solid was used without purification for 
a LCMS experiment.  
POMTide 155 and ProTide 157 Human Stability Assay Procedure147 
In a NMR tube, POMTide 155 (3 mg) and ProTide 157 (3 mg) were dissolved in DMSO-d6 (0.10 mL) 
and D2O (0.15 mL), forming a colourless solution. A 
31P NMR (202 MHz) experiment was 
conducted at 37 °C, as a control study. Defrosted human serum (0.30 mL) was then added to the 
NMR tube, forming a white solution, and a 31P NMR experiment (202 MHz) was conducted every 
30 minutes, for a total of 13 hours at 37 °C.  
POMTide 155 pH-1 Stability Assay Procedure147 
In a NMR tube, POMTide 155 (5 mg) was dissolved in DMSO-d6 (0.10 mL), forming a colourless 
solution. A 31P NMR (202 MHz) experiment was conducted at 25 °C, as a control study. Acid buffer 
(0.30 mL, 1 pH), prepared from equal parts of 0.2 M HCl and 0.2 M KCl, was then added to the 
NMR tube, forming a colourless solution. A 31P NMR experiment (202 MHz) was conducted at 15 
minutes, 30 minutes, 1 hour and every hour after for a total of 6 hours at 25 °C.  
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POMTide 155 pH-7.4 Stability Assay Procedure147 
In a NMR tube, POMTide 155 (5 mg) was dissolved in DMSO-d6 (0.10 mL), forming a colourless 
solution. A 31P NMR (202 MHz) experiment was conducted at 25 °C, as a control study. Trizma 
buffer (0.30 mL, 7.4 pH) was then added to the NMR tube, forming a colourless solution, and a 31P 
NMR experiment (202 MHz) was conducted at 15 minutes, 30 minutes, one hour and every hour 
after for a total of six hours at 25 °C.  
S31-201 POMTic 224 Human Stability Assay Procedure147 
In a NMR tube, POMTic 224 (5 mg) was dissolved in DMSO-d6 (0.10 mL) and D2O (0.15 mL), 
forming a grey solution. A 31P NMR (202 MHz) experiment was conducted at 37 °C, as a control 
study. Defrosted human serum (0.30 mL) was then added to the NMR tube, forming a white 
solution, and a 31P NMR experiment (202 MHz) was conducted every 30 minutes, for a total of 13 
hours at 37 °C. 
14-3-3 Prodrug 292 Human Stability Assay Procedure147 
In a NMR tube, prodrug 292 (5 mg) was dissolved in DMSO-d6 (0.10 mL) and D2O (0.15 mL), 
forming a colourless solution. A 31P NMR (202 MHz) experiment was conducted at 37 °C, as a 
control study. Defrosted human serum (0.30 mL) was then added to the NMR tube, forming a 
white suspension, and a 31P NMR experiment (202 MHz) was conducted every 30 minutes, for a 
total of 13 hours at 37 °C. After 13 hours, the contents of the NMR tube was dissolved in water 
(10 mL) and extracted into ethyl acetate (3 x 10 mL), with the organic phase dried over MgSO4, 
filtered and concentrated under reduced pressure to afford a white solid. The white solid was 
used, without purification, for a LCMS experiment. 
10.3. Immunoblotting Procedures 
ISS-610 Library Immunoblots146 
MDA-MB-468 cells were cultured in RPMI 1640 media (Gibco) supplemented with 10% fetal 
bovine serum (FBS) (Gibco) and 1% of PenStrep (Gibco). The cell was maintained at 37 °C with 5% 
CO2 incubator to reach 70–80% confluency to be used in the experiment. The cells were treated 
with ISS-610, ISS-610-Met, or prodrugs 74-76 in various concentrations (0.1, 1, 10, 30 and 100 
μM) for 24 hours. Protein lysates were prepared using 1% NP40 lysis buffer containing 50 mM 
Tris– HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1% Nonidet-40, 0.27 M sucrose, 1 mM sodium 
orthovanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate supplemented with 1 mM 
benzamidine and 0.1 mM PMSF. Protein concentrations were measured using Bradford assay and 
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SDS samples were prepared by boiling the protein sample at 90 °C for 5 minutes in SDS sample 
loading buffer. 20 μg of each sample was loaded per lane and subjected to separation in 
polyacrylamide gels and transfer on to nitrocellulose membrane. Membranes were blocked in 
10% skim milk in TBST [50 mM Tris/HCl (pH 7.5), 0.15 M NaCl containing 0.25% Tween-20] for 30 
minutes at room temperature. The membranes were then incubated with the primary antibodies 
STAT3 (Cell Signalling Technology, #4904), Survivin (Cell Signalling Technology, #2808), Bcl-xl (Cell 
Signalling Technology, #2764) and β-actin (Cell Signalling Technology, #3700), overnight at 4 °C 
and secondary antibodies: anti-rabbit (Cell Signalling Technology, #7074) or anti-mouse (Cell 
Signalling Technology, #7076), for 1 h at room temperature. Finally, protein detection using 
horseradish peroxidase-conjugated secondary antibodies and the ECL® reagent (Amersham 
Bioscience) was performed. 
10.4. Cytotoxicity Procedures 
5FdU Library MTT Assay 
MCF-7 cells were cultured in DMEM-high glucose medium (Sigma) supplemented with 10% Fetal 
Bovine Serum (FBS) (Gibco) and 1% of PenStrep (Gibco). The cells were maintained at 37 °C in the 
incubator with 5% CO2 to reach 70-80% confluency to be used in the experiment. In a 96-well 
plate, 50 µL of complete growth media was added to each well. Each compound was prepared in 
a concentration of 400 µM to reach the final concentration of 100 µM for the highest 
concentration after several dilutions. Afterwards, 50 µL of each compound solution was mixed 
with the 50 µL of growth media in the first well. Serial dilution (2x dilution each step) was then 
performed by pipetting out 50 µL of each compound solution from the first well and pipetted in 
the next well, which contains 50 µL growth media and so on until the last well (11th well). The 
series of final concentration was ranging from 100 µM to 0.10 µM, and all compounds were 
prepared in triplicates. A 50 µL of MCF-7 cells containing 5,000 cells were added to each well, 
which contained 50 µL of compounds solution in the growth medium. The 96 well plates were 
incubated at 37 °C in the incubator with 5% CO2 for 48 and 72 hr before the MTT assay was 
performed. The MTT assay was performed using a CellTiter 96 Non-radioactive Proliferation Assay 
Kit (Promega). A 15 µL dye solution was then added on each well. After incubation for 4 hr at 37 
°C in the incubator with 5% CO2, 100 µL of stop solution was added to each well. The plates were 
then left overnight in room temperature before the absorbance was read on the microplate 
reader at 570 nm wavelength. As a control, DMSO was included in the experiments with 100% 
DMSO as the highest final concentration following serial dilution steps as the compounds. The 
same set of plates without cells (as a blank) were also measured its absorbance to be used for 
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correcting the absorbance of the sample. Finally, the measured absorbance was then used for 
calculating the % cell availability by the formula:  
% Cell viability = ((Absorbance sample−Absorbance blank)/Absorbance control DMSO) x 100%  
14-3-3 Library MTT Assay 
A549 cells were cultured in Ham’s F12K (Kaighn’s) medium (TermoFisher) supplemented with 10% 
Fetal Bovine Serum (FBS) (Gibco) and 1% of PenStrep (Gibco). The cells were maintained at 37 °C 
in the incubator with 5% CO2 to reach 70-80% confluency to be used in the experiment. In a 96-
well plate, 50 µL of complete growth media was added to each well. Each compound was 
prepared in a concentration of 400 µM to reach the final concentration of 100 µM for the highest 
concentration after several dilutions. Afterwards, 50 µL of each compound solution was mixed 
with the 50 µL of growth media in the first well. Serial dilution (2x dilution each step) was then 
performed by pipetting out 50 µL of each compound solution from the first well and pipetted in 
the next well, which contains 50 µL growth media and so on until the last well (11th well). The 
series of final concentration was ranging from 100 µM to 0.10 µM, and all compounds were 
prepared in triplicates. A 50 µL of A459 cells containing 5,000 cells were added to each well, which 
contained 50 µL of compounds solution in the growth medium. The 96 well plates were incubated 
at 37 °C in the incubator with 5% CO2 for 48 and 72 hr before the MTT assay was performed. The 
MTT assay was performed using a CellTiter 96 Non-radioactive Proliferation Assay Kit (Promega). 
A 15 µL dye solution was then added on each well. After incubation for 4 hr at 37 °C in the 
incubator with 5% CO2, 100 µL of stop solution was added to each well. The plates were then left 
overnight in room temperature before the absorbance was read on the microplate reader at 570 
nm wavelength. As a control, DMSO was included in the experiments with 100% DMSO as the 
highest final concentration following serial dilution steps as the compounds. The same set of 
plates without cells (as a blank) were also measured its absorbance to be used for correcting the 
absorbance of the sample. Finally, the measured absorbance was then used for calculating the % 
cell availability by the formula:  
% Cell viability = ((Absorbance sample−Absorbance blank)/Absorbance control DMSO) x 100%  
10.5. Docking Procedures 
S31-201, Phosphoric Acids 169 and 170 Docking with STAT3147 
PC Windows 7 with Intel Core i7-4790/3.6GHz microprocessor, 16 GB RAM, and 64 bit operating 
system was used to execute the computational studies. Docking was performed applying the 
Experimental Procedures                                                               Chapter 10 
  
174 
 
molecular modelling modules, namely, Omega2, FRED, and VIDA, provided by OpenEye Scientiﬁc 
Software (http://www.eyesopen. com). The three-dimensional crystal structure of the STAT3β 
homodimer bound to DNA was retrieved from the Protein Data Bank (PDB code = 1BG1) and the 
SH2 domain was subsequently identiﬁed on the basis of the bound ligand.53 Multiple conformers 
for compounds 10, 169 and 170 were generated by Omega2 using the default settings. FRED (fast 
rigid exhaustive docking) implements a rigid docking approach to ﬁt these conformers into the 
predeﬁned binding site and rank the poses by scoring functions.209 The VIDA module was then 
used to visualise and inspect the docked poses within the SH2 domain and to identify the main 
interacting residues.210, 211 
10.6. Chemistry Procedures 
Standard Procedure A: Preparation of Phosphorodichloridate Species 
In a flame-dried flask, POCl3 (1 equivalent) was added to a solution of the appropriate alcohol (1 
equivalent) in anhydrous diethyl ether. The solution was stirred at room temperature, for 30 
minutes, under an atmosphere of argon. The solution was then cooled to -78 oC, where 
triethylamine (1 equivalent) was added dropwise and then allowed to stir for 30 minutes, before 
being left to stir for one hour at room temperature. The white precipitate was filtered out of the 
solution and washed with anhydrous diethyl ether. The yellow filtrate was concentrated under 
reduced pressure to afford the desired phosphorochloridate, which was used without purification.  
 
Standard Procedure B: Preparation of Phosphorochloridate Species 
To a stirring solution of the appropriate phosphorodichloridate (1.1 equivalents) and anhydrous 
DCM, in a flame-dried flask, was added the desired L-alanine ester hydrochloride (1 equivalent) 
and stirred for 15 minutes at room temperature, under an argon atmosphere. Triethylamine (1 
equivalents) was added dropwise to the yellow solution, at -78 oC, to form a suspended white 
precipitate. The reaction mixture was stirred for 30 minutes before being left to stir and warm to 
room temperature for 2.5 hours. Upon reaction completion, the grey/white solution was 
concentrated under reduced pressure and filtered with ether. The yellow filtrate was 
concentrated under reduced pressure to afford a yellow oil, which was purified with flash column 
chromatography (6:4 ethyl acetate: hexane) to yield the phosphoramidate. 
Standard Procedure C: Preparation of ISS-610 Phosphoramidate Species 
In a flame-dried flask, a solution of the appropriate alcohol (1 equivalent) in anhydrous DCM was 
stirred with anhydrous triethylamine (2.2 equivalents) at room temperature for 15 minutes, under 
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an argon atmosphere. The desired phosphorochloridate (1.5 equivalents) was added dropwise in 
anhydrous DCM. The yellow solution was stirred at room temperature for five hours and was then 
concentrated under reduced pressure, forming a dense yellow oil. The oil was diluted in water 
and the product was extracted into ethyl acetate, where the yellow combined organic layers were 
washed with water and brine, dried over MgSO4, filtered and concentrated to form a white solid. 
Column chromatography (2:1 ethyl acetate: hexane) was used to isolate the desired prodrug. 
Standard Procedure D: Preparation of POM Phosphate 
The appropriate alkyl phosphate (1 equivalent), sodium iodide (1 equivalent) and chloromethyl 
pivalate (1.1 equivalents) were dissolved in anhydrous acetonitrile. The suspension was then 
refluxed, under an atmosphere of nitrogen, for 24 hours. After reaction completion was deemed 
by TLC, the solvent was removed under reduced pressure and the yellow suspension was 
dissolved in water. The product was then extracted into DCM, where the combined organic layers 
were washed with 5% Na2S2O3 solution, dried over MgSO4, filtered and concentrated under 
reduced pressure to afford a yellow oil. The oil was purified by flash column chromatography (1:5 
ethyl acetate: hexane) to yield the desired POM phosphate. 
Standard Procedure E: Preparation of BisPOM Phosphate 
The appropriate bis alkyl phosphate (1 equivalent), sodium iodide (2 equivalents) and 
chloromethyl pivalate (2.2 equivalents) were dissolved in anhydrous acetonitrile. The suspension 
was then refluxed, under an atmosphere of nitrogen, for 24 hours. After reaction completion was 
deemed by TLC, the solvent was removed under reduced pressure and the yellow suspension was 
dissolved in water. The product was then extracted into DCM, where the combined organic layers 
were washed with 5% Na2S2O3 solution, dried over MgSO4, filtered and concentrated under 
reduced pressure to afford a yellow oil. The oil was purified by flash column chromatography (1:5 
ethyl acetate: hexane) to yield the desired bisPOM phosphate. 
Standard Procedure F: Preparation of Phenolic Amides 
To a stirring solution of the appropriate amine (1 equivalent) in anhydrous THF, triethylamine (3 
equivalents) was added and stirred at room temperature, under a nitrogen atmosphere, for 30 
minutes. A solution of the desired acid chloride (1.1 equivalents), in anhydrous THF, was added 
dropwise at 0 °C and left to stir overnight, at room temperature. Water was added to the brown 
solution and the product was extracted into ethyl acetate. The combined organic layers were 
dried over MgSO4, filtered and concentrated under reduced pressure to afford a brown oil. 
Column chromatography (5:95 methanol: DCM) was used to isolate the desired amide. 
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Standard Procedure G: Preparation of S31-201 Phosphate Species 
To a stirring solution of the appropriate phenol (1 equivalent), under a nitrogen atmosphere in 
anhydrous THF, was added the desired phosphorochloridate (2 equivalents) and triethylamine (2 
equivalents). The orange solution was stirred at room temperature overnight. Upon reaction 
completion the mixture was quenched with methanol and stirred for ten minutes. The solvent 
was then removed under reduced pressure and the resultant orange oil was subjected to silica 
flash column chromatography (3:97 methanol: DCM), to isolate the desired product. 
Standard Procedure H: Preparation of Sulphonamide Amides 
To a stirring solution of the appropriate phenol (1 equivalent) in anhydrous THF, was added 
triethylamine (1 equivalent) and the resulting mixture then stirred at room temperature, under a 
nitrogen atmosphere, for 30 minutes. A solution of the desired acid chloride (1 equivalent), in 
anhydrous THF, was added dropwise at 0 °C and left to stir overnight, at room temperature. 
Water was added to the brown solution and the product was extracted into ethyl acetate. The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure to afford a yellow oil. Column chromatography (97:3 DCM: methanol) was used to the 
desired amide product. 
Standard Procedure I: Preparation of 14-3-3 Phosphate Species 
In a flame-dried flask and under a nitrogen atmosphere, peptide 18 (1 equivalent) was dissolved 
in a solution of anhydrous acetonitrile and anhydrous pyridine. Tert-butyl magnesium chloride (2 
equivalents) and the appropriate phosphorochloridate (1 equivalent) were added and stirred for 
24 hours, at room temperature. After reaction completion confirmed by TLC, the orange crude 
mixture was concentrated under reduced pressure and co-evaporated with methanol to 
azeotropically remove pyridine. The resulting orange oil was purified directly by flash column 
chromatography (5:95 methanol: DCM) to isolate the furnished desired prodrug. 
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Synthesis of methyl (tert-butoxycarbonyl)-L-tyrosyl-L-leucinate (78) 
 
 
 
 
To a stirring, colourless solution of Boc-L-tyrosine 91 (175 mg, 0.615 mmol), in anhydrous DCM (5 
mL), HOBt (74 mg, 0.550 mmol), N,N'-dicyclohexylcarbodiimide (107 mg, 0.525 mmol), L-leucine 
methyl ester hydrochloride (100 mg, 0.550 mmol) and triethylamine (0.09 mL, 0.630 mmol) were 
added at 0 °C. The white suspended solution was then stirred at room temperature for 12 hours, 
under an argon atmosphere. After reaction completion, the cloudy suspension was concentrated 
under reduced pressure and diluted with water (50 mL), where the product was extracted into 
ethyl acetate (3 x 50 mL). The combined organic layers were concentrated to 50 mL and washed 
with water (1 x 50 mL) and brine (1 x 50 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure to afford a colourless oil. Flash column chromatography (1:1 ethyl acetate: 
hexane) was utilised to purify the product and yield dipeptide 78 as a white crystalline solid (54 
mg, 25%).  
δH (400 MHz, CDCl3) 7.22 (d, J = 8.5 Hz, 2H, H-16), 7.09 (d, J = 8.5 Hz, 2H, H-17), 6.41 (d, J = 7.7 Hz, 
1H, H-7), 5.05 (d, J = 6.7 Hz, 1H, H-4), 4.58 (dd, J = 8.6, 5.1 Hz, 1H, H-5), 4.39 – 4.31 (m, H-8), 3.23 
(s, 3H, H-13), 3.05 (d, J = 8.3 Hz, 2H, H-14), 1.52 – 1.43 (m, 3H, H-9 + H-10), 1.42 (s, 9H, H-1), 0.90 
(t, J = 6.1 Hz, 6H, H-11). δC (101MHz, CDCl3) 172.8 (C=O), 170.9 (C=O), 151.9 (C=O), 150.0 (C-Ar), 
134.1 (CH-Ar), 130.4 (C-Ar), 121.4 (CH-Ar), 83.3 (C), 55.5 (CH), 52.3 (CH), 50.8 (CH3), 41.5 (CH2), 
37.2 (CH2), 28.2 (CH3), 27.5 (CH), 24.6 (CH3), 21.8 (CH3). MS (ES+) 431.2 [M+Na]
+.  
Analytical data is in agreement with literature values.131 
Synthesis of methyl (tert-butoxycarbonyl)-L-tyrosyl-L-leucinate (78) 
 
 
 
To a stirring, colourless solution of Boc-L-tyrosine 77 (125 mg, 0.444 mmol), in anhydrous THF (5 
mL), PyBOP (277 mg, 0.532 mmol), L-leucine methyl ester hydrochloride (162 mg, 0.889 mmol) 
and triethylamine (0.19 mL, 1.332 mmol) were added. The white suspended solution was stirred 
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at room temperature for eight hours, under an argon atmosphere. After reaction completion, the 
orange solution was concentrated under reduced pressure and diluted with water (50 mL), where 
the product was extracted into ethyl acetate (3 x 50 mL). The combined organic layers were 
concentrated to 50 mL and washed with brine (1 x 50 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure to afford a colourless oil. Flash column chromatography 
(2:1 ethyl acetate: hexane) was utilised to purify the product and yield dipeptide 78 as a white 
crystalline solid (170 mg, 94%).  
δH (500 MHz, CDCl3) 7.03 (d, J = 8.2 Hz, 2H, H-16), 6.73 (d, J = 8.5 Hz, 2H, H-17), 6.48 (s, 1H, H-19), 
6.34 (d, J = 8.2 Hz, 1H, H-7), 5.11 (s, 1H, H-4), 4.60 – 4.50 (m, 1H, H-5), 4.31 – 4.22 (m, 1H, H-8), 
3.69 (s, 3H, H-13), 2.97 (d, J = 6.8 Hz, 2H, H-14), 1.62 – 1.52 (m, 2H, H-9), 1.50 – 1.45 (m, 1H, H-10), 
1.43 (s, 9H, H-1), 0.90 (t, J = 6.6 Hz, 6H, H-11). δC (101MHz, CDCl3) 172.9 (C=O) 171.7 (C=O), 155.7 
(C=O), 155.5 (C-Ar), 130.4 (CH-Ar), 127.5 (C-Ar), 115.6 (CH-Ar), 80.5 (CCH3), 55.9 (CH), 52.3 (CH), 
50.8 (CH3), 41.4 (CH2), 37.4 (CH2), 28.2 (CH3), 24.6 (CH), 27.7 (CH3), 21.8 (CH3). MS (ES+) 431.2 
[M+Na]+, 331.2 [M-Boc+Na]+.  
Analytical data is in agreement with literature values.131 
Synthesis of methyl L-tyrosyl-L-leucinate (79) 
 
 
 
 
To a stirring solution of compound 78 (350 mg, 0.857 mmol) in DCM (8 mL), TFA (2.5 mL) was 
carefully added. The orange solution was left to stir at room temperature for two hours. Upon 
reaction completion, the orange solution was concentrated under reduced pressure, diluted with 
water (50 mL) and neutralised to pH 8 with 10% NaOH solution. The product was extracted from 
the orange solution with ethyl acetate (4 x 50 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure to yield peptide 79 as a white solid 
(260 mg, 99%). The product was used without purification. 
δH (500 MHz, CD3OD) 7.14 (d, J = 8.4 Hz, 2H, H-4), 6.79 (d, J = 8.4 Hz, 2H, H-3), 4.52 (t, J = 7.3 Hz, 
1H, H-11), 4.13 – 3.99 (m, 1H, H-7), 3.73 (s, 3H, H-16), 3.24 – 2.87 (m, 2H, H-6), 1.75 – 1.58 (m, 3H, 
H-12 + H-13), 0.97 (dd, J = 15.8, 6.1 Hz, 6H, H-14). δC (126 MHz, CD3OD) 172.5 (C=O), 168.7 (C=O), 
156.8 (C-Ar), 130.3 (CH-Ar), 124.6 (CH-Ar), 115.4 (C-Ar), 54.4 (CH), 51.3 (CH), 50.9 (CH3), 40.2 
(CH2), 36.5 (CH2), 24.5 (CH), 21.8 (CH3), 20.4 (CH3). MS (ES+) m/z 317.1 [M+Na]
+, 295.1 [M+H]+.  
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Analytical data is in agreement with literature values.200 
Synthesis of 4-cyanobenzoyl chloride (91) 
 
 
 
In a flame-dried flask, compound 90 (367 mg, 2.494 mmol) was dissolved in excess SOCl2 (3 mL) 
and catalytic anhydrous DMF (3 drops) was then added, under an argon atmosphere. The solution 
was refluxed at 68 °C for two hours, under an argon atmosphere. The dark yellow solution was 
then concentrated under reduced pressure to afford acid chloride 91 as a cream/yellow solid (412 
mg, >99%), which was used without purification. 
The compound was progressed as crude and could not be fully characterised. 
Synthesis of methyl (4-cyanobenzoyl)-L-tyrosyl-L-leucinate (80) 
 
 
 
 
Compound 79 (118 mg, 0.382 mmol) was dissolved in anhydrous THF (4 mL) with triethylamine 
(0.11 mL, 0.764 mmol) and stirred under an argon atmosphere, at room temperature, for 30 
minutes. To the colourless solution, acid chloride 91 (70 mg, 0.421 mmol) in anhydrous THF (2 mL) 
was added dropwise and left to stir overnight at room temperature. The cream solution, with a 
suspension of white precipitate, was concentrated under reduced pressure and then diluted in 
water (20 mL), where the product was extracted into ethyl acetate (3 x 20 mL). The combined 
orange organic layers were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure to afford an orange oil. Column chromatography (2:1 ethyl 
acetate: hexane) was used to yield dipeptide 80 as white crystals (70 mg, 42%).  
δH (300 MHz, CDCl3) 7.84 (d, J = 8.5 Hz, 2H, H-4), 7.73 (d, J = 8.5 Hz, 2H, H-3), 7.13 (d, J = 8.5 Hz, 
2H, H-19), 7.04 (d, J = 7.5 Hz, 1H, H-7), 6.75 (d, J = 8.5 Hz, 2H, H-20), 6.07 (d, J = 7.9 Hz, 1H, H-10), 
4.87 – 4.76 (m, 1H, H-11), 4.59 – 4.49 (m, 1H, H-8), 3.75 (s, 3H, H-16), 3.12 (dd, J = 13.9, 6.7 Hz, 
2H, H-17), 1.58 – 1.39 (m, 3H, H-12 + H-13), 0.89 (d, J = 5.6 Hz, 6H, H-14). δC (101MHz, CDCl3) 
172.8 (C=O), 171.2 (C=O), 165.5 (C=O), 155.3 (C-Ar), 137.4 (C-Ar), 132.4 (CH-Ar), 130.5 (CH-Ar), 
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127.9 (CH-Ar), 126.3 (C-Ar), 117.9 (CN), 115.6 (CH-Ar), 115.10 (C-Ar), 55.0 (CH), 52.5 (CH), 51.2 
(CH3), 41.2, (CH2), 37.8 (CH2), 24.8 (CH), 22.6 (CH3), 21.9 (CH3). MS (ES+) m/z 460.2 [M+Na]
+.  
Synthesis of naphthalen-1-yl phosphorodichloridate (94) 
 
 
 
 
Prepared according to Standard Procedure A, from POCl3 (0.56 mL, 6.000 mmol), 1-naphthol (864 
mg, 6.000 mmol), triethylamine (0.84 mL, 6.000 mmol) and anhydrous diethyl ether (6 mL). The 
product phosphorochloridate 94 was isolated as a clear yellow oil (1.54 g, 98%), which was used 
without purification.  
δH (500 MHz, CDCl3) 8.10 (d, J = 8.3 Hz, 1H, H-2), 7.91 (d, J = 7.3 Hz, 1H, H-5), 7.82 (d, J = 8.3 Hz, 
1H, H-7), 7.64 – 7.54 (m, 3H, H-3 + H-4 + H9), 7.52 – 7.44 (m, 1H, H-8). δP (121 MHz, CDCl3) 3.81.  
Analytical data is in agreement with literature values.201  
 
Synthesis of methyl (chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate (95) 
 
 
 
 
Prepared according to Standard Procedure B, from compound 94 (513 mg, 1.970 mmol), L-alanine 
methyl ester hydrochloride (250 mg, 1.790 mmol), triethylamine (0.50 mL, 3.580 mmol) and 
anhydrous DCM (5 mL). The product phosphoramidate 95 was isolated as a yellow oil (411 mg, 
70%). Product isolated as a mixture of diastereoisomers. 
δH (300 MHz, CDCl3) 8.10 – 8.02 (m, 1H, H-2), 7.88 (d, J = 7.5 Hz, 1H, H-5), 7.74 (d, J = 8.2 Hz, 1H, H-
7), 7.64 – 7.50 (m, 3H, H-3 + H-4 + H-9), 7.55 – 7.45 (m, 1H, H-8), 4.45 – 4.24 (m, 2H, H-10 + H-11), 
3.79 (d, J = 14.2 Hz, 3H, H-14), 1.55 (dd, J =9.2, 5.3 Hz, 3H, H-12). δP (121MHz, CDCl3) 8.29, 7.93.  
Analytical data is in agreement with literature values.202 
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Synthesis of isopropyl (chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate 
(96) 
 
 
 
 
Prepared according to Standard Procedure B, from compound 94 (513 mg, 1.970 mmol), L-alanine 
isopropyl ester hydrochloride (300 mg, 1.790 mmol), triethylamine (0.50 mL, 3.580 mmol) and 
anhydrous DCM (5 mL). The product compound 96 was isolated as a yellow oil (504 mg, 72%).  
Product isolated as a mixture of diastereoisomers. 
δH (300MHz, CDCl3) 8.13 – 8.01 (m, 1H, H-2), 7.91 – 7.83 (m, 1H, H-5), 7.74 (d, J = 8.3 Hz, 1H, H-7), 
7.58 (m, 3H, H-3 + H-4 + H-8), 7.50 – 7.34 (m, 1H, H-9), 5.09 (dq, J = 12.6, 6.3 Hz, 1H, H-15), 4.41 
(dd, J = 21.7, 9.4 Hz, 1H, H-11), 4.26 (ddd, J = 6.6, 5.1, 3.4 Hz, 1H, H-12), 1.54 (d, J = 6.5 Hz, 3H, H-
13), 1.35 – 1.20 (m, 6H, H-16). δP (121MHz, CDCl3) 8.29, 7.93.  
Analytical data is in agreement with literature values.202 
Synthesis of benzyl (chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate (97) 
 
 
 
 
Prepared according to Standard Procedure B, from compound 107 (513 mg, 1.970 mmol), L-
alanine benzyl ester hydrochloride (386 mg, 1.790 mmol), triethylamine (0.50 mL, 3.580 mmol)  
and anhydrous DCM (5 mL). The product compound 110 was isolated as a yellow oil (700 mg, 
97%). Product isolated as a mixture of diastereoisomers. 
δH (300MHz, CDCl3) 8.12 – 7.98 (m, 1H, H-2), 7.91 – 7.83 (m, 1H, H-5), 7.73 (d, J = 8.3 Hz, 1H, H-7), 
7.61 – 7.49 (m, 3H, H-3 + H-4 + H-8), 7.44 (dd, J = 11.5, 3.6 Hz, 1H, H-9), 7.39 – 7.30 (m, 5H, H-17 + 
H-18 + H-19), 5.26 – 5.15 (m, 2H, H-15), 4.42 – 4.25 (m, 2H, H-11 + H-12), 1.56 (d, J = 6.6 Hz, 3H, H-
13). δP (121MHz, CDCl3) 8.11, 7.80.  
Analytical data is in agreement with literature values.202 
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Synthesis of Methyl ((2S)-2-(4-cyanobenzamido)-3-(4-(((((S)-1-methoxy-1-
oxopropan-2-yl)amino)(naphthalen-1-
yloxy)phosphoryl)oxy)phenyl)propanoyl)-L-leucinate (74) 
 
 
 
 
 
 
 
Prepared according to Standard Procedure C, from compound 80 (100 mg, 0.229 mmol), 
anhydrous triethylamine (0.07 mL, 0.504 mmol), phosphorochloridate 95 (113 mg, 0.344 mmol) 
and anhydrous DCM (9 mL). The product prodrug 74 was isolated as white crystals (120 mg, 72%).  
Product isolated as a mixture of diastereoisomers. 
δH (400MHz, CDCl3) 8.00 (d, J = 6.6 Hz, 1H, H-35), 7.90 – 7.77 (m, 1H, H-32), 7.79 – 7.67 (m, 2H, H-
4), 7.63 (d, J = 12.4 Hz, 1H, H-30), 7.58 – 7.41 (m, 5H, H-3 + H-28 + H-33 + H-34), 7.41 – 7.30 (m, 
2H, H-7 + H-29), 7.17 – 7.10 (m, 4H, H-19 + H-20), 6.93 (d, J = 7.4 Hz, 1H, H-10), 5.01 – 4.78 (m, 1H, 
H-8), 4.55 (t, J = 4.7 Hz, 1H, H-11), 4.53 – 4.38 (m, 1H, H-22), 4.15 (q, J = 8.2 Hz, 1H, H-23), 3.67 (d, 
J = 4.7 Hz, 3H, H-16), 3.57 (d, J = 16.3 Hz, 3H, H-26), 3.21 – 2.99 (m, 2H, H-17), 1.69 – 1.43 (m, 3H, 
H-12 + H-13), 1.36 (d, J = 7.0 Hz, 3H, H-24), 0.82 (dd, J = 10.8, 5.0 Hz, 6H, H-14). δC (101MHz, 
CDCl3) 173.6 (C=O), 173.0 (C=O), 171.1 (C=O), 165.5 (C=O), 149.7 (C-Ar), 146.5 (C-Ar), 137.4 (C-Ar), 
134.7 (C-Ar), 133.6 (C-Ar), 133.5 (C-Ar), 132.2 (CH-Ar), 130.8 (CH-Ar), 127.9 (CH-Ar), 126.7 (CH-Ar), 
126.6 (CH-Ar), 126.4 (CH-Ar), 126.3 (C-Ar), 125.6 (CH-Ar), 125.4 (CH-Ar), 125.0 (CH-Ar), 121.4 (CH-
Ar), 120.4 (CH-Ar), 118.0 (CN), 54.9 (CH), 52.4 (CH3), 52.4 (CH3), 51.0 (CH), 50.4 (CH), 41.1 (CH2), 
37.4 (CH2), 24.8 (CH), 22.6 (CH3), 21.8 (CH3), 20.8 (CH3). δP (121MHz, CDCl3) -2.50, -2.58. MS (ES+) 
m/z 751.4 [M+Na]+. HRMS (ESI) C38H41N4O9NaP calcd. 751.2509 [M+Na]
+, found 751.2513. HPLC 
(reverse-phase) CH3CN/H2O 0:100 to 100:0 in 50 min, λ = 254 nm, tR = 27.57 min (98.5%). 
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Synthesis of methyl ((2S)-2-(4-cyanobenzamido)-3-(4-(((((S)-1-isopropoxy-1-
oxopropan-2-yl)amino)(naphthalen-1-
yloxy)phosphoryl)oxy)phenyl)propanoyl)-L-leucinate (75) 
 
 
 
 
 
 
Prepared according to Standard Procedure C, from compound 80 (70 mg, 0.160 mmol), 
triethylamine (0.05 mL, 0.352 mmol), compound 80 (252 mg, 0.708 mmol) and anhydrous DCM (5 
mL). The product prodrug 75 was isolated as white crystals (110 mg, 91%). Product isolated as a 
mixture of diastereoisomers. 
δH (400MHz, CDCl3) 8.01 (d, J = 8.0, 1H, H-36), 7.87 – 7.79 (m, 1H, H-33), 7.73 (d, J = 11.7 Hz, 2H, 
H-4), 7.64 (d, J = 10.9 Hz, 1H, H-31), 7.55 – 7.50 (m, 5H, H-2 + H-29 + H-34 + H-35), 7.47 – 7.22 (m, 
2H, H-7 + H-30), 7.21 – 7.12 (m, 4H, H-19 + H-20), 6.64 (dd, J = 46.4, 8.1 Hz, 1H, H-10), 5.05 – 4.88 
(m, 1H, H-26), 4.90 – 4.77 (m, 1H, H-8), 4.62 – 4.49 (m, 1H, H-11), 4.22 (d, J = 10.6 Hz, 1H, H-22), 
4.18 – 4.03 (m, 1H, H-23), 3.68 (d, J = 9.2 Hz, 3H, H-16), 3.12 (dd, J = 15.8, 10.6 Hz, 2H. H-17), 1.65 
– 1.40 (m, 3H, H-12 + H-13), 1.43 – 1.28 (m, 3H, H-24), 1.17 (ddd, J = 16.0, 11.0, 6.6 Hz, 6H, H-27), 
0.88 – 0.75 (m, 6H, H-14). δC (101MHz, CDCl3) 172.8 (C=O), 172.7 (C=O), 170.5 (C=O), 165.4 (C=O), 
149.8 (C-Ar), 146.6 (C-Ar), 137.5 (C-Ar), 134.8 (C-Ar), 133.4 (C-Ar), 133.2 (C-Ar), 132.3 (CH-Ar), 
130.8 (CH-Ar), 127.8 (CH-Ar), 126.6 (CH-Ar), 126.5 (CH-Ar), 126.4 (CH-Ar), 125.5 (CH-Ar), 125.0 
(CH-Ar), 121.4 (CH-Ar), 120.5 (CH-Ar), 118.0 (CN), 115.4 (C-Ar), 115.0 (CH-Ar), 69.4 (CH), 54.8 (CH), 
52.4 (CH3), 51.0 (CH), 50.6 (CH), 41.3 (CH2), 37.5 (CH2), 24.8 (CH), 22.6 (CH3), 21.8 (CH3), 21.6 (CH3), 
21.0 (CH3). δP (121MHz, CDCl3) -2.48, -2.52. MS (ES+) m/z 757.3 [M+H]
+, 779.3 [M+Na]+. HRMS 
(ESI) C40H45N4O9NaP calcd. 779.2822 [M+Na]
+, found 779.2825. HPLC (reverse-phase) CH3CN/H2O 
0:100 to 100:0 in 50 min, λ = 254 nm, tR = 29.53 min (99.2%). 
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Synthesis of methyl ((2S)-3-(4-(((((S)-1-(benzyloxy)-1-oxopropan-2-
yl)amino)(naphthalen-1-yloxy)phosphoryl)oxy)phenyl)-2-(4-
cyanobenzamido)propanoyl)-L-leucinate (76) 
 
 
 
 
 
 
Prepared according to Standard Procedure C, from compound 80 (70 mg, 0.160 mmol), anhydrous 
triethylamine (0.05 mL, 0.352 mmol), compound 97 (350 mg, 0.867 mmol) and anhydrous DCM (5 
mL). The product prodrug 76 was isolated as white crystals (120 mg, 93%). Product isolated as a 
mixture of diastereoisomers. 
δH (400MHz, CDCl3) 8.05 – 7.92 (m, 1H, H-39), 7.83 (d, J = 8.3 Hz, 1H, H-36), 7.72 (d, J = 8.5 Hz, 2H, 
H-4), 7.67 – 7.57 (m, 1H, H-7), 7.57 – 7.50 (m, 2H, H-3), 7.50 – 7.44 (m, 3H, H-34 + H-37 + H-38), 
7.42 (dd, J = 6.9, 1.1 Hz, 1H, H-33), 7.34 (d, J = 6.7 Hz, 1H, H-32), 7.30 – 7.22 (m, 5H, H-28 + H-29 + 
H-30), 7.17 – 7.05 (m, 4H, H-19 + H-20), 6.81 (d, J = 8.1 Hz, 1H, H-10), 5.03 (dd, J = 22.8, 10.6 Hz, 
2H, H-26), 4.90 (t, J = 5.9 Hz, 1H, H-8), 4.56 (t, J = 4.4 Hz, 1H, H-11), 4.39 (d, J =, 10.0 Hz, 1H, H-22), 
4.29 – 4.10 (m, 1H, H-23), 3.66 (d, J = 7.0 Hz, 3H, H-16), 3.20 – 3.05 (m, 2H, H-17), 1.61 – 1.51 (m, 
2H, H-12), 1.42 – 1.34 (m, 1H, H-13), 1.35 (d, J = 7.1 Hz, 3H, H-24), 0.89 – 0.73 (m, 6H, H-14). δC 
(101MHz, CDCl3) 173.0 (C=O), 172.8 (C=O), 170.8 (C=O), 165.4 (C=O), 149.8 (C-Ar), 146.5 (C-Ar), 
137.5 (C-Ar), 135.1 (C-Ar), 134.7 (C-Ar), 133.5 (C-Ar), 133.4 (C-Ar) 132.3 (CH-Ar), 130.8 (CH-Ar), 
128.6 (CH-Ar), 128.5 (CH-Ar), 128.1 (CH-Ar), 127.8 (CH-Ar), 126.6 (CH-Ar), 126.4 (CH-Ar), 126.3 (C-
Ar), 125.5 (CH-Ar), 125.0 (CH-Ar), 121.4 (CH-Ar), 120.4 (CH-Ar), 118.0 (CN), 115.1 (CH-Ar), 115.0 
(CH-Ar), 67.2 (CH2), 54.9 (CH), 52.4 (CH3), 51.0 (CH), 50.6 (CH), 41.2 (CH2), 37.4 (CH2), 24.8 (CH), 
22.6 (CH3), 21.8 (CH3), 20.9 (CH3). δP (121MHz, CDCl3) -2.48, -2.60. MS (ES+) m/z 827.3 [M+Na]
+. 
HRMS (ESI) C44H45N4O9NaP calcd. 827.2822 [M+Na]
+, found 827.2826. HPLC (reverse-phase) 
CH3CN/H2O 0:100 to 100:0 in 50 min, λ = 254 nm, tR = 30.50 min (97.2%). 
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Synthesis of dibenzyl phosphorochloridate (100) 
 
 
 
 
To a stirring solution of phosphate 99 (200 mg, 0.719 mmol) in oxalyl chloride (3 mL) was added 
three drops of anhydrous DMF which was then stirred for two hours, under an atmosphere of 
argon. After reaction completion was deemed through TLC, the colourless solution was 
concentrated under reduced pressure to afford chloridate 100 as a colourless oil (218 mg, >99%). 
The crude oil was used without purification, progressed as crude and could not be fully 
characterised. 
Synthesis of dibenzyl phosphorochloridite (102) 
 
 
 
Under an argon atmosphere, benzyl alcohol 101 (200 mg, 1.849 mmol) was dissolved in 
anhydrous DCM (10 mL). NMI (0.15 mL, 1.849 mmol) and PCl3 (0.08 mL, 0.925 mmol) was added 
at -78 oC and then stirred at room temperature for 12 hours. After reaction conversion was 
observed by TLC analysis, the desired product was isolated through vacuum distillation to yield 
chloridite 102 as a colourless oil (262 mg, >99%). The crude oil was used without purification, 
progressed as crude and could not be fully characterised. 
Synthesis of methyl ((S)-3-(4-((bis(dimethylamino)phosphoryl)oxy)phenyl)-2-
(4-cyanobenzamido)propanoyl)-L-leucinate (113) 
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To a stirring solution of compound 80 (100 mg, 0.229 mmol), under a nitrogen atmosphere in 
anhydrous THF (20 mL), was added N,N,N',N'-tetramethylphosphorodiamidic chloride (0.07 mL, 
0.457 mmol), DMAP (56 mg, 0.457 mmol) and DBU (0.05 mL, 0.344 mmol). The orange solution 
was stirred at room temperature overnight. Upon reaction completion the mixture was quenched 
with methanol (10 mL) and stirred for ten minutes. The solvent was then removed under reduced 
pressure and the resultant orange oil was subjected to silica flash column chromatography (3:97 
methanol: DCM) to isolate diamidate 113 as a white solid (65 mg, 50%).  
δH (500MHz, CDCl3) 7.79 (d, J = 8.4 Hz, 2H, H-4), 7.65 (d, J = 7.6 Hz, 1H, H-7), 7.62 (d, J = 8.4 Hz, 2H, 
H-3), 7.18 (d, J = 8.5 Hz, 2H, H-20), 7.06 (d, J = 7.8 Hz, 2H, H-19), 7.02 (d, J = 7.9 Hz, 1H, H-10), 4.89 
(q, J = 6.9 Hz, 1H, H-8), 4.55 (t, J = 8.5, 1H, H-11), 3.73 (s, 3H, H-16), 3.11 (dd, J = 14.1, 6.7 Hz, 2H, 
H-17), 2.69 (dd, J = 15.7, 10.1 Hz, 12H, H-23), 1.68 – 1.56 (m, 2H, H-12), 1.53 (ddd, J = 12.0, 9.0, 4.5 
Hz, 1H, H-13), 0.87 (dd, J = 6.1, 4.7 Hz, 6H, H-14). δC (126 MHz, CDCl3) 172.8 (C=O), 170.8 (C=O), 
165.5 (C=O), 150.3 (C-Ar), 137.7 (C-Ar), 132.5 (C-Ar), 132.2 (CH-Ar), 130.7 (CH-Ar), 127.9 (CH-Ar), 
120.2 (CH-Ar), 118.0 (CN), 115.1 (C-Ar), 54.8 (CH), 52.3 (CH3), 51.1 (CH), 41.1 (CH2), 37.1 (CH2), 
36.7 (CH3), 24.8 (CH), 22.7 (CH3), 21.8 (CH3). δP (202MHz, CDCl3) 15.79. MS (ES+) m/z 594.3 
[M+Na]+.  
Synthesis of methyl ((S)-2-(4-cyanobenzamido)-3-(4-(phosphonooxy) 
phenyl)propanoyl)-L-leucinate (98) 
 
 
 
 
 
 
A solution of diamidate 113 (60 mg, 0.102 mmol) in a solution of 9:1 TFA (9 mL): H2O (1 mL) was 
stirred overnight at ambient temperature. Upon reaction completion was confirmed by TLC 
analysis, the solvent was removed to afford a cream solid. The solid was further dried over 
vacuum until constant weight, yielding acid 98 as a white solid (40 mg, 76%). The compound was 
used without purification.  
δH (500 MHz, CD3OD)  7.74 (d, J = 8.1 Hz, 2H, H-4), 7.70 (d, J = 8.1 Hz, 2H, H-3), 7.15 (d, J = 7.2 Hz, 
2H, H-20), 7.05 (d, J = 7.6 Hz, 2H, H-19), 4.39 (dd, J = 9.4, 5.6 Hz, 1H, H-8), 3.86 – 3.75 (m, 1H, H-
11), 3.60 (s, 3H, H-16), 3.01 (dd, J = 14.3, 7.5 Hz, 2H, H-17), 1.70 – 1.60 (m, 1H, H-13), 1.58 – 1.50 
(m, 2H, H-12), 0.83 (dd, J = 22.1, 6.5 Hz, 6H, H-14). δC (126 MHz, CD3OD) 173.0 (C=O), 172.4 (C=O), 
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167.1 (C=O), 138.2 (C-Ar), 132.1 (CH-Ar), 132.0 (C-Ar), 131.9 (C-Ar), 129.7 (CH-Ar), 128.0 (CH-Ar), 
120.0 (CH-Ar), 117.6 (CN), 114.7 (C-Ar), 55.2 (CH), 51.4 (CH3), 50.9 (CH), 40.1 (CH2), 36.5 (CH2), 
24.5 (CH), 21.9 (CH3), 20.4 (CH3). δP (202 MHz, CD3OD) -4.48. MS (ES-) m/z 516.3 [M-H]
-. HRMS 
(ESI) C24H26N3O8P calcd. 516.1541 [M-H]
-, found 516.1541. HPLC (reverse-phase) MeOH/H2O 0:100 
to 100:0 in 12 min, λ = 254 nm, tR = 0.70 min (86.8%). 
Synthesis of methyl diphenyl phosphate (134) 
 
 
 
 
Diphenyl phosphorochloridate (0.23 mL, 1.068 mmol) was treated to anhydrous methanol (4 mL) 
and stirred at 0 oC, under an atmosphere of nitrogen. Sodium methoxide (57 mg, 1.068 mmol) 
was slowly added and the colourless solution was left to stir for 30 minutes, at 0 oC. The white 
solution was then stirred at room temperature for 90 minutes. Upon reaction completion, the 
solvent was removed under reduced pressure and the orange oil was dissolved in water (30 mL). 
The product was extracted into ethyl acetate (2 x 30 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. The product was then purified directly by flash column 
chromatography (1:3 ethyl acetate: hexane) to yield methyl phosphate 134 as a colourless liquid 
(280 mg, 99%).  
δH (500 MHz, CDCl3) 7.34 (dd, J = 8.0, 7.4 Hz, 4H, H-3), 7.24 – 7.13 (m, 6H, H-2 + H-4), 3.95 (d, J = 
11.6 Hz, 3H, H-5). δC (126 MHz, CDCl3) 150.6 (C-Ar), 129.8 (CH-Ar), 125.4 (CHAr, 120.0 (CHAr, 55.4 
(CH3). δP (202 MHz, CDCl3) -10.82. MS (ES+) m/z 287.0 [M+Na]
+.  
Analytical data is in agreement with literature values.203 
Synthesis of ((diphenoxyphosphoryl)oxy)methyl pivalate (135) 
 
 
 
 
Prepared according to Standard Procedure D, from compound 134 (280 mg, 1.060 mmol), sodium 
iodide (159 mg, 1.060 mmol), chloromethyl pivalate (0.17 mL, 1.166 mmol) and anhydrous 
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acetonitrile (5 mL).The product POM phosphate 135 was isolated as a colourless liquid (351 mg, 
91%).  
δH (500 MHz, CDCl3) 7.37 (dd, J = 8.0, 7.5 Hz, 4H, H-3), 7.28 – 7.19 (m, 6H, H-2 + H-4), 5.82 (d, J = 
14.4 Hz, 2H, H-5), 1.19 (s, 9H, H-8). δC (126 MHz, CDCl3) 176.7 (C=O), 150.3 (C-Ar), 129.9 (CH-Ar), 
125.6 (CH-Ar), 120.1 (CH-Ar), 83.2 (CH2), 38.7 (C), 26.8 (CH3). δP (202 MHz, CDCl3) -13.16. MS (ES+) 
m/z 387.1 [M+Na]+.  
Synthesis of methyl phenyl phosphorochloridate (138) 
 
 
 
Phenyl phosphorodichloridate (0.28 mL, 1.896 mmol) was treated to anhydrous diethyl ether (5 
mL) and stirred at 0 oC, under an atmosphere of nitrogen. Anhydrous methanol (0.08 mL, 1.896 
mmol) and pyridine (0.15 mL, 1.896 mmol) were carefully added dropwise and left to stir for 30 
minutes, at 0 oC. The white suspension was then stirred at room temperature for 30 minutes. 
Upon reaction completion, the white precipitate was filtered and triturated several times with 
anhydrous diethyl ether. The filtrate was concentrated under reduced pressure and purified by 
flash column chromatography (6:4 ethyl acetate: hexane) to yield phosphorochloridate 138 as a 
colourless liquid (351mg, 89%). Product isolated as a mixture of enantiomers. 
δH (500 MHz, CDCl3) 7.32 (dd, J = 8.1, 7.4 Hz, 2H, H-3), 7.23 – 7.16 (m, 3H, H-2 + H-4), 3.95 (d, J = 
13.9 Hz, 3H, H-5). δP (202 MHz, CDCl3) 1.06.  
Analytical data is in agreement with literature values.164 
Synthesis of methyl ((5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-
dihydrofuran-2-yl)methyl) phenyl phosphate (139) 
  
 
 
 
 
To a stirring solution of methyl phenyl phosphorochloridate 138 (220 mg, 1.065 mmol) in 
anhydrous acetonitrile (5 mL) was added d4T (236 mg, 0.968 mmol), under a nitrogen 
atmosphere. The mixture was then cooled to 0 oC and triethylamine (0.16 mL, 1.162 mmol) was 
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added dropwise and left to stir for 30 minutes. The reaction was then left to warm to room 
temperature and stirred for 12 hours. The solvent was then removed under reduced pressure and 
the resultant colourless oil was dissolved in water (30 mL) and the product was extracted into 
ethyl acetate (3 x 30 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure to afford a colourless oil. The oil was purified by flash 
column chromatography (4:96 methanol: DCM) to yield nucleotide 139 as a colourless oil (171 
mg, 45%). Product isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.25 (d, J = 11.8 Hz, 1H, H-2), 7.37 – 7.31 (m, 2H, H-14), 7.27 (d, J = 1.3 Hz, 1H, 
H-4), 7.22 – 7.14 (m, 3H, H-13 + H-15), 7.04 (ddd, J = 8.7, 3.6, 1.9 Hz, 1H, H-7), 6.37 – 6.21 (m, 1H, 
H-8), 5.94 – 5.80 (m, 1H, H-9), 5.02 (d, J = 1.0 Hz, 1H, H-10), 4.47 – 4.23 (m, 2H, H-11), 3.86 (d, J = 
11.0 Hz, 3H, H-16), 1.83 (d, J = 25.7 Hz, 3H, H-6). δC (126MHz, CDCl3) 163.4 (C=O), 150.7 (C=O), 
135.9 (CH), 132.9 (CH), 129.8 (CH), 127.7 (CH), 125.6 (CH), 120.0 (CH), 111.4 (C-Ar), 89.5 (CH), 84.5 
(CH), 68.0 (CH2/C), 63.7 (CH2/C), 55.0 (CH3), 12.2 (CH3). δP (202 MHz, CDCl3) -4.95, -5.07. MS (ES+) 
m/z 417.1 [M+Na]+. 
Synthesis of ((((5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-
dihydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)oxy)methyl pivalate (121) 
  
 
 
 
 
Prepared according to Standard Procedure D, from phosphate 139 (20 mg, 0.051 mmol), sodium 
iodide (8 mg, 0.051 mmol), chloromethyl pivalate (0.01 mL, 0.056 mmol) and anhydrous 
acetonitrile (5 mL). The product POM phosphate 121 was isolated as a colourless oil (8 mg, 33%). 
Product isolated as a mixture of diastereoisomers. 
δH (500 MHz, CDCl3) 8.08 (d, J = 12.7 Hz, 1H, H-2), 7.32 – 7.21 (m, 3H, H-4 + H-14), 7.16 – 7.07 (m, 
3H, H-13 + H-15), 6.96 (ddd, J = 8.4, 4.5, 2.6 Hz, 1H, H-7), 6.22 (dd, J = 6.0, 3.7 Hz, 1H, H-8), 5.82 
(dd, J = 5.6, 3.0 Hz, 1H, H-9), 5.71 – 5.56 (m, 2H, H-16), 4.94 (s, 1H, H-10), 4.31 (d, J = 10.8 Hz, 2H, 
H-11), 1.76 (d, J = 1.2 Hz, 3H, H-6), 1.11 (d, J = 9.7 Hz, 9H, H-19). δC (126MHz, CDCl3) 164.1 (C=O), 
164.1 (C=O), 150.7 (C=O), 135.9 (CH), 132.8 (CH), 129.8 (CH), 127.8 (CH), 125.8 (CH), 120.1 (CH), 
111.4 (C-Ar), 89.6 (CH), 84.4 (CH), 83.0 (CH2/C), 68.3 (CH2/C), 68.3 (CH2/C), 29.7 (CH2), 26.8 (CH3), 
12.2 (CH3). δP (202 MHz, CDCl3) -7.63, -7.73. MS (ES+) m/z 517.1 [M+Na]
+. 
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Synthesis of dimethyl phenyl phosphate (140) 
 
 
 
 
Phenyl phosphorodichloridate (0.56 mL, 3.792 mmol) was treated to anhydrous diethyl ether (20 
mL) and stirred at 0 oC, under an atmosphere of nitrogen. Anhydrous methanol (0.32 mL, 7.584 
mmol) and pyridine (0.60 mL, 7.584 mmol) were added dropwise and left to stir for 30 minutes, at 
0 oC. The white suspension was then stirred at room temperature for 30 minutes. Upon reaction 
completion, the white precipitate was filtered and washed with anhydrous diethyl ether. The 
filtrate was concentrated under reduced pressure and purified by flash column chromatography 
(6:4 ethyl acetate: hexane) to yield phosphorochloridate 140 as a colourless liquid (686 mg, 89%).  
δH (500 MHz, CDCl3) 7.39 – 7.30 (m, 2H, H-3), 7.24 – 7.14 (m, 3H, H-2 + H-4), 3.84 (d, J = 11.3 Hz, 
6H, H-5). δC (126MHz, CDCl3) 150.5 (C-Ar), 129.7 (CH-Ar), 124.9 (CH-Ar), 119.8 (CH-Ar), 54.8 (CH3). 
δP (202MHz, CDCl3) -4.18. MS (ES+) m/z 255.1 [M+Na]
+.  
Analytical data is in agreement with literature values.204 
Synthesis of (((phenoxy)phosphoryl)bis)methoxy pivalate (141) 
 
 
 
 
 
Prepared according to Standard Procedure E, from phosphate 140 (150 mg, 0.742 mmol), sodium 
iodide (245 mg, 1.632 mmol), chloromethyl pivalate (0.26 mL, 1.781 mmol) and anhydrous 
acetonitrile (10 mL) was. The product phosphate 141 was isolated as a colourless oil (194 mg, 
65%).  
δH (500 MHz, CDCl3) 7.39 – 7.31 (m, 2H, H-3), 7.24 – 7.16 (m, 3H, H-2 + H-4), 5.73 (dd, J = 14.1, 5.1 
Hz, 4H, H-5), 1.20 (s, 18H, H-8). δC (126MHz, CDCl3) 176.6 (C=O), 150.1 (C-Ar), 129.8 (CH-Ar), 125.5 
(CH-Ar), 120.0 (CH-Ar), 83.0 (CH-Ar), 38.7 (CH2), 26.8 (CH3). δP (202MHz, CDCl3) -9.00. MS (ES+) 
m/z 425.2 [M+Na]+.  
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Synthesis of ((hydroxy(phenoxy)phosphoryl)oxy)methyl pivalate (136) 
 
 
 
 
 
BisPOM phosphate 141 (100 mg, 0.249 mmol) was stirred in anhydrous piperidine (3 mL), under a 
nitrogen atmosphere, for 24 hours. After reaction completion was deemed, by the full 
consumption of the starting material by TLC, the piperidine was removed under reduced pressure 
to afford an orange oil. Anhydrous methanol was treated and removed under reduced pressure to 
azeotropically remove excess piperidine, to afford the phosphoric acid pyridinium salt as an 
orange oil. The oil was then dissolved in water (5 mL) and washed through a Dowex 50WX2-100 
ion-exchange column, charged with HCl, to afford phosphoric acid 136 as a cream solid (4 mg, 
7%). Product isolated as a mixture of enantiomers. 
δH (500 MHz, CDCl3) 7.28 – 7.18 (m, 5H, H-2 + H-3 + H-4), 5.63 (d, J = 12.8 Hz, 2H, H-5), 1.16 (s, 9H, 
H-8). δP (202MHz, CDCl3) -7.19. MS (ES-) m/z 287.1 [M-H]
-.  
Too little material and too impure for viable 31C NMR spectra. 
Synthesis of benzyl methyl phenyl phosphate (142) 
 
 
 
 
To a stirring solution of methyl phenyl phosphorochloridate 138 (570 mg, 2.760 mmol) in 
anhydrous DCM (15 mL) was added benzyl alcohol (0.24 mL, 2.300 mmol), Proton Sponge (986 
mg, 4.600 mmol) and pyridine-N-oxide (11 mg, 0.115 mmol) under a nitrogen atmosphere. The 
clear yellow solution was stirred at room temperature for six hours. After reaction completion, 
methanol (2 mL) was added to quench the reaction and then stirred for ten minutes. The solvent 
was then removed under reduced pressure and the resultant orange oil was dissolved in water 
(30 mL) and the product was extracted into ethyl acetate (3 x 30 mL), dried over MgSO4, filtered 
Experimental Procedures                                                               Chapter 10 
  
192 
 
and concentrated under reduced pressure. Flash column chromatography (98:2 DCM: methanol) 
was used to yield phosphate 142 as a colourless liquid (330 mg, 52%).  
δH (500 MHz, CDCl3) 7.42 – 7.28 (m, 7H), 7.22 – 7.13 (m, 3H), 5.25 – 5.09 (m, 2H, H-6), 3.81 (d, J = 
11.4 Hz, 3H, H-5). δC (126MHz, CDCl3) 150.7 (C-Ar), 135.6 (C-Ar), 129.8 (CH-Ar), 128.7 (CH-Ar), 
128.6 (CH-Ar), 128.0 (CH-Ar), 125.1 (CH-Ar), 120.0 (CH-Ar), 70.0 (CH2), 54.8 (CH3). δP (202MHz, 
CDCl3) -5.12. MS (ES+) m/z 301.1 [M+Na]
+. Product isolated as a mixture of enantiomers. 
Synthesis of ((methoxy(phenoxy)phosphoryl)oxy)methyl pivalate (144) 
 
 
 
 
Prepared according to Standard Procedure D, from benzyl phosphate 142 (280 mg, 1.001 mmol), 
sodium iodide (150 mg, 1.001 mmol), chloromethyl pivalate (0.16 mL, 1.107 mmol) and in 
anhydrous acetonitrile (10 mL). The product POM phosphate 144 was isolated as a colourless oil 
(166 mg, 55%). Product isolated as a mixture of enantiomers. 
δH (500 MHz, CDCl3) 7.39 – 7.32 (m, 2H, H-3), 7.25 – 7.10 (m, 3H, H-2 + H-4), 5.72 (dd, J = 14.0, 2.5 
Hz, 2H, H-6), 3.87 (d, J = 11.6 Hz, 3H, H-5), 1.20 (s, 9H, H-9). δC (126MHz, CDCl3) 176.7 (C=O), 150.4 
(C-Ar), 129.8 (CH-Ar), 125.4 (CH-Ar), 120.0 (CH-Ar), 83.0 (CH2), 55.1 (CH3), 38.73 (C), 26.8 (CH3). δP 
(202MHz, CDCl3) -6.62. MS (ES+) m/z 325.1 [M+Na]
+.  
Synthesis of (((phenoxy)phosphoryl)bis)methoxy pivalate (141) 
 
 
 
 
Prepared according to Standard Procedure E, from benzyl phosphate 142 (170 mg, 0.611 mmol), 
sodium iodide (202 mg, 1.341 mmol), chloromethyl pivalate (0.20 mL, 1.341 mmol) and 
anhydrous acetonitrile (10 mL). The product bisPOM phosphate 141 was isolated as a colourless 
oil (209 mg, 85%).  
δH (500 MHz, CDCl3) 7.38 – 7.33 (m, 2H, H-3), 7.25 – 7.13 (m, 3H, H-2 + H-4), 5.72 (dd, J = 14.1, 5.1 
Hz, 4H, H-5), 1.19 (s, 18H, H-8). δC (126MHz, CDCl3) 176.5 (C=O), 150.1 (C-Ar), 129.8 (CH-Ar), 125.5 
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(CH-Ar), 120.0 (CH-Ar), 82.9 (CH2), 38.7 (C), 26.7 (CH3). δP (202 MHz, CDCl3) -9.06. MS (ES+) m/z 
425.1 [M+Na]+.  
Analytical data is in agreement with the previous synthetic route. 
Synthesis of ((methoxy(phenoxy)phosphoryl)oxy)methyl pivalate (144) 
 
 
 
 
Prepared according to Standard Procedure D, from dimethyl phosphate 140 (830 mg, 4.106 
mmol), sodium iodide (677 mg, 4.516 mmol), chloromethyl pivalate (0.65 mL, 4.516 mmol) and 
anhydrous acetonitrile (10 mL). The product POM phosphate 144 was isolated as a colourless oil 
(470 mg, 38%). Product isolated as a mixture of enantiomers. 
δH (500 MHz, CDCl3) 7.34 (dd, J = 5.9, 3.9 Hz, 2H, H-3), 7.26 – 7.13 (m, 3H, H-2 + H-4), 5.72 (dd, J = 
14.0, 2.7 Hz, 2H, H-6), 3.87 (d, J = 11.6 Hz, 3H, H-5), 1.20 (s, J = 5.8 Hz, 9H, H-9). δC (126MHz, 
CDCl3) 176.7 (C=O), 150.4 (C-Ar), 129.8 (CH-Ar), 125.4 (CH-Ar), 119.9 (CH-Ar), 83.0 (CH2), 55.1 
(CH3), 38.8 (C), 26.8 (CH3). δP (202 MHz, CDCl3) -6.65. MS (ES+) m/z 325.1 [M+Na]
+.  
Analytical data is in agreement with the previous synthetic route. 
Synthesis of phenyl ((pivaloyloxy)methyl) phosphate (145) 
 
 
 
 
Phosphate 144 (70 mg, 0.232 mmol) was dissolved in anhydrous acetone (5 mL) and cooled to 0 
°C, under a nitrogen atmosphere. Sodium iodide (42 mg, 0.278 mmol) was added in acetone (1 
mL) dropwise and the solution was then refluxed overnight. The resultant yellow suspension was 
filtered and the resultant solid triturated several times to with acetone, to yield phosphoric acid 
sodium salt 145 as a white solid (70 mg, 98%). The product was used without further purification 
and isolated as a mixture of enantiomers. 
δH (500 MHz, CD3OD) 7.35 – 7.25 (m, 2H, H-3), 7.22 (dd, J = 7.8, 0.9 Hz, 2H, H-2), 7.06 (t, J = 7.1 Hz, 
1H, H-4), 5.62 (d, J = 13.2 Hz, 2H, H-6), 1.14 (s, 9H, H-9). δC (126MHz, CD3OD) 177.5 (C=O), 153.0 
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(C-Ar), 128.8 (CH-Ar), 122.8 (CH-Ar), 119.9 (CH-Ar), 83.1 (CH2), 38.3 (C), 25.9 (CH3). δP (202MHz, 
CD3OD) -6.87. MS (ES-) m/z 287.1 [M-H]
-.  
Synthesis of ((chloro(phenoxy)phosphoryl)oxy)methyl pivalate (125) 
 
 
 
 
To a stirring solution of phosphate sodium salt 145 (70 mg, 0.226 mmol) in anhydrous DCM (3 mL) 
was added oxalyl chloride (0.30 mL, 0.338 mmol) and catalytic anhydrous DMF (3 drops). The 
solution was stirred under a nitrogen atmosphere, at room temperature, for three hours. The 
solvent and excess oxalyl chloride were removed under reduced pressure to afford 
phosphorochloridate 125 as a grey oil (68 mg, 99%). The product was used without purification 
and isolated as a mixture of enantiomers. 
δH (500 MHz, CDCl3) 7.30 – 7.19 (m, 5H, H-2 + H-3 + H-4), 5.87 (d, J = 15.7 Hz, 2H, H-5), 1.24 (s, 9H, 
H-8). δP (202MHz, CDCl3) -0.90.  
Synthesis of ((((5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-
dihydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)oxy)methyl pivalate (121) 
 
  
 
 
 
In a flame-dried flask, phosphorochloridate 125 (68 mg, 0.226 mmol) and d4T (46 mg, 0.205 
mmol) were dissolved in anhydrous acetonitrile, under a nitrogen atmosphere. Anhydrous 
triethylamine (0.03 mL, 0.205 mmol) was added dropwise and the grey solution was stirred 
overnight at room temperature. The solvent was then removed under reduced pressure and 
treated with water (20 mL). The product was extracted into ethyl acetate (3 x 30 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure to afford an orange oil. The oil was 
purified directly by flash column chromatography (98:2 DCM: methanol) to yield POMTide 121 as 
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a colourless oil (46 mg, 46%). The product was used without purification and isolated as a mixture 
of diastereoisomers. 
δH (500 MHz, CDCl3) 8.31 (d, J = 11.5 Hz, 1H, H-2), 7.38 – 7.28 (m, 3H, H-4 + H-14), 7.24 – 7.13 (m, 
3H, H-13 + H-15), 7.02 (dd, J = 4.5, 2.7 Hz, 1H, H-7), 6.29 (dd, J = 3.8, 2.2 Hz, 1H, H-8), 5.89 (dd, J = 
6.0, 3.8 Hz, 1H, H-9), 5.81 – 5.63 (m, 2H, H-16), 5.01 (s, 1H, H-10), 4.39 (dd, J = 5.9, 2.7 Hz, 2H, H-
11), 1.83 (d, J = 27.3 Hz, 3H, H-6), 1.18 (d, J = 9.6 Hz, 9H, H-19). δC (126MHz, CDCl3) 163.5 (C=O), 
163.5 (C=O), 150.7 (C=O), 135.8 (CH), 132.8 (CH), 129.8 (CH), 127.8 (CH), 125.9 (CH), 120.1 (CH), 
111.5 (C-Ar), 89.6 (CH), 84.4 (CH), 83.0 (CH2/C), 68.3 (CH2/C), 68.3 (CH2/C), 29.7 (CH2), 26.8 (CH3), 
12.2 (CH3). δP (202 MHz, CDCl3) -7.66, -7.76. MS (ES+) m/z 517.2 [M+Na]
+. 
Analytical data is in agreement with the previous synthetic route. 
Synthesis of methyl naphthalen-1-yl phosphorochloridate (152) 
 
 
 
 
Napthyl phosphorodichloridate 94 (1.000 g, 3.831 mmol) was treated to anhydrous diethyl ether 
(30 mL) and stirred at 0 oC, under an atmosphere of nitrogen. Anhydrous methanol (0.15 mL, 
3.831 mmol) and pyridine (0.34 mL, 3.831 mmol) were carefully added dropwise and left to stir 
for 30 minutes, at 0 oC. The white suspension was then stirred at room temperature for 30 
minutes. Upon reaction completion, the white precipitate was filtered and triturated several 
times with anhydrous diethyl ether. The filtrate was concentrated under reduced pressure and 
purified by flash column chromatography (6:4 ethyl acetate: hexane) to yield phosphorochloridate 
152 as a light brown liquid (717 mg, 73%). The product was used without purification and isolated 
as a mixture of enantiomers. 
δH (500 MHz, CDCl3) 8.11 (d, J = 4.6 Hz, 1H, H-9), 7.88 (d, J = 8.2Hz, 1H, H-6), 7.75 (d, J = 8.2 Hz, 1H, 
H-4), 7.62 – 7.49 (m, 3H, H-3 + H-7 + H-8), 7.45 (d, J = 7.9 Hz, 1H, H-2), 4.09 (d, J = 14.0 Hz, 3H, H-
11). δP (202 MHz, CDCl3) -1.46. 
Analytical data is in agreement with literature values.92 
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Synthesis of ((3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
hydroxytetrahydrofuran-2-yl)methyl methyl phenyl phosphate (161) 
 
  
 
 
 
To a stirring solution of methyl phenyl phosphorochloridate 138 (547 mg, 2.648 mmol) in 
anhydrous THF (12 mL) was added 5-FdU (550 mg, 2.207 mmol), under a nitrogen atmosphere. 
The mixture was then cooled to -78 oC and NMI (0.90 mL, 11.034 mmol) was added dropwise and 
left to stir for ten minutes. The reaction mixture was then left to warm to room temperature and 
stirred for 12 hours. The solvent was then removed under reduced pressure and the resultant 
colourless oil was dissolved in water (30 mL) and the product was extracted into DCM (3 x 30 mL). 
The combined organic layers were washed with 0.5N-HCl (30 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure to afford a colourless oil. The oil was purified by flash 
column chromatography (5:95 methanol: DCM) to yield nucleotide 161 as a white solid (297 mg, 
32%). The product was used without purification and isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 7.65 (d, J = 6.2 Hz, 1H, H-2), 7.33 (dd, J = 7.5, 6.8 Hz, 2H, H-14), 7.22 – 7.13 (m, 
3H, H-13 + H-15), 6.99 – 6.94 (m, 1H, H-4), 6.26 (d, J = 6.5 Hz, 1H, H-6), 4.52 – 4.42 (m, 1H, H-8), 
4.40 (dd, J = 10.6, 4.1 Hz, 2H, H-11), 4.14 – 4.07 (m, 1H, H-9), 3.89 (d, J = 5.5 Hz, 3H, H-16), 3.69 (s, 
1H, H-10), 2.40 (dd, J = 7.8, 2.8 Hz, 1H, H-7a/b), 2.02 (dd, J = 14.0, 7.0 Hz, 1H, H-7a/b). δC 
(126MHz, CDCl3) 176.6 (C=O), 156.8 (C-Ar), 150.3 (C=O/C=C), 148.9 (C=O/C=C), 130.0 (CH-Ar), 
125.7 (CH-Ar), 124.0 (CH=C), 119.8 (CH-Ar), 85.4 (CH), 84.9 (CH), 70.4 (CH), 67.1 (CH2), 55.4 (CH2), 
40.4 (CH3). δF (471 MHz, CDCl3) δ -164.09, -164.16. δP (202 MHz, CDCl3) -4.88, -4.98. MS (ES+) m/z 
439.1 [M+Na]+.  
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Synthesis of ((3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
hydroxytetrahydrofuran-2-yl)methyl methyl naphthalen-1-yl phosphate (162) 
 
  
 
 
 
To a stirring solution of methyl napthyl phosphorochloridate 152 (990 mg, 3.858 mmol) in 
anhydrous THF (24 mL) was added 5-FdU (791 mg, 3.215 mmol), under a nitrogen atmosphere. 
The mixture was then cooled to -78 oC and NMI (1.28 mL, 16.075 mmol) was added dropwise and 
left to stir for ten minutes. The reaction mixture was then left to warm to room temperature and 
stirred for 12 hours. The solvent was then removed under reduced pressure and the resultant 
colourless oil was dissolved in water (30 mL) and the product was extracted into DCM (3 x 30 mL). 
The combined organic layers were washed with 0.5N-HCl (30 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure to afford a brown oil. The oil was purified by flash column 
chromatography (5:95 methanol: DCM) to yield nucleotide 162 as a white solid (720 mg, 48%). 
The product was used without purification and isolated as a mixture of diastereoisomers. 
δH (500 MHz, CDCl3) 9.93 (bs, 1H, H-2), 8.09 (d, J = 7.9 Hz, 1H, H-20), 7.83 (d, J = 7.3 Hz, 1H, H-17), 
7.66 (dd, J = 13.1, 6.4 Hz, 1H, H-15), 7.60 – 7.45 (m, 3H, H-14 + H-18 + H-19), 7.47 – 7.33 (m, 2H, H-
4 + H-13), 6.17 (dt, J = 13.3, 6.4 Hz, 1H, H-6), 4.40 (dd, J = 10.2, 6.7 Hz, 2H, H-11), 4.27 (d, J = 6.1, 
3.0 Hz, 1H, H-9), 4.07 (dd, J = 8.5, 2.7 Hz, 1H, H-8), 3.92 (d, J = 11.8 Hz, 3H, H-22), 2.28 (dd, J = 6.4 
Hz, 1H, H-7a/b), 1.84 (dd, J = 13.8, 6.8 Hz, 1H, H-7a/b). δC (126MHz, CDCl3) 156.9 (C=O), 149.0 (C), 
146.1 (C), 141.5 (C), 139.6 (C), 134.7 (C), 128.0 (CH-Ar), 127.0 (CH-Ar), 126.8 (CH-Ar), 125.6 (CH-
Ar), 125.5 (CH-Ar), 123.7 (CH=C), 121.1 (CH-Ar), 115.0 (CH-Ar), 85.3 (CH), 85.0 (CH), 70.9 (CH), 67.7 
(CH2), 55.6 (CH3), 40.3 (CH2). δF (471 MHz, CDCl3) δ -163.84, -164.03. δP (202 MHz, CDCl3) -4.46, -
4.61. MS (ES+) m/z 489.1 [M+Na]+. 
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Synthesis of (((((3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)oxy)methyl pivalate 
(155) 
 
  
 
 
 
Prepared according to Standard Procedure D, from nucleotide 161 (250 mg, 0.601 mmol), sodium 
iodide (91 mg, 0.601 mmol), chloromethyl pivalate (0.15 mL, 0.661 mmol) and anhydrous 
acetonitrile (12 mL). The product POMTide 155 was isolated as a white fluffy solid (127mg, 41%). 
Product isolated as a mixture of diastereoisomers. 
δH (500 MHz, CDCl3) 7.61 (s, 1H, H-2), 7.34 (dd, J = 8.1, 7.5 Hz, 2H, H-14), 7.24 – 7.15 (m, 4H, H-13 
+ H-15 + H-4), 6.30 – 6.19 (m, 1H, H-6), 5.83 – 5.62 (m, 2H, H-16), 4.49 (ddd, J = 17.1, 8.5, 3.7 Hz, 
1H, H-8), 4.41 (dd, J = 6.3, 2.8 Hz, 2H, H-11), 4.11 (dt, J = 6.1, 3.2 Hz, 1H, H-9), 3.76 – 3.71 (m, 1H, 
H-10), 2.46 – 2.30 (m, 1H, H-7a/b), 2.02 (dt, J = 13.7, 6.8 Hz, 1H, H-7a/b), 1.18 (d, J = 5.0 Hz, 9H, H-
19). δC (126MHz, CDCl3) 177.1 (C=O), 156.9 (C), 148.9 (C), 141.5 (C), 139.6 (C), 130.0 (CH-Ar), 125.9 
(CH-Ar), 123.8 (CH=C), 119.9 (CH-Ar), 85.4 (CH), 84.8 (CH), 83.3 (CH2), 70.6 (CH), 67.4 (CH2), 40.2 
(CH2), 38.8 (C), 26.8 (CH3). δF (471 MHz, CDCl3) δ -163.77, -163.81. δP (202 MHz, CDCl3) -7.59, -
7.82. MS (ES+) m/z 539.1 [M+Na]+. HRMS (ESI) C21H26FN2NaO10P calcd. 539.1201 [M+Na]
+, found 
539.1208. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 5.59 min 
(96.6%). 
Synthesis of (((((3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-
hydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)oxy)methyl 
pivalate (156) 
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Prepared according to Standard Procedure D, from nucleotide 162 (100 mg, 0.214 mmol), sodium 
iodide (32 mg, 0.214 mmol), chloromethyl pivalate (0.03 mL, 4.516 mmol) and anhydrous 
acetonitrile (12 mL). The product POMTide 156 was isolated as a fluffy white solid (48 mg, 40%). 
Product isolated as a mixture of diastereoisomers. 
δH (500 MHz, CDCl3) 9.42 (bs, 1H, H-2), 8.09 (d, J = 8.5 Hz, 1H, H-20), 7.84 (dd, J = 6.2, 4.4 Hz, 1H, 
H-17), 7.69 (dd, J = 8.0, 3.7 Hz, 1H, H-15), 7.59 – 7.47 (m, 3H, H-14 + H-18 + H-19), 7.49 – 7.34 (m, 
2H, H-4 + H-13), 6.16 (dd, J = 9.6, 3.6 Hz, 1H, H-6), 5.91 – 5.64 (m, 2H, H-22), 4.50 – 4.35 (m, 2H, H-
11), 4.29 (dd, J = 8.0, 4.8 Hz, 1H, H-9), 4.07 (dt, J = 6.0, 4.5 Hz, 1H, H-8), 3.34 (bs, 1H, H-10), 2.40 – 
2.11 (m, 1H, H-7a/b), 1.77 (dt, J = 13.9, 6.8 Hz, 1H, H-7a/b), 1.14 (d, J = 9.8 Hz, 9H, H-25). δC 
(126MHz, CDCl3) 177.0 (C=O), 156.7 (C), 148.7 (C), 141.4 (C), 139.6 (C), 134.8 (C), 127.9 (CH-Ar), 
127.0 (CH-Ar), 126.8 (CH-Ar), 125.8 (CH-Ar), 125.4 (CH-Ar), 123.7 (CH=C), 121.2 (CH-Ar), 115.3 (CH-
Ar), 85.4 (CH), 84.8 (CH), 83.4 (CH2), 70.7 (CH), 67.5 (CH2), 40.1 (CH2), 38.7 (C), 26.7 (CH3). δF (471 
MHz, CDCl3) δ -163.52, -163.64. δP (202 MHz, CDCl3) -7.13, -7.37. MS (ES+) m/z 589.1 [M+Na]
+. 
HRMS (ESI) C25H28FN2NaO10P calcd. 589.1358 [M+Na]
+, found 589.1366. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 8.20 min (95.8%). 
Synthesis of ethyl 2-hydroxyacetate (166) 
 
 
Compound 165 (5 g, 65.70 mmol) was dissolved in anhydrous ethanol (15 mL) and refluxed with 
12-N H2SO4 (0.35 mL, 0.570 mmol) for six hours. After reaction completion was deemed by TLC, 
the colourless solution was then carefully neutralised to pH 7 with saturated NaHCO3, where 
diethyl ether (4 x 15 mL) was then used to extract the product from the aqueous layer. The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure to afford ester 166 as a colourless oil (3.2 g, 47%), which was used directly without 
purification.  
δH (300MHz, CDCl3) 4.25 (q, J = 7.1 Hz, 2H, H-2), 4.16 (s, 2H, H-4), 3.23 (s, 1H, H-5), 1.30 (t, J = 7.2 
Hz, 3H, H-1). δC (101MHz, CDCl3) 173.4 (C=O), 61.4 (CH2), 60.6 (CH2), 14.1 (CH3). MS (ES+) m/z 
105.1 [M+H]+, 104.1 [M]+.  
Analytical data is in agreement with literature values.164 
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Synthesis of ethyl 2-(tosyloxy)acetate (167) 
 
 
To a stirring solution of ester 166 (2.5 g, 24.038 mmol) and p-toluenesulfonyl chloride (4.6 g, 
24.038 mmol) in anhydrous diethyl ether (30 mL), cooled to 0 °C, was added triethylamine (6.6 
mL, 48.076 mmol). The colourless solution was left to stir overnight at 0 °C, under an argon 
atmosphere. Upon reaction completion, a white precipitate formed in the reaction mixture. 
Water (30 mL) was used to quench the mixture and the product was extracted into diethyl ether 
(3 x 15 mL). The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure to afford white crystals. Product 167 was isolated, by column chromatography 
(1:3 ethyl acetate: hexane), as a white crystalline solid (501 mg, 81%).  
δH (300MHz, CDCl3) 7.84 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H, H-6), 4.58 (s, 2H, H-4, H-7), 4.19 
(q, J = 7.1 Hz, 2H, H-2), 2.46 (s, 3H, H-9), 1.25 (t, J = 7.1 Hz, 3H, H-1). δC (101MHz, CDCl3) 145.3 
(C=O), 132.7 (C-Ar), 129.9 (CH-Ar), 128.2 (CH-Ar), 122.3 (C-Ar), 64.7 (CH2), 61.9 (CH2), 21.7 (CH3), 
14.0 (CH3). MS (ES+) m/z 281.0 [M+Na]
+.  
Analytical data is in agreement with literature values.205 
Synthesis of 2-(tosyloxy)acetic acid (168) 
 
 
A solution of 5% NaOH (50 mL) was added to a stirring solution of ester 167 (4.3 g, 16.667 mmol) 
in ethanol (50 mL) and left to stir at room temperature, for two hours. The colourless solution was 
concentrated under reduced pressure to remove ethanol, before being subjected to acidification 
to pH-1 with 6N-HCl. The white suspended precipitate was filtered to yield acid 168 as a white 
crystalline solid (3.3 g, 86%), which was used without purification.  
δH (300MHz, CDCl3) 7.83 (d, J = 8.3 Hz, 2H, H-5), 7.37 (d, J = 8.0 Hz, 2H, H-6), 4.64 (s, 2H, H-3), 2.46 
(s, 3H, H-8). δC (101MHz, CDCl3) 170.3 (C=O), 145.6 (C-Ar), 132.3 (C-Ar), 130.0 (CH-Ar), 128.3 (CH-
Ar), 63.8 (CH2), 21.7 (CH3). MS (EI-) m/z 229.0 [M-H]
-.  
Analytical data is in agreement with literature values.165  
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Synthesis of 2-chloro-2-oxoethyl 4-methylbenzenesulfonate (171) 
 
 
In a flame-dried flask, acid 168 (200 mg, 0.890 mmol) was dissolved in excess SOCl2 (2 mL) and 
refluxed for one hour, under an argon atmosphere. After reaction completion was confirmed by 
TLC analysis, the colourless solution was then concentrated under reduced pressure to afford acid 
chloride 171 as a white solid (220 mg, >99%), which was used without purification. 
The compound was progressed as crude and could not be fully characterised. 
Synthesis of 2-hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid (10) 
 
 
 
 
Prepared according to Standard Procedure F, from 4-aminosalicylic (133 mg, 0.870 mmol), 
triethylamine (0.36 mL, 2.610), chloride 171 (216 mg, 0.870 mmol) and anhydrous THF (7 mL). 
Flash column chromatography (5:94:1 methanol: DCM: acetic acid) isolated the product amide 10 
as a cream crystalline solid (196 mg, 69%).  
δH (500 MHz, CD3OD) 7.88 (d, J = 8.4 Hz, 2H, H-14), 7.78 (d, J = 8.5 Hz, 1H, H-8), 7.45 (d, J = 8.0 Hz, 
2H, H-15), 7.10 (s, 1H, H-5), 6.89 (d, J = 8.6 Hz, 1H, H-7), 4.66 (s, 2H, H-12), 2.43 (s, 3H, H-17). δC 
(126MHz, CD3OD) 174.3 (C=O), 164.5 (C=O), 162.0 (C-Ar), 145.7 (C-Ar), 142.1 (C-Ar), 133.4 (C-Ar), 
132.4 (C-Ar), 130.9 (CH-Ar), 129.8 (CH-Ar), 127.9 (CH-Ar), 109.9 (CH-Ar), 107.0 (CH-Ar), 67.0 (CH2), 
20.2 (CH3). MS (ES-) m/z 364.1 [M-H]
-. HRMS (ESI) C16H14NO7S calcd. 364.0491 [M-H]
-, found 
364.0499. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 4.97 min 
(99.4%). 
Analytical data is in agreement with literature values.177 
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Synthesis of 2-((3-hydroxyphenyl)amino)-2-oxoethyl 4-
methylbenzenesulfonate (169) 
 
 
 
 
Prepared according to Standard Procedure F, from 3-aminophenol (1.888 g, 7.381 mmol), 
triethylamine (1.02 mL, 7.381 mmol), chloride 171 (671 mg, 6.151 mmol) and anhydrous THF (17 
mL). The product amide 169 was isolated as a white crystalline solid (1.201 g, 61%).  
δH (500 MHz, DMSO) 9.97 (s, 1H, H-1), 9.43 (s, 1H, H-8), 7.85 (d, J = 8.2 Hz, 2H, H-12), 7.50 (d, J = 
8.0 Hz, 2H, H-13), 7.12 – 7.02 (m, 2H, H-4 + H-7), 6.87 (d, J = 7.9 Hz, 1H, H-3), 6.48 (d, J = 8.1 Hz, 
1H, H-5), 4.66 (s, 2H, H-10), 2.42 (s, 3H, H-15). δC (126MHz, DMSO) 163.4 (C=O), 158.1 (C-Ar), 
145.8 (C-Ar), 139.5 (C-Ar), 132.5 (C-Ar), 130.7 (CH-Ar), 128.3 (CH-Ar), 126.0 (CH-Ar), 111.4 (CH-Ar), 
110.6 (CH-Ar), 107.0 (CH-Ar), 67.9 (CH2), 21.6 (CH3). MS (ES+) m/z 344.0 [M+Na]
+. HRMS (ESI) 
C15H16NO5S calcd. 322.0749 [M+H]
+, found 322.0746. HPLC (reverse-phase) MeOH/H2O 0:100 to 
100:0 in 12 min, λ = 254 nm, tR = 5.27 min (96.6%). 
Synthesis of 2-((4-hydroxyphenyl)amino)-2-oxoethyl 4-
methylbenzenesulfonate (170) 
 
 
 
 
Prepared according to Standard Procedure F, from 4-aminophenol (79 mg, 0.725 mmol), 
triethylamine (0.12 mL, 0.870), chloride 171 (216 mg, 0.870 mmol) and anhydrous THF (7 mL). The 
product amide 170 was isolated as a white crystalline solid (158 mg, 85%).  
δH (500 MHz, DMSO) 9.85 (s, 1H, H-1), 9.26 (s, 1H, H-6), 7.84 (d, J = 8.3 Hz, 2H, H-10), 7.49 (d, J = 
8.0 Hz, 2H, H-11), 7.26 (d, J = 8.9 Hz, 2H, H-4), 6.69 (d, J = 8.9 Hz, 2H, H-3), 4.61 (s, 2H, H-8), 2.41 
(s, 3H, H-13). δC (126 MHz, DMSO) 162.9 (C=O), 154.4 (C-Ar), 145.7 (C-Ar), 132.5 (C-Ar), 130.6 (CH-
Ar), 130.0 (C-Ar), 128.3 (CH-Ar), 121.8 (CH-Ar), 115.6 (CH-Ar), 67.9 (CH2), 21.6 (CH3). MS (ES+) m/z 
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344.1 [M+Na]+. HRMS (ESI) C15H15NO5NaS calcd. 344.0563 [M+Na]
+, found 344.0546. HPLC 
(reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 5.15 min (99.9%). 
Synthesis of 4-nitrophenyl phosphorodichloridate (172) 
 
 
 
 
 
Prepared according to Standard Procedure A, from POCl3 (0.74 mL, 7.907 mmol), 4-nitrophenol (1 
g, 7.189 mmol), triethylamine (1.10 mL, 7.907 mmol) and anhydrous diethyl ether (10 mL). The 
product phosphorochloridate 172 was isolated as a yellow solid (1.8 g, 98%), which was used 
without purification.  
δH (500 MHz, CDCl3) 8.35 (d, J = 8.3 Hz, 2H, H-3), 7.49 (d, J = 2.0 Hz, 2H, H-2). δP (202 MHz, CDCl3) 
3.33. Analytical data is in agreement with literature values.206 
 
Synthesis of methyl (chloro(4-nitrophenoxy)phosphoryl)-L-alaninate (173) 
 
 
 
 
 
Prepared according to Standard Procedure B, from compound 172 (600 mg, 2.131 mmol), L-
alanine methyl ester hydrochloride (300 mg, 2.144 mmol), triethylamine (0.60 mL, 4.262 mmol) 
and anhydrous DCM (10 mL). The product phosphorochloridate 173 was isolated as a colourless 
oil (401 mg, 58%), which was used without purification. Product isolated as a mixture of 
diastereoisomers. 
δH (500MHz, CDCl3) 8.28 (dd, J = 1.4, 0.8 Hz, 2H, H-3), 7.45 (dd, J = 7.0, 2.3 Hz, 2H, H-2), 4.40 (d, J = 
10.8 Hz, 1H, H-5), 4.27 – 4.21 (m, 1H, H-6), 3.81 (d, J = 6.5 Hz, 3H, H-9), 1.54 (dd, J = 9.4, 3.6 Hz, 
3H, H-7). δP (202MHz, CDCl3) 7.57, 7.26.  
 
Experimental Procedures                                                               Chapter 10 
  
204 
 
Synthesis of isopropyl (chloro(4-nitrophenoxy)phosphoryl)-L-alaninate (174) 
 
 
 
 
 
Prepared according to Standard Procedure B, from compound 172 (504 mg, 1.969 mmol), L-
alanine isopropyl ester hydrochloride (300 mg, 1.790 mmol), triethylamine (0.5 mL, 3.580 mmol)   
and anhydrous DCM (10 mL). The product phosphorochloridate 174 was isolated as a colourless 
oil (401 mg, 64%) which was used without purification. Product isolated as a mixture of 
diastereoisomers. 
δH (500MHz, CDCl3) 8.27 (dd, J = 6.1, 4.1 Hz, 2H, H-3), 7.43 (dd, J = 9.3, 1.0 Hz, 2H, H-2), 5.14 – 4.97 
(m, 1H, H-9), 4.50 – 4.43 (m, 1H, H-5), 4.22 – 3.99 (m, 1H, H-6), 1.52 – 1.38 (m, 3H, H-7), 1.29 (dd, J 
= 7.5, 6.3 Hz, 6H, H-10). δP (202MHz, CDCl3) 7.81, 7.48. 
Synthesis of tert-butyl (chloro(4-nitrophenoxy)phosphoryl)-L-alaninate (175) 
 
 
 
 
 
Prepared according to Standard Procedure B, from compound 172 (930 mg, 3.633 mmol), L-
alanine tert-butyl ester hydrochloride (600 mg, 3.303 mmol), triethylamine (0.92 mL, 6.606 mmol) 
and anhydrous DCM (15 mL). The product phosphorochloridate 175 was isolated as a colourless 
oil (630 mg, 52%) which was used without purification. Product isolated as a mixture of 
diastereoisomers. 
δH (500MHz, CDCl3) 8.27 (d, J = 0.9 Hz, 2H, H-3), 7.44 (dd, J = 5.7, 3.6 Hz, 2H, H-2), 4.38 – 4.32 (m, 
1H, H-5), 4.11 – 4.01 (m, 1H, H-6), 1.49 (dd, J = 9.6, 8.2 Hz, 9H, H-10), 1.43 (dd, J = 5.6, 4.1 Hz, 3H, 
H-7). δP (202MHz, CDCl3) 7.85, 7.47. 
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Synthesis of benzyl (chloro(4-nitrophenoxy)phosphoryl)-L-alaninate (176) 
 
 
 
 
 
Prepared according to Standard Procedure B, from compound 172 (784 mg, 3.063 mmol), L-
alanine benzyl ester hydrochloride (600 mg, 2.782 mmol), triethylamine (0.78 mL, 5.564 mmol) 
and anhydrous DCM (15 mL). The product phosphorochloridate 176 was isolated as a colourless 
oil (770 mg, 69%) which was used without purification. Product isolated as a mixture of 
diastereoisomers. 
δH (500MHz, CDCl3) 8.25 (dd, J = 11.8, 9.1 Hz, 2H, H-3), 7.45 – 7.28 (m, 7H, H-2 + H-11 + H-12 + H-
13), 5.22 (d, J = 5.7 Hz, 2H, H-9), 4.44 – 4.17 (m, 2H, H-5 + H-6), 1.54 (dd, J = 7.0, 3.7 Hz, 3H, H-7). 
δP (202MHz, CDCl3) 7.52, 7.18.  
Synthesis of methyl ((4-nitrophenoxy)(3-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)-L-alaninate (177) 
 
 
 
 
Prepared according to Standard Procedure G, from compound 169 (149 mg, 0.465 mmol), 
chloride 173 (300 mg, 0.930 mmol), triethylamine (0.13 mL, 0.930 mmol) and anhydrous THF (5 
mL). The product prodrug 177 was isolated as a white solid (29 mg, 10%). Product isolated as a 
mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.21 (d, J = 9.0 Hz, 2H, H-17), 8.09 (d, J = 9.2 Hz, 1H, H-8), 7.83 (d, J = 8.4 Hz, 
2H, H-4), 7.66 – 7.59 (m, 1H, H-11), 7.43 – 7.34 (m, 3H, H-14 + H-16), 7.29 (dd, J = 7.9, 5.4 Hz, 2H, 
H-3), 7.01 (d, J = 3.1 Hz, 1H, H-10), 6.85 (d, J = 6.2 Hz, 1H, H-12), 4.52 (s, 2H, H-6), 4.21 – 4.08 (m, 
1H, H-20), 4.07 – 3.97 (m, 1H, H-19), 3.71 (d, J = 2.8 Hz, 3H, H-23), 2.45 (s, 3H, H-1), 1.41 (d, J = 6.5 
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Hz, 3H, H-21). δC (126MHz, CDCl3) 173.4 (C=O), 163.5 (C=O), 162.1 (C-Ar), 155.3 (C-Ar), 150.4 (C-
Ar), 146.3 (C-Ar), 137.8 (C-Ar), 131.4 (C-Ar), 130.4 (CH-Ar), 128.2 (CH-Ar), 125.7 (CH-Ar), 120.8 
(CH-Ar), 117.2 (CH-Ar), 116.8 (CH-Ar), 115.6 (CH-Ar), 112.3 (CH-Ar), 66.9 (CH2), 52.8 (CH), 50.5 
(CH3), 21.8 (CH3), 20.9 (CH3). δP (202MHz, CDCl3) -3.36, -3.41. MS (ES+) m/z 630.1 [M+Na]
+. HRMS 
(ESI) C25H26N3O11NaPS calcd. 608.0918 [M+Na]
+, found 630.0926. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 6.39 min (97.1%). 
Synthesis of isopropyl ((4-nitrophenoxy)(3-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)-L-alaninate (178) 
 
 
 
 
 
Prepared according to Standard Procedure G, from compound 169 (150 mg, 0.467 mmol), 
chloride 174 (326 mg, 0.934 mmol), triethylamine (0.13 mL, 0.934 mmol) and anhydrous THF (10 
mL). The product prodrug 178 was isolated as a white solid (32 mg, 11%). Product isolated as a 
mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.24 – 8.15 (m, 3H, H-8 + H-17), 7.84 (d, J = 8.4 Hz, 2H, H-4), 7.59  – 7.56 (m, 
1H, H-11), 7.45 – 7.36 (m, 4H, H-10 + H-14 + H-16), 7.33 – 7.26 (m, 2H, H-3), 7.05 (d, J = 9.9 Hz, 1H, 
H-12), 5.01 (dq, J = 12.5, 6.3 Hz, 1H, H-23), 4.53 (s, 2H, H-6), 4.19 – 3.93 (m, 2H, H-19 + H-20), 2.46 
(s, 3H, H-1), 1.40 (d, J = 6.0 Hz, 3H, H-21), 1.22 (dd, J = 5.5, 3.8 Hz, 6H, H-24). δC (126MHz, CDCl3) 
172.5 (C=O), 163.4 (C=O), 155.5 (C-Ar), 150.6 (C-Ar), 146.2 (C-Ar), 144.7 (C-Ar), 138.0 (C-Ar), 131.5 
(C-Ar), 130.3 (CH-Ar), 130.2 (CH-Ar), 128.2 (CH-Ar), 125.7 (CH-Ar), 120.9 (CH-Ar), 117.1 (CH-Ar), 
116.6 (CH-Ar), 112.3 (CH-Ar), 69.7 (CH/CH3), 69.6 (CH/CH3), 66.9 (CH2), 50.6 (CH3), 21.7 (CH3), 20.9 
(CH). δP (202MHz, CDCl3) -3.18, -3.23. MS (ES+) m/z 658.1 [M+Na]
+. HRMS (ESI) C27H30N3O11NaPS 
calcd. 658.1231 [M+Na]+, found 658.1220. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 
min, λ = 254 nm, tR = 8.08 min (96.7%). 
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Synthesis of tert-butyl ((4-nitrophenoxy)(3-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)-L-alaninate (179) 
 
 
 
 
Prepared according to Standard Procedure G, from compound 169 (150 mg, 0.467 mmol), 
chloride 175 (300 mg, 0.934 mmol), triethylamine (0.12 mL, 0.934 mmol) and anhydrous THF (10 
mL). The product prodrug 179 was isolated as a white solid (37 mg, 12%). Product isolated as a 
mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.14 (dd, J = 6.4, 2.7 Hz, 2H, H-17), 8.05 (d, J = 14.8 Hz, 1H, H-8), 7.77 (d, J = 
8.3 Hz, 2H, H-4), 7.55 – 7.50 (m, 1H, H-11), 7.38 – 7.30 (m, 4H, H-10 + H-14 + H-15), 7.22 (dd, J = 
3.9, 1.7 Hz, 2H, H-3), 7.01 – 6.94 (m, 1H, H-12), 4.46 (s, 2H, H-6), 4.04 – 3.84 (m, 2H, H-19 + H-20), 
2.39 (s, 3H, H-1), 1.36 (d, J = 2.3 Hz, 9H, H-24), 1.31 (d, J = 6.1 Hz, 3H, H-21). δC (126MHz, CDCl3) 
172.1 (C=O), 163.4 (C=O), 155.4 (C-Ar), 150.6 (C-Ar), 146.2 (C-Ar), 144.8 (C-Ar), 137.8 (C-Ar), 131.4 
(C-Ar), 130.4 (CH-Ar), 130.2 (CH-Ar), 128.2 (CH-Ar), 125.7 (CH-Ar), 120.8 (CH-Ar), 117.1 (CH-Ar), 
115.6 (CH-Ar), 112.3 (CH-Ar), 82.5 (C), 66.9 (CH2), 51.0 (CH), 27.9 (CH3), 21.7 (CH3), 21.0 (CH3). δP 
(202MHz, CDCl3) -3.08, -3.13. MS (ES+) m/z 672.1 [M+Na]
+. HRMS (ESI) C28H32N3O11NaPS calcd. 
672.1387 [M+Na]+, found 672.1375. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ 
= 254 nm, tR = 8.61 min (96.0%). 
Synthesis of benzyl ((4-nitrophenoxy)(3-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)-L-alaninate (180) 
 
 
 
 
 
 
Prepared according to Standard Procedure G, from compound 169 (50 mg, 0.156 mmol), chloride 
176 (124 mg, 0.312 mmol), triethylamine (0.04 mL, 0.312 mmol) and anhydrous THF (5 mL). The 
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product prodrug 180 was isolated as a white solid (26 mg, 25%). Product isolated as a mixture of 
diastereoisomers. 
δH (500MHz, CDCl3) 8.16 (d, J = 9.5 Hz, 1H, H-8), 8.07 (d, J = 9.1 Hz, 2H, H-17), 7.75 (d, J = 0.8 Hz, 
2H, H-4), 7.49 (d, J = 21.3 Hz, 1H, H-11), 7.34 – 7.13 (m, 11H, H-3 + H-10 + H-14 + H-16, H-25 + H-
26 + H-27), 6.98 – 6.86 (m, 1H, H-12), 5.05 (d, J = 3.3 Hz, 2H, H-23), 4.43 (s, 2H, H-6), 4.29 – 4.01 
(m, 2H, H-19 + H-20), 2.37 (s, 3H, H-1), 1.35 (d, J = 6.9 Hz, 3H, H-21). δC (126MHz, CDCl3) 172.8 
(C=O), 163.4 (C=O), 155.3 (C-Ar), 150.5 (C-Ar), 146.2 (C-Ar), 144.7 (C-Ar), 138.0 (C-Ar), 135.1 (C-
Ar), 131.5 (C-Ar), 130.3 (CH-Ar), 130.2 (CH-Ar), 128.7 (CH-Ar), 128.3 (CH-Ar), 128.2 (CH-Ar), 125.7 
(CH-Ar), 125.6 (CH-Ar), 120.8 (CH-Ar), 117.1 (CH-Ar), 116.5 (CH-Ar), 112.2 (CH-Ar), 67.5 (CH2), 66.9 
(CH2), 50.6 (CH), 21.7 (CH3), 20.8 (CH3). δP (202MHz, CDCl3) -3.30, -3.42. MS (ES+) m/z 706.1 
[M+Na]+. HRMS (ESI) C31H30N3O11NaPS calcd. 706.1231 [M+Na]
+, found 706.1213. HPLC (reverse-
phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 7.63 min (98.9%). 
Synthesis of isopropyl ((4-nitrophenoxy)(4-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)-L-alaninate (182) 
 
 
 
 
 
Prepared according to Standard Procedure G, from compound 170 (100 mg, 0.312 mmol), 
chloride 174 (219 mg, 0.624 mmol), triethylamine (0.09 mL, 0.624 mmol) and anhydrous THF (5 
mL). The product prodrug 182 was isolated as a white solid (31 mg, 16%). Product isolated as a 
mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.16 (dd, J = 9.2, 2.6 Hz, 2H, H-15), 7.90 (s, 1H, H-8), 7.78 (d, J = 8.4 Hz, 2H, H-
4), 7.43 (dd, J = 9.0, 2.3 Hz, 2H, H-10), 7.37 – 7.24 (m, 4H, H-3 + H-14), 7.15 (d, J = 9.0 Hz, 2H, H-
11), 4.99 – 4.92 (m, J = 12.5, 6.3, 1.5 Hz, 1H, H-21), 4.47 (s, 2H, H-6), 4.01 (dt, J = 23.0, 7.8 Hz, 1H, 
H-18), 3.82 (dd, J = 12.0, 9.3 Hz, 1H, H-17), 2.40 (d, J = 8.1 Hz, 3H, H-1), 1.32 (dd, J = 7.0, 4.4 Hz, 
3H, H-19), 1.20 – 1.12 (m, 6H, H-22). δC (126MHz, CDCl3) 176.6 (C=O), 163.2 (C=O), 156.3 (C-Ar), 
147.1 (C-Ar), 146.2 (C-Ar), 133.8 (C-Ar), 131.5 (C-Ar), 131.1 (C-Ar), 130.4 (CH-Ar), 128.2 (CH-Ar), 
125.7 (CH-Ar), 121.8 (CH-Ar), 120.8 (CH-Ar), 120.8 (CH-Ar), 69.7 (CH), 66.9 (CH2), 50.6 (CH3), 21.7 
(CH3), 21.0 (CH3). δP (202 MHz, CDCl3) -3.05, -3.11. MS (ES+) m/z 658.1 [M+Na]
+. HRMS (ESI) 
C27H30N3O11NaPS calcd. 658.1231 [M+Na]
+, found 658.1212. HPLC (reverse-phase) MeOH/H2O 
0:100 to 100:0 in 12 min, λ = 254 nm, tR = 7.26 min (95.0%). 
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Synthesis of tert-butyl ((4-nitrophenoxy)(4-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)-L-alaninate (183) 
 
 
 
 
Prepared according to Standard Procedure G, from compound 170 (150 mg, 0.467 mmol), 
chloride 175 (341 mg, 0.935 mmol), triethylamine (0.13 mL, 0.935 mmol) and anhydrous THF (10 
mL). The product prodrug 183 was isolated as a white solid (36 mg, 12%). Product isolated as a 
mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.22 (dd, J = 9.0, 2.2 Hz, 2H, H-15), 8.02 (d, J = 2.5 Hz, 1H, H-8), 7.85 (d, J = 8.4 
Hz, 2H, H-4), 7.50 (dd, J = 8.8, 1.5 Hz, 2H, H-10), 7.44 – 7.31 (m, 4H, H-3 + H-14), 7.30 – 7.20 (m, 
2H, H-11), 4.54 (s, 2H, H-6), 4.04 – 3.84 (m, 2H, H-17 + H-18), 2.47 (s, 3H, H-1), 1.43 (d, J = 2.9 Hz, 
9H, H-22), 1.37 (dd, J = 6.8, 4.6 Hz, 3H, H-19). δC (126MHz, CDCl3) 172.1 (C=O), 163.3 (C=O), 155.5 
(C-Ar), 147.1 (C-Ar), 146.2 (C-Ar), 144.7 (C-Ar), 133.8 (C-Ar), 131.5 (C-Ar), 130.4 (CH-Ar), 128.2 (CH-
Ar), 125.7 (CH-Ar), 121.8 (CH-Ar), 120.8 (CH-Ar), 120.7 (CH-Ar), 82.6 (C), 67.0 (CH2), 51.0 (CH), 27.9 
(CH3), 21.8 (CH3), 21.1 (CH3). δP (202 MHz, CDCl3) -2.85, -2.95. MS (ES+) m/z 672.2 [M+Na]
+. HRMS 
(ESI) C28H32N3O11NaPS calcd. 672.1387 [M+Na]
+, found 672.1374. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 6.39 min (98.9%). 
Synthesis of benzyl ((4-nitrophenoxy)(4-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)-L-alaninate (184) 
 
 
 
 
Prepared according to Standard Procedure G, from compound 170 (130 mg, 0.405 mmol), 
chloride 176 (322 mg, 0.810 mmol), triethylamine (0.12 mL, 0.810 mmol) and anhydrous THF (10 
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mL). The product phosphate 184 was isolated as a white solid (5 mg, 2%). Product isolated as a 
mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.24 – 8.18 (m, 3H, H-8 + H-15), 8.15 (d, J = 9.1 Hz, 2H, H-10), 7.52 (d, J = 8.9 
Hz, 2H, H-14), 7.38 – 7.32 (m, 9H, H-3 + H-4 + H-23 + H-24 + H-25), 6.90 (d, J = 9.1 Hz, 2H, H-11), 
5.16 (d, J = 12.1 Hz, 2H, H-21), 4.19 (s, 2H, H-6), 4.07 (dd, J = 16.4, 8.5 Hz, 1H, H-17/18), 3.84 (dd, J 
= 16.4, 9.5 Hz, 1H, H-17/18), 1.42 (d, J = 7.0 Hz, 3H, H-19), 1.25 (s, 3H, H-1). δC (126MHz, CDCl3) 
172.8 (C=O), 163.8 (C=O), 155.4 (C-Ar), 149.6 (C-Ar), 143.7(C-Ar), 142.1 (C-Ar), 139.8 (C-Ar), 135.0 
(C-Ar), 134.2 (C-Ar), 128.7 (CH-Ar), 128.7 (CH-Ar), 128.3 (CH-Ar), 126.2 (CH-Ar), 125.7 (CH-Ar), 
125.6 (CH-Ar), 121.5 (CH-Ar), 120.8 (CH-Ar), 115.6 (CH-Ar), 68.7 (CH), 67.6 (CH2), 50.6 (CH3), 42.8 
(CH2), 21.0 (CH3). δP (202MHz, CDCl3) -3.19, -3.31. MS (ES+) m/z 684.1 [M+H]
+. HRMS (ESI) 
C31H30N3O11NaPS calcd. 706.1231 [M+Na]
+, found 706.1208. HPLC (reverse-phase) MeOH/H2O 
0:100 to 100:0 in 12 min, λ = 254 nm, tR = 7.05 min (80.1%). 
Synthesis of methyl ((4-(2-hydroxyacetamido)phenoxy)(4-
nitrophenoxy)phosphoryl)-L-alaninate (185) 
 
 
 
 
 
Prepared according to Standard Procedure G, from compound 170 (100 mg, 0.408 mmol), 
chloride 173 (263 mg, 0.815 mmol), triethylamine (0.11 mL, 0.815 mmol) and anhydrous THF (5 
mL). The product prodrug 185 was isolated as a white solid (37 mg, 20%). Product isolated as a 
mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.30 (s, 1H, H-4), 8.23 (dd, J = 8.9, 1.8 Hz, 2H, H-11), 7.54 (dd, J = 8.8, 1.7 Hz, 
2H, H-6), 7.39 (d, J = 9.9 Hz, 2H, H-10), 7.30 – 7.16 (m, 2H, H-7), 4.19 (d, J = 9.7 Hz, 2H, H-2), 4.19 – 
4.07 (m, 1H, H-14), 4.01 (dd, J = 9.4, 4.6 Hz, 1H, H-13), 3.72 (d, J = 1.9 Hz, 3H, H-17), 1.42 (dd, J = 
7.0, 4.1 Hz, 3H, H-15). δC (126MHz, CDCl3) 167.0 (C=O), 163.9 (C=O), 155.4 (C-Ar), 147.1 (C-Ar), 
144.8 (C-Ar), 134.2 (C-Ar), 125.7 (CH-Ar), 121.6 (CH-Ar), 120.8 (CH-Ar), 120.8 (CH-Ar), 52.8 (CH3), 
50.4 (CH), 42.8 (CH2), 21.0 (CH3). δP (202MHz, CDCl3) -3.13, -3.19. MS (ES+) m/z 474.1 [M+Na]
+. 
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Synthesis of 2-((3-((diethoxyphosphoryl)oxy)phenyl)amino)-2-oxoethyl 4-
methylbenzenesulfonate (186) 
 
 
 
 
Prepared according to Standard Procedure G, from compound 169 (150 mg, 0.467 mmol), diethyl 
chlorophosphate (0.07 mL, 0.934 mmol), triethylamine (0.13 mL, 0.934 mmol) and anhydrous THF 
(10 mL). The product prodrug 186 was isolated as a colourless oil (41 mg, 19%).  
δH (500MHz, CDCl3) 8.08 (s, 1H, H-8), 7.77 (d, J = 8.4 Hz, 2H, H-4), 7.42 (s, 1H, H-14), 7.32 (d, J = 8.0 
Hz, 2H, H-3), 7.24 – 7.15 (m, 2H, H-10 + H-11), 6.95 (d, J = 3.2 Hz, 1H, H-12), 4.47 (s, 2H, H-6), 4.22 
– 4.09 (m, 4H, H-15), 2.38 (s, 3H, H-1), 1.29 (t, J = 7.1 Hz, 6H, H-16). δC (126MHz, CDCl3) 163.3 
(C=O), 151.0 (C-Ar), 146.1 (C-Ar), 137.7 (C-Ar), 131.6 (C-Ar), 130.3 (CH-Ar), 130.0 (CH-Ar), 128.2 
(CH-Ar), 116.6 (CH-Ar), 116.5 (CH-Ar), 112.1 (CH-Ar), 66.9 (CH2), 64.8 (CH2), 21.7 (CH3), 16.2 (CH3). 
δP (202MHz, CDCl3) -6.58. MS (ES+) m/z 480.1 [M+Na]
+. HRMS (ESI) C19H24NO8NaPS calcd. 
480.0852 [M+Na]+, found 480.0851.  HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ 
= 254 nm, tR = 5.97 min (97.0%). 
Synthesis of 2-((4-((diethoxyphosphoryl)oxy)phenyl)amino)-2-oxoethyl 4-
methylbenzenesulfonate (187) 
 
 
 
 
Prepared according to Standard Procedure G, from compound 170 (150 mg, 0.467 mmol), diethyl 
chlorophosphate (0.14 mL, 0.934 mmol), triethylamine (0.13 mL, 0.934 mmol) and anhydrous THF 
(10 mL). The product prodrug 187 was isolated as a colourless oil (39 mg, 18%).  
δH (500MHz, CDCl3) 7.92 (s, 1H, H-8), 7.78 (d, J = 7.8 Hz, 2H, H-4), 7.40 (d, J = 8.7 Hz, 2H, H-10), 
7.33 (d, J = 7.9 Hz, 2H, H-3), 7.12 (d, J = 8.8 Hz, 2H, H-11), 4.48 (s, 2H, H-6), 4.18 – 4.07 (m, 4H, H-
13), 2.40 (s, 3H, H-1), 1.28 (t, J = 7.0 Hz, 6H, H-14). δC (126MHz, CDCl3) 163.2 (C=O), 147.7 (C-Ar), 
146.2 (C-Ar), 133.3 (C-Ar), 131.5 (C-Ar), 130.4 (CH-Ar), 128.2 (CH-Ar), 121.6 (CH-Ar), 120.6 (CH-Ar), 
67.0 (CH2), 64.7 (CH2), 21.7 (CH3), 16.1 (CH3). δP (202MHz, CDCl3) -6.31. MS (ES+) m/z 480.1 
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[M+Na]+. HRMS (ESI) C19H25NO8PS calcd. 458.1038 [M+H]
+, found 458.1030. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 5.65 min (95.0%). 
Synthesis of ethyl 2-((tert-butyldimethylsilyl)oxy)acetate (201) 
 
 
 
Ethyl glycolate (2 g, 19.211 mmol) was dissolved in anhydrous DCM (50 mL) and treated with tert-
butyldimethylsilyl chloride (3.475 g, 23.053 mmol) and imidazole (1.569 g, 23.053 mmol) under a 
nitrogen atmosphere, at 0 °C, for one hour. The yellow solution was then left to warm to room 
temperature and stirred for 11 hours. After reaction completion, water (50 mL) was added to the 
suspicion and the product was extracted into DCM (2 x 50 mL). The combined yellow organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure to afford an 
orange oil. The oil was then subjected to flash column chromatography (1:9 ethyl acetate: 
hexane) to yield product 201 as a colourless oil (2.010 g, 48%).  
δH (500MHz, CDCl3) 4.23 (s, 2H, H-4), 4.20 (q, J = 7.1 Hz, 2H, H-2), 1.28 (t, J = 7.1 Hz, 3H, H-1), 0.92 
(s, 9H, H-7), 0.11 (s, 6H, H-5). δC (126MHz, CDCl3) 171.8 (C=O), 61.9 (CH2), 60.7 (CH2), 25.8 (CH3), 
18.4 (C), 14.2 (CH3), -5.4 (CH3). MS (ES+) m/z 251.4 [M+Na]
+.  
Analytical data is in agreement with literature values.169 
Synthesis of tert-butyldimethylsilyl 2-((tert-butyldimethylsilyl)oxy)acetate 
(211) 
 
 
Glycolic acid (1.0 g, 13.140 mmol) was dissolved in anhydrous DMF (12 mL), under a nitrogen 
atmosphere, at 0 °C. Imidazole (2.7 g, 39.400 mmol) and tert-butyldimethylsilyl chloride (4.3 g, 
27.600 mmol) were carefully added and stirred for one hour. The reaction mixture was then left 
to warm to room temperature and stirred for 11 hours. Once TLC had confirmed reaction 
completion, water (100 mL) was added to the suspension and the product was extracted into 
diethyl ether (2 x 50 mL). The organic fractions were combined and dried over MgSO4, filtered and 
concentrated under reduced pressure to afford a white gel. The gel was purified by flash column 
chromatography (19:1 hexane: ethyl acetate) to yield product 211 as a white solid (3.821 g, 95%).  
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δH (500MHz, CDCl3) 4.17 (s, 2H, H-5), 0.94 – 0.91 (m, 18H, H-1 + H-8), 0.27 (s, 6H, H-3/H-6), 0.09 (s, 
6H, H-3/H-6). δC (126MHz, CDCl3) 171.9 (C=O), 62.4 (CH2), 25.8 (CH3), 25.5 (CH3), 18.4 (C), 17.7 (C), 
-4.8 (CH3), -5.5 (CH3). MS (ES+) m/z 327.2 [M+Na]
+.  
Analytical data is in agreement with literature values.172 
Synthesis of 2-((tert-butyldimethylsilyl)oxy)acetyl chloride (212) 
 
 
 
At 0 °C, and under a nitrogen atmosphere, silyl ether 211 (1.63 g, 5.352 mmol) was dissolved in 
anhydrous DCM (10 mL) with oxalyl chloride (0.54 mL, 6.155 mmol). Catalytic DMF (three drops) 
was added and the solution was stirred for 15 minutes at 0 °C and then left to stir at room 
temperature, for two hours. After reaction completion was deemed by TLC analysis, the solvent 
and excess oxalyl chloride was removed under reduced pressure, to afford chloride 212 as a 
yellow oil (1.116 g, >99%), which was used without purification.  
The compound was progressed as crude and could not be fully characterised. 
Synthesis of 2-((tert-butyldimethylsilyl)oxy)-N-(3-hydroxyphenyl)acetamide 
(213) 
 
 
 
Prepared according to Standard Procedure F, from acid chloride 212 (558 mg, 2.676 mmol), 3-
aminophenol (292 mg, 2.676 mmol), triethylamine (0.5 mL, 3.211 mmol) and anhydrous THF (10 
mL). Flash column chromatography (3:1 hexane: ethyl acetate) isolated product amide 213 as a 
light cream solid (401 mg, 53%).  
δH (500MHz, CDCl3) 8.54 (s, 1H, H-8), 8.13 – 7.99 (m, 2H, H-1 + H-7), 7.17 (t, J = 8.1 Hz, 1H, H-4), 
6.66 (dd, J = 8.2, 0.8 Hz, 1H, H-5), 6.53 (dd, J = 7.9, 1.1 Hz, 1H, H-3), 4.22 (s, 2H, H-10), 0.97 (s, 9H, 
H-13), 0.15 (s, 6H, H-11). δC (126MHz, CDCl3) 170.1 (C=O), 157.7 (C-Ar), 137.8 (C-Ar), 129.8 (CH-
Ar), 112.1 (CH-Ar), 110.3 (CH-Ar), 107.0 (CH-Ar), 63.1 (CH2), 25.8 (CH3), 18.1 (C), -5.5 (CH3). MS 
(ES+) m/z 304.2 [M+Na]+. 
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Synthesis of 2-((tert-butyldimethylsilyl)oxy)-N-(4-hydroxyphenyl)acetamide 
(214) 
 
 
 
Prepared according to Standard Procedure F, from acid chloride 212 (558 mg, 2.676 mmol), 4-
aminophenol (292 mg, 2.676 mmol), triethylamine (0.5 mL, 3.211 mmol) and anhydrous THF (10 
mL). Flash column chromatography (3:1 hexane: ethyl acetate) isolated amide 214 as a light 
cream solid (410 mg, 54%).  
δH (500MHz, CDCl3) 8.37 (bs, 1H, H-6), 7.36 (d, J = 8.9 Hz, 2H, H-4), 6.80 (d, J = 8.9 Hz, 2H, H-3), 
6.29 (s, 1H, H-1), 4.19 (s, 2H, H-8), 0.99 – 0.91 (m, 9H, H-11), 0.18 – 0.08 (m, 6H, H-9). δC (126MHz, 
CDCl3) 169.5 (C=O) , 153.4 (C-Ar), 129.5 (C-Ar), 122.0 (CH-Ar), 115.9 (CH-Ar), 63.2 (CH2), 25.8 (CH3), 
18.2 (C), -5.5 (CH3). MS (ES+) m/z 304.2 [M+Na]
+. 
Synthesis of dibenzyl (3-(2-((tert-butyldimethylsilyl)oxy)acetamido)phenyl) 
phosphate (215) 
 
 
 
 
 
To a stirring solution of phenol 213 (200 mg, 0.711 mmol) in anhydrous acetonitrile (10 mL), was 
added dibenzyl phosphite (0.21 mL, 0.924 mmol), tetrabromomethane (283 mg, 0.853 mmol) and 
anhydrous triethylamine (0.20 mL, 1.422 mmol), under a nitrogen atmosphere. The mixture was 
then stirred for 24 hours where the solvent was then removed under reduced pressure. The 
resultant yellow oil was diluted in water (50 mL) and the product was extracted into DCM (3 x 50 
mL). The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure to form a yellow oil. The oil was subjected to flash column chromatography (3:1 
hexane: ethyl acetate) to yield phosphate 215 as a colourless oil (248 mg, 64%).  
δH (500MHz, CDCl3) 8.34 (s, 1H, H-6), 7.34 (s, 1H, H-12), 7.28 – 7.25 (m, 1H, H-8), 7.25 – 7.19 (m, 
10H, H-15 + H-16 + H-17), 7.15 (t, J = 8.2 Hz, 1H, H-9), 6.87 (dd, J = 8.2, 2.4 Hz, 1H, H-10), 5.03 (d, J 
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= 8.4 Hz, 4H, H-13), 4.09 (s, 2H, H-4), 0.88 (s, 9H, H-1), 0.07 (s, 6H, H-3). δC (126MHz, CDCl3) 169.1 
(C=O), 150.9 (C-Ar), 138.4 (C-Ar), 135.5 (C-Ar), 135.4 (C-Ar) 130.1 (CH-Ar), 128.6 (CH-Ar), 128.6 
(CH-Ar), 128.1 (CH-Ar), 116.1 (CH-Ar), 115.9 (CH-Ar), 111.5 (CH-Ar), 70.0 (CH2), 63.4 (CH2), 25.8 
(CH3), 18.2 (C), -5.5 (CH3). δP (202MHz, CDCl3) -6.43. MS (ES+) m/z 541.2 [M+H]
+. 
Synthesis of dibenzyl (4-(2-((tert-butyldimethylsilyl)oxy)acetamido)phenyl) 
phosphate (216) 
 
 
 
 
To a stirring solution of phenol 214 (150 mg, 0.533 mmol) in anhydrous acetonitrile (10 mL), was 
added dibenzyl phosphite (0.15 mL, 0.693 mmol), tetrabromomethane (212 mg, 0.640 mmol) and 
anhydrous triethylamine (0.15 mL, 1.066 mmol), under a nitrogen atmosphere. The mixture was 
then stirred for 24 hours where the solvent was then removed under reduced pressure. The 
resultant yellow oil was diluted in water (50 mL) and the product was extracted into DCM (3 x 50 
mL). The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure to form a yellow oil. The oil was subjected to flash column chromatography (3:1 
hexane: ethyl acetate) to yield phosphate 216 as a colourless oil (193 mg, 67%).  
δH (500MHz, CDCl3) 8.43 (s, 1H, H-6), 7.49 (d, J = 8.8 Hz, 2H, H-8), 7.40 – 7.28 (m, 10H, H-13 + H-14 
+ H-15), 7.12 (d, J = 9.0 Hz, 2H, H-9), 5.11 (d, J = 8.4 Hz, 4H, H-11), 4.19 (s, 2H, H-4), 0.98 (s, 9H, H-
1), 0.16 (s, 6H, H-3). δC (126MHz, CDCl3) 176.6 (C=O), 169.0 (C-Ar), 146.9 (C-Ar), 135.5 (C-Ar), 134.3 
(C-Ar), 128.7 (CH-Ar), 128.6 (CH-Ar), 128.1 (CH-Ar), 120.7 (CH-Ar), 120.7 (CH-Ar), 70.0 (CH2), 63.3 
(CH2), 25.8 (CH3), 18.2 (C), -5.5 (CH3). δP (202MHz, CDCl3) -6.10. MS (ES+) m/z 564.2 [M+Na]
+. 
Synthesis of dibenzyl (4-(2-hydroxyacetamido)phenyl) phosphate (218) 
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Dibenzyl phosphate 216 (50 mg, 0.092 mmol) was dissolved in anhydrous THF (5 mL), under a 
nitrogen atmosphere. The colourless solution was then cooled to 0 °C and TBAF (0.10 mL, 0.102 
mmol) was treated dropwise. The reaction was stirred for 30 minutes and then warmed and 
stirred at room temperature for 1.5 hours. After reaction completion, water (20 mL) was carefully 
added and the product was extracted into ethyl acetate (3 x 20 mL). The combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure to afford a clear yellow 
oil. The oil was then purified by flash column chromatography (3:1 ethyl acetate: hexane) to yield 
alcohol 218 as a white foam (20 mg, 51%).  
δH (500MHz, CDCl3) 8.62 (s, 1H, H-4), 7.30 (d, J = 8.9 Hz, 2H, H-6), 7.27 – 7.15 (m, 10H, H-11 + H-12 
+ H-13), 6.90 (d, J = 8.4 Hz, 2H, H-7), 5.01 (d, J = 8.5 Hz, 4H, H-9), 4.66 (bs, 1H, H-1), 4.05 (s, 2H, H-
2). δC (126MHz, CDCl3) 170.7 (C=O), 146.6 (C-Ar), 135.1 (C-Ar), 134.6 (C-Ar), 128.8 (CH-Ar), 128.7 
(CH-Ar), 128.1 (CH-Ar), 121.2 (CH-Ar), 120.4 (CH-Ar), 70.3 (CH2), 62.2 (CH2). δP (202MHz, CDCl3) -
6.61. MS (ES+) m/z 450.1 [M+Na]+. 
Synthesis of dibenzyl (3-(2-
((bis(benzyloxy)phosphoryl)oxy)acetamido)phenyl) phosphate (219) 
 
 
 
 
 
Dibenzyl phosphate 215 (200 mg, 0.368 mmol) was dissolved in anhydrous THF (5 mL), under a 
nitrogen atmosphere. The colourless solution was then cooled to 0 °C and TBAF (0.37 mL, 0.368 
mmol) was treated dropwise. The reaction was stirred for 30 minutes and then warmed and 
stirred at room temperature for 1.5 hours. After reaction completion, water (30 mL) was carefully 
added and the product was extracted into ethyl acetate (3 x 30 mL). The combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure to afford a clear yellow 
oil. The oil was then purified by flash column chromatography (3:1 ethyl acetate: hexane) to yield 
bisphosphate 219 as a colourless oil (115 mg, 46%).  
δH (500MHz, CDCl3) 8.03 (s, 1H, H-8), 7.38 – 7.27 (m, 20H, H-1 + H-2 + H-3 + H-17 + H-18 + H-19), 
7.22 – 7.18 (m, 2H, H-10 + H-11), 6.95 (dd, J = 3.6, 2.4 Hz, 1H, H-12), 5.17 – 5.03 (m, 8H, H-5 + H-
15), 4.39 (d, J = 7.5 Hz, 2H, H-6). δC (126MHz, CDCl3) 150.3 (C=O), 140.8 (C-Ar), 138.5 (C-Ar), 138.0 
(C-Ar), 135.3 (C-Ar), 129.1 (CH-Ar), 128.9 (CH-Ar), 128.8 (CH-Ar), 128.7 (CH-Ar), 128.6 (CH-Ar), 
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128.6 (CH-Ar), 128.5 (CH-Ar), 128.4 (CH-Ar), 128.3 (CH-Ar), 128.3 (CH-Ar), 128.1 (CH-Ar), 127.8 
(CH-Ar), 127.7 (CH-Ar), 127.0 (CH-Ar), 72.1 (CH2), 70.4 (CH2), 65.4 (CH2). δP (202MHz, CDCl3) -1.59, 
-6.37. MS (ES+) m/z 710.2 [M+Na]+, 688.2 [M+H]+. 
Synthesis of dibenzyl (3-(2-hydroxyacetamido)phenyl) phosphate (217) 
 
 
 
 
 
Dibenzyl phosphate 215 (180 mg, 0.332 mmol) was dissolved in anhydrous THF (4 mL). The 
colourless solution was then cooled to 0 °C and a 1:1 mixture of TFA (0.5 mL) and water (0.5 mL) 
was treated dropwise. The reaction was stirred for 30 minutes and then warmed and stirred at 
room temperature for 2.5 hours. After reaction completion, the solution was basified to pH 7 with 
saturated NaHCO3 solution and the product was extracted into ethyl acetate (3 x 20 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure to afford a white solid. The solid was then purified by flash column chromatography 
(100% ethyl acetate) to yield alcohol 217 as a white foam (80 mg, 56%).  
δH (500MHz, CDCl3) 8.68 (s, 1H, H-4), 7.47 (s, 1H, H-10), 7.28 – 7.17 (m, 10H, H-13 + H-14 + H-15), 
7.11 (d, J = 8.2 Hz, 1H, H-6), 7.05 (t, J = 8.1 Hz, 1H, H-7), 6.73 (d, J = 5.9 Hz, 1H, H-8), 5.00 (d, J = 8.6 
Hz, 4H, H-11), 4.44 (s, 1H, H-1), 3.97 (s, 2H, H-2). δC (126MHz, CDCl3) 171.0 (C=O), 150.6 (C-Ar), 
138.8 (C-Ar), 135.1 (C-Ar), 130.0 (CH-Ar), 128.9 (CH-Ar), 128.7 (CH-Ar), 128.1 (CH-Ar), 116.6 (CH-
Ar), 115.5 (CH-Ar), 111.6 (CH-Ar), 70.4 (CH2), 62.3 (CH2). δP (202MHz, CDCl3) -6.67. MS (ES+) m/z 
450.1 [M+Na]+. 
Synthesis of dibenzyl (4-(2-hydroxyacetamido)phenyl) phosphate (218) 
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Dibenzyl phosphate 216 (220 mg, 0.406 mmol) was dissolved in anhydrous THF (5 mL). The 
colourless solution was then cooled to 0 °C and a 1:1 mixture of TFA (0.5 mL) and water (0.5 mL) 
was treated dropwise. The reaction was stirred for 30 minutes and then warmed and stirred at 
room temperature for 2.5 hours. After reaction completion, the solution was basified to pH 7 with 
saturated NaHCO3 solution and the product was extracted into ethyl acetate (3 x 20 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure to afford a white solid. The solid was then purified by flash column chromatography 
(100% ethyl acetate) to yield alcohol 218 as a white foam (116 mg, 67%).  
δH (500MHz, CDCl3) 8.87 (s, 1H, H-4), 7.28 (d, J = 8.9 Hz, 2H, H-6), 7.24 – 7.13 (m, 10H, H-11 + H-12 
+ H-13), 6.86 (d, J = 8.5 Hz, 2H, H-7), 5.47 (bs, 1H, H-1), 4.97 (d, J = 8.6 Hz, 4H, H-9), 4.01 (s, 2H, H-
2). δC (126MHz, CDCl3) 171.4 (C=O), 146.6 (C-Ar), 135.1 (C-Ar), 134.6 (C-Ar), 128.9 (CH-Ar), 128.7 
(CH-Ar), 128.1 (CH-Ar), 121.4 (CH-Ar), 120.4 (CH-Ar), 70.4 (CH2), 62.1 (CH2). δP (202MHz, CDCl3) -
6.78. MS (ES+) m/z 450.1 [M+Na]+. 
Synthesis of 2-((3-((bis(benzyloxy)phosphoryl)oxy)phenyl)amino)-2-oxoethyl 
4-methylbenzenesulfonate (221) 
 
 
 
 
 
Dibenzyl phosphate 217 (80 mg, 0.187 mmol) was dissolved in anhydrous DCM (14 mL) with p-
toluenesulfonyl chloride (39 mg, 0.206 mmol), under a nitrogen atmosphere. Triethylamine (0.05 
mL, 0.374 mmol) as added dropwise and the reaction was stirred for six hours, at room 
temperature. The solvent was then removed under reduced pressure to afford a yellow oil. The oil 
was purified directly by flash column chromatography (2:1 ethyl acetate: hexane) to isolate 
tosylate 221 as a colourless oil (95 mg, 87%).  
δH (500MHz, CDCl3) 8.02 (s, 1H, H-8), 7.76 (d, J = 8.4 Hz, 2H, H-4), 7.33 – 7.21 (m, 14H, H-3 + H-10 + 
H-14 + H-17 + H-18 + H-19), 7.12 (t, J = 8.4 Hz, 1H, H-11), 6.86 (d, J = 9.2 Hz, 1H, H-12), 5.04 (dd, J = 
8.6, 3.0 Hz, 4H, H-15), 4.45 (s, 2H, H-6), 2.35 (s, 3H, H-1). δC (126MHz, CDCl3) 163.2 (C=O), 150.8 
(C-Ar), 146.1 (C-Ar), 137.7 (C-Ar), 135.4 (C-Ar), 131.6 (C-Ar), 130.3 (CH-Ar), 130.1 (CH-Ar), 128.7 
(CH-Ar), 128.7 (CH-Ar), 128.2 (CH-Ar), 128.1 (CH-Ar), 116.9 (CH-Ar), 116.6 (CH-Ar), 112.3 (CH-Ar), 
70.2 (CH2), 66.9 (CH2), 21.7 (CH3). δP (202MHz, CDCl3) -6.45. MS (ES+) m/z 604.1 [M+Na]
+. 
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Synthesis of 2-((4-((bis(benzyloxy)phosphoryl)oxy)phenyl)amino)-2-oxoethyl 
4-methylbenzenesulfonate (222) 
 
 
 
 
 
Dibenzyl phosphate 218 (17 mg, 0.040 mmol) was dissolved in anhydrous DCM (5 mL) with p-
toluenesulfonyl chloride (8 mg, 0.040 mmol), under a nitrogen atmosphere. Triethylamine (0.01 
mL, 0.080 mmol) as added dropwise and the reaction was stirred for six hours, at room 
temperature. The solvent was then removed under reduced pressure to afford a yellow oil. The oil 
was purified directly by flash column chromatography (2:1 ethyl acetate: hexane) to isolate 
tosylate 222 as a colourless oil (21 mg, 90%).  
δH (500MHz, CDCl3) 7.98 (s, 1H, H-8), 7.77 (d, J = 8.1 Hz, 2H, H-4), 7.52 – 7.16 (m, 14H, H-3 + H-10 + 
H-15 + H-16 + H-17), 7.01 (d, J = 8.7 Hz, 2H, H-11), 5.04 (dd, J = 8.3, 3.7 Hz, 4H, H-13), 4.46 (s, 2H, 
H-6), 2.37 (s, 3H, H-1). δC (126MHz, CDCl3) 163.2 (C=O), 147.5 (C-Ar), 146.1 (C-Ar), 135.4 (C-Ar), 
133.5 (C-Ar), 131.6 (C-Ar), 130.3 (CH-Ar), 128.7 (CH-Ar), 128.7 (CH-Ar), 128.2 (CH-Ar), 128.1 (CH-
Ar), 121.6 (CH-Ar), 120.6 (CH-Ar), 70.1 (CH2), 67.0 (CH2), 21.7 (CH3). δP (202MHz, CDCl3) -6.24. MS 
(ES+) m/z 604.1 [M+Na]+. 
Synthesis of 2-oxo-2-((4-(phosphonooxy)phenyl)amino)ethyl 4-
methylbenzenesulfonate (163) 
 
 
 
 
In a flame-dried Schlenk tube, was added a 1:1 mixture of anhydrous ethyl acetate (4 mL) and 
anhydrous ethanol (4 mL). The tube was purged with nitrogen and the solvent was degassed. 
After degassing, catalytic 10% Pd/C was carefully added to the solution and washed from the tube 
walls with degassed 1:1 ethyl acetate and ethanol. The black suspension was further degassed 
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and then treated with dibenzyl phosphate 222 (21 mg, 0.036 mmol). The nitrogen atmosphere 
was then removed by vacuum and the flask was charged with hydrogen. The reaction was left to 
stir at room temperature for two hours. After reaction completion, the suspension was filtered 
through a pad of Celite and washed with ethanol. The filtrate was concentrated under reduced 
pressure to afford phosphoric acid 163 (14 mg, 99%) as a cream powder. The product was used 
without purification. 
δH (500MHz, DMSO) 7.84 (d, J = 7.8 Hz, 2H, H-4), 7.55 – 7.45 (m, 4H, H-3 + H-10/H-11), 7.40 (s, 1H, 
H-8), 7.12 (d, J = 7.6 Hz, 2H, H-10/H-11), 4.65 (s, 2H, H-6), 2.40 (s, 3H, H-1), 2.29 (s, 2H, H-13). δC 
(126MHz, DMSO) 168.4 (C=O), 163.3 (C-Ar), 145.8 (C-Ar), 138.1 (C-Ar), 132.5 (C-Ar), 130.7 (CH-Ar), 
128.5 (CH-Ar), 128.3 (CH-Ar), 126.0 (CH-Ar), 67.9 (CH2), 21.3 (CH3). δP (202MHz, DMSO) -5.49. MS 
(ES-) m/z 400.1 [M-H]-. HRMS (ESI) C15H15NO8PS calcd. 400.0256 [M-H]
-, found 400.0261. HPLC 
(reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 4.43 min (96.1%). 
Synthesis of 2-oxo-2-((3-(phosphonooxy)phenyl)amino)ethyl 4-
methylbenzenesulfonate (164) 
 
 
 
 
 
In a flame-dried Schlenk tube, was added a 1:1 mixture of anhydrous ethyl acetate (5 mL) and 
anhydrous ethanol (5 mL). The tube was purged with nitrogen and the solvent was degassed. 
After degassing, catalytic 10% Pd/C was carefully added to the solution and washed from the tube 
walls with degassed 1:1 ethyl acetate and ethanol. The black suspension was further degassed 
and then treated with dibenzyl phosphate 221 (20 mg, 0.034 mmol). The nitrogen atmosphere 
was then removed by vacuum and the flask was charged with hydrogen. The reaction was left to 
stir at room temperature for two hours. After reaction completion, the suspension was filtered 
through a pad of Celite and washed with ethanol. The filtrate was concentrated under reduced 
pressure to afford phosphoric acid 164 (14 mg, 99%) as a cream powder. The product was used 
without purification. 
δH (500MHz, DMSO) 7.83 (d, J = 7.9 Hz, 2H, H-4), 7.48 (d, J = 7.9 Hz, 2H, H-3), 7.31 (d, J = 7.4 Hz, 
1H, H-8), 7.25 – 7.15 (m, 2H, H-11 + H-14), 7.11 (d, J = 7.8 Hz, 1H, H-10), 6.87 (s, 1H, H-12), 4.66 (s, 
2H), 2.40 (s, 3H, H-1), 2.29 (s, 2H, H-15). δC (126MHz, DMSO) 163.6 (C=O), 145.8 (C-Ar), 139.3 (C-
Ar), 138.1 (C-Ar), 132.5 (C-Ar), 130.7 (CH-Ar), 129.8 (CH-Ar), 128.5 (CH-Ar), 128.3 (CH-Ar), 126.0 
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(CH-Ar), 114.7 (CH-Ar), 67.8 (CH2), 21.6 (CH3). δP (202MHz, DMSO) -5.73. MS (ES+) m/z 424.0 
[M+Na]+. HRMS (ESI) C15H15NO8PS calcd. 400.0256 [M-H]
-, found 400.0264. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 4.51 min (97.5%). 
Synthesis of 2-((3-((methoxy(phenoxy)phosphoryl)oxy)phenyl)amino)-2-
oxoethyl 4-methylbenzenesulfonate (225) 
 
 
 
 
Prepared according to Standard Procedure G, from compound 169 (283 mg, 0.882 mmol), 
chloride 138 (200 mg, 0.970 mmol), triethylamine (0.13 mL, 0.970 mmol) and anhydrous THF (5 
mL). The product phosphate 225 was isolated as a colourless oil (336 mg, 19%). Product isolated 
as a mixture of enantiomers. 
δH (500MHz, CDCl3) 8.24 (s, 1H, H-8), 7.74 (d, J = 8.3 Hz, 2H, H-4), 7.44 (s, 1H, H-14), 7.30 – 7.07 
(m, 9H, H-3 + H-10 + H-11 + H-16 + H-17 + H-18), 6.92 (dd, J = 8.0, 1.0 Hz, 1H, H-12), 4.45 (s, 2H, H-
6), 3.87 (d, J = 11.6 Hz, 3H, H-19), 2.34 (s, 3H, H-1). δC (126MHz, CDCl3) 163.4 (C=O), 150.7 (C-Ar), 
150.4 (C-Ar), 146.1 (C-Ar), 138.0 (C-Ar), 131.6 (C-Ar), 130.3 (CH-Ar), 130.1 (CH-Ar), 129.9 (CH-Ar), 
128.2 (CH-Ar), 125.5 (CH-Ar), 120.0 (CH-Ar), 117.1 (CH-Ar), 116.5 (CH-Ar), 112.2 (CH-Ar), 66.9 
(CH2), 55.6 (CH3), 21.7 (CH3). δP (202MHz, CDCl3) -11.03. MS (ES+) m/z 514.1 [M+Na]
+. 
 
Synthesis of ((phenoxy(3-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)oxy)methyl pivalate (223) 
 
 
 
 
 
Prepared according to Standard Procedure G, from Compound 169 (91 mg, 0.282 mmol), chloride 
138 (70 mg, 0.338 mmol), triethylamine (0.07 mL, 0.338 mmol) and anhydrous THF (5 mL). The 
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product prodrug 223 was isolated as a colourless oil (18 mg, 11%). Product isolated as a mixture 
of enantiomers. 
δH (500MHz, CDCl3) 8.00 (s, 1H, H-8), 7.85 (d, J = 8.4 Hz, 2H, H-4), 7.46 (s, 1H, H-14), 7.41 (d, J = 8.0 
Hz, 2H, H-16), 7.38 – 7.32 (m, 3H, H-17 + H-18), 7.30 (t, J = 8.2 Hz, 1H, H-11), 7.23 (dd, J = 7.7, 1.0 
Hz, 2H, H-3), 7.20 (d, J = 8.1 Hz, 1H, H-10), 7.04 (dd, J = 7.6, 1.7 Hz, 1H, H-12), 5.80 (dd, J = 14.3, 
2.7 Hz, 2H, H-19), 4.54 (s, 2H, H-6), 2.46 (s, 3H, H-1), 1.17 (s, 9H, H-22). δC (126MHz, CDCl3) 163.2 
(C=O), 150.6 (CO/CAr), 150.5 (CO/CAr), 150.2 (C-Ar), 146.2 (C-Ar), 137.7 (C-Ar), 131.5 (C-Ar), 130.4 
(CH-Ar), 130.3 (CH-Ar), 129.9 (CH-Ar), 128.2 (CH-Ar), 125.7 (CH-Ar), 120.1 (CH-Ar), 117.2 (CH-Ar), 
116.7 (CH-Ar), 112.2 (CH-Ar), 83.3 (CH2), 66.9 (CH2), 29.7 (C), 26.8 (CH3), 21.7 (CH3). δP (202MHz, 
CDCl3) -13.35, -13.37. MS (ES+) m/z 614.1 [M+Na]
+. HRMS (ESI) C27H30NO10NaPS calcd. 614.1220 
[M+Na]+, found 614.1211. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, 
tR = 8.76 min (95.5%). 
Synthesis of 4-(2-((tert-butyldimethylsilyl)oxy)acetamido)phenyl methyl 
phenyl phosphate (227) 
 
 
 
To a stirring solution of phenol 214 (1.292 g, 4.590 mmol) in anhydrous acetonitrile (30 mL) was 
added chloridate 138 (862 mg, 4.173 mmol) and anhydrous triethylamine (1.30 mL, 9.180 mmol), 
under a nitrogen atmosphere. The mixture was then stirred for 24 hours where the solvent was 
then removed under reduced pressure. The resultant yellow oil was diluted in water (50 mL) and 
the product was extracted into DCM (3 x 50 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure to form an orange oil. The oil was 
subjected to flash column chromatography (3:1 hexane: ethyl acetate) to yield the desired 
phosphate 227 as a colourless oil (46 mg, 10%). Product isolated as a mixture of enantiomers. 
δH (500MHz, CDCl3) 8.46 (s, 1H, H-6), 7.55 (d, J = 8.8 Hz, 2H, H-8), 7.35 (dd, J = 8.0, 7.5 Hz, 2H, H-
14), 7.25 – 7.14 (m, 5H, H-9 + H-13 + H-15), 4.19 (s, 2H, H-4), 3.95 (d, J = 11.6 Hz, 3H, H-11), 0.98 
(s, 9H, H-1), 0.16 (s, 6H, H-3). δC (126MHz, CDCl3) 169.0 (C=O), 150.5 (C-Ar), 146.8 (C-Ar), 134.5 (C-
Ar), 129.9 (CH-Ar), 125.4 (CH-Ar), 120.8 (CH-Ar), 120.7 (CH-Ar), 120.0 (CH-Ar), 63.3 (CH2), 55.5 
(CH3), 25.8 (CH3), 18.2 (C), -5.5 (CH3). δP (202MHz, CDCl3) -10.69. MS (ES+) m/z 474.2 [M+Na]
+. 
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Synthesis of 4-(2-((tert-butyldimethylsilyl)oxy)acetamido)phenyl methyl 
phenyl phosphate (227) 
 
 
 
To a stirring solution of phenol 214 (400 mg, 1.421 mmol) in anhydrous acetonitrile (20 mL) was 
added chloridate 138 (352 mg, 1.705 mmol), DMAP (174 mg, 1.421 mmol) and anhydrous 
triethylamine (0.40 mL, 2.843 mmol), under a nitrogen atmosphere. The mixture was then stirred 
for 24 hours where the solvent was then removed under reduced pressure. The resultant orange 
oil was diluted in water (30 mL) and the product was extracted into DCM (3 x 30 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure to form an orange oil. The oil was subjected to flash column chromatography (3:1 
hexane: ethyl acetate) to yield the desired phosphate 227 as a colourless oil (189 mg, 42%). 
Product isolated as a mixture of enantiomers. 
δH (500MHz, CDCl3) 8.45 (s, 1H, H-6), 7.52 (d, J = 8.8 Hz, 2H, H-8), 7.30 (t, J = 7.8 Hz, 2H, H-14), 7.21 
– 7.09 (m, 5H, H-9 + H-13 + H-15), 4.15 (s, 2H, H-4), 3.90 (d, J = 11.6 Hz, 3H, H-11), 0.93 (s, 9H, H-
1), 0.12 (s, 6H, H-3). δC (126MHz, CDCl3) 169.0 (C=O), 150.5 (C-Ar), 146.8 (C-Ar), 134.6 (C-Ar), 129.8 
(CH-Ar), 125.4 (CH-Ar), 120.8 (CH-Ar), 120.6 (CH-Ar), 120.0 (CH-Ar), 63.3 (CH2), 55.5 (CH3), 25.9 
(CH3), 18.2 (C), -5.5 (CH3). δP (202MHz, CDCl3) -10.73. MS (ES+) m/z 474.1 [M+Na]
+. 
Synthesis of 4-(2-hydroxyacetamido)phenyl methyl phenyl phosphate (228) 
 
 
 
Phosphate 227 (150 mg, 0.332 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. A 1:1 
mixture of TFA (1 mL) and water (1 mL) was added dropwise and stirred for ten minutes. The 
solution was left to warm and stir at room temperature, for two hours. After TLC showed 
complete consumption of the starting material, the colourless solution was neutralised to pH 7 
with saturated NaHCO3 solution. The product was then extracted into ethyl acetate (3 x 30 mL), 
where the combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure to afford a colourless oil. The oil was then subjected to flash column 
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chromatography (100% ethyl acetate) to yield the desired alcohol 228 as a colourless oil (111 mg, 
99%). Product isolated as a mixture of enantiomers. 
δH (500MHz, CDCl3) 8.67 (s, 1H, H-4), 7.46 (d, J = 8.9 Hz, 2H, H-7), 7.35 (t, J = 7.9 Hz, 2H, H-12), 7.23 
– 7.16 (m, 3H, H-11 + H-13), 7.10 (d, J = 9.0 Hz, 2H, H-7), 4.04 (s, 2H, H-2), 3.95 (d, J = 11.6 Hz, 3H, 
H-9). δC (126MHz, CDCl3) 170.7 (C=O), 150.3 (C-Ar), 146.5 (C-Ar), 134.9 (C-Ar), 130.0 (CH-Ar), 125.8 
(CH-Ar), 121.2 (CH-Ar), 120.4 (CH-Ar), 119.9 (CH-Ar), 62.2 (CH2), 55.8 (CH3). δP (202MHz, CDCl3) -
10.78. MS (ES+) m/z 360.1 [M+Na]+. 
Synthesis of (((4-(2-
hydroxyacetamido)phenoxy)(phenoxy)phosphoryl)oxy)methyl pivalate (229) 
 
 
 
 
Prepared according to Standard Procedure D, from phosphate 228 (60 mg, 0.178 mmol), sodium 
iodide (30 mg, 0.196 mmol), chloromethyl pivalate (0.03 mL, 0.196 mmol) and anhydrous 
acetonitrile (10 mL). Flash column chromatography (100% ethyl acetate) isolated product 229 as a 
colourless oil (38 mg, 49%). Product isolated as a mixture of enantiomers. 
δH (500MHz, CDCl3) 8.51 (s, 1H, H-4), 7.49 (d, J = 8.9 Hz, 2H, H-6), 7.35 (t, J = 7.2 Hz, 2H, H-11), 7.22 
– 7.17 (m, 3H, H-10 + H-12), 7.12 (d, J = 9.0 Hz, 2H, H-7), 5.79 (dd, J = 14.3, 3.3 Hz, 2H, H-13), 4.12 
(s, 2H, H-2), 3.73 (bs, 1H, H-1), 1.18 (s, 9H, H-16). δC (126MHz, CDCl3) 176.7 (C=O), 170.0 (C=O), 
150.1 (C-Ar), 146.3 (C-Ar), 135.0 (C-Ar), 130.0 (CH-Ar), 125.8 (CH-Ar), 121.1 (CH-Ar), 120.6 (CH-Ar), 
120.0 (CH-Ar), 83.3 (CH2), 62.3 (CH2), 38.8 (C), 26.8 (CH3). δP (202MHz, CDCl3) -13.09. MS (ES+) m/z 
460.1 [M+Na]+. 
Synthesis of ((phenoxy(4-(2-
(tosyloxy)acetamido)phenoxy)phosphoryl)oxy)methyl pivalate (224) 
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At 0 °C and under a nitrogen atmosphere, compound 229 (27 mg, 0.062 mmol) was dissolved in 
anhydrous DCM (12 mL) and treated with p-toluenesulfonyl chloride (13 mg, 0.068 mmol) and 
triethylamine (0.02 mL, 0.124 mmol). The colourless solution was warmed and stirred at room 
temperature for 12 hours. Upon reaction completion, the mixture was quenched with methanol 
(10 mL) and stirred for ten minutes. The solvent was then removed under reduced pressure and 
the resultant yellow oil was subjected to silica flash column chromatography (2:98 methanol: 
DCM) to isolate prodrug 224 as a colourless oil (32 mg, 88%). Product isolated as a mixture of 
enantiomers. 
δH (500MHz, CDCl3) 7.95 (s, 1H, H-8), 7.85 (d, J = 8.4 Hz, 2H, H-4), 7.48 (d, J = 8.9 Hz, 2H, H-10), 
7.41 (d, J = 8.0 Hz, 2H, H-3), 7.34 (t, J = 6.7 Hz, 2H, H-15), 7.23 – 7.16 (m, 5H, H-11 + H-14 + H-16), 
5.79 (d, J = 14.4 Hz, 2H, H-17), 4.54 (s, 2H, H-6), 2.47 (s, 3H, H-1), 1.17 (s, 9H, H-20). δC (126MHz, 
CDCl3) 176.6 (C=O), 163.2 (C=O), 150.2 (C-Ar), 147.1 (C-Ar), 146.2 (C-Ar), 133.8 (C-Ar), 131.5 (C-Ar), 
130.4 (CH-Ar), 129.9 (CH-Ar), 128.2 (CH-Ar), 125.7 (CH-Ar), 121.7 (CH-Ar), 120.8 (CH-Ar), 120.0 
(CH-Ar), 83.3 (CH2), 83.2 (C), 66.9 (CH2), 26.8 (CH3), 21.8 (CH3). δP (202MHz, CDCl3) -13.15. MS 
(ES+) m/z 614.1 [M+Na]+. HRMS (ESI) C27H30NO10NaPS calcd. 614.1220 [M+Na]
+, found 614.1214. 
HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 8.63 min (92.3%). 
Synthesis of ((hydroxyphosphoryl)bis(oxy))bis(methylene) bis(2,2-
dimethylpropanoate (230) 
 
 
 
 
 
In a flame-dried Schlenk tube, was added a 1:1 mixture of anhydrous ethyl acetate (5 mL) and 
anhydrous ethanol (5 mL). The tube was purged with nitrogen and the solvent was degassed. 
After degassing, platinum oxide (250 mg) was carefully added to the solution and washed from 
the tube walls with degassed 1:1 ethyl acetate and ethanol. The black suspension was further 
degassed and then treated with bisPOM phosphate 141 (600 mg, 1.491 mmol). The nitrogen 
atmosphere was then removed by vacuum and the flask was charged with hydrogen. The reaction 
was left to stir at room temperature for 48 hours. The suspension was filtered through a pad of 
Celite and washed with ethanol. The filtrate was concentrated under reduced pressure to afford a 
cream powder which was triturated with DCM and purified by flash column chromatography 
(10:89:1 methanol: DCM: acetic acid) to yield phosphoric acid 230 as a white solid (38 mg, 8%).  
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δH (500MHz, CDCl3) 5.53 (s, 4H, H-1), 1.18 (s, 18H, H-4). δC (126MHz, CDCl3) 161.1 (C=O), 83.3 
(CH2), 38.7 (C), 26.9 (CH3). δP (202MHz, CDCl3) -8.06. MS (ES+) m/z 325.1 [M-H]
-.  
Analytical data is in agreement with literature values.152 
Synthesis of (((methoxy)phosphoryl)bis)methoxy pivalate (232) 
 
 
 
 
Prepared according to Standard Procedure E, from phosphate 231 (1.000 g, 7.139 mmol), sodium 
iodide (2.140 g, 14.278 mmol), chloromethyl pivalate (2.16 mL, 14.992 mmol) and anhydrous 
acetonitrile (10 mL). The product bisPOM phosphate 232 was isolated as a colourless liquid (1.212 
g, 50%).  
δH (500 MHz, CDCl3) 5.66 (dd, J = 13.6, 4.1 Hz, 4H, H-2), 3.81 (d, J = 11.6 Hz, 3H, H-1), 1.24 (s, 18H, 
H-5). δC (126MHz, CDCl3) 176.7 (C=O), 82.7 (CH2), 54.8 (CH3), 38.7 (C), 26.8 (CH3). δP (202MHz, 
CDCl3) -2.78. MS (ES+) m/z 363.1 [M+Na]
+.  
Analytical data is in agreement with literature values.152 
Synthesis of ((phosphoryl)tris)methoxy pivalate (234) 
 
 
 
 
To a stirring solution of trimethyl phosphate (1.500 g, 10.709 mmol) in anhydrous acetonitrile (12 
mL) was added sodium iodide (4.820 g, 32.157 mmol) and chloromethyl pivalate (6.01 mL, 41.700 
mmol), under a nitrogen atmosphere. The suspension was refluxed for 24 hours where the 
solvent was the removed under reduced pressure. The yellow solid was dissolved in water (50 mL) 
and the product extracted into DCM (3 x 50 mL), washed with 5% Na2S2O3 solution, dried over 
MgSO4, filtered and concentrated under reduced pressure to afford a yellow oil. The oil was 
purified by flash column chromatography (9:1 hexane: ethyl acetate) to yield bisPOM phosphate 
234 as a colourless liquid (3.110 g, 66%).  
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δH (500 MHz, CDCl3) 5.66 (d, J = 13.7 Hz, 6H, H-1), 1.24 (s, 27H, H-4). δC (126MHz, CDCl3) 176.6 
(C=O), 82.8 (CH2), 38.8 (C), 26.8 (CH3). δP (202MHz, CDCl3) -5.23. MS (ES+) m/z 463.2 [M+Na]
+.  
Analytical data is in agreement with literature values.152 
Synthesis of ((hydroxyphosphoryl)bis(oxy))bis(methylene) bis(2,2-
dimethylpropanoate) (230) 
 
 
 
 
Trimethyl phosphate 234 (800 mg, 1.903 mmol) was stirred in anhydrous piperidine (13 mL), 
under a nitrogen atmosphere, for 24 hours. After the reaction was deemed completed, by the full 
consumption of starting material 234 by TLC, the piperidine was removed under reduced pressure 
to afford an orange oil. Anhydrous methanol was treated and removed under reduced pressure to 
azeotropically remove excess piperidine, to afford the phosphoric acid pyridinium salt as an 
orange oil. The oil was then dissolved in DCM (20 mL) and washed with ice cold 0.5-N HCL (20 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure to yield the native 
phosphoric acid 230 as a white crystalline solid (354 mg, 60%). The product was then used 
without purification.  
δH (500 MHz, CDCl3) 11.90 (s, 1H, H-5), 5.60 (d, J = 13.2 Hz, 4H, H-1), 1.22 (s, 18H, H-4). δC 
(126MHz, CDCl3) 176.9 (C=O), 82.8 (CH2), 38.7 (C), 26.7 (CH3). δP (202MHz, CDCl3) -4.49. MS (ES-) 
m/z 325.1 [M-H]-.   
Analytical data is in agreement with literature values.152 
Synthesis of ((chlorophosphoryl)bis(oxy))bis(methylene) bis(2,2-
dimethylpropanoate) (235) 
 
 
 
 
To a stirring solution of phosphoric acid 230 (160 mg, 0.491 mmol) in anhydrous DCM (8 mL) was 
added oxalyl chloride (0.2 mL, 2.454 mmol) and catalytic anhydrous DMF (2 drops), under a 
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nitrogen atmosphere. After evanescence had finished, the orange solution was stirred at room 
temperature, for two hours. After reaction was deemed complete, by the full consumption of 
starting material 230 by TLC, the solvent was removed under reduced pressure to afford 
phosphorochloridate 235 as a brown oil (125 mg, 75%). The crude phosphorochloridate was then 
used without purification.  
δH (500 MHz, CDCl3) 5.74 (d, J = 18.2 Hz, 4H, H-1), 1.25 (s, 18H, H-4). δP (202MHz, CDCl3) -2.57.  
Analytical data is in agreement with literature values.152 
Synthesis of (((4-(2-hydroxyacetamido)phenoxy) phosphoryl)bis-oxy)methyl 
pivalate (238) 
 
 
 
 
Prepared according to Standard Procedure E, from dibenzyl phosphate 217 (250 mg, 0.585 mmol), 
sodium iodide (175 mg, 1.170 mmol), chloromethyl pivalate (0.19 mL, 1.287 mmol) and 
anhydrous acetonitrile (20 mL). Flash column chromatography (3:1 ethyl acetate: hexane) isolated 
the product bisPOM 238 as a colourless oil (149 mg, 54%).  
δH (500 MHz, CDCl3) 8.69 (s, 1H, H-4), 7.58 (s, 1H, H-10), 7.36 (d, J = 8.2 Hz, 1H, H-6), 7.28 – 7.23 
(m, 1H, H-7), 6.93 (d, J = 8.2 Hz, 1H, H-8), 5.73 (dd, J = 13.9, 2.6 Hz, 4H, H-11), 4.14 (s, 2H, H-2), 
1.21 (s, 18H, H-14). δC (126MHz, CDCl3) 176.7 (C=O), 170.5 (C=O), 150.2 (C-Ar), 138.8 (C-Ar), 130.1 
(CH-Ar), 116.9 (CH-Ar), 115.6 (CH-Ar), 111.5 (CH-Ar), 83.1 (CH2), 62.4 (CH2), 38.8 (C), 26.8 (CH3). δP 
(202MHz, CDCl3) -9.39. MS (ES+) m/z 498.1 [M+Na]
+.   
Synthesis of (bis-oxy)methyl pivalate (3-(2-hydroxyacetamido)phenyl) 
phosphate (239) 
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Prepared according to Standard Procedure E, from dibenzyl phosphate 218 (250 mg, 0.585 mmol), 
sodium iodide (176 mg, 1.170 mmol), chloromethyl pivalate (0.19 mL, 1.287 mmol) and 
anhydrous acetonitrile (20 mL). Flash column chromatography (100% ethyl acetate) isolated 
product bisPOM 239 as a colourless oil (157 mg, 57%).  
δH (500 MHz, CDCl3) 8.59 (s, 1H, H-4), 7.51 (d, J = 8.9 Hz, 2H, H-6), 7.14 (d, J = 9.0 Hz, 2H, H-7), 5.72 
(dd, J = 13.9, 1.1 Hz, 4H, H-9), 4.16 (s, 2H, H-2), 1.21 (s, 18H, H-12). δC (126MHz, CDCl3) 176.7 
(C=O), 170.2 (C=O), 146.2 (C-Ar), 135.0 (C-Ar), 121.1 (CH-Ar), 120.6 (CH-Ar), 83.1 (CH2), 62.4 (CH2), 
38.8 (C), 26.8 (CH3). δP (202MHz, CDCl3) -9.18. MS (ES+) m/z 498.1 [M+Na]
+.   
Synthesis of 2-((4-(bis-oxy)methyl pivalate phosphoryl)oxy)phenyl)amino)-2-
oxoethyl 4-methylbenzenesulfonate (236) 
 
 
 
 
 
BisPOM phosphate 238 (30 mg, 0.063 mmol) was dissolved in anhydrous DCM (20 mL) with p-
toluenesulfonyl chloride (13 mg, 0.069 mmol), under a nitrogen atmosphere. Triethylamine (0.02 
mL, 0.126 mmol) as added dropwise and the reaction was stirred for 12 hours, at room 
temperature. The solvent was then removed under reduced pressure to afford a yellow oil. The oil 
was purified directly by flash column chromatography (1:1 ethyl acetate: hexane) to isolate 
tosylate 236 as a colourless oil (36 mg, 92%).  
δH (500MHz, CDCl3) 8.10 (s, 1H, H-8), 7.85 (d, J = 8.4 Hz, 2H, H-4), 7.45 (s,  1H, H-14), 7.41 (d, J = 
8.0 Hz, 2H, H-3), 7.38 (dd, J = 8.2, 1.0 Hz, 1H, H-10), 7.29 (t, J = 8.3 Hz, 1H, H-11), 7.03 (dd, J = 7.7, 
1.8 Hz, 1H, H-12), 5.73 (dd, J = 14.0, 4.6 Hz, 4H, H-15), 4.54 (s, 2H, H-6), 2.47 (s, 3H, H-1), 1.20 (s, 
18H, H-18). δC (126MHz, CDCl3) 176.6 (C=O), 163.4 (C=O), 150.3 (C-Ar), 146.2 (C-Ar), 137.8 (C-Ar), 
131.5 (C-Ar), 130.4 (CH-Ar), 130.2 (CH-Ar), 128.2 (CH-Ar), 117.2 (CH-Ar), 116.6 (CH-Ar), 112.2 (CH-
Ar), 83.0 (CH2), 66.9 (CH2), 38.7 (C), 26.78 (CH3), 21.7 (CH3). δP (202MHz, CDCl3) -9.28. MS (ES+) 
m/z 652.2 [M+Na]+. HRMS (ESI) C27H36NO12NaPS calcd. 652.1588 [M+Na]
+, found 652.1587. HPLC 
(reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 9.49 min (94.8%). 
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Synthesis of 2-((4-(((bis-oxy)methyl pivalate phosphoryl)oxy)phenyl)amino)-2-
oxoethyl 4-methylbenzenesulfonate (237) 
 
 
 
 
 
BisPOM phosphate 239 (30 mg, 0.063 mmol) was dissolved in anhydrous DCM (20 mL) with p-
toluenesulfonyl chloride (13 mg, 0.069 mmol), under a nitrogen atmosphere. Triethylamine (0.02 
mL, 0.126 mmol) as added dropwise and the reaction was stirred for 12 hours, at room 
temperature. The solvent was then removed under reduced pressure to afford a yellow oil. The oil 
was purified directly by flash column chromatography (1:1 ethyl acetate: hexane) to isolate 
tosylate 237 as a colourless oil (35 mg, 90%).  
δH (500MHz, CDCl3) 7.99 (s, 1H, H-8), 7.85 (d, J = 8.4 Hz, 2H, H-4), 7.48 (d, J = 8.9 Hz, 2H, H-10), 
7.41 (d, J = 8.0 Hz, 2H, H-3), 7.19 (d, J = 9.0 Hz, 2H, H-11), 5.72 (dd, J = 14.0, 7.9 Hz, 4H, H-13), 4.54 
(s, 2H, H-6), 2.47 (s, 3H, H-1), 1.20 (s, 18H, H-16). δC (126MHz, CDCl3) 176.6 (C=O), 163.2 (C=O), 
147.0 (C-Ar), 146.2 (C-Ar), 133.8 (C-Ar), 131.5 (C-Ar), 130.4 (CH-Ar), 128.2 (CH-Ar), 121.7 (CH-Ar), 
120.7 (CH-Ar), 83.1 (CH2), 67.0 (CH2), 38.8 (C), 26.8 (CH3), 21.7 (CH3). δP (202MHz, CDCl3) -9.01. MS 
(ES+) m/z 652.2 [M+Na]+. HRMS (ESI) C27H36NO12NaPS calcd. 652.1588 [M+Na]
+, found 652.1579. 
HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 9.04 min (91.6%). 
Synthesis of ethyl 2-(tosyloxy)acetate (241) 
 
 
 
To a stirring solution of glycine (750 mg, 10.000 mmol) in 1-N NaOH (20 mL) was added p-
toluenesulfonyl chloride (1.910 g 10.000 mmol), at 0 oC. The white suspension was left to warm 
and stir overnight. Upon reaction completion, the white solid was filtered and the filtrate was 
acidified to pH 2. The product was then extracted into ethyl acetate (3 x 60 mL), dried over 
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MgSO4, filtered and concentrated under reduced pressure to afford product 241 as a white solid 
(1.680 g, 73%). The product was used without purification.  
δH (500MHz, CD3OD) 7.76 (d, J = 8.3 Hz, 2H, H-6), 7.38 (d, J = 8.1 Hz, 2H, H-7), 3.68 (s, 2H, H-3), 
2.44 (s, 3H, H-9). δC (126MHz, CD3OD) 170.8 (C=O), 143.4 (C-Ar), 137.4 (C-Ar), 129.3 (CH-Ar), 126.8 
(CH-Ar), 43.4 (CH2), 20.0 (CH3). MS (ES-) m/z 228.1 [M-H]
-.   
Analytical data is in agreement with literature values.178 
Synthesis of tosylglycinoyl chloride (242) 
 
 
 
In a flame-dried flask, acid 241 (1.280 g, 5.583 mmol) was dissolved in excess oxalyl chloride (3 
mL) and treated with catalytic anhydrous DMF (3 drops) and then refluxed for two hours, under a 
nitrogen atmosphere. After TLC analysis confirmed the reaction was complete, the yellow solution 
was then concentrated under reduced pressure to afford acid chloride 242 as a yellow oil (1.37 g, 
>99%) which was used without purification. 
The compound was progressed as crude and could not be fully characterised. 
Synthesis of N-(3-hydroxyphenyl)-2-((4-methylphenyl)sulfonamido)acetamide 
(243) 
 
 
 
 
Prepared according to Standard Procedure E, from 3-aminophenol (201 mg, 1.845 mmol), 
triethylamine (0.31 mL, 1.845 mmol), chloride 242 (457 mg, 1.845 mmol) and anhydrous THF (14 
mL). The product phenol 243 was isolated as a cream solid (288 mg, 49%).  
δH (500 MHz, CD3OD) 7.78 (d, J = 8.3 Hz, 2H, H-13), 7.36 (d, J = 7.9 Hz, 2H, H-14), 7.09 (t, J = 8.1 Hz, 
1H, H-4), 7.05 (s, 1H, H-7), 6.84 (dd, J = 8.5, 1.5 Hz, 1H, H-5), 6.54 (dd, J = 8.1, 0.8 Hz, 1H, H-3), 3.70 
(s, 2H, H-10), 2.40 (s, 3H, H-16). δC (126MHz, CD3OD) 167.2 (C=O), 157.5 (C-Ar), 143.7 (C-Ar), 138.8 
(C-Ar), 136.8 (C-Ar), 129.4 (CH-Ar), 129.1 (CH-Ar), 126.9 (CH-Ar), 111.0 (CH-Ar), 111.0 (CH-Ar), 
107.1 (CH-Ar), 45.7 (CH2), 20.0 (CH3). MS (ES+) m/z 343.1 [M+Na]
+. HRMS (ESI) C15H16N2O4NaS 
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calcd. 343.0723 [M+Na]+, found 343.0735. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 
min, λ = 254 nm, tR = 5.03 min (99.8%). 
Synthesis of N-(4-hydroxyphenyl)-2-((4-methylphenyl)sulfonamido)acetamide 
(244) 
 
 
 
 
Prepared according to Standard Procedure E, from 4-aminophenol (201 mg, 1.845 mmol), 
triethylamine (0.31 mL, 1.845 mmol), chloride 242 (457 mg, 1.845 mmol) and anhydrous THF (14 
mL). The product phenol 244 was isolated as a cream solid (270 mg, 46%).  
δH (500 MHz, CD3OD) 7.76 (d, J = 8.1 Hz, 2H, H-11), 7.35 (d, J = 8.0 Hz, 2H, H-12), 7.19 (d, J = 8.7 Hz, 
2H, H-4), 6.70 (d, J = 8.7 Hz, 2H, H-3), 3.65 (s, 2H, H-8), 2.39 (s, 3H, H-14). δC (126MHz, CD3OD) 
167.1 (C=O), 154.3 (C-Ar), 143.7 (C-Ar), 143.7 (C-Ar), 136.8 (C-Ar), 129.4 (CH-Ar), 126.9 (CH-Ar), 
122.1 (CH-Ar), 114.8 (CH-Ar), 45.6 (CH2), 20.1 (CH3). MS (ES+) m/z 343.1 [M+Na]
+. HRMS (ESI) 
C15H16N2O4NaS calcd. 343.0723 [M+Na]
+, found 343.0735. HPLC (reverse-phase) MeOH/H2O 0:100 
to 100:0 in 12 min, λ = 254 nm, tR = 4.94 min (99.8%). 
Synthesis of 2-hydroxy-4-(2-((4-methylphenyl)sulfonamido)acetamido)benzoic 
acid (245) 
 
 
 
 
Prepared according to Standard Procedure E, from 4-aminosalicylic (283 mg, 1.845 mmol), 
triethylamine (0.56 mL, 4.059 mmol), chloride 242 (457 mg, 1.845 mmol) and anhydrous THF (14 
mL). Trituration with 3% methanol in DCM (3 x 50 mL) then isolated the product phenol 245 as a 
cream solid (178 mg, 26%) which was used without purification.  
δH (500 MHz, CD3OD) 7.80 – 7.69 (m, 3H, H-8 + H-15), 7.33 (d, J = 7.9 Hz, 2H, H-16), 7.17 (s, 1H, H-
5), 6.91 (d, J = 8.7 Hz, 1H, H-7), 3.72 (s, 2H, H-12), 2.37 (s, 3H, H-18). δC (126MHz, CD3OD) 171.7 
(C=O), 167.5 (C=O), 162.6 (C-Ar), 144.3 (C-Ar), 143.7 (C-Ar), 136.9 (C-Ar), 130.8 (CH-Ar), 129.4 (CH-
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Ar), 126.9 (CH-Ar), 110.2 (CH-Ar), 108.3 (C-Ar), 106.7 (CH-Ar), 45.8 (CH2), 20.0 (CH3). MS (ES-) m/z 
363.1 [M-H]-. HRMS (ESI) C16H15N2O6NaS calcd. 363.0651 [M-H]
_, found 363.0658. HPLC (reverse-
phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 4.63 min (99.9%). 
Analytical data is in agreement with literature values.177 
Synthesis of benzyl 6-hydroxy-2-naphthoate (250) 
 
 
 
Compound 249 (500 mg, 2.657 mmol) was dissolved in anhydrous methanol (10 mL) and stirred 
with caesium carbonate (433 mg, 3.200 mmol), under a nitrogen atmosphere, for 30 minutes. The 
solvent was removed under reduced pressure and then co-evaporated with toluene (2 x 20 mL). 
The caesium salt was then dissolved in anhydrous DMF (10 mL) and stirred with benzyl bromide 
(0.32 mL, 2.657 mmol) at 0 oC, under a nitrogen atmosphere, for one hour. The reaction was then 
left to warm and stir at room temperature for 11 hours. Upon reaction completion, the yellow 
solution was diluted with water (100 mL) and the product was extracted in ethyl acetate (3 x 50 
mL). The combined yellow organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure to afford a yellow oil, which was purified by column chromatography (4:1 
hexane: ethyl acetate) to yield compound 250 as a white solid (230 mg, 31%).  
δH (500 MHz, CDCl3)  8.56 (d, J = 0.8 Hz, 1H, H-6), 8.04 (dd, J = 8.6, 1.7 Hz, 1H, H-9), 7.84 (d, J = 8.8 
Hz, 1H, H-4), 7.68 (d, J = 8.7 Hz, 1H, H-8), 7.48 (d, J = 7.3 Hz, 2H, H-15), 7.43 – 7.37 (m, 2H, H-16), 
7.37 – 7.32 (m, 1H, H-17), 7.18 – 7.11 (m, 2H, H-3 + H-11), 5.42 (s, 2H, H-13), 5.36 (s, 1H, H-1). δC 
(126MHz, CDCl3) 166.9 (C=O), 155.7 (C-Ar), 137.2 (C-Ar), 136.2 (C-Ar), 131.6 (CH-Ar), 131.3 (CH-
Ar), 128.7 (CH-Ar), 128.3 (CH-Ar), 128.3 (CH-Ar), 127.8 (C-Ar), 126.5 (CH-Ar), 126.1 (CH-Ar), 125.1 
(C-Ar), 118.7 (CH-Ar), 109.5 (CH-Ar), 66.8 (CH2). MS (ES+) m/z 279.1 [M+H]
+.  
Analytical data is in agreement with literature values.56   
 
Synthesis of benzyl 6-hydroxy-2-naphthoate (250) 
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Compound 249 (500 mg, 2.657 mmol) was dissolved in anhydrous DMF (10 mL) and stirred with 
KHCO3 (320 mg, 3.200 mmol) and benzyl bromide (0.38 mL, 3.200 mmol) at 40 
oC, for eight hours, 
under an argon atmosphere. Upon reaction completion, the brown solution, with a suspension of 
white precipitate, was diluted with water (100 mL) and the product was extracted in ethyl acetate 
(3 x 50 mL). The combined brown organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure to afford a yellow oil, which was purified by column 
chromatography (4:1 hexane: ethyl acetate) to yield compound 250 as a white solid (660 mg, 
86%).  
δH (300MHz, CDCl3) 8.57 (d, J = 0.9 Hz, 1H, H-6), 8.05 (dd, J = 8.6, 1.7 Hz, 1H, H-9), 7.86 (d, J = 8.5 
Hz, 1H, H-4), 7.70 (d, J = 8.7 Hz, 1H, H-8), 7.50 (d, J = 7.3 Hz, 2H, H-15 ), 7.45 – 7.37 (m, J = 8.0 Hz, 
2H, H-16), 7.42 (t, J = 3.1 Hz, 1H, H-6), 7.40 – 7.37 (m, 1H, H-17), 7.19 – 7.13 (m, 2H, H-3 + H-11), 
5.42 (s, 2H, H-13), 5.28 (s, 1H, H-1). δC (101MHz, CDCl3) 166.8 (C=O), 155.5 (C-Ar), 137.2 (C-Ar), 
136.2 (C-Ar), 131.6 (CH-Ar), 131.2 (CH-Ar), 128.6 (CH-Ar), 128.3 (CH-Ar), 128.3 (CH-Ar), 127.9 (C-
Ar), 126.5 (CH-Ar), 126.1 (CH-Ar), 125.2 (C-Ar), 118.7 (CH-Ar), 109.5 (CH-Ar), 66.8 (CH2). MS (ES+) 
m/z 301.1 [M+Na]+.  
Analytical data is in agreement with literature values.56  
Synthesis of benzyl 6-(2-ethoxy-2-oxoethoxy)-2-naphthoate (251) 
 
 
 
 
To a stirring solution of compound 250 (550 mg, 1.976 mmol) in anhydrous DMF (6 mL), was 
added K2CO3 (546 mg, 3.953 mmol) and ethyl bromoacetate (0.26 mL, 2.571 mmol). The yellow 
solution was left to stir at room temperature for one hour, under an argon atmosphere. Water 
(100 mL) was added to the white suspended solution, where the product was extracted into ethyl 
acetate (3 x 50 mL). The combined colourless organic layers were dried over MgSO4, filtered and 
concentrated to yield compound 251 as a white crystalline solid (600 mg, 84%), which was used 
without purification.  
δH (300MHz, CDCl3) 8.57 (s, 1H, H-9), 8.07 (dd, J = 8.6, 1.7 Hz, 1H, H-12), 7.88 (d, J = 9.1 Hz, 1H, H-
7), 7.74 (d, J = 8.7 Hz, 1H, H-11), 7.54 – 7.32 (m, 5H, H-18 + H-19 + H-20), 7.28 (dd, J = 9.1, 2.7 Hz, 
1H, H-6), 7.09 (d, J = 2.5 Hz, 1H, H-14), 5.42 (s, 2H, H-16), 4.76 (s, 2H, H-4), 4.31 (q, J = 7.1 Hz, 2H, 
H-2), 1.31 (t, J = 7.1 Hz, 3H, H-1). δC (101MHz, CDCl3) 163.6 (C=O), 155.1 (C=O), 150.9 (C-Ar), 134.4 
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(C-Ar), 133.6 (C-Ar), 128.7 (CH-Ar), 128.4 (CH-Ar), 126.1 (CH-Ar), 125.7 (CH-Ar), 125.7 (CH-Ar), 
124.5 (CH-Ar), 123.6 (CH-Ar), 123.2 (C-Ar), 122.9 (C-Ar), 117.0 (CH-Ar), 104.4 (CH-Ar), 64.2 (CH2), 
62.8 (CH2), 59.0 (CH2), 11.6 (CH3). MS (AP) m/z 365.1 [M+H]
+, 364.1 [M]+, 257.1 [M-BnO]+.  
Analytical data is in agreement with literature values.56 
Synthesis of 6-(2-ethoxy-2-oxoethoxy)-2-naphthoic acid (252) 
 
 
 
 
Under an atmosphere of hydrogen, compound 251 (575 mg, 1.586 mmol) was dissolved in a 1:1 
mixture of de-gassed anhydrous ethanol (4 mL) and anhydrous ethyl acetate (4 mL). Catalytic 
amounts of palladium on charcoal (10 wt. %) was carefully added and the black solution was left 
to stir for four hours, at room temperature. The black solution was then filtered through Celite 
and washed several times with ethyl acetate. The colourless filtrate was concentrated under 
reduced pressure to afford compound 252 as a white crystalline solid (435 mg, >99%), which was 
used without purification.  
δH (300MHz, DMSO) 12.91 (s, 1H, H-16), 8.53 (s, 1H, H-9), 8.05 (d, J = 9.1 Hz, 1H, H-12), 7.94 (dd, J 
= 8.6, 1.7 Hz, 1H, H-7), 7.86 (d, J = 8.7 Hz, 1H, H-11), 7.38 (d, J = 2.5 Hz, 1H, H-14), 7.30 (dd, J = 9.0, 
2.6 Hz, 1H, H-6), 4.95 (s, 2H, H-4), 4.20 (q, J = 7.1 Hz, 2H, H-2), 1.23 (t, J = 7.1 Hz, 3H, H-1). δC (101 
MHz, CDCl3) 173.0 (C=O), 172.9 (C=O), 161.5 (C-Ar), 140.8 (C-Ar), 135.2 (CH-Ar), 135.0 (CH-Ar), 
132.3 (C-Ar), 130.9 (CH-Ar), 130.0 (CH-Ar), 129.9 (C-Ar), 123.2 (CH-Ar), 110.8 (CH-Ar), 69.2 (CH2), 
65.6 (CH2), 17.9 (CH3). MS (AP) m/z 275.1 [M+H]
+, 274.1 [M]+.  
Analytical data is in agreement with literature values.56 
Synthesis of ethyl 2-((6-(phenylcarbamoyl)naphthalen-2-yl)oxy)acetate (253) 
 
 
 
Compound 252 (434 mg, 1.582 mmol) was dissolved in anhydrous DMF (10 mL) with aniline (0.22 
mL, 2.37 mmol) and PyBOP (988 mg, 1.898 mmol) and stirred at room temperature for 15 
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minutes, under an argon atmosphere. Triethylamine (0.44 mL, 3.16 mmol) was added dropwise 
and the yellow solution was left to stir for four hours. The yellow solution was diluted with water 
(100 mL) and the product was extracted into ethyl acetate (5x50 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure to afford a 
yellow oil. Column chromatography (2:1 hexane: ethyl acetate) was used to isolate compound 253 
as a white crystalline solid (405 mg, 73%).  
δH (300MHz, CDCl3) 8.32 (s, 1H, H-9), 7.95 – 7.86 (m, 3H, H-6 + H-7 + H-12), 7.81 (d, J = 8.6 Hz, 1H, 
H-11), 7.69 (dd, J = 8.5, 1.0 Hz, 2H, H-18), 7.41 (t, J = 7.9 Hz, 2H, H-19), 7.32 (dd, J = 9.0, 2.6 Hz, 1H, 
H-14), 7.18 (d, J = 7.4 Hz, 1H, H-20), 7.13 (d, J = 4.9 Hz, 1H, H-16), 4.77 (s, 2H, H-4), 4.32 (q, J = 7.1 
Hz, 2H, H-2), 1.32 (t, J = 7.1 Hz, 3H, H-1). δC (101MHz, CDCl3) 168.3 (C=O), 165.7 (C=O), 157.4 (C-
Ar), 138.0 (C-Ar), 134.5 (C-Ar), 130.9 (CH-Ar), 130.3 (C-Ar), 129.2 (CH-Ar), 128.6 (C-Ar), 127.6 (CH-
Ar), 127.3 (CH-Ar), 124.6 (CH-Ar), 124.3 (CH-Ar), 120.2 (CH-Ar), 119.9 (CH-Ar), 107.0 (CH-Ar), 65.29 
(CH2), 61.6 (CH2), 14.4 (CH3). MS (AP) m/z 350.1 [M+H]
+, 349.1 [M]+, 257.1 [M-PhHN]+.  
Analytical data is in agreement with literature values.56 
Synthesis of 2-((6-(phenylcarbamoyl)naphthalen-2-yl)oxy)acetic acid (254) 
 
 
 
 
To a stirring solution of compound 253 (385 mg, 1.102 mmol) in THF (4 mL), NaOH solution (4 mL, 
1M) was added dropwise. The colourless solution was left to stir at room temperature for one 
hour. After reaction completion, a thick white precipitate had formed. Water (40 mL) was added 
to the reaction mixture and the solution was acidified to pH-1 with 2-N HCl. The product was then 
extracted into ethyl acetate (4 x 20 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure to yield compound 254 as a pink/cream solid (340 mg, 98%), which was used 
without purification.  
δH (300MHz, DMSO) 13.04 (bs, 1H, H-1) 10.36 (s, 1H, H-16), 8.52 (s, 1H, H-8), 8.12 – 7.96 (m, J = 
13.3, 5.3 Hz, 2H, 2 x CHAr), 7.91 (d, J = 8.7 Hz, 1H, H-12), 7.85 – 7.79 (m, 2H, H-18), 7.37 (dd, J = 
9.2, 6.7 Hz, 3H, 3 x CHAr)), 7.30 (dd, J = 8.9, 2.6 Hz, 1H, H-14), 7.11 (t, J = 7.4 Hz, 1H, H-20), 4.84 (s, 
2H, H-3). δC (101MHz, DMSO) 170.4 (C=O), 166.03 (C=O), 157.6 (C-Ar), 139.8 (C-Ar), 136.2 (C-Ar), 
131.1 (CH-Ar), 130.6 (C-Ar), 129.1 (CH-Ar), 128.3 (CH-Ar), 128.0 (C-Ar), 127.3 (CH-Ar), 125.5 (CH-
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Ar), 124.0 (CH-Ar), 120.8 (CH-Ar), 119.9 (CH-Ar), 107.4 (CH-Ar), 65.2 (CH2). MS (AP) m/z 321.1 
[M]+, 229.0 [M-PhHN]+.  
Analytical data is in agreement with literature values.56 
Synthesis of 6-(2-((3,4-dihydroxybenzyl)amino)-2-oxoethoxy)-N-phenyl-2-
naphthamide (255) 
 
 
 
 
 
Under an atmosphere of argon, compound 254 (327 mg, 1.018 mmol) was dissolved in anhydrous 
DMF (8 mL) and stirred with 4-(aminomethyl)benzene-1,2-diol hydrobromide (246 mg, 1.120 
mmol) and PyBOP (636 mg, 1.222 mmol) at room temperature, for 15 minutes. Triethylamine 
(0.28 mL, 2.035 mmol) was added dropwise to the brown solution, which was then left to stir 
overnight. The brown reaction mixture was diluted in water (30 mL) and the product was 
extracted into ethyl acetate (5x30 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated under reduced pressure to afford a brown oil. Compound 255 was 
precipitated out of DCM as a white crystalline solid (250 mg, 56%) and used without further 
purification.  
δH (300MHz, DMSO) 10.39 (s, 1H, H-24), 8.89 (s, 1H, H-1), 8.80 (s, 1H, H-8), 8.66 (t, J = 6.1, 1H, H-
10), 8.53 (s, 1H, H-17), 8.13 – 7.96 (m, 2H, 2H, 2 x CHAr), 7.95 – 7.87 (m, 1H, H-20), 7.83 (d, J = 7.7 
Hz, 2H, H-26), 7.28-7.39 (m, 4H, 4 x CHAr), 7.12 (t, J = 7.0 Hz, 1H, H-28), 6.73 (s, 1H, H-6), 6.65 (d, J 
= 7.9 Hz, 1H, H-4), 6.54 (d, J = 7.6 Hz, 1H, H-3), 4.71 (s, 2H, H-12), 4.21 (d, J = 5.1 Hz, 2H, H-9). δC 
(101MHz, DMSO) 167.6 (C=O), 166.1 (C=O), 157.6 (C-Ar), 145.5 (C-Ar), 144.6 (C-Ar), 139.8 (C-Ar), 
136.1 (C-Ar), 131.1 (CH-Ar), 130.7 (C-Ar), 130.6 (C-Ar), 129.1 (CH-Ar), 128.3 (CH-Ar), 128.1 (C-Ar), 
127.4 (CH-Ar), 125.5 (CH-Ar), 124.1 (CH-Ar), 120.8 (CH-Ar), 120.1 (CH-Ar), 118.7 (CH-Ar), 115.7 
(CH-Ar), 115.5 (CH-Ar), 107.7 (CH-Ar), 67.5 (CH2), 42.0 (CH2). MS (ES+) m/z 465.1 [M+Na]
+, 443.2 
[M+ H]+.  
Analytical data is in agreement with literature values.56 
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Synthesis of methyl (chloro(phenoxy)phosphoryl)-L-alaninate (256) 
 
 
 
 
Prepared according to Standard Procedure B, from phenol 137 (0.35 mL, 2.370 mmol), added L-
alanine methyl ester hydrochloride (301 mg, 2.155 mmol), triethylamine (0.62 mL, 4.262 mmol)  
and anhydrous DCM (10 mL) The product phosphorochloridate 256 was isolated as a colourless oil 
(505 mg, 84%). Product isolated as a mixture of diastereoisomers. 
δH (300MHz, CDCl3) 7.37 (dd, J = 7.2, 2.1 Hz, 2H, H-3), 7.29 – 7.23 (m, 3H, H-2 + H-4), 4.24 – 3.93 
(m, 2H, H-5 + H-6), 3.78 (d, J = 5.2 Hz, 3H, H-9), 0.97 (dd, J = 6.4, 3.0 Hz, 3H, H-7). δP (121MHz, 
CDCl3) 7.91, 7.55.  
Analytical data is in agreement with literature values.202 
Synthesis of methyl (5-((2-((5,6-di(phenylcarbamoyl)naphthalen-2-
yl)oxy)acetamido)methyl)phenoxy)(phenoxy)phosphoryl)-L-alaninate (248) 
 
 
 
 
 
 
 
To a stirring solution of catechol 255 (100 mg, 0.226 mmol) in anhydrous acetonitrile (5 mL) was 
added triethylamine (0.06 mL, 0.452 mmol), DMAP (11 mg, 0.904 mmol) and chloridate 256 (600 
mg, 3.347 mmol). The orange solution was stirred under an atmosphere of argon, for 72 hours, at 
room temperature. The mixture was then concentrated under reduced pressure and diluted in 
water (20 mL) and the product was extracted into ethyl acetate washes (3 x 20 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated under reduced pressure to 
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afford an orange oil. The oil was purified by flash column chromatography (3:97 methanol: DCM) 
to afford diphosphoramidate 248 as a white solid (2 mg, 1%).  
δP (121MHz, CDCl3) -1.54, -1.61, -1.76, -1.89. MS (ES+) m/z 925.3 [M+H]
+. HRMS C46H4642O13NaP2 
calcd. 947.2434 [M+Na]+, found 947.2440.  
Insufficient quantity of product to obtain viable 1H and  13C NMR spectras. 
Synthesis of 1,2-di(methyl (diphenoxyphosphoryl)-L-alaninate) (258) 
 
 
 
 
 
To a stirring solution of catechol 257 (106 mg, 0.976 mmol) in anhydrous acetonitrile (5 mL) was 
added triethylamine (0.54 mL, 3.905 mmol), DMAP (477 mg, 3.905 mmol) and chloridate 256 (700 
mg, 3.905 mmol). The orange solution was stirred under an atmosphere of argon overnight, at 
room temperature. The mixture was then concentrated under reduced pressure and diluted in 
water (20 mL) and the product was extracted into ethyl acetate (3 x 20 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure to afford an 
orange oil. The oil was purified by flash column chromatography (3:97 methanol: DCM) to afford 
the phosphoramidate 258 as a colourless oil (90 mg, 16%).  
δH (300MHz, CDCl3) 7.47 – 7.43 (m, 2H, H-8), 7.36 – 7.20 (m, 10H, 10 x CHAr), 7.17 – 7.10 (m, 2H, 
H-9), 4.69 – 4.60 (m, 1H, H-5a/b), 4.35 (s, 1H, H-5a/b), 4.22 – 4.05 (m, 2H, H-3), 3.64 (d, J = 13.9 
Hz, 6H, H-1), 1.30 – 1.23 (m, 6H, H-4). δC (101MHz, CDCl3) 173.8 (C-Ar), 150.6 (C-Ar), 141.8 (C-Ar), 
129.7 (CH-Ar), 125.8 (CH-Ar), 125.1 (CH-Ar), 122.2 (CH-Ar), 120.5 (CH-Ar), 52.4 (CH), 50.5 (CH3), 
20.8 (CH3). δP (121MHz, CDCl3) -1.58, -1.62. MS (ES+) m/z 615.1 [M+Na]
+. HRMS C26H30N2O10NaP2 
calcd. 615.1273 [M+Na]+, found 615.1277.  
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Synthesis of dichloro(phenoxy)phosphane (260) 
 
 
 
 
Under an atmosphere of argon, phenol 58 (200 mg, 2.126 mmol) was dissolved in excess PCl3 
(3mL) and refluxed in a flame-dried flask, for 16 hours. After reaction success was confirmed by 
TLC, excess PCl3 was removed under reduced pressure to afford phosphite 260 (412 mg, >99%) as 
a colourless liquid. The crude was used without purification. 
The compound was progressed as crude and could not be fully characterised. 
Diethyl (difluoro(phenyl)methyl)phosphonate (267) 
 
 
 
 
Under an atmosphere of argon, cadmium (441 mg, 3.920 mmol) and diethyl 
(bromodifluoromethyl) phosphonate (0.68 mL, 3.798 mmol) were dissolved in anhydrous DMF (4 
mL). The brown solution was stirred overnight at room temperature. In a separate round bottom 
flask, under an atmosphere of argon, was added CuCl (485 mg, 4.900 mmol) to a solution of 
iodobenzene 265 (250 mg, 1.225 mmol) in anhydrous DMF (4 mL). When full conversion of 
iodobenzene was evident by TLC analysis, the brown solution of the initial flask was transferred to 
the green suspension via cannula and positive argon pressure. The resultant reaction mixture was 
left to stir under argon, for 36 hours. After completion, the green suspension was diluted with 
diethyl ether (20 mL) and filtered through a pad of Celite. The turquoise filtrate was washed with 
brine (10 mL) and dried over MgSO4, filtered and concentrated under reduced pressure to afford a 
golden oil. The oil was purified by flash column chromatography (1:9 ethyl acetate: hexane) to 
yield the phosphonate product 267 as a colourless oil (125 mg, 39%).  
δH (300MHz, CDCl3) 7.62 (dd, J = 10.9, 4.3 Hz, 2H, H-5), 7.53 – 7.39 (m, 3H, H-6 + H-7), 4.41 – 4.02 
(m, 4H, H-2), 1.31 (t, J = 7.3 Hz, 6H, H-1). δC (101MHz, CDCl3) 133.7 (C-Ar), 130.8 (CH-Ar), 128.4 
(CH-Ar), 126.2 (CH-Ar), 118.9 (C-Ar), 64.8 (CH2), 16.3 (CH3). δP (121MHz, CDCl3) 6.39 (t, J = 116.2 
Hz). δF (300MHz, CDCl3) -108.48 (d, J = 116.3 Hz). MS (ES+) m/z 264.2 [M]
+.  
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Analytical data is in agreement with literature values.207  
Synthesis of 4-amino-3-iodobenzoic acid (270) 
 
 
 
Iodine (925 mg, 3.646 mmol) was dissolved in anhydrous ethanol (40 mL) in a round bottom flask 
wrapped in aluminium foil. To the purple solution was added Ag2SO4 (1.137 g, 3.646 mmol) and 4-
aminobenzoic acid 269 (500 mg, 3.646 mmol), to be then stirred for 2 hours at room temperature. 
The yellow suspension was filtered through a pad of Celite and triturated with ethanol to afford a 
brown filtrate. The reaction mixture was then evaporated under reduced pressure, diluted in 
ethyl acetate (40 mL) and washed with 5% NaOH solution. All organic layers were combined, dried 
over MgSO4, filtered and concentrated under reduced pressure to afford the product 270 as a 
cream solid (627 mg, 65%) and used without purification.  
δH (400 MHz, DMSO) 12.37 (s, 1H, H-8), 8.09 (s, 1H, H-1), 7.63 (dd, J = 8.5, 1.9 Hz, 1H, H-5), 6.72 (d, 
J = 8.2 Hz, 1H, H-4), 5.99 (s, 2H, H-9). δC (101MHz, DMSO) 166.6 (C=O), 153.1 (C-Ar), 141.0 (CH-Ar), 
131.1 (CH-Ar), 119.8 (C-Ar), 113.3 (CH-Ar), 81.5 (C-Ar). MS (ES-) m/z 261.9 [M-H]-, 126.9 [M-I]-.  
Analytical data is in agreement with literature values.189  
Synthesis of 3,4-diiodobenzoic acid (271) 
 
 
 
 
4-Amino-3-iodobenzoic acid 270 (190 mg, 0.722 mmol) was slowly added to a round bottom flask 
charged with sulphuric acid (4 mL). After stirring for ten minutes, the black solution was cooled to 
0 oC and potassium nitrate was carefully added and stirred at room temperature, for five hours. 
Small pieces of ice were then safely added to the thick black reaction mixture, followed by 
addition of potassium iodide. The mixture was allowed to stir for 12 hours to generate a purple 
suspension. The reaction was quenched with 10% Na2SO4 to allow for extraction with ethyl 
acetate (2 x 100 mL). The combined orange organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure to form a red solid, which was purified via trituration with 
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DCM, to yield the desired diiodobenzoic acid 271 as an orange solid (232 mg, 86%) and used 
without further purification.  
δH (300 MHz, DMSO) 8.34 (s, 1H, H-1), 8.07 (d, J = 8.2 Hz, 1H, H-4), 7.61 (dd, J = 8.2, 2.0 Hz, 1H, H-
5). δC (101MHz, DMSO) 166.2 (C=O), 140.0 (CH-Ar), 139.7 (CH-Ar), 132.3 (C-Ar), 130.2 (CH-Ar), 
115.6 (C-Ar), 109.5 (C-Ar). MS (ES-) m/z 372.8 [M-H]-.  
Analytical data is in agreement with literature values.189 
Synthesis of (3,4-diiodophenyl)methanol (272) 
 
 
 
 
Under an atmosphere of argon, diiodobenzoic acid 271 (1.620 g, 4.332 mmol) was dissolved in 
anhydrous THF (60 mL). 1N-Borane solution (10.5 mL, 10.489 mmol) was then added dropwise 
and stirred at room temperature for 16 hours. Upon reaction completion, water (20 mL) was 
carefully added to the colourless solution, producing evanescence. The orange solution was 
concentrated under reduced pressure to yield an orange oil, which was purified by flash column 
chromatography (4:1 hexane: ethyl acetate). After purification, the product 272 was isolated as a 
white solid (1.200 g, 77%).  
δH (400MHz, CDCl3) 7.88 (s, 1H, H-1), 7.83 (d, J = 8.1 Hz, 1H, H-4), 7.02 (dd, J = 8.1, 2.0 Hz, 1H, H-5), 
4.60 (s, 2H, H-7), 1.84 (s, 1H, H-8). δC (101MHz, CDCl3) 142.4 (CH-Ar), 139.4 (C-Ar), 137.7 (C-Ar), 
127.7 (C-Ar), 108.0 (CH-Ar), 106.4 (CH-Ar), 63.7 (CH2). MS (ES+) m/z 360.1 [M]
+.  
Analytical data is in agreement with literature values.189 
Synthesis of 3,4-diiodobenzyl methanesulfonate (273) 
 
 
 
To a stirring solution of 3,4-Diiodophenyl)methanol 272 (140 mg, 0.389 mmol) in anhydrous THF 
(10 mL) was added anhydrous triethylamine (0.11 mL, 0.778 mmol) and methanesulfonyl chloride 
(0.03 mL, 0.428 mmol). The cloudy white solution was left to stir for 12 hours, under an 
atmosphere of argon. Once complete, the reaction was quenched with water (40 mL) and the 
product was extracted from the yellow suspension with ethyl acetate (3 x 40 mL) to generate a 
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colourless organic solution. The mixture was dried over MgSO4, filtered and concentrated under 
reduced pressure to yield an orange oil. The desired product was purified by flash column 
chromatography (3:1 hexane: ethyl acetate) to yield the sulphate 273 as a white solid (143 mg, 
84%).  
δH (300MHz, CDCl3) 7.91 (s, 1H, H-1), 7.89 (d, J = 5.2 Hz, 1H, H-4), 7.09 (dd, J = 8.1, 2.0 Hz, 1H, H-5), 
5.11 (s, 2H, H-7), 3.00 (s, 3H, H-8). δC (101MHz, CDCl3) 139.8 (CH-Ar), 139.2 (CH-Ar), 134.9 (C-Ar), 
129.2 (CH-Ar), 109.1 (C-Ar), 108.4 (C-Ar), 69.1 (CH2), 38.4 (CH3). MS (ES+) m/z 460.8 [M+Na]
+.  
Analytical data is in agreement with literature values.189 
Synthesis of 4-(azidomethyl)-1,2-diiodobenzene (274) 
 
 
 
Under an argon atmosphere, 3,4-diiodobenzyl methanesulfonate 273 (1.230 g, 2.815 mmol) was 
dissolved in anhydrous DMF (40 mL). Sodium azide (732 mg, 11.26 mmol) was added to the 
colourless solution and stirred at room temperature, for six hours. The reaction was then 
quenched with water (40 mL) and the product was extracted into ethyl acetate (3 x 40 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated to afford a yellow oil. 
Flash column chromatography (9:1 hexane: ethyl acetate) isolated the desired azide product 274 
as a colourless oil 1.01 g, 93%).  
δH (400MHz, CDCl3) 7.86 (d, J = 8.1 Hz, 1H, H-4), 7.83 (d, J = 2.1 Hz, 1H, H-1), 6.99 (dd, J = 8.1, 2.1 
Hz, 1H, H-5), 4.26 (s, 2H, H-7). δC (101MHz, CDCl3) 139.7 (CH-Ar), 138.8 (CH-Ar), 137.0 (C-Ar), 128.8 
(CH-Ar), 108.4 (C-Ar), 107.6 (C-Ar), 53.3 (CH2). MS (AP) m/z 364.8 [M]
+, 357.8 [M-N2]
+.  
Analytical data is in agreement with literature values.189 
Synthesis of (3,4-diiodophenyl)methanamine (268) 
 
 
 
Under an atmosphere of argon, 4-(azidomethyl)-1,2-diiodobenzene 274 (1.070 g, 2.780 mmol) 
and triphenylphosphine (1.027 g, 3.895 mmol) were dissolved in anhydrous THF (25 mL) and 
stirred at room temperature, for 12 hours. Water (5 mL) was then added to the colourless 
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solution, which was then stirred for two hours. The yellow solution was concentrated under 
reduced pressure and diluted with water (30 mL) and the product was extracted into ethyl acetate 
3 x 30 mL). The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure to afford an orange oil. Flash column chromatography (5:95 methanol: DCM) 
isolated the amine product 268 as a white solid (675 mg, 68%).  
δH (300MHz, CD3OD) 7.93 (s, 1H, H-1), 7.85 (d, J = 8.1 Hz, 1H, H-4), 7.07 (dd, J = 8.1, 2.1 Hz, 1H, H-
5), 3.70 (s, 2H, H-7). δC (101MHz, DMSO) 139.2 (CH-Ar), 138.4 (CH-Ar), 129.2 (CH-Ar), 108.9 (C-Ar), 
105.9 (C-Ar), 103.7 (C-Ar), 44.5 (CH2). MS (ES+) m/z 359.9 [M+H]
+.  
Analytical data is in agreement with literature values.189 
Synthesis of tert-butyl (S)-(3-hydroxy-1-((4-hydroxyphenethyl)amino)-1-
oxopropan-2-yl)carbamate (298) 
 
 
 
 
Under a nitrogen atmosphere, N-(tert-Butoxycarbonyl)-L-serine 297 (500 mg, 2.437 mmol) was 
dissolved in anhydrous THF (10 mL). Triethylamine (0.68 mL, 4.874 mmol), PyBOP (1.522 g, 2.924 
mmol) and tyramine (368 mg, 2.680 mmol) were then added to the yellow solution and stirred at 
room temperature, for 12 hours. Upon reaction completion, the THF was removed under vacuum 
and water (100 mL) was added to the orange oil and the product was then extracted into ethyl 
acetate (3 x 40 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure to afford a yellow oil. The oil was purified by flash column 
chromatography (1:9 methanol: DCM) to afford amide 298 as a white solid (720 mg, 91%).  
δH (500 MHz, CD3OD) 6.93 (d, J = 8.5 Hz, 2H, H-13), 6.60 (d, J = 8.5 Hz, 2H, H-14), 3.97 (s, 1H, H-5), 
3.59 (d, J = 5.2 Hz, 2H, H-6), 3.37 – 3.27 (m, 2H, H-10), 2.59 (t, J = 7.3 Hz, 2H, H-11), 1.35 (s, 9H, H-
1). δC (126 MHz, CD3OD) 171.7 (C=O), 167.8 (C=O), 155.6 (C-Ar), 129.8 (C-Ar), 129.4 (CH-Ar), 114.9 
(CH-Ar), 62.0 (CH2), 56.9 (CH), 46.6 (C), 41.0 (CH2), 34.2 (CH2), 27.3 (CH3). MS (ES+) m/z 347.2 
[M+Na]+. 
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Synthesis of o-benzyl-N-(tert-butoxycarbonyl)-L-serine (302) 
 
 
 
Under a nitrogen atmosphere, N-(tert-Butoxycarbonyl)-L-serine 297 (500 mg, 2.437 mmol) was 
dissolved in anhydrous DMF (10 mL) and cooled to 0 oC. NaH (215 mg, 5.361 mmol) was slowly 
added, followed by dropwise addition of benzyl bromide (0.35 mL, 2.949 mmol), producing 
evanescence. The white suspension was stirred at room temperature, for 10 hours. Upon reaction 
completion, water (100 mL) was slowly added to the orange solution and the product was then 
extracted into ethyl acetate (3 x 40 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated under reduced pressure to afford a yellow oil. The oil was purified by 
flash column chromatography (15:85 methanol: DCM) to afford ether 302 as a white solid (502 
mg, 70%).  
δH (500MHz, CDCl3) 11.11 (s, 1H, H-7), 7.42 – 7.13 (m, 5H, H-11 + H-12 + H-13), 5.42 (d, J = 8.3 Hz, 
1H, H-4), 4.53 (s, 2H, H-9), 4.51 – 4.42 (m, 1H, H-5), 3.81 (d, J = 6.6 Hz, 2H, H-8), 1.45 (s, 9H, H-1). 
δC (126MHz, CDCl3) 175.5 (C=O), 155.8 (C=O), 137.3 (C-Ar), 128.5 (CH-Ar), 128.0 (CH-Ar), 127.9 
(CH-Ar), 80.4 (C), 73.4 (CH2), 69.7 (CH2), 53.9 (CH), 28.3 (CH3). MS (ES-) m/z 294.2 [M-H]
-, 589.3 
[2M-H]-.  
Analytical data is in agreement with literature values.208 
Synthesis of tert-butyl (S)-(3-(benzyloxy)-1-((4-hydroxyphenethyl)amino)-1-
oxopropan-2-yl)carbamate (299) 
 
 
 
 
To a stirring solution of compound 302 (502 mg, 1.699 mmol) in anhydrous THF (10 mL) was 
added triethylamine (0.43 mL, 3.048 mmol) and the resultant mixture stirred for five minutes. 
PyBOP (952 mg, 1.829 mmol) and tyramine (230 mg, 1.676 mmol) were then treated and the 
solution was left to stir for 12 hours, at room temperature. The orange solution was concentrated 
to an orange oil and diluted with water (40 mL) and the product was extracted into ethyl acetate 
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(3 x 40 mL). The combined orange organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure to afford an orange oil. The oil was purified by flash column 
chromatography (7:3 ethyl acetate: hexane) to yield the desired product 299 as a white solid (670 
mg, 95%).  
δH (500MHz, CDCl3) 7.36 – 7.25 (m, 5H, H-9 + H-10 + H-11), 6.97 (d, J = 8.0 Hz, 2H, H-17), 6.73 (d, J 
= 8.1 Hz, 2H, H-18), 6.48 (s, 1H, H-13), 6.03 (s, 1H, H-4), 5.36 (bs, 1H, H-20), 4.48 (d, J = 11.7 Hz, 
2H, H-7), 4.23 (s, 1H, H-5), 3.92 – 3.50 (m, 2H, H-6), 3.48 (t, J = 9.3 Hz, 2H, H-14), 2.69 (t, J = 6.9 Hz, 
2H, H-15), 1.43 (s, 9H, H-1). δC (126MHz, CDCl3) 170.3 (C=O), 154.6 (C=O), 154.6 (C-Ar), 137.4 (C-
Ar), 130.4 (C-Ar), 129.8 (CH-Ar), 128.5 (CH-Ar), 128.0 (CH-Ar), 127.8 (CH-Ar), 115.5 (CH-Ar), 73.4 
(CH2), 69.9 (CH2), 65.9 (C), 41.1 (CH2), 34.7 (CH2), 28.3 (CH3), 28.1 (CH). MS (ES+) m/z 437.2 
[M+Na]+.  
Synthesis of (S)-2-amino-3-(benzyloxy)-N-(4-hydroxyphenethyl)propanamide 
(300) 
 
 
 
Compound 299 (651 mg, 1.571 mmol) was dissolved in DCM (5 mL) and stirred with TFA (4 mL) at 
room temperature for three hours, producing evanescence. The dark red solution was then 
quenched with water (50 mL) and washed with DCM (1 x 20 mL), which was used to remove any 
residual impurities. The aqueous layer was then basified to pH 12 with 10% NaOH solution. The 
product was then extracted into ethyl acetate (3 x 30 mL) extraction. The colourless organic layers 
were combined, dried over MgSO4, filtered and concentrated under reduced pressure to afford 
the desired amine 300 as a white solid (480 mg, 97%). The product was used without purification.  
δH (500MHz, CD3OD) 7.33 – 7.22 (m, 5H, H-15 + H-16 + H-17), 7.00 (d, J = 8.0 Hz, 2H, H-4), 6.72 (d, 
J = 8.0 Hz, 2H, H-3), 4.47 (s, 2H, H-13), 3.57 (d, J = 4.9 Hz, 2H, H-7), 3.54 – 3.46 (m, 1H, H-10), 3.44 
–  3.32 (m, 2H, H-12), 2.67 (t, J = 7.1 Hz, 2H, H-6). δC (126MHz, CD3OD) 170.2 (C=O), 155.7 (C-Ar), 
137.0 (C-Ar), 129.7 (C-Ar), 129.4 (CH-Ar), 129.4 (CH-Ar), 128.2 (CH-Ar), 127.8 (CH-Ar), 114.9 (CH-
Ar), 73.1 (CH2), 67.9 (CH2), 53.1 (CH), 41.0 (CH2), 34.0 (CH2). MS (ES+) m/z 651.3 [2M+Na]
+.  
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Synthesis of ethyl (4-azidobenzoyl)glycinate (304) 
 
 
 
 
4-Azidobenzoic acid 303 (322 mg, 2.000 mmol) was dissolved in anhydrous DCM (20 mL) and 
stirred with DIPEA (0.77 mL, 4.400 mmol) for five minutes at room temperature. PyBOP (1.145 g, 
2.200 mmol) and glycine ethyl ester hydrochloride (307 mg, 2.200 mmol) were added to the 
colourless solution at 0 oC, which was then stirred at room temperature, for three hours. Water 
(20 mL) was then poured into the yellow solution and the product was extracted into DCM (2 x 20 
mL). The organic layers were combined, dried over MgSO4, filtered and concentrated under 
reduced pressure to afford an orange oil. The oil was purified via flash column chromatography 
(1:1 ethyl acetate: hexane) to yield amide 304 as a white solid (455 mg, 92%).  
δH (500MHz, CDCl3) 7.82 (d, J = 8.2 Hz, 2H, H-3), 7.08 (d, J = 8.2 Hz, 2H, H-2), 6.60 (s, 1H, H-6), 4.27 
(q, J = 7.1 Hz, 2H, H-9), 4.23 (d, J = 4.8 Hz, 2H, H-7), 1.32 (t, J = 7.1 Hz, 3H, H-10). δC (126MHz, 
CDCl3) 170.1 (C=O), 166.3 (C=O), 143.7 (C-Ar), 130.2 (C-Ar), 128.9 (CH-Ar), 119.1 (CH-Ar), 61.8 
(CH2), 41.9 (CH2), 14.2 (CH3). MS (ES+) m/z 271.1 [M+Na]
+, 519.2 [2M+Na]+.  
Analytical data is in agreement with literature values.122 
Synthesis of (4-azidobenzoyl)glycine (305) 
 
 
 
To a stirring solution of azide 304 (300 mg, 1.218 mmol) in THF (8 mL), was added  10% NaOH (30 
mg, 1.218 mmol) solution, which was then stirred at room temperature for one hour. After TLC 
confirmed reaction completion, the orange solution was concentrated under reduced pressure 
and diluted with water (20 mL) and carefully acidified to pH with 6-N HCl, forming a white 
suspension. The product was extracted out of the suspension with ethyl acetate (3 x 20 mL), dried 
over MgSO4, filtered and concentrated under reduced pressure to yield the desired acid 305 as a 
white solid (263 mg, 98%).  
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δH (500MHz, CD3OD) 7.90 (d, J = 8.2 Hz, 2H, H-3), 7.16 (d, J = 8.3 Hz, 2H, H-2), 4.08 (d, J = 4.5 Hz, 
2H, H-7). δC (126MHz, CD3OD) 171.7 (C=O), 168.0 (C=O), 143.7 (C-Ar), 130.2 (C-Ar), 128.9 (CH-Ar), 
118.6 (CH-Ar), 40.9 (CH2). MS (ES-) m/z 215.1 [M-H]
-.  
Analytical data is in agreement with literature values.122 
Synthesis of 2,5-Dioxopyrrolidin-1-yl (4-azidobenzoyl)glycinate (306) 
 
 
 
 
Acid 305 (250 mg, 1.146 mmol) and N-Hydroxysuccinimide (132 mg, 1.146 mmol) was dissolved in 
anhydrous THF (10 mL) and stirred at -75 oC, for ten minutes, under a nitrogen atmosphere. N′-
ethylcarbodiimide hydrochloride (220 mg, 1.146 mmol) was slowly added and the orange solution 
was warmed to room temperature and stirred for 12 hours. The dark orange suspension was 
cooled to -75 oC and was filtered to yield a light orange filtrate, which was concentrated under 
reduced pressure to afford the desired crude product 306 as a cream solid (321 mg, 77%). The 
product was used without purification.  
δH (500MHz, CDCl3) 7.76 (d, J = 7.4 Hz, 2H, H-2), 7.01 (d, J = 7.1 Hz, 2H, H-2), 6.72 (s, 1H, H-6), 4.52 
(d, J = 3.9 Hz, 2H, H-7), 2.78 (s, 4H, H-10).  
Analytical data is in agreement with literature values.122 
Synthesis of (S)-4-azido-N-(2-((3-(benzyloxy)-1-((4-hydroxyphenethyl)amino)-
1-oxopropan-2-yl)amino)-2-oxoethyl)benzamide (301) 
 
 
 
At 0 oC, acid 305 (240 mg, 1.061 mmol) was dissolved in anhydrous DMF (8 mL). DIPEA (0.69 mL, 
2.703 mmol) and PyBOP (675 mg, 1.297 mmol) were added to the yellow solution, which was 
then stirred for five minute, under a nitrogen atmosphere. Amine 300 (260 mL, 1.189 mmol) was 
treated to the solution, which was left to warm to room temperature and stir for 12 hours. Brine 
(100 mL) was used to dilute the mixture, followed by an ethyl acetate (4 x 30 mL) wash to extract 
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the product. The combined organic layers were dried over MgSO4, filtered and concentrated 
under reduced pressure to afford an orange oil. Flash column chromatography (5:95 methanol: 
DCM) isolated the peptide product 314 as a white solid (366 mg, 71%).  
δH (500MHz, CD3OD) 7.89 (d, J = 8.4 Hz, 2H, H-2), 7.31 – 7.21 (m, 5H, H-13 + H-14 + H-15), 7.15 (d, 
J = 8.4 Hz, 2H, H-3), 7.00 (d, J = 8.2 Hz, 2H, H-21), 6.67 (d, J = 8.2 Hz, 2H, H-22), 4.53 (t, J = 4.7 Hz, 
1H, H-9), 4.49 (s, 2H, H-11), 4.05 (ABq, J = 16.1 Hz, 2H, H-6), 3.72 (dd, J = 9.7, 4.9 Hz, 2H, H-10), 
3.37 (t, J = 6.4 Hz, 2H, H-18), 2.69 (t, J = 7.1 Hz, 2H, H-19). δC (126MHz, CD3OD) 170.5 (C=O), 170.5 
(C=O), 168.3 (C=O), 155.5 (C-Ar), 143.9 (C-Ar), 137.8 (C-Ar), 130.0 (C-Ar), 129.8 (C-Ar), 129.4 (CH-
Ar), 129.0 (CH-Ar), 128.0 (CH-Ar), 127.4 (CH-Ar), 127.4 (CH-Ar), 118.7 (CH-Ar), 114.9 (CH-Ar), 72.8 
(CH2), 69.3 (CH2), 53.6 (CH), 43.0 (CH2), 41.2 (CH2), 34.2 (CH2). MS (ES+) m/z 1055.5 [2M+Na]
+.  
Synthesis of (S)-4-azido-N-(2-((3-hydroxy-1-((4-hydroxyphenethyl)amino)-1-
oxopropan-2-yl)amino)-2-oxoethyl)benzamide (18) 
 
 
 
 
To a stirring solution of compound 301 (100 mg, 0.194 mmol) in 1:1 mixture of anhydrous ethyl 
acetate (4 mL) and anhydrous ethanol (4 mL) was added a catalytic amount of Pd/C, under a 
nitrogen atmosphere. The black solution was degassed with nitrogen several times before being 
purged with hydrogen and being left to stir at room temperature, for one hour. The reaction 
mixture was filtered through a pad of Celite and washed with ethanol several times. Solvents 
were removed from the filtrate under reduced pressure to afford a white solid. Flash column 
chromatography (1:9 methanol: DCM) of the crude isolated the desired product 18 as a cream 
solid (9 mg, 11%).  
δH (500MHz, CD3OD) 7.94 (d, J = 8.7 Hz, 2H, H-2), 7.18 (d, J = 8.7 Hz, 2H, H-3), 7.05 (d, J = 8.4 Hz, 
2H, H-17), 6.72 (d, J = 8.5 Hz, 2H, H-18), 4.43 (t, J = 5.2 Hz, 1H, H-9), 4.09 (ABq, J = 16.3 Hz, 2H, H-
6), 3.86 – 3.76 (m, 2H, H-10), 3.42 – 3.36 (m, 2H, H-14), 2.73 (t, J = 7.0 Hz, 2H, H-15). δC (126MHz, 
CD3OD) 172.7 (C=O), 172.6 (C=O), 170.3 (C=O), 157.5 (C-Ar), 145.9 (C-Ar), 132.0 (C-Ar), 131.8 (C-
Ar), 131.4 (CH-Ar), 131.1 (CH-Ar), 120.7 (CH-Ar), 116.9 (CH-Ar), 63.5 (CH2), 57.6 (CH), 45.1 (CH2), 
43.2 (CH2), 36.2 (CH2). MS (ES+) m/z 449.2 [M+Na]
+.  
Analytical data is in agreement with literature values.67 
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Synthesis of (S)-2-amino-3-hydroxy-N-(4-hydroxyphenethyl)propanamide 
(309) 
 
 
 
 
To a stirring solution of compound 300 (1.1 g, 3.499 mmol) in 1:1 mixture of anhydrous ethyl 
acetate (5 mL) and anhydrous ethanol (5 mL), was added a catalytic amount of Pd/C under a 
nitrogen atmosphere. The black suspension was degassed with nitrogen several times before 
being purged with hydrogen and being left to stir at room temperature, for one hour. The 
reaction mixture was filtered through a pad of Celite and washed with ethanol several times. 
Solvents were removed from the filtrate under reduced pressure to afford the product 309 as a 
white solid (770 mg, 99%), which was used without purification.  
δH (500MHz, DMSO) 9.30 (s, 1H, H-13), 8.59 (t, J = 5.2 Hz, 1H, H-6), 8.22 (s, 2H, H-1), 7.00 (d, J = 
8.1 Hz, 2H, H-10), 6.70 (d, J = 8.2 Hz, 2H, H-11), 5.49 (s, 1H, H-4), 3.74 (dd, J = 15.8, 8.5 Hz, 2H, H-
7), 3.69 – 3.60 (m, 1H, H-2), 3.35 – 3.17 (m, 2H, H-3), 2.62 (t, J = 7.2 Hz, 2H, H-8). δC (126MHz, 
DMSO) 167.0 (C=O), 156.3 (C-Ar), 130.0 (CH-Ar), 129.6 (C-Ar), 115.6 (CH-Ar), 60.8 (CH2), 54.9 (CH), 
41.3 (CH2), 34.5 (CH2). MS (ES+) m/z 449.3 [2M+H]
+, 471.2 [2M+Na]+. 
Synthesis of (S)-4-azido-N-(2-((3-hydroxy-1-((4-hydroxyphenethyl)amino)-1-
oxopropan-2-yl)amino)-2-oxoethyl)benzamide (18) 
 
 
 
 
Carboxylic acid 305 (100 mg, 0.454 mmol), triethylamine (0.32 mL, 2.270 mmol) and PyBOP (236 
mg, 0.454 mmol) were dissolved in a solution of anhydrous DMF (4 mL) and then stirred for five 
minutes, at room temperature, under a nitrogen atmosphere. Compound 309 (102 mg, 0.454 
mmol) was then treated to the brown solution and stirred at room temperature, for 16 hours. The 
crude was diluted with water (50 mL) and the product was extracted into ethyl acetate (4 x 20 
mL). The combined organic layers were dried over MgSO4, filtered and concentrated under 
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reduced pressure to afford a dark orange oil. Flash column chromatography (1:9 methanol: DCM) 
isolated the product 18 as a light cream solid (156 mg, 80%).  
δH (500 MHz, CD3OD) 7.91 (d, J = 8.8 Hz, 2H, H-2), 7.16 (d, J = 8.8 Hz, 2H, H-3), 7.02 (d, J = 8.6 Hz, 
2H, H-17), 6.69 (d, J = 8.5 Hz, 2H, H-18), 4.40 (t, J = 5.2 Hz, 1H, H-9), 4.06 (ABq, J = 16.3 Hz, 2H, H-
6), 3.78 (td, J = 11.1, 5.2 Hz, 2H, H-10), 3.36 (dd, J = 9.1, 6.6 Hz, 2H, H-14), 2.70 (t, J = 7.5 Hz, 2H, H-
15). δC (126MHz, CD3OD) 170.7 (C=O), 170.6 (C=O), 168.3 (C=O), 155.5 (C-Ar), 143.9 (C-Ar), 130.0 
(C-Ar) 129.8 (C-Ar), 129.4 (CH-Ar), 129.1 (CH-Ar), 118.6 (CH-Ar), 114.8 (CH-Ar), 61.5 (CH2), 55.6 
(CH), 43.1 (CH2), 41.2 (CH2), 34.2 (CH2). MS (ES+) m/z 449.2 [M+Na]
+. HRMS (ESI) C20H23N6O5 calcd. 
427.1730 [M+H]+, found 427.1731. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 
254 nm, tR = 5.17 min (96.0%). 
Analytical data is in agreement with literature values.67 
Synthesis of tert-butyl (chloro(phenoxy)phosphoryl)-L-alaninate (310) 
 
 
 
 
 
Prepared according to Standard Procedure B, from compound 137 (0.27 mL, 1.818 mmol), L-
alanine tert-butyl ester hydrochloride (300 mg, 1.652 mmol), triethylamine (0.46 mL, 3.303 mmol)  
and anhydrous DCM (10 mL). The product phosphorochloridate 310 was isolated as a yellow oil 
(488 mg, 92%). Product isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 7.37 (t, J = 7.8 Hz, 2H, H-3), 7.28 – 7.20 (m, 3H, H-2 + H-4), 4.27 – 4.21 (m, 1H, 
H-5), 4.13 – 3.96 (m, 1H, H-6), 1.56 – 1.49 (m, 12H, H-7 + H-10). δP (202MHz, CDCl3) 8.14, 7.75.  
Analytical data is in agreement with literature values.147 
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Synthesis of tert-butyl (((S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-
hydroxyphenethyl)amino)-3-oxopropoxy)(phenoxy)phosphoryl)-L-alaninate 
(295) 
 
 
 
 
 
Prepared according to Standard Procedure I, from peptide 18 (149 mg, 0.469 mmol), tert-butyl 
magnesium chloride (1.03 mL, 1.032 mmol), phosphorochloridate 310 (200 mg, 0.469 mmol), 
anhydrous acetonitrile (7 mL) and anhydrous pyridine (3 mL). The product prodrug 295 was 
isolated as a cream solid (86 mg, 26%). Product isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 7.95 (dd, J = 8.3, 4.4 Hz, 1H, H-6), 7.81 (dd, J = 14.0, 8.6 Hz, 2H, H-2), 7.38 – 
7.28 (m, 3H, H-9 + H-14), 7.25 – 7.13 (m, 3H, H-13 + H-15), 7.11 – 7.00 (m, 5H, H-23 + H-27 + H-
28), 6.95 (dd, J = 8.6, 2.8 Hz, 2H, H-3), 4.40 (dd, J = 8.4, 4.1 Hz, 1H, H-10), 4.32 – 4.13 (m, 1H, H-
16), 4.04 – 3.76 (m, 4H, H-7 + H-11a/b + H-17), 3.59 (d, J = 3.6 Hz, 1H, H-11a/b), 3.53 – 3.35 (m, 
2H, H-24), 2.76 (dd, J = 14.2, 7.3 Hz, 2H, H-25), 1.43 (d, J = 5.1 Hz, 9H, H-21), 1.37 (dd, J = 7.0, 3.2 
Hz, 3H, H-18). δC (126MHz, CDCl3) 170.6 (C=O), 170.2 (C=O), 170.1 (C=O), 167.4 (C=O), 150.5 (C-
Ar), 149.0 (C-Ar), 143.6 (C-Ar), 135.8 (C-Ar), 130.2 (CH-Ar), 129.9 (CH-Ar) 129.7 (C-Ar), 129.3 (CH-
Ar), 125.3 (CH-Ar), 120.3 (CH-Ar), 120.2 (CH-Ar), 118.9 (CH-Ar), 82.3 (C), 62.2 (CH2), 54.3 (CH), 50.9 
(CH), 43.9 (CH2), 40.2 (CH2), 34.3 (CH2), 27.9 (CH3), 21.0 (CH3). δP (202MHz, CDCl3) -1.76, -1.85. MS 
(ES+) m/z 732.2 [M+Na]+. HRMS (ESI) C33H41N7O9P calcd. 710.2703 [M+H]
+, found 710.2704. HPLC 
(reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 8.56 min (97.7%). 
Synthesis of isopropyl (chloro(phenoxy)phosphoryl)-L-alaninate (311) 
 
 
 
 
 
Prepared according to Standard Procedure B, from compound 137 (0.30 mL, 1.969 mmol), L-
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alanine isopropyl ester hydrochloride (300 mg, 1.790 mmol), triethylamine (0.51 mL, 3.580 mmol) 
and anhydrous DCM (10 mL). The product phosphorochloridate 324 was isolated as a yellow oil 
(461 mg, 85%). Product isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 7.38 (t, J = 9.0 Hz, 2H, H-3), 7.29 – 7.18 (m, 3H, H-2 + H-4), 5.19 – 5.00 (m, 1H, 
H-9), 4.36 – 3.94 (m, 2H, H-5 + H-6), 1.49 (d, J = 2.3 Hz, 3H, H-7), 1.27 (dd, J = 8.0, 6.2 Hz, 6H, H-
10). δP (202MHz, CDCl3) 8.04, 7.65.  
Analytical data is in agreement with literature values.147 
Synthesis of benzyl (chloro(phenoxy)phosphoryl)-L-alaninate (312) 
 
 
 
 
 
Prepared according to Standard Procedure B, from compound 137 (0.23 mL, 1.530 mmol), L-
alanine benzyl ester hydrochloride (300 mg, 1.391 mmol), triethylamine (0.39 mL, 2.782 mmol)  
and anhydrous DCM (10 mL). The product phosphorochloridate 312 was isolated as a yellow oil 
(410 mg, 83%). Product isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 7.45 – 7.28 (m, 7H, H-3 + H-11 + H-12 + H-13), 7.28 – 7.21 (m, 3H, H-2 + H-4), 
5.21 (d, J = 7.7 Hz, 2H, H-9), 4.36 – 4.12 (m, 2H, H-5 + H-6), 1.52 (dd, J = 6.8, 3.0 Hz, 3H, H-7). δP 
(202MHz, CDCl3) 7.84, 7.49.  
Analytical data is in agreement with literature values.147 
Synthesis of methyl (((S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-
hydroxyphenethyl)amino)-3-oxopropoxy)(phenoxy)phosphoryl)-L-alaninate 
(292) 
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Prepared according to Standard Procedure I, from peptide 18 (50 mg, 0.117 mmol), tert-butyl 
magnesium chloride (0.26 mL, 0.257 mmol), phosphorochloridate 256 (36 mg, 0.129 mmol), 
anhydrous acetonitrile (7 mL) and anhydrous pyridine (3 mL). The product prodrug 292 was 
isolated as a cream solid (23 mg, 29%). Product isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 8.01 – 7.91 (m, 1H, H-6), 7.80 (dd, J = 11.2, 6.3 Hz, 2H, H-2), 7.46 (dd, J = 11.3, 
5.9 Hz, 1H, H-9), 7.33 (dd, J = 11.2, 7.5 Hz, 2H, H-14), 7.28 – 7.19 (m, 3H, H-13 + H-15), 7.13 – 6.97 
(m, 5H, H-22 + H-26 + H-27), 6.94 (dd, J = 8.6, 3.7 Hz, 2H, H-3), 4.52 – 4.29 (m, 2H, H-10 + H-16), 
4.15 – 3.80 (m, 4H, H-7 + H-11a/b + H-17), 3.68 (d, J = 7.5 Hz, 3H, H-20), 3.63 – 3.55 (m, 1H, H-
11a/b), 3.46 – 3.36 (m, 2H, H-23), 2.75 (t, J = 6.3 Hz, 2H, H-24), 1.39 (d, J = 3.1 Hz, 3H, H-18). δC 
(126MHz, CDCl3) 176.6 (C=O), 170.7 (C=O), 170.0 (C=O), 167.4 (C=O), 150.4 (C-Ar), 148.9 (C-Ar), 
143.7 (C-Ar), 135.8 (C-Ar), 130.2 (CH-Ar), 129.8 (CH-Ar), 129.7 (C-Ar), 129.3 (CH-Ar), 125.4 (CH-Ar), 
120.3 (CH-Ar), 120.2 (CH-Ar), 118.9 (CH-Ar), 62.2 (CH2), 54.2 (CH), 52.6 (CH3), 50.4 (CH), 43.9 (CH2), 
40.1 (CH2), 34.3 (CH2), 20.8 (CH3). δP (202MHz, CDCl3) -2.07, -2.13. MS (ES+) m/z 690.2 [M+Na]
+. 
HRMS (ESI) C30H35N7O9P calcd. 668.2234 [M+H]
+, found 668.2230. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 6.20 min (95.8%). 
Synthesis of isopropyl (((S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-
hydroxyphenethyl)amino)-3-oxopropoxy)(phenoxy)phosphoryl)-L-alaninate 
(293) 
 
 
 
 
Prepared according to Standard Procedure I, from peptide 18 (50 mg, 0.117 mmol), tert-butyl 
magnesium chloride (0.26 mL, 0.257 mmol), phosphorochloridate 311 (40 mg, 0.129 mmol), 
anhydrous acetonitrile (7 mL) and anhydrous pyridine (3 mL). The product prodrug 293 was 
isolated as a cream solid (22 mg, 27%). Product isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 7.97 (dd, J = 10.2, 4.4 Hz, 1H, H-6), 7.81 (dd, J = 8.5, 2.4 Hz, 2H, H-2), 7.45 (dd, 
J = 12.9, 6.3 Hz, 1H, H-9), 7.36 – 7.30 (m, 2H, H-14), 7.25 – 7.14 (m, 3H, H-13 + H-15), 7.13 – 6.99 
(m, 5H, H-23 + H-27 + H-28), 6.93 (dd, J = 8.6, 3.6 Hz, 2H, H-3), 5.09 – 5.00 (m, 1H, H-20), 4.46 – 
4.24 (m, 2H, H-10 + H-16), 4.08 – 3.79 (m, 4H, H-7 + H-11a/b + H-17), 3.59 (d, J = 6.4 Hz, 1H, H-
11a/b), 3.41 (dt, J = 11.2, 6.4 Hz, 2H, H-24), 2.80 – 7.75 (m, 2H, H-25), 1.38 (dd, J = 6.9, 3.1 Hz, 3H, 
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H-18), 1.22 (dd, J = 5.3, 3.3 Hz, 6H, H-21). δC (126MHz, CDCl3) 172.8 (C=O), 170.6 (C=O), 170.1 
(C=O), 167.4 (C=O), 150.5 (C-Ar), 149.0 (C-Ar), 143.6 (C-Ar), 135.8 (C-Ar), 130.2 (CH-Ar), 129.8 (CH-
Ar), 129.7 (C-Ar), 129.3 (CH-Ar), 125.3 (CH-Ar), 120.3 (CH-Ar), 120.2 (CH-Ar), 118.9 (CH-Ar), 69.4 
(CH), 62.2 (CH2), 54.5 (CH), 50.5 (CH), 43.8 (CH2), 40.3 (CH2), 34.3 (CH2), 21.6 (CH3), 20.9 (CH3). δP 
(202MHz, CDCl3) -1.93, -2.03. MS (ES+) m/z 718.2 [M+Na]
+. HRMS (ESI) C32H39N7O9P calcd. 
696.2547 [M+H]+, found 696.2541. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 
254 nm, tR = 7.53 min (96.0%). 
Synthesis of benzyl (((S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-
hydroxyphenethyl)amino)-3-oxopropoxy)(phenoxy)phosphoryl)-L-alaninate 
(294) 
 
 
 
 
 
Prepared according to Standard Procedure I, from peptide 18 (160 mg, 0.375 mmol), tert-butyl 
magnesium chloride (0.83 mL, 0.825 mmol), phosphorochloridate 312 (133 mg, 0.375 mmol), 
anhydrous acetonitrile (7 mL) and anhydrous pyridine (3 mL). The product prodrug 294 was 
isolated as a cream solid (58 mg, 29%). Product isolated as a mixture of diastereoisomers. 
δH (500MHz, CDCl3) 7.90 (dd, J = 15.5, 5.0 Hz, 1H, H-6), 7.81 (dd, J = 9.6, 2.8 Hz, 2H, H-2), 7.43 – 
7.34 (m, 1H, H-9), 7.35 – 7.25 (m, 7H, H-14 + H-22 + H-23 + H-24), 7.24 – 7.13 (m, 3H, H-13 + H-
15), 7.08 – 6.97 (m, 5H, H-26 + H-30 + H-31), 6.93 (dd, J = 8.6, 4.4 Hz, 2H, H-3), 5.12 (dd, J = 5.9, 
2.0 Hz, 2H, H-20), 4.53 – 4.28 (m, 2H, H-10 + H-16), 4.12 (dd, J = 9.2, 4.9 Hz, 1H, H-17), 4.04 – 3.76 
(m, 3H, H-7 + H-11a/b), 3.62 – 3.54 (m, 1H, H-11a/b), 3.46 – 3.40 (m, 2H, H-27), 2.84 – 2.64 (m, 
2H, H-28), 1.40 (dd, J = 6.7, 2.4 Hz, 3H, H-18). δC (126MHz, CDCl3) 173.1 (C=O), 170.6 (C=O), 170.0 
(C=O), 167.4 (C=O), 150.4 (C-Ar), 148.9 (C-Ar), 143.6 (C-Ar), 135.8 (C-Ar), 135.1 (C-Ar), 130.2 (CH-
Ar), 129.8 (CH-Ar), 129.7, (C-Ar) 129.3 (CH-Ar), 128.7 (CH-Ar), 128.6 (CH-Ar), 128.2 (CH-Ar), 125.4 
(CH-Ar), 120.3 (CH-Ar), 120.2 (CH-Ar), 118.9 (CH-Ar), 67.4 (CH2), 62.2 (CH2), 54.4 (CH), 50.5 (CH), 
43.8 (CH2), 40.3 (CH2), 34.3 (CH2), 20.8 (CH3). δP (202MHz, CDCl3) -2.03, -2.13. MS (ES+) m/z 766.2 
[M+Na]+. HRMS (ESI) C36H39N7O9P calcd. 744.2547 [M+H]
+, found 744.2548. HPLC (reverse-phase) 
MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 8.64 min (95.3%). 
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Synthesis of (S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-
hydroxyphenethyl)amino)-3-oxopropyl diethyl phosphate (296) 
 
 
 
 
Prepared according to Standard Procedure I, from peptide 18 (60 mg, 0.141 mmol), tert-butyl 
magnesium chloride (0.28 mL, 0.282 mmol), diethyl chlorophosphate 313 (0.02 mL, 0.155 mmol), 
anhydrous acetonitrile (7 mL) and anhydrous pyridine (3 mL). The product prodrug 296 was 
isolated as a colourless oil (24 mg, 30%).  
δH (500MHz, CDCl3) 7.92 (t, J = 5.2 Hz, 1H, H-6), 7.86 (d, J = 8.6 Hz, 2H, H-2), 7.32 (d, J = 7.6 Hz, 1H, 
H-9), 7.11 (d, J = 8.5 Hz, 2H, H-3), 7.08 – 7.00 (m, 4H, H-19 + H-20), 6.93 (t, J = 5.7 Hz, 1H, H-15), 
4.39 (dt, J = 7.8, 4.0 Hz, 1H, H-10), 4.28 – 4.16 (m, 4H, H-12), 4.10 – 3.82 (m, 3H, H-7 + H-11a/b), 
3.60 (dd, J = 11.3, 4.7 Hz, 1H, H-11a/b), 3.57 – 3.39 (m, 2H, H-16), 2.84 – 2.79 (m, 2H, H-17), 1.38 
(dd, J = 7.5, 6.6 Hz, 6H, H-13). δC (126MHz, CDCl3) 170.7 (C=O), 170.1 (C=O), 167.5 (C=O), 149.1 (C-
Ar), 143.8 (C-Ar), 135.7 (C-Ar), 130.2 (CH-Ar), 129.7 (C-Ar), 129.3 (CH-Ar), 120.1 (CH-Ar), 118.9 
(CH-Ar), 64.8 (CH2), 62.1 (CH2), 54.2 (CH), 44.1 (CH2), 40.2 (CH2), 34.3 (CH2), 16.1 (CH3). δP 
(202MHz, CDCl3) -6.11. MS (ES+) m/z 585.2 [M+Na]
+. HRMS (ESI) C24H32N6O8P calcd. 563.2019 
[M+H]+, found 563.2034. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, 
tR = 5.87 min (96.1%). 
Synthesis of (S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-
hydroxyphenethyl)amino)-3-oxopropyl di(N,N-diisopropylphosphonamidate)  
(314) 
 
 
 
 
Prepared according to Standard Procedure I, from peptide 18 (144 mg, 0.338 mmol), tert-butyl 
magnesium chloride (0.75 mL, 0.743 mmol), N,N,N′,N′-tetramethylphosphorodiamidic chloride 
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112 (0.05 mL, 0.338 mmol), anhydrous acetonitrile (7 mL) and anhydrous pyridine (3 mL). The 
product diamidate 314 was isolated as a cream solid (76 mg, 40%).  
δH (500MHz, CDCl3) 8.29 (s, 1H, H-6), 7.82 (d, J = 8.2 Hz, 2H, H-2), 7.58 (d, J = 5.4 Hz, 1H, H-9), 7.26 
(d, J = 9.1 Hz, 1H, H-14), 7.04 (d, J = 8.1 Hz, 2H, H-3), 6.99 – 6.90 (m, 4H, H-18 + H-19), 4.39 (s, 1H, 
H-10), 3.91 (d, J = 12.0 Hz, 2H, H-7), 3.72 – 3.66 (m, 2H, H-11), 3.36 (dd, J = 11.9, 6.0 Hz, 2H, H-15), 
2.74 – 2.60 (m, 14H, H-12 + H-16). δC (126MHz, CDCl3) 170.6 (C=O), 170.6 (C=O), 167.6 (C=O), 
149.5 (C-Ar), 143.6 (C-Ar), 135.1 (C-Ar), 130.1 (CH-Ar), 129.5 (C-Ar), 129.4 (CH-Ar), 120.1 (CH-Ar), 
118.8 (CH-Ar), 62.2 (CH2), 55.0 (CH), 43.9 (CH2), 40.6 (CH2), 36.6 (CH3), 34.3 (CH2). δP (202MHz, 
CDCl3) 10.53. MS (ES+) m/z 583.2 [M+Na]
+.  
Synthesis of (S)-2-(2-(4-azidobenzamido)acetamido)-3-((4-
hydroxyphenethyl)amino)-3-oxopropyl dihydrogen phosphate (17) 
 
 
 
 
To a solution of diamidate 314 (67 mg, 0.120 mmol) in 1,4-dioxane (5 mL) was added 2-N HCl 
solution (5 mL). The clear colourless/yellow solution was stirred at room temperature for nine 
hours. After TLC analysis confirmed total conversion, the mixture was concentrated under 
reduced pressure to afford the product 17 as a cream solid (55 mg, 91%). The product was then 
triturated with ethyl acetate (3 x 30 mL) and used without further purification. 
δH (500MHz, CD3OD) δ 7.94 (d, J = 8.7 Hz, 2H, H-2), 7.21 – 7.03 (m, 6H, H-3 + H-18 + H-19), 4.39 (t, 
J = 5.1 Hz, 1H, H-10), 4.06 (ABq, J = 16.4 Hz, 2H, H-7), 3.78 (dd, J = 11.2, 5.3 Hz, 2H, H-11), 3.50 –  
3.41 (m, 2H, H-15), 2.77 (t, J = 6.2 Hz, 2H, H-16). δC (126MHz, DMSO) 170.2 (C=O), 169.5 (C=O), 
166.2 (C=O), 151.3 (C-Ar), 142.9 (C-Ar), 134.4 (C-Ar), 131.0 (C-Ar), 129.8 (CH-Ar), 129.8 (CH-Ar), 
121.4 (CH-Ar), 119.4 (CH-Ar), 62.0 (CH2), 55.8 (CH), 43.3 (CH2), 41.0 (CH2), 34.8 (CH2). δP (202MHz, 
CD3OD) -5.14. MS (ES+) m/z 507.1 [M+H]
+. HRMS (ESI) C20H24N6O8P calcd. 507.1393 [M+H]
+, found 
507.1396. HPLC (reverse-phase) MeOH/H2O 0:100 to 100:0 in 12 min, λ = 254 nm, tR = 5.66 min 
(87.6%). 
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